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Abstract 
Restless Legs Syndrome (RLS) is a common neurological disorder affecting nearly 
15% of the general population. Ironically, RLS can be described as the most 
common condition one has never heard of. It is usually characterised by 
uncomfortable, unpleasant sensations in the lower limbs inducing an uncontrollable 
desire to move the legs. RLS exhibits a circadian pattern with symptoms present 
predominantly in the evening or at night, thus leading to sleep disruption and 
daytime somnolence.  
RLS is generally classified into primary (idiopathic) and secondary (symptomatic) 
forms. Primary RLS includes sporadic and familial cases of which the age of onset is 
usually less than 45 years and progresses slowly with a female to male ratio of 2:1. 
Secondary forms often occur as a complication of another health condition, such as 
iron deficiency or thyroid dysfunction. The age of onset is usually over 45 years, 
with an equal male to female ratio and more rapid progression.  
Ekbom described the familial component of the disorder in 1945 and since then 
many studies have been published on the familial forms of the disorder. Molecular 
genetic studies have so far identified ten loci (5q, 12q, 14p, 9p, 20p, 16p, 19p, 4q, 
17p). No specific gene within these loci has been identified thus far. Association 
mapping has highlighted a further five areas of interest. RLS6 has been found to be 
associated with SNPs in the BTBD9 gene. Four other variants were found within 
intronic and intergenic regions of MEIS1, MAP2K5/LBXCOR1, PTPRD and NOS1. 
vi 
The pathophysiology of RLS is complex and remains to be fully elucidated. 
Conditions associated with secondary RLS, such as pregnancy or end-stage renal 
disease, are characterised by iron deficiency, which suggests that disturbed iron 
homeostasis plays a role. Dopaminergic dysfunction in subcortical systems also 
appears to play a central role.  
An ongoing study within the Department of Pathology (University College Cork) is 
investigating the genetic characteristics of RLS in Irish families. A three generation 
RLS pedigree RLS3002 consisting of 11 affected and 7 unaffected living family 
members was recruited. The family had been examined for four of the known loci 
(5q, 12q, 14p and 9p) (Abdulrahim 2008). The aim of this study was to continue 
examining this Irish RLS pedigree for possible linkage to the previously described 
loci and associated regions. Using informative microsatellite markers linkage was 
excluded to the loci on 5q, 12q, 14p, 9p, 20p, 16p, 19p, 4q, 17p and also within the 
regions reported to be associated with RLS. This suggested the presence of a new 
unidentified locus. A genome-wide scan was performed using two microsatellite 
marker screening sets (Research Genetics Inc. Mapping set and the Applied 
Biosystems Linkage mapping set version 2.5). Linkage analysis was conducted 
under an autosomal dominant model with a penetrance of 95% and an allele 
frequency of 0.01. A maximum LOD score of 3.59 at θ=0.00 for marker D19S878 
indicated significant linkage on chromosome 19p. Haplotype analysis defined a 
genetic region of 6.57 cM on chromosome 19p13.3, corresponding to 2.5 Mb. There 
are approximately 100 genes annotated within the critical region. Sequencing of two 
candidate genes, KLF16 and GAMT, selected on the assumed pathophysiology of 
RLS, did not identify any sequence variant.  
vii 
This study provides evidence of a novel RLS locus in an Irish pedigree, thus 
supporting the picture of RLS as a genetically heterogeneous trait. 
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Chapter 1 
 
Restless Legs Syndrome 
 
  
2 
1.1 Introduction 
Restless legs syndrome (RLS) is a neurological condition characterised by a 
distressing need or urge to move the legs (an akathisia focused on the legs), usually 
accompanied by an uncomfortable sensation in the legs (a paresthesia) described as a 
crawling, muscle ache or tension (Earley 2003). It is usually brought on by rest, 
worse in the evening or night and partially or totally relieved by movement. This 
scenario leads to nocturnal sleep disruption and consequently to daytime 
somnolence. Although the entity was mentioned in English literature by Thomas 
Willis in 1965, it was not until the Swedish neurologist Karl Axel Ekbom‟s lucid 
description in 1945, under the heading “Restless legs: a clinical study”, that the 
scientific world became aware of this condition. Therefore, this disorder is often 
referred to as Ekbom‟s syndrome (Hening 2004).  
RLS is a heterogenous disorder, the common feature of which is a circadian 
occurrence of disabling sensory symptoms at rest. However, in addition to sensorial 
symptoms such as dyesthesias, patients experience motor symptoms. These rhythmic 
or semirhythmic movements of the legs are otherwise known as periodic limb 
movements during sleep (PLMS) that occur every 5-90 seconds. PLMS, which occur 
in various sleep disorders as well as other neurological diseases, are observed in at 
least 80% of RLS patients (Montplaisir, Boucher et al. 1997).When present, PLMS 
support the diagnosis, and provide a measure of the clinical severity of this disorder. 
RLS can be classified into two broad groups, according to the age of onset and the 
presence or absence of a familial history of RLS. Primary RLS is also known as 
idiopathic RLS. The name is applied to those cases of RLS where there is a positive 
family history of RLS and the age of onset is less than 45. The positive family 
3 
history and early age of onset indicate that genetic factors play a role in this RLS 
phenotype (Allen and Earley 2000). RLS familial aggregation accounts for up to 
65% of reported cases (primary), with inheritance following an autosomal dominant 
pattern in at least one-third of familial cases (Montplaisir, Boucher et al. 1997; Ondo, 
Vuong et al. 2000). Secondary RLS is also known as “symptomatic RLS” or 
“sporadic RLS”. The name “secondary RLS”, represents cases of RLS where age of 
onset is usually greater than 45 years and there is no familial link with the syndrome. 
This indicates that environmental factors play a role in this phenotype. The sudden 
and late onset of the disease usually occurs secondary to other conditions, 
particularly iron-deficiency anemia and end-stage renal disease. Familial (primary) 
and sporadic (secondary) RLS cases present similar signs, symptoms and clinical 
course. However the symptoms of secondary RLS are usually resolved when the 
underlying conditions are corrected. 
Epidemiological studies indicate that the symptoms of RLS are present in about 5-
10% of the general population. Despite this high frequency of affected individuals, 
experience suggests the disease is often misdiagnosed, under-diagnosed or 
undiagnosed. It follows that there is a need to understand more about RLS and 
increase awareness of how it is most likely to present in a medical practice. 
  
4 
1.2 Diagnosing RLS 
1.2.1 Clinical features of RLS 
In 1995, the International Restless Legs Syndrome Study Group (IRLSSG) 
developed standardized criteria for the diagnosis of restless legs syndrome. Since 
that time, additional scientific scrutiny and clinical experience led to a better 
understanding of the condition. Subsequently a consensus conference held at the 
NIH in conjunction with the IRLSSG, resulted in revised diagnostic criteria for RLS 
to replace the previously proposed criteria. The primary revision from the previously 
proposed criteria include four criteria that are essential for the diagnosis of RLS in 
cognitively intact adult, three supportive criteria which may support the diagnosis in 
uncertain clinical cases, and three additional features of the disorder which deserve 
consideration when evaluating the patient with a potential diagnosis of RLS (Allen, 
Picchietti et al. 2003). These criteria are outlined in Table 1.1 below. 
Table 1.1: The clinical features and diagnostic criteria for RLS 
Essential Diagnostic Criteria for RLS 
An urge to move the lower limbs, usually accompanied or caused by uncomfortable and 
unpleasant sensations in the lower limbs (sometimes the urge to move is present without the 
uncomfortable sensations and sometimes the arms or other body parts are involved in 
addition to the legs). 
The urge to move or unpleasant sensations begin to worsen during periods of rest or 
inactivity such as lying or sitting. 
The urge to move or unpleasant sensations are partially or totally relieved by movement, 
such as walking or stretching, at least as long as the activity continues. 
The urge to move or unpleasant sensations are worse in the evening or at night than during 
the day or only occur in the evening or night (When symptoms are very severe, the 
worsening at night may not be noticeable but must have been previously present).  
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Table 1.1: The clinical features and diagnostic criteria for RLS (continued) 
Supportive Clinical Features of RLS 
 Periodic Limb Movements during Sleep (PLMS) 
Although the presence of PLMS is not specific to RLS an elevated PLM index (i.e. 
>5 movements/hr of sleep) is supportive of the diagnosis of RLS. Approximately 
80% of patients with RLS have associated PLMS, which are usually present in the 
legs and less often in the arms. 
 Response to Dopaminergic Therapy 
Nearly all people with RLS show at least an initial positive therapeutic response to 
either L-dopa dopamine-receptor agonist at doses considered to be very low in 
relation to the traditional doses of these medications used for the treatment of 
Parkinson‟s disease. This initial response is not, however, universally maintained.  
 Family History 
The presence of RLS among first degree relatives is 3 to 5 times greater than in 
people without family history of RLS. 
Associated Features of RLS 
 Natural Clinical Course 
The clinical course of the disorder varies considerably, but certain patterns have been 
identified that may be helpful to the experienced clinician. When the age of onset of 
RLS symptoms is less than 50 years, the onset is often more insidious; when the age 
of onset is more than 50 years, the symptoms often occur more abruptly and more 
severely. In some patients, RLS can be intermittent and may spontaneously remit for 
many years.  
 Sleep Disturbance  
Disturbed sleep is a common major morbidity for RLS and deserves special 
consideration in planning treatment. This symptom is often the primary reason the 
patient seeks medical attention.  
 Medical Evaluation/ Physical evaluation 
The physical examination is generally normal and does not contribute to the 
diagnosis except for the identification of comorbid or secondary causes of RLS. Iron 
status, in particular, should be evaluated because decreased iron stores are significant 
potential risk factors that can be treated. The presence of peripheral neuropathy and 
radiculopathy should also be determined because the conditions have a possible, 
although uncertain, association with RLS and may require different treatment. 
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The uncomfortable sensations occur only when the limbs are at rest for a length of 
time, and they are typically relieved by movement. Individuals declare that they 
experience an almost irresistible urge to move the limbs. Symptoms of RLS can be 
very severe e.g. during flights, train or car journeys, at the cinema or the theatre. 
Symptoms can be especially troublesome in the late evening when patients are 
preparing for or attempting to sleep. Sensations may last for hours and persist, in 
some unfortunate suffers, into the early hours of the morning. Individuals often have 
to get up and walk around a few times per night to get relief. This form of coping 
behaviour has been named „Night-walker‟s syndrome‟. Loss of sleep is a grim 
consequence both to patients and their partners (Ekbom and Ulfberg 2009). 
In addition to the standard criteria, the IRLSSG also outlined diagnostic criteria for 
RLS in special populations including children, adolescents and the cognitively 
impaired elderly (Allen, Picchietti et al. 2003). If a clear verbal description cannot be 
given, the diagnosis in children can be supported by a positive family history or a 
PLM index >5 per hour in overnight polysomnography. On the contrary, in elderly 
patients with cognitive impairment, diagnosis may be difficult when memory or 
language problems prevent a proper history taking. In this patient group, the 
consensus paper advises referral for observation, e.g., leg kicking, holding the legs 
and rubbing them etc.  
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1.2.2 Assessment Scales 
RLS is said to be a subjective disorder, therefore it may be difficult for examiners to 
evaluate the exact severity of symptoms in individuals. However, in 2003, the 
IRLSSG rating scale was established. This scale is an easily administered 
instrument, which can be applied to all patients with RLS. It contains 10 items that 
are completed by patients themselves assessing the frequency and severity of 
symptoms over the preceding week. Responses are graded from 0 to 4 (e.g. 0 = 
absence of symptoms, 4 = very severe symptoms), with a maximum total score of 
40. It can be used to accurately measure disease severity for clinical assessment, 
research, or therapeutic trials (Walters, LeBrocq et al. 2003). It is said to be the gold 
standard for measuring symptom severity in patients with RLS. A different scale, 
The John Hopkins Severity Scale (JHSS), predominantly assesses the time of daily 
onset of RLS symptoms. Other scales are used to examine quality of life in RLS. A 
list of assessment scales used in RLS are listed in Table 1.2. 
Table 1.2: Scales for assessing RLS (Hogl, Garcia-Borreguero et al. 2009). 
Severity scales 
IRLS ( International RLS Study Group Severity Scale) 
John Hopkins Severity Scale (JHSS) 
Quality of life scales 
RLS Quality of life (QoL) questionnaire by Kohnen 
RLS QoL questionnaire by Allen 
RLS-QLI instrument 
Other scales for RLS 
Clinical Global Impression, Patient Global Impression  
RLS diagnostic index (RLS-DI) 
Augmentation Severity Rating Scale of the European RLS study group  
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1.2.3 Diagnosis 
According to the mentioned diagnostic criteria, the diagnosis of RLS is based 
primarily on the patient‟s history. Approximately 60-80% of all RLS cases are 
idiopathic (primary). However, it is necessary that secondary causes or RLS-
associated conditions are considered, and addressed where possible. Neurological 
examinations and neurophysiological examinations along with laboratory tests may 
be carried out to identify signs or symptoms of secondary RLS (Odin, Mrowka et al. 
2002). Such laboratory tests include: complete blood panel; renal parameters; iron, 
transferrin and ferritin levels. 
The diagnosis of RLS is based primarily on clinical criteria. Nonetheless, some of 
the following instrumental tools may be useful in doubtful cases, to confirm the 
diagnosis, or to aid in differential diagnosis. Instrumental diagnosis however is not 
commonly used to diagnose RLS (Zucconi and Ferini-Strambi 2004). 
Polysomnography (PSG) enables recording of PLMS and periodic/non-periodic leg 
movements during wakefulness, either before or after sleep onset. These movements 
may be detected by Electromyography (EMG) recordings, most commonly of the 
tibialis anterior muscle. It is advised that PLM scoring is carried out according to the 
American Sleep Disorder Association rules; per hour of sleep, a pathological value is 
defined as more than five PLM/hour of sleep (Chaudhuri 2003). In using the PSG for 
assessment it should be noted that not all patients with RLS have demonstrated a 
Periodic Limb Movement Index (PLMI) greater than five, PLMS are present in other 
sleep pathologies, and at least 30% of older people have a PLMS index greater than 
5 (Zucconi and Ferini-Strambi 2004) 
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Suggested immobilization test (SIT) is a new tool to evaluate the effect of 
immobility on sensory and motor symptoms. The patient attempts to maintain a 
seated posture without moving their legs for a 60 minute period, while the anterior 
tibialis EMG is again used to detect PLM. A PLM measure, along with 
quantification of the sensory symptoms, allows discrimination between RLS patients 
and controls (Michaud, Chabli et al. 2000). 
Actigraphy is a method used to monitor muscle activity during the night, using an 
ankle placed portable activity meter. It has certain advantages such as avoiding the 
need for laboratory studies, allowing monitoring in the patients home, and increased 
accuracy and sensitivity since recordings can be made over multiple nights. 
However, the majority of actigraphical devices cannot differentiate between PLM 
and other involuntary movements associated with apnoea (Hening, Walters et al. 
1999).  
Other methods used to evaluate RLS include: Singe Photon Emission Tomographic 
(SPECT), Position Emission Tomographic (PET), Magnetic Resonance Imaging 
(MRI) and functional MRI. 
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1.2.4 Co-Morbid conditions & Differential diagnosis 
The majority of RLS cases appear idiopathic, however a vast number of co-morbid 
conditions have been described in association with RLS. The majorities of these co-
morbid conditions, with a few exceptions, have an unknown relationship to RLS, and 
most likely represent coincidental occurrence.  
In recent years, several studies identified a higher prevalence of RLS in patients with 
migraine (d'Onofrio, Bussone et al. 2008). Migraine has been reported to have an 
association with poor sleep quality. It is uncertain if RLS is also associated with 
other primary headache disorders, however, it was found that the frequencies of RLS 
in patients with migraine were higher in those with tension type headaches or cluster 
headaches (Chen, Fuh et al. 2010). This study also demonstrated co-morbid RLS in 
migraine patients worsened sleep quality. It is thought that a shared underlying 
mechanism, related to the dopaminergic system, may account for the association 
between migraine features and co-morbid RLS. 
Contrary to co-morbidity issues, differential diagnosis should distinguish RLS from 
conditions related to movement as well as sleep disorders. Conditions that can often 
be confused with RLS include those with prominent sensory symptoms in the legs 
such as neuropathies (patients complaining of numbness, tingling or pain), nerve 
conditions due to compression (meralgia paraesthetica), and radiculopathies. Several 
other conditions relating to motor restlessness and /or sensory symptoms include: 
painful legs and moving toes with segmental and semi-continuous distal movements 
during wakefulness, continuing during sleep and not alleviated by movements; 
neuropathic pain syndromes not consistently associated with rest and sleep; akathisia 
(excessive movement) which does not correlate with rest or time of day, which may 
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result from medications such as neuroleptics or other dopamine blocking agents; 
perplexing restlessness associated with insomnia, anxiety and panic attacks; 
nocturnal leg cramps unrelated to sensory symptoms or the urge to move the legs 
during the evening or the day, and different from nocturnal myoclonus; and 
propiospinal myclonus which is associated with relaxed wakefulness and recognized 
by axial and diffuse myoclonic jerks (Chaudhuri 2003; Garcia-Borreguero, Odin et 
al. 2004; Zucconi and Ferini-Strambi 2004). Apart from PLMS, most forms of 
“myoclonus” are either shorter in duration, suppressed during sleep or have a very 
different periodicity (Montplaisir 2004). Vesper‟s Curse, which is the combination 
of mild underlying congestive heart failure and lumbar stenosis, often causes 
nocturnal pain in the lower limbs and should be regarded in the differential diagnosis 
(Stiasny, Oertel et al. 2002). The majority of these conditions may not present with 
an urge to move the legs, may be present throughout the day, and symptoms may not 
be consistently worse in the evening or at rest. Nonetheless satisfying the four RLS 
diagnostic criteria outlined above will typically distinguish RLS dysthesias from 
other types of leg discomfort. 
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1.3.5 Diagnostic rates 
With regard to the rates of diagnosing, the Dortmund Health Study, which was a 
population-based survey in Germany (n=1312), conducted face-to-face interviews in 
randomly selected individuals aged 25-75 years (Happe, Vennemann et al. 2008). 
They reported that the overall prevalence of people with a known doctor diagnosis of 
RLS was 2.3%; however, a further 6.5% fulfilled the four minimal criteria yet were 
not aware of their RLS. The overall prevalence was 8.8% in this sample, with a ratio 
of diagnosed:undiagnosed RLS of 1:3.  
In the European context, the lowest diagnostic rate for RLS was reported from the 
UK. In a general practice research database involving 1,516,692 individuals, the 
prevalence of RLS with a registered diagnosis of RLS was only 0.25%. Only 0.6% 
of these patients had received a prescription for levodopa or a dopamine agonists, 
while many were prescribed medications not effective in RLS (e.g. oxerutins and 
quinine)(Van De Vijver, Walley et al. 2004). These findings are further supported by 
the French epidemiological survey where 60% of the RLS affected individuals had 
previously received a vascular diagnosis (Tison, Crochard et al. 2005) and an Irish 
study reported that only 16.7% of RLS sufferers were diagnosed with RLS 
(O'Keeffe, Egan et al. 2007). Furthermore, these findings are supported by the RLS 
epidemiology, symptoms and treatment (REST) studies where patients with RLS had 
been given a diagnosis of lower back pain, depression, spinal problems, depression, 
anxiety, peripheral neuropathy and were transferred to psychiatrists, vascular 
surgeons and orthopaedics (Hening, Walters et al. 2004). 
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1.3 Epidemiology 
At least in Western countries, prevalence rates of RLS reveal this disorder as one of 
the most common neurological movement disorders. From the initial work of Ekbom 
to the end of the 1980s, a prevalence rate between 1 and 5% was estimated in the 
general population (Garcia-Borreguero, Odin et al. 2004). However, these studies 
were very limited and comprised of imprecise diagnostic criteria. Diagnostic criteria 
for RLS has provided data that is more detailed and population-based studies have 
shown that RLS affects 5 to 15% of the general population (Table 1.3). It has been 
noted however that prevalence estimates in the general population do not overlap 
across certain studies. Such discrepancies may be due to the different targeted patient 
population, the fluctuating course of initial symptoms and the numerous 
methodological tactics used such as telephone interviews, questionnaire surveys, 
direct observations and face-to-face interviews. It was found that in certain studies in 
western countries that used only the International Restless Legs Syndrome Study 
Group (IRLSSG) criteria the RLS prevalence rates ranged from 7.2 to 11.5% (Allen, 
Walters et al. 2005; Bjorvatn, Leissner et al. 2005). 
In Western countries there is a female preponderance ranging from 13-17% (Lavigne 
and Montplaisir 1994) to 13.8% (Rothdach, Trenkwalder et al. 2000). A number of 
factors have been considered in explaining this sex difference. Firstly, patterns of 
inheritance may be a reason for female dominance. There will be a disproportionate 
number of women with RLS if the transmission of RLS is sex-linked and 
compromises females. A second contribution to the increased numbers of women in 
treatment studies may be a result of a gender bias in co-morbid medical disorders. 
Depression, anxiety and other common psychological disorders have a higher 
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prevalence in women. Such disorders may intensify the symptoms of RLS 
(Rothdach, Trenkwalder et al. 2000), or provide a secondary cause for insomnia, thus 
increasing the likelihood of RLS being reported. A third reason for the gender bias 
may be related to the impact of RLS on sleep. The gender bias in sleep complaints 
with RLS correlates with the gender bias found in other forms of insomnia. It was 
therefore proposed that female subjects with RLS are more likely to have increased 
sleep disturbances than their male counterparts (Bentley, Rosman et al. 2006). 
Furthermore it has been shown that female preponderance may be related to parity. 
Interestingly, nulliparous women had the same risk for RLS as age-matched men, 
whereas the risk for RLS increased gradually for women with one child (OR, 1.98; 
95% CI, 1.25-3.13), two children (OR, 3.04; 95% CI;2.11-4.40), and three or more 
children (OR, 3.57;95% CI, 2.30-5.55)(Berger, Luedemann et al. 2004). 
While RLS can occur in all ethnic backgrounds, epidemiologic studies suggest ethnic 
variation. Asian studies reported a prevalence rate of 0.6% in a selected healthy 
general population 55 years of age and older (Tan, Seah et al. 2001). A similar low 
prevalence rate of 1.5% and <1% was also reported in Japan (Mizuno, Miyaoka et al. 
2005) and Singapore, respectively. Prevalence estimates also vary in Western 
countries; for example, prevalence is considerably higher in Norway (14.3%) than in 
Denmark (8.8%) (Bjorvatn, Leissner et al. 2005). Regional variations may be caused 
by environmental factors, awareness or the complex influence of variable genetic 
susceptibility. 
Prevalence of RLS also increases with age (Lavigne and Montplaisir 1994; Allen, 
Walters et al. 2005). RLS is often associated with diseases of middle to old age. 
However, assessments indicate that the onset of the syndrome may occur before the 
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age of twenty years in up to 43% of adult cases (Chaudhuri, Appiah-Kubi et al. 
2001). Thus far, no definite age of onset can be determined. Onset before 18 years of 
age has been reported (Walters, Hickey et al. 1996). However, children with RLS 
often describe symptoms that do not meet IRLSSG criteria but rather correspond to 
growing pains. One study, which used the newly established diagnostic criteria for 
RLS in children (Allen, Picchietti et al. 2003), concluded a prevalence rate of 5.9% 
in children (Kotagal and Silber 2004). Table 1.3 summarises the population 
prevalence studies which were carried out in recent years. 
Table 1.3: Population prevalence of RLS (Mata, Bodkin et al. 2006). 
Reference Population N/age Frequency Comments 
Ekbom (1960)  Sweden n=500 ~5% Healthy controls 
Strang (1967) Australia n=320 2.5% Relatives of P.D. 
Lavigne (1994) Canada  n=2019 0-15% Face to face interview 
Kageyama (2000) Japan n=4612 5-15% Questionnaire survey 
Rothdach (2000) Germany n=369 9.8% Face to face interview 
Berger (2004) NE 
Germany 
n=4310 10.6% Face to face interview 
Henning (2004) Europe & N. 
America 
n=23,052 11.1% Questionnaire survey 
Allen (2005) Europe & N. 
America 
n=15,391 2.7% Face to face interview 
Hogl (2005) N. Italy n=701 10.6% Face to face interview 
Bjorvtan (2005) Denmark n=2005 11.5% Telephone interview 
Hadjigeorgiou 
(2007) 
Central 
Greece 
n=3033 3.9% Face to face interview 
& physical examination 
Ulfberg (2007) Sweden n=1000 5.0% Telephone interview 
Happe (2008) Germany n=1312 8.8% Face to face interview 
(Lavigne and Montplaisir 1994; Kageyama, Kabuto et al. 2000; Rothdach, 
Trenkwalder et al. 2000; Berger, Luedemann et al. 2004; Hening, Walters et al. 
2004; Allen, Walters et al. 2005; Bjorvatn, Leissner et al. 2005; Hogl, Kiechl et al. 
2005; Hadjigeorgiou, Stefanidis et al. 2007; Ulfberg, Bjorvatn et al. 2007; Happe, 
Vennemann et al. 2008). 
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1.4 Pathophysiology 
The pathophysiologic basis of RLS has not been fully elucidated. However, multiple 
etiologies including abnormalities of the central and peripheral Nervous System 
(CNS and PNS), vascular, metabolic, and genetic components have been proposed 
(Chaudhuri, Appiah-Kubi et al. 2001). In determining the pathophysiology of RLS, 
the primary areas of interest may be divided into three main themes, CNS 
dysfunction, the dopaminergic system and iron insufficiency. The genetics of RLS is 
discussed separately (section 1.9). 
1.4.1 Localisation of CNS dysfunction in RLS 
One important cue to pathophysiology may be the immediate and almost complete 
therapeutic response of RLS to dopamine treatment (Hening, Allen et al. 1999; 
Hening, Walters et al. 2004). This indicates rather clearly that RLS results from 
abnormal functioning of the CNS rather than the PNS. Treatment with centrally 
active dopamine antagonists causes intensification of RLS symptoms and thus the 
reversal of the dramatic benefits from treatment. However, such a striking effect is 
not experienced when treated with a peripherally active dopamine antagonist (Allen 
and Earley 2001). Although it is clear that RLS dysfunction involves the CNS, the 
exact areas of the CNS involved are somewhat unclear. So far no structural 
abnormalities have been noted in MRI imaging. However, Bucher and associates 
localized for the first time cerebral generators associated with sensory leg discomfort 
and periodic limb movements in 19 patients with restless legs syndrome, using high-
resolution functional magnetic resonance imaging. It was therefore proposed that and 
thalamic activation may occur because of sensory leg discomfort and that the red 
nucleus and brainstem are involved in the generation of periodic limb movements in 
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patients with restless legs syndrome (Bucher, Seelos et al. 1997). These results 
correspond with the absence of a cortical prepotential in patients with RLS before 
they experience PLMS providing further confirmation of a subcortical site (Stiasny, 
Oertel et al. 2002). The subcortical dopamine systems, in particular, have been 
suggested as candidates given their involvement in sensory and motor regulation, 
including modulation of spinal activity. 
Transcranial magnetic stimulation studies have also found that, compared with 
controls, RLS patients show reduced intracortical inhibition for both foot and hand, 
as well as an increased cortical silent period without other changes. These findings 
also suggest abnormal (i.e., subcortical) functioning of the CNS (Bucher, 
Trenkwalder et al. 1996). 
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1.5 Dopamine Dysfunction in RLS 
Dopamine (DA) is a neurotransmitter that is involved in behaviours such as 
movement, motivaton, cognition, reward and feeding. Dopamine has various 
functions within the CNS, including regulation of sensory and motor functions. 
Dopaminergic systems have been connected with a number of movement disorders, 
such as Tourette‟s syndrome, Parkinson‟s disease and Huntington‟s corea. In 
addition, animal studies have supported suggestions that the dopaminergic system is 
involved in the regulation of sleep (Bagetta, De Sarro et al. 1988).  
1.5.1 Dopamine pathways 
Three dopamine pathways are seen in the central nervous system (figure 1.1). The 
first is the nigrostriatal DA pathway. It originates in the substantia nigra pars 
compacta neurons and targets dorsal striatum. It is thought to be involved in 
modulating movement. The second pathway is the mesocorticolimbic DA system, 
which originates in the midbrain ventral tegmental area (VTA) and targets the 
ventral striatum (nucleus accumbens), the limbic system, the hippocampus, the 
prefrontal cortex, and modulates cognition, emotion and reward. The third pathway 
is the tuberoinfundibular pathway which originates in the hypothalamic 
paraventricular and acuate nuclei and targets the anterior pituitary where is inhibits 
prolactin release.  
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Figure 1.1: Dopamine Pathways 
The three dopaminergic pathways; the nigrostriatal pathway which originates from 
the substantia nigra, the mesocorticolimbic pathway which originates from ventral 
tegmental area, and the tuberoindundibular pathway which originates from the 
hypothalamus 
(http://www.cnsforum.com/imagebank/item/Neuro_path_DA/default.aspx).  
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Tyrosine hydroxylase (TH) is the rate limiting enzyme in dopamine biosynthesis, 
which converts the amino acid tyrosine to 2,3-dihydroxyphenylalanine (DOPA). The 
conversion of DOPA to dopamine is catalysed by the enzyme DOPA decarboxylase 
(DDC) (figure 1.2). 
 
 
Figure 1.2. Dopamine Biosynthesis 
A diagram of dopamine biosynthesis from tyrosine 
(http://scienceblogs.com/neurotopia). 
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Dopamine is moved into vesicles by the vesicular monamine transporter (VMAT), 
after being synthesised. The vesicles fuse with synaptic membrane with the electrical 
firing of the neuron, thus releasing DA into the synaptic cleft. DA then acts on pre- 
and post-synaptic DA receptors. There are at least five subtypes of DA receptors; 
D1, D2, D3. D4 and D5. They are divided into D1-like (D1, D5) and D2-like (D2, 
D3, D4) classes. The D2-like receptors have a high affinity for DA and dominate 
while asleep when DA levels are low. On the contrary D1-like receptors have a low 
affinity for DA and function while awake (during the day). The dopamine transporter 
(DAT) is a membrane spanning protein which terminates dopamine action. This 
rapidly reuptakes DA into the pre-synaptic terminal. Catechol-O-methyltransferase 
(COMT) also terminates DA activity by degrading it into homovanillic acid. 
Similarly, monamine oxidase (MAO) has the ability to degrade dopamine to 
dihydroxyphenylacetic acid (DOPAC). 
  
22 
1.5.2 Evidence for the involvement of Dopamine in the 
pathophysiology of RLS 
Akpinar first suggested the dopaminergic deficiency theory of RLS in 1982. 
Pharmacologic and neuroimaging studies have subsequently provided evidence of 
the involvement of the central dopaminergic system, the striatonigral system 
particularly implicated.  
Parkinson‟s Disease (PD) 
RLS and Parkinson‟s disease (PD) both respond positively to dopaminergic 
treatments, both show dopaminergic abnormalities on functional imaging and are 
both associated with PLMS. RLS significantly improves with dopaminergic 
medications, usually at doses lower than those required to treat Parkinson‟s disease. 
Owing to the manner in which RLS responds to these medications, and observed 
coexistence within the same patients, an etiologic link between RLS and PD has 
been proposed. 
The phenomenon of rebound and augmentation in RLS patients is essentially similar 
to fluctuations in motor responses and dyskinesias that can be observed in PD 
following long-term levodopa treatment (Appiah-Kubi, Pal et al. 2002). Ondo and 
colleagues (2002) suggested that RLS is not a risk factor for developing PD, as they 
observed that PD symptoms preceded RLS symptoms in 68% of cases (Ondo, Vuong 
et al. 2002). The study found a high prevalence of RLS symptoms; however, it failed 
to address the matter of whether or not they occur more often in PD patients than in 
the general population. Another population-based study with a larger sample did not 
find parkinsonian symptoms among RLS patients (Rothdach, Trenkwalder et al. 
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2000). The prevalence of RLS in PD patients is similar to that of the general 
population (Appiah-Kubi, Pal et al. 2002). In PD, the olfactory function is abnormal 
whereas it is normal in patients with RLS, thus reflecting the integrity of the A16 
dopaminergic group (Adler, Gwinn et al. 1998). In addition, in patients with PD, an 
increase in total iron concentration in the Substantia Nigra (SN) was demonstrated 
by both pathologic and MRI approaches, but the opposite was demonstrated in RLS 
(Barriere, Cazalets et al. 2005). For these reason it has been suggested that the two 
diseases do not share the same pathophysiological mechanisms. Nonetheless, the 
positive response of RLS patients to dopmainergic treatments presents a strong 
argument in favour of the dopaminergic system involvement in the pathogenesis of 
RLS. 
1.5.3 Central Nervous System (CNS) 
Cerebrospinal fluid (CSF) 
The dopmaine system has also been explored by measuring the metabolites of 
dopmaine synthesis and the degradation of CSF. It has been suggested that the 
dopamine system is largely involved in the circadian pattern of RLS (Section 1.5.1). 
Lower dopamine and homovanillic acid levels in nocturnal urinary excretion have 
been found in subjects with PLMS. Larger circadian changes in CSF dopamine 
metabolites have been reported in RLS patients compared to controls: in patients, all 
metabolites were higher in the morning (at 10am) compared to the evening values (at 
10p.m.) values (Earley, Hyland et al. 2006). 
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Neuroimaging studies: 
Some positron emission tomography (PET) and single-photon emission computed 
tomography (SPECT) studies have suggested mild but significant pre- and post-
synaptic dopamine receptor abnormalities in the basal ganglia (Stiasny, Oertel et al. 
2002), while other studies contradict these findings (Allen, Picchietti et al. 2003). 
Furthermore several studies have shown decreased striatal dopmaine uptake and 
dopaminergic (D2) striatal binding in RLS patients, while results of other studies 
have not demonstrated differences on functional imaging in RLS patients compared 
with controls (Trenkwalder, Walters et al. 1999; Turjanski, Lees et al. 1999). PET 
studies on 13 patients with idiopathic RLS showed significantly decreased D2 
binding potentials in the caudate and putamen compared to controls (Michaud, 
Soucy et al. 2002). Similarly in a SPECT study the dopamine status was assessed in 
10 RLS/PLMS patients, and significantly lower striatal D2 binding was observed in 
patients compared to controls (Ruottinen, Partinen et al. 2000). Furthermore, 
fluorodopa PET studies of 9 patients with RLS showed a statistically significant, 
88% reduction in fluorodopa uptake in the caudate and an 89% reduction in the 
putamen compared to controls. These findings indicated striatal presynaptic and 
postsynaptic dopaminergic dysfunction in RLS (Trenkwalder, Walters et al. 1996). 
Differences in striatal dopamine transporter and dopamine D2-receptor binding on 
SPECT among 25 RLS drug-naive or L-dopa-treated patients and 10 controls could 
not be demonstrated in another study (Trenkwalder, Walters et al. 1999). Therefore 
brain-imaging studies of the dopmainergic system failed to reveal consistent 
abnormalities. Dysfunction of dopaminergic pathways other than the nigrostriatal 
axis, e.g the diencephalospinal system, may play an important role in the 
pathogenesis of RLS (Chahine and Chemali 2006).   
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1.5.4 Pharmocological evidence 
The strongest argument for a dopaminergic role in RLS is the excellent response to 
low-dose dopaminergic agents (DA) (Hening, Allen et al. 1999). To date, all 
evaluated agents that enhance dopamine activity in the body have been found to 
reduce RLS symptoms in open-labelled uncontrolled trials. Double-blind, placebo 
controlled studies have demonstrated the treatment benefit for Levodopa (Brodeur, 
Montplaisir et al. 1988; Trenkwalder, Stiasny et al. 1995) and for the currently used 
major dopamine agonists, i.e. pergolide (Wetter, Stiasny et al. 1999; Trenkwalder, 
Hundemer et al. 2004), pramipexole (Montplaisir, Nicolas et al. 1999) and ropinirole 
(Bliwise, Freeman et al. 2005). These medications are effective at remarkably low 
doses relative to that given for Parkinson‟s disease, often at the minimum tablet size 
available to the patient e.g. carbidopa/Levodopa at 25/100 mg or pergolide at 12.5 
mg (Allen 2004). Furthermore, they are effective immediately after the first 
therapeutic dose for almost all RLS patients. The immediate, universal and almost 
complete relief of RLS symptoms by low doses of Das provides strong support for a 
possible dopaminergic abnormality in this disorder. 
Reversal of beneficial effects of dopamine agonists by antagonists further support 
the role of dopamine. This was first reported in a study published in 1991, when 
Pimozide, a dopamine agonist was shown to reverse treatment benefits of the opioid 
Codeine in an RLS patient (Montplaisir, Lorrain et al. 1991). In a later study, 
Metoclopramide given intravenously produced RLS symptoms on a suggested 
immobilization test in five out of six subjects evaluated and produced an increase in 
prolactin release that was at least three times greater than that expected from age-
matched normals (Winkelmann, Schadrack et al. 2001).  
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1.6 Iron pathology in RLS 
The connection between iron deficiency and RLS was first proposed in the 1950‟s 
when intravenous infusions of iron were used for the treatment of RLS. Norlander 
reported that the creeping sensations in the legs of his patients ceased with iron 
therapy (Norlander 1953). Two years later in 1955, K.A. Ekbom discussed the 
relationship between RLS and iron deficiency when he described two male patients 
with malignancies that were severely iron deficient and also suffered from RLS 
(Ekbom 1955). Ekbom also noted that one in four of his RLS patients were iron 
deficient and that the RLS was increased among blood donors. This hypothesis of 
the relationship between RLS and low iron levels has prompted numerous studies 
into the role of iron in RLS. Investigations have shown a correlation between low 
body stores of iron and symptoms of RLS. 
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1.6.1 Evidence for the involvement of iron in the pathophysiology 
of RLS 
Pregnancy 
Pregnant women have a two to three times higher risk of experiencing RLS than the 
general population (Manconi, Govoni et al. 2004). In 11-27% of pregnant women in 
Western countries, RLS symptoms are reported, despite supplementation with iron 
and folate. In a Japanese survey, a similar prevalence rate of 19% was reported 
(Suzuki, Ohida et al. 2003). Those women affected by RLS were also found to have 
a lower haemoglobin level and lower average red blood cell size, or Mean 
Corpuscular Volume (MCV), than those who did not experience RLS symptoms. In 
2007, Tunc et al agreed that low iron levels were a risk factor for RLS in pregnant 
women. First signs and symptoms of RLS may only appear during pregnancy. 
However, pre-existing RLS is considerably exacerbated during pregnancy, mostly 
during the third trimester (Goodman, Brodie et al. 1988; Suzuki, Ohida et al. 2003; 
Manconi, Govoni et al. 2004). In the study carried out by Manconi and associates 
(2004), 16.7% of the women never experienced RLS symptoms before the 
pregnancy, whereas 9.9% had already experienced symptoms (Manconi, Govoni et 
al. 2004). In 2009 Dzaja et al found RLS to occur in some pregnant women during 
the third trimester, however this study concluded that transiently elevated Estradiol 
levels were responsible for triggering the RLS among this patient group (Dzaja, 
Wehrle et al. 2009). Notably, this study was conducted on a particularly small 
number of subjects, therefore analysis could not have fully assessed all of the factors 
influencing RLS symptoms. In 2008, Ghorayeb et al also discussed female hormonal 
changes as a factor in RLS symptoms severity, but on a larger number of patients, 
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and concluded that in those female patients with RLS, hormonal changes during 
pregnancy could not account for the worsening of symptoms (Ghorayeb, Bioulac et 
al. 2008). This study agreed with the findings by Manconi and associates that 
approximately 23% of women with RLS admitted worsening of symptoms during 
pregnancy and concluded that these changes in iron status could best explain these 
changes in symptom severity. Pregnancy related RLS is usually mild and transitory, 
with a tendency to disappear after delivery. One of the largest studies on RLS during 
pregnancy reported complete resolution of RLS in 96% of women 4 weeks after 
delivery (Goodman, Brodie et al. 1988). 
Uremia and End-stage renal disease (ESRD) 
One of the best-studied secondary causes of RLS is end-stage renal disease (ESRD) 
with dialysis. Reports found 62% of individuals with ESRD presented with mild 
RLS. Furthermore, prevalence rates of 20-25% were observed in patients with more 
severe RLS (Winkelman, Chertow et al. 1996; Hui, Wong et al. 2000). RLS 
symptoms with ESRD have been associated with increased mortality, with kidney 
transplantation resolving the renal disease and, also leading to complete resolution of 
RLS within 1-21 days after transplant (Allen 2004). Uremic patients who also were 
diagnosed with RLS had lower hemoglobin than those who did not have RLS 
(Takaki, Nishi et al. 2003). Moreover, RLS symptoms improved in patients on 
dialysis by regulation of anemia with erythroprotein and intravenous iron (Benz, 
Pressman et al. 1999). Another study linked low parathormone levels in uremic 
patients with RLS (Rijsman and de Weerd 1999). These studies show that it is the 
iron insufficiency associated with ESRD that produces the RLS symptoms. 
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Iron Deficiency 
Anaemic patients have been studied and oral iron suuplements has been found to 
improve RLS symptoms in some of these patients (O'Keeffe, Gavin et al. 1994). In 
2004, Earley et al showed successful treatment of 7 out of 10 RLS patients with IV 
iron treatment (Earley, Heckler et al. 2004). 
Other conditions which have been investigated include low-density lipoprotein 
apheresis (Tings, Schettler et al. 2004), and these studies agree with the hypothese 
put forward by Allen et al in 2007 that “all conditions that compromise iron 
availability will increase the risk of RLS leading to a higher than expected 
prevalence of RLS in these conditions” (Allen and Earley 2007). 
The hypothesis that iron status correlated with RLS symptom occurrence led to 
further studies of iron and how it affected RLS patients. 
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1.6.3 Peripheral Iron Status 
Ferritin generally provides a measure of iron storage, with low values indicating low 
iron storage. Serum ferritin reflects the levels of iron in the peripheral stores and 
CSF ferritin reflects the levels of iron in the brain stores. Similarly, transferrin 
provides a measure of the tissues need for iron ,where the serum transferring reflects 
the peripheral tissue‟s iron needs, and the CSF transferrin reflects the brain‟s iron 
needs. As the iron requirements of a tissue increase, the level of transferring found in 
the fluid associated with that tissue also increase. 
The serum ferritin values of patients believed to be iron deficient was compared to 
the iron status of their bone marrow in a study carried out by Guyatt and colleagues 
(Guyatt, Patterson et al. 1990). It was discovered that a serum ferritin of below 45 
µg/L indicated that the patients peripeheral iron stores were depleted. Nonetheless it 
is important to keep in mind that ferritin has phase-reactive properties and can give 
falsely elevated results. Therefore measurements of percentage transferrin saturation 
and total iron binding capacity (TIBC) are more useful for clinically determining 
iron store status. TIBC is a measurement of the maximum amount of iron that the 
blood can carry. In 2006 a double-blind controlled study found that for those RLS 
patients with low ferritin values oral iron treatment was successful in treating their 
symptoms , thereby agreeing with the 1994 study by O‟ Keeffe et al (O'Keeffe, 
Gavin et al. 1994), but disagreeing with the findings of the 2000 study by Davis et al 
(Davis, Rajput et al. 2000). This study by Davis et al, found no improvement of RLS 
symptoms following administration of oral iron, however the study did not include a 
sufficient number of patients with low serum ferritin. The American National Heart, 
Lung and Blood institute suggest that in RLS patients with a serum ferritin of less 
31 
than 50 µg/L, iron deficiency can be implicated in the syndrome (National Heart 
2000). Thereby in a 2004 study it was recommended that RLS patients with a serum 
ferritin of less than 50 µg/L should be considered for oral iron treatment (Silber, 
Ehrenberg et al. 2004).  
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1.6.4 Central Nervous System (CNS)  
Autopsy Studies 
Generally when cells are iron deficient they respond to this deficient state by 
increasing the quantity of Transferrin Receptors (TfR) on their surface, thereby 
increasing the chance that transferrin will bind to the cell and supply iron (Aisen, 
Enns et al. 2001). The ability to either increase or decrease the cells TfRs 
concentration is achieved by post-transcriptional regulation by two iron regulation 
proteins (IRPs); IRP1 and IRP2. 
Autopsy studies which have been performed so far have focused primarily on the 
substantia nigra. This is due to its dopmaine producing activity. These autopsy 
studies have demonstrated the following: 
a) Neuromelanin cells are the darkly pigmented neuronal cells present in the 
brain. These cells produce monoamine neurotransmitters e.g. dopamine. The 
neuromelanin cells of the substantia nigra are similar in density between the 
brains of RLS patients and those of controls (Connor, Boyer et al. 2003). 
b) Compared to the brains of control subjects, the neuromelanin cells of the 
substantia nigra of RLS patients have an increased concentration of Tyrosine 
Hydroxylase (Connor, Wang et al. 2004). 
c) In comparison to the brains of control subjects, iron concentration in the 
neuromelanin cells of the substantia nigra of RLS patients is decreased 
(Connor, Boyer et al. 2003). 
d) In RLS patient brains, IRP1 activity is decreased (Connor, Wang et al. 2004). 
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e) In RLS patient brains, IRP2 activity is normal/increased. (This may be a 
compensatory mechanism in response to the decreased IRP1) (Connor, Wang 
et al. 2004). 
f) In comparison to the brains of control subjects , the expression of the TfR on 
the neuromelanin cells of the substantia nigra of RLS patients is decreased, 
thereby consistent with the reduced activity of IRP1 (Connor, Wang et al. 
2004). 
g) Thy-1 is a T-cell protein which is expressed on some neuronal cells i.e. at the 
dopmainergic synapses (Morris 1985). The function of Thy-1 is believed to 
be in the association of pre-synaptic and post-synaptic membranes, and the 
fusion of vesicles to the pre-synaptic membrane (Jeng, McCarroll et al. 
1998). Thy-1 is responsive to iron status (Ye and Connor 2000). It is thought 
that a Thy-1 deficiency would lead to the decreased structural integrity of the 
cells on which it is expressed.  
It was found that Thy-1 expression is decreased not only in RLS brains but in 
models which were iron deficient. If this deficiency results in loss of 
structural integrity, this might explain why no morphological differences 
have been observed between the brains of RLS patients and controls, and the 
reason that RLS symptoms appear to improve with the treatment of 
dopmainergic agonists (Wang, Wiesinger et al. 2004). 
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Cerebrospinal Fluid (CSF) 
CSF was utilised for the indirect measurement of brain iron status. As previously 
mentioned, in iron deficiency, serum ferritin levels are usually low and serum 
transferrin levels high. In 2000, Earley and associates carried out a study which 
analysed the CSF concentrations of ferritin and transferrin in RLS patients (Earley, 
Connor et al. 2000). They discovered that CSF ferritin concentrations were low and 
transferrin levels were high, thus indicating brain iron insufficiency in RLS patients. 
In 2005 these results were further verified (Mizuno, Mihara et al. 2005).  
In the report published by Earley and associates in 2000, it was found that the CSF 
ferritin levels of the controls improved as their peripheral ferritin status moved closer 
to the normal 100 µg/L. However, the normal CSF ferritin concentrations observed 
in the control subjects with normal serum ferritin concentrations would only occur 
for the RLS patients with a serum ferritin of over 400 µg/L. This would be 
considered highly elevated in a normal population. Therefore one hypothesised that 
RLS patients had an impaired ability to get brain iron from peripheral iron, which 
could in turn be due to impaired iron transport in the brain and/or an impaired ability 
of the brain to retain iron.  
Neuroimaging Studies 
To date Neuroimaging studies include Magnetic Resonance Imaging (MRI) which 
measures the brain iron status; Positron Emission Tomography (PET) and Single 
Photon Emission Computed Tomography (SPECT), both which examine the 
dopaminergic system;.MRI studies have been performed to measure regional brain 
iron concentrations. These studies found that decreases in iron concentration in the 
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nigrostriatal areas correlate with RLS severity (Allen, Barker et al. 2001). The 
decrease in iron was most evident in patients with a severe form of RLS. This 
finding was confirmed in a large sample of subjects with early-onset RLS (Earley, B. 
Barker et al. 2006), as well as in other studies using a transcranial ultrasound method 
(Schmidauer, Sojer et al. 2005). A more recent MRI study showed that the decrease 
in brain iron insufficiency extended beyond the nigrostriatal areas, indicating that the 
iron deficiency was brain-wide, thus emphasizing the importance of correct 
interpretation of MRI results when assessing brain iron status (Lee 2007).  
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1.6.5 Role of Iron in the Dopaminergic Pathway 
Iron distribution in the brain is highly heterogenous and is higher in the 
dopaminergic regions such as the substantia nigra and striatum. The strong evidence 
of the role of iron deficiency and the role of the dopaminergic system raises the 
question of the relationship between iron and dopamine. There are two leading 
arguments indicating that decreased iron would lead to abnormal dopaminergic 
transmission (Krieger and Schroeder 2001). Firstly, iron is a known co-factor for 
tyrosine hydroxylase, a rate-limiting enzyme involved in the synthesis of dopamine. 
This enzyme catalyses the hydroxylation of troine into dihydroxyphenylalanine 
(DOPA) which is ultimately transformed into dopamine. The second is that iron is 
involved in the physiological regulation of the dopamine D2 receptor binding sites 
and the effect of iron deficiency is specific for these receptors, however, the exact 
mechanism remains to be resolved (Earley, Allen et al. 2000). Iron deprivation in 
rats results in a 40-60% reduction of D2 postsynaptic receptors, while dopamine 
type-1 receptors are not affected (Erikson, Jones et al. 2001). 
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1.7 Circadian Pattern of RLS 
RLS symptoms display a true circadian pattern, with an increase in both sensorial 
and motor symptoms occurring most frequently in the evening and at night. 
Typically, the untreated patient reaches a maximum symptomology between 11pm 
and 4am, with the symptoms being reduced between 6am and 12pm (Garcia-
Borreguero, Larrosa et al. 2002). Since the dopamine system is proposed to play a 
central role in the pathophysiology of RLS, it is likely that alteration in the circadian 
variation of the dopaminergic system or related compounds might account for RLS 
symptom fluctuations. For example, changes in melatonin secretion, as a maker of 
the circadian rhythm, preceed the increase in sensory and motor symptoms in 
patients with the syndrome (Trenkwalder, Paulus et al. 2005). Nevertheless, the 
circadian rhythymicity is overridden and symptoms are present 24 hours a day in 
patients with increased disease severity.  
In 2009, Sharifan et al published a study which investigated the relationship between 
shift work patterns and the occurrence of RLS. The study was conducted in an 
automobile manufacturing factory in Iran. During the study they noted that there was 
a greater percentage of antihitamanic and antidepressant drug consumption, a higher 
percentage of chronic disorders and a higher percentage of smokers among the RLS 
individuals than in controls. The study found that the prevalence of RLS was 
significantly higher in rotational shift workers (15%) than in worker with permanent 
morning work schedules (8.5%). Work during the night shift is much more likely to 
have adverse effects on health than work during morning or afternoon shifts because 
the circadian organisation of the body is disrupted. This indicates that the association 
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between rotational shift work and RLS is most likely mediated by disruption of 
circadian rhythmicity (Sharifian, Firoozeh et al. 2009).   
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1.8 Periodic Limb Movements during Sleep (PLMS) 
Periodic limb movements during sleep (PLMS) have been classically described as 
rhythmic extension of the big toe and dorsiflexion of the ankle, with occasional 
flexion at the knee and hip (Allen, Picchietti et al. 2003). PLMS may be 
accompanied by brief awakenings that result in sleep fragmentation and subsequent 
excessive daytime sleepiness. Diagnosis of periodic limb movements during sleep is 
based on the definition of the American Sleep Disorders Association (Trenkwalder, 
Paulus et al. 2005). These movements are measured by surface electromyography 
from the tibialis muscle and are scored only if they occur in a series of four 
consecutive movements lasting 0.5-5 s and recurring at intervals of 5-90 s. The 
muscle contractions must have amplitude of at least 25% of the toe dorsiflexion 
during calibration. An index (number of PLMS per hour of sleep) greater than five 
for the entire night is considered pathologic.  
The presence of PLMS in patients with RLS was first documented in 1965, and was 
originally called “nocturnal myoclonus”. Since then, several studies have been 
carried out, and it was estimated that about 80% of patients with RLS have periodic 
limb movements during sleep (Montplaisir, Boucher et al. 1997). A recent study 
carried out by Boehm et al., (2008) characterised PLMS and their association with 
sleep disturbances in RLS patients and healthy controls without sleep complaints 
(Boehm, Wetter et al. 2008). Measures of PLMS showed that the RLS patients have 
a significantly longer mean duration of single PLM during wakefulness and non 
rapid eye movement (NREM) sleep. For future studies this mean duration of single 
PLM might be an appropriate parameter to discriminate between RLS patients and 
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healthy subjects with PLM. Decreased sleep efficiency was associated with a higher 
number and shorter duration of PLM sequences (Boehm, Wetter et al. 2008). 
It should be emphasized that RLS remains a distinct clinical diagnosis. However, 
PLMS occur frequently in several other sleep disorders, including narcolepsy, rapid 
eye-movement sleep behaviour disorder, and obstructive sleep apnoea; as well as an 
isolated occurrence (Trenkwalder, Paulus et al. 2005). PLMS also appear more 
abundant among the elderly, possibly indicating a general aging process. Therefore, 
although the presence of PLMS is not specific to RLS, an elevated PLMS is 
supportive of the diagnosis of RLS. Effective treatments for RLS generally decrease 
episodes of PLMS. 
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1.9 Genetics of RLS 
1.9.1 Familial Aggregation 
Primary (genetic or familial) RLS may be difficult to distinguish from RLS 
associated with uraemia, iron deficiency, neuropathy, or other disorders (secondary 
RLS). Ekbom first described the familial component of RLS in 1945, estimating the 
frequency of hereditary RLS compared to sporadic cases as „one-third‟ (Ekbom 
1945). In 1960, Ekbom also reported that 49 out of 112 unselected probands with 
severe, typical RLS knew of one or several close relatives with creeping sensations 
in their legs (Ekbom 1960). Since then many studies have been published on the 
substantial genetic contribution in the aetiology of this sleep disorder. Clinical 
surveys have shown that up to 60% of idiopathic RLS patients report a positive 
family history (Walters, Hickey et al. 1996). Furthermore, RLS is 3-5 times greater 
amongst first degree relatives of subjects suffering from RLS than relatives of 
subjects without RLS. Clinical manifestations and the course of the disease appear 
similar in familial and sporadic cases (Winkelmann, Wetter et al. 2000). However, 
familial RLS undoubtedly correlates with an earlier age at onset, a much slower 
progression of symptoms, and a limited relation to serum iron status in contrast to 
late-onset RLS patients (Walters, Hickey et al. 1996; Allen and Earley 2000). 
One of the best methods for evaluating the genetic and environmental contributions 
to a disease is twin study. Two twin studies have been published to date (Ondo, 
Vuong et al. 2000; Desai, Cherkas et al. 2004). One study examined twelve pairs of 
monozygotic (MZ) twins in which both members of ten pairs had definite RLS based 
on the IRLSSG criteria. The high concordance rate suggested, similar to other 
investigations, an autosomal dominant mode of inheritance with a high penetrance. 
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Despite this, however the symptom descriptions and age of symptom onset varied 
markedly (Allen and Earley 2001). Desai and associates evaluated RLS symptoms in 
933 MZ pairs and 1004 dizygotic (DZ) pairs. Concordance rates were found to be 
61% and 45% respectively (Desai, Cherkas et al. 2004). 
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1.9.2 Pattern of Inheritance 
Pattern of inheritance or mode of inheritance, refers to the way in which genes are 
passed down from generation to generation. By analyzing the pattern of inheritance, 
the relative risk for and penetrance of an illness can be estimated. An autosomal 
dominant mode of inheritance with variable expressivity was suggested following 
several investigations of single families with RLS (Walters, Picchietti et al. 1990; 
Trenkwalder, Seidel et al. 1996). The possibility of anticipation – i.e. the disease 
starts earlier with each new generation – has been described in three large pedigrees 
of familial RLS. In 1996, Trenkwalder et al., (1996), demonstrated evidence of 
anticipation in one large German pedigree. In this German kindred which included 
20 affected members, the mean age of onset fell from 51.5 years in the second 
generation to 19.8 years in the fourth generation (ANOVA, p = 0.025) (Trenkwalder, 
Seidel et al. 1996).  
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1.9.3 Linkage studies 
To identify the gene(s) involved in a disorder the most powerful method is pedigree 
analysis. This involves using linkage statistics to compare the distribution of disease 
inheritance in high-risk families with the inheritance of a specific chromosomal 
region (locus) and disease-causing gene mutations. Linkage studies typically use 
polymorphic microsatellite repeat markers, spaced evenly at about 10 cM (10 Mb) 
intervals. A likelihood of ~3.3 (described in section 1.12), at or adjacent to a marker 
in a genome wide study, is considered significant evidence that a disease and a 
chromosomal region co-segregate within a family (P-value <0.05). Linkage studies 
in families with RLS have identified ten loci that are associated with RLS, however 
no causal sequence variant has yet been recognised. 
The first major susceptibility locus for RLS was identified in a French-Canadian 
family in 2001 (Desautels, Turecki et al. 2001). About 380 genetic makers spaced 
throughout the genome, were analysed in 25 individuals (14 affected, 4 at risk and 7 
healthy). The locus was found on the long arm of chromosome 12 and connected 
with a series of adjacent microsatellite markers with an autosomal recessive mode of 
inheritance. The linkage was followed up by a study of 276 individuals from 19 
families. Five of these lineages, which had a French-Canadian origin, were 
consistent with the chromosome 12q linkage. The results also indicated the presence 
of other loci involved in this disorder due to six of the larger pedigrees not 
demonstrating any linkage to chromosome 12 (Desautels, Turecki et al. 2005). 
Furthermore a linkage signal was found in the Icelandic population (D.B. Reye 
2005), and in a number of German families using the transmission disequilibrium 
test (Winkelmann, Lichtner et al. 2006).  
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Almost two years later, a second locus was identified on chromosome 14. In this 
study, 24 individuals (13 affected) in a large family from Northern Italy were 
genotyped for 382 polymorphic microsatellite markers. Five potential candidate loci 
were recognized. However, only a locus on chromosome 14 remained significant 
following the incorporation of more markers and increasing the number of 
individuals analysed. An autosomal dominant model was obtained, with variable 
penetrance depending on whether patients have periodic limb movements with or 
without RLS symptoms. The locus, which spans 9.1 cM on chromosome 14, 
contains at least 60 genes (Bonati, Ferini-Strambi et al. 2003).  
In 2004, Chen and associates identified significant linkage to a third locus on the 
short arm of chromosome 9 (Chen, Ondo et al. 2004). In this investigation, 15 
multiplex American families were genotyped for more than 400 markers and 
significant linkage to a third locus was found in two of the larger families. Chen and 
colleagues (2004) used an autosomal-dominant model-based analysis for this study. 
This study represented the first model-free linkage analysis used to genetically 
dissect RLS. The locus spans 34.43 cM and is located on chromosome 9p24-22. 
In 2005, a large Irish family with autosomal dominant RLS was studied with the 
subsequent identification of a novel locus on chromosome 5q. Microsatellite markers 
spaced throughout the genome were analysed in 29 family members (12 affected). A 
genome scan for linkage was performed. Recombination events in two of the 
affected family members defined the flanking markers, thus placing the locus in an 
11.5cM region. This interval is 16.8Mb long and contains approximately 120 known 
or predicted genes. The authors also highlighted four candidate genes for mutation 
analysis. These genes included the neurolysin (NLN) gene, which is involved in 
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central dopaminergic regulation; the CART gene involved in the regulation of 
dopamine levels; the HTR1A gene that encodes the 5-hydroxytryptamine (serotonin) 
receptor; and the PMCHL2 gene, which exhibits diurnal variation and is active 
during certain phases of sleep (Parfrey et al., 2006). 
In 2006, Levchenko and associates reported the first autosomal dominant locus in the 
French-Canadian population, mapping to chromosome 20p13. Desautels et al., had 
previously described an RLS locus in a French-Canadian population, but  under an 
autosomal recessive model. Genomic DNA from fifty-six members of this French-
Canadian family was used, and investigators performed a 10-cM genome-wide scan 
using a panel of 377 microsatellite markers. The chromosome 20 candidate region is 
flanked by the telomeric end of chromosome 20p and by a 0.56cM interval between 
markers D20S849 and D20S835. This region spans approximately 16cM or 5.2 Mb 
containing 84 annotated genes (Levchenko, Provost et al. 2006).  
Later that same year Pichler et al., (2006) published a paper in The American Journal 
of Human Genetics providing strong evidence for the identification of a new 
susceptibility locus for RLS at 2q33. An isolated population in the South Tyrolean 
Alps was identified and 530 adults took part in the study, 37 of which were 
identified with having idiopathic RLS. A 4-cM genome-wide linkage scan was 
performed on the DNA from all the 530 participants and the data was analysed using 
both nonparametric and parametric analysis. A shared disease haplotype from two of 
these families defined a candidate region of 8.2 cM on chromosome 2q. This study 
illustrates the use of isolated populations i.e. the western Alps of South Tyrol (Italy), 
where there are few founders, expansion is slow, traditional lifestyle has been 
maintained, and historical documents are highly available and accessible. The use of 
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such population can reduce genetic complexity and potentially the environmental 
heterogeneity (Pichler, Marroni et al. 2006). 
Two loci were identified in a single RLS family on chromosome 4q and 17p under 
the assumption of an autosomal-dominant model (Winkelmann J 2006). A genome-
wide linkage analysis was conducted on a large RLS family of German origin. Two-
point linkage analysis of this pedigree revealed a LOD score of 2.3 and 2.1 and a 
multipoint LOD score of 3.08 and 2.78 on chromosome 4 and 17 respectively. The 
disease associated region on chromosome 4 was refined between D4S406 and 
D4S402, defining a 8.4 Mb (7.39 cM) region. The disease associated region on 
chromosome 17 was located between markers D17S1857 and D17S1294, thus 
defining a 9.05 Mb (7.73 cM) region. The latter finding was replicated in an 
independent family-based linkage study of 159 RLS trios from 8 European countries. 
A novel locus for RLS on chromosome 16p12.1 was reported by Levchenko and 
colleagues in October 2008 (Levchenko, Montplaisir et al. 2008). The locus was 
identified in a French-Canadian family and supporting evidence of linkage was 
presented in a smaller pedigree of similar origin. An overall candidate region of 1.18 
Mb was revealed. This region was divided in two linked regions of ~850 kb and 350 
kb each by an uncommon and rare double recombination in one individual. It was 
hypothesized that this recombination may have taken place in the situation of 
genomic rearrangement, e.g. duplication, therefore it was decided to follow with a 
karyotype analysis and copy number variation (CNV) analysis. Both analyses 
showed that the region has a normal chromosomal region. Furthermore, no disease-
causing variants were uncovered following sequencing of eight positional candidate 
genes (Levchenko, Montplaisir et al. 2008).   
48 
Kemlink and associates (2008) provided suggestive evidence for a new susceptibility 
locus for RLS on chromosome 19p. A genome-wide linkage study was conducted in 
a large RLS family of Italian origin with 12 affected members in 3 generations. 
5,861 SNPs were used initially, and 13 additional microsatellite markers on 
chromosome 19p and 7 markers on chromosome 10p were subsequently genotyped 
to confirm the SNP genotyping and to reduce the candidate regions. The genome-
wide scan resulted in suggestive linkage on chromosome 19p with a maximum 
multipoint logarithm of the odds score of 2.61. Although this value is below the 
threshold typically used for a Mendelian trait (i.e., a LOD > 3), Kemlink and 
associates did not observe a simulated result above this threshold. This may be due 
to the small pedigree used for the study. To confirm linkage to chromosome 19p, the 
locus was replicated in a family-based association study in a set of 159 trios of 
European origin. This study presents a further susceptibility locus for RLS mapped 
within a 1.90 cM (0.3 Mbp) interval between D19S429 and D19S915. Two 
candidate genes, RAB3A and KCNN1 were subsequently chosen based on location 
and the believed pathophysiogy of RLS. However, no mutation was identified 
(Kemlink, Plazzi et al. 2008).  
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1.9.4 Molecular genetic studies 
Few molecular genetic studies have been undertaken to determine genes that 
predispose to RLS, despite the many reports that have been published suggesting a 
genetic contribution.  
In the studies that were performed, emphasis was put on the genes encoding for the 
GABA A receptor subunits and the gene for the alpha1 subunit of the glycine 
receptor (Winkelmann and Ferini-Strambi 2006). However, no significant findings 
were reported. 
Desautels and colleagues (2002) investigated the role of Monoamine Oxidase (MAO) 
A and B genes in association with the RLS phenotype. Females were found to have 
high activity alleles, consequently resulting in an elevated MAO-A activity. It was 
concluded that an elevated MAO-A activity would lead to an increased 
dopaminergic catabolism and cause a reduction in synaptic levels of this 
neurotransmitter. It is postulated that the high activity of the MAO-A gene may 
represent a modifying factor in the severity of the RLS manifestation. Estrogens may 
in turn interact with specific MAO alleles (Desautels, Turecki et al. 2002). The 
involvement of the dopaminergic system in the etiology of idiopathic RLS has also 
been suggested. Eight relevant candidate genes involved in metabolism and 
dopaminergic transmission were examined in a study. The study was carried out on 
92 patients and 182 controls; however, no significant difference was established in 
the genotypic or allelic distribution between the two groups. Nonetheless, the 
significance of the dopaminergic system in the pathogenesis of RLS has not been 
ruled out. Other loci implicated in the dopaminergic system remain to be studied 
(Desautels, Turecki et al. 2001).  
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1.9.5  Genome-wide Association Studies 
Association studies compare the frequencies of alleles in case and control 
populations. A higher frequency of the allele tested in the cases is accepted as 
evidence that the allele or genotype is associated with an increased risk for the 
disease.  
In 2007, Stefansson et al., reported the results of a genome-wide association study in 
an Icelandic discovery sample of patients with RLS and PLMS. The study revealed 
that one single nucleotide polymorphism (SNP) in the BTB (POZ) domain-
containing 9 (BTBD9) gene was associated with RLS. This association was 
replicated in a second smaller sample from Iceland and a United States sample. It 
showed that the discovery originated form a subgroup of patients with RLS who 
presented with PLMS. The absence of such an association for RLS without PLMS 
suggests that a genetic determinant of PLMS has been identified. Furthermore the 
serum ferritin levels were decreased by 13% per allele of the at-risk variant (95% 
confidence interval, 5 to 20; p=0.002). This inverse correlation of the variant with 
iron stores is consistent with the suspected involvement of iron reduction in the 
pathogenesis of the disease (Stefansson, Rye et al. 2007). 
Also in 2007, Winkelmann et al. performed a similar analysis for patients with RLS 
who were of European decent. A total of 236,758 SNPs were used for the first stage 
of the study. For stage 2, 13 SNPs (based on P value) and 15 neighbouring SNPs, 
were replicated in a German and French-Canadian case/control sample.  The study 
highlighted SNP associations in four genes in three chromosomal loci; MEIS1, 
BTBD9 and MAP2K5/LBXCOR1.  The second region mentioned here is interesting 
as it confirms the association with BTBD9 found also by Stefansson et al.,(2007).  
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BTB stands for broad complex, tramtrack and bric a brac, genes that in Drosophila 
melanogaster are required for embryonic development, cell fate determination in the 
eye and pattern formation in the limbs. In humans, BTBD9 is widely expressed in 
parts of the brain, such as the amygdala, cerebellum, hippocampus, and caudate and 
subthalmic nuclei, and in other organs, such as the heart, kidneys, pancreas and liver. 
The BTBD9 protein is not well characterised, and its function has not yet been 
determined (Winkelmann, Schormair et al. 2007).  
Further analysis was carried out in the Mayo clinic in 2008, and genotyping was 
carried out on 11 SNPs spanning all three reported loci for disease susceptibility. The 
subjects used in this study consisted of 244 patients with RLS and 497 controls. 
Statistical analysis verified the association with MEIS1 and BTBD9 genes but 
showed only a trend for variants in MAP2K5/LBXCOR1 and RLS. The odds ratio for 
the associated risk alleles ranged from 1.8 to 2.9 for BTBD9 and from 2.6 to 3.7 for 
MEIS1. It is interesting that MEIS1 was not detected in the original study of the 
Icelandic population, given the magnitude of the results. There could be many 
reasons for this such as, the use of different genotyping platforms or the diversity 
between populations (Vilarino-Guell, Farrer et al. 2008). 
Furthermore, Kemlink and associates investigated if these three variants, which had 
been previously identified in German and Canadian RLS cases, were relevant among 
other European (Czech, Austrian, and Finnish) RLS cases (Kemlink, Polo et al. 
2009). The study proved that these three loci present consistent disease risks in 
patients of European descent. Therefore these genetic determinants, observed in 
BTBD9, MEIS1, and MAP2K5/LBXCOR1, are risk factors for RLS in multiple 
populations. The study also found that BTBD9 was the most consistent in its effect 
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on RLS across populations and was also more independent of familial clustering 
than the other two variants. 
The genome-wide association studies that were carried by Winkelmann and 
associates and by Steffansson and colleagues (2007) identified four genes in total. 
However none of these genes are located in any of the previously described linkage 
regions for RLS. Schormair et al., (2008) analysed the five known loci (RLS1- 
RLS5) in a genome-wide association study, which resulted in significant signals in 
RLS3 on 9p23-24. From this 31 Mb region (9p, 0.5-31.5 Mb), an association study 
with 3,270 SNPs was carried out. For the exploaratory genome-wide scan, 628 RLS 
cases and 1,644 population-based controls were genotyped from the KORA-S3/F3 
study, as previously used by Winkelmann et al., 2007. Of the 3,270 SNPs analysed 
in RLS3, 8 SNPs passed the criterion for replication. In the replication phase, these 
SNPs were genotyped in German, Czech, and Canadian samples. Two independent 
SNPs (rs4626664 and rs1975197) in the 5‟ UTR of splice variants showed highly 
significant P values. The association signals were located 0.41 Mb apart and mapped 
to introns 8 and 10 of protein tyrosine phosphatase receptor type delta (PTPRD) 
gene within two separate linkage disequilibrium (LD) blocks. Several PTPRD 
mRNA isoforms are expressed in developmental and tissue-specific manner. Both 
RLS-associated SNPs are located within the 5‟UTR, which consists of ten noncoding 
exons contained in two known long splice variants expressed predominantly in fetal 
and adult brain tissue. The involvement of PTPRD in RLS remains unknown. These 
two RLS-associated SNPs are common. Rare alleles with strong effects within this 
gene that could explain the linkage signal were not detected (Schormair, Kemlink et 
al. 2008). 
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To further identify genes related to RLS Winkelmann and associates (2008) 
performed another association study. This time they carried out a three-stage 
association study in two Caucasian RLS case-control samples, which contained 918 
independent cases and controls. In the first stage (explorative study), 1536 SNPs in 
366 genes in a 21 Mb region encompassing the RLS1 critical region on chromosome 
12 were screened. Three genomic regions were identified which were significant (P 
< 0.05). The second stage (the replication stage) consisted of genotyping the most 
significant SNPs of stage 1. Following correction for multiple testing, an association 
was found with SNP rs7977109. This SNP is found in the neuronal nitric oxide 
synthase (NOS1) gene. In addition to the five SNPs typed in the first two stages, an 
extra 29 SNPs were used for fine mapping the NOS1 gene in the third and final 
stage, thus further confirming the significant association results to NOS1. Nitric 
oxide synthase action in the CNS has been associated with pain perception as well as 
the control of sleep regulation. Nitric oxide (NO) performs as an intracellular 
messenger in the CNS, and moreover the NO-arginine pathway is intimately 
connected to the modulation of the dopaminergic transmission. A positive response 
to dopaminergic agents supports the diagnosis of RLS. The pathophysiology of the 
disorder is thought to be related to an alteration of the dopaminergic neuro-
transmission. A relationship between the opioidergic system and NO could also be 
relevant in the pathophysiology of RLS. In conclusion this study provides indication 
for an association of variants in the NOS1 gene and RLS, and points to the 
involvement of the NO-arginine pathway in the pathogenesis of RLS (Winkelmann, 
Lichtner et al. 2008).  
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1.10 Management 
The high prevalence of RLS does not necessarily mean that all patients with RLS 
should be treated with pharmacological therapy. Patients with sporadic or only mild 
symptoms who do not suffer from considerable impairment are unlikely to require 
pharmacological treatment. The proportion of such patients within the whole RLS 
population is currently the subject of ongoing studies. According to previous studies 
it is estimated that approximately 2-3% of the population have RLS that is severe 
enough to merit treatment (Trenkwalder, Hogl et al. 2009). The latest 
epidemiological study from Germany reported that among 1312 individuals the 
prevalence of RLS was 8.8%; and only 1.6% of the study population wanted 
treatment. Unfortunately, there is no data available for mild to intermittent RLS and 
its response to treatment. Before beginning pharmacological treatment, it is 
important that sleep hygiene measures be suggested, and that all causes of secondary 
RLS, such as iron deficiency, be ruled out.  
1.10.1 Nonpharmocological Treatments 
Behaviour therapy- Many physicians recommend certain lifestyle changes and 
activities to reduce or eliminate symptoms. Researchers have found that alcohol, 
tobacco, and caffeine may aggravate or trigger symptoms in RLS patients. Decreased 
use or elimination of such substances may relieve symptoms. Physicians suggest a 
program of regular moderate exercise. A small randomized controlled trial of 23 
patients illustrated improvement in symptoms of RLS with a program consisting of 
lower body resistance training and aerobic exercise (Aukerman, Aukerman et al. 
2006). Some patients also benefit from hot or cold baths, whirlpool baths, 
acupuncture, chiropractic therapy, stress/relaxation therapy, and mental alerting 
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activities such as math/computer work. More recently, advances in additional 
psychotherapeutic interventions have been described and are presently under 
investigation (Hornyak, Grossmann et al. 2008).  
Iron supplementation – Treatment of RLS should initially be directed toward any 
underlying illness, if possible. For example, clinicians should consider determining 
the serrum ferritin levels in RLS patients, especially those with a history of 
gastrointestinal blood loss, frequent blood donation or menorrhagia. A serum ferritin 
concentration lower than 45 to 50 μg/ml has been observed in patients with increased 
severity of RLS (O'Keeffe, Gavin et al. 1994; Sun, Chen et al. 1998). If the serrum 
ferritin level is low, or percent iron saturation is low, replacement treatment is 
recommended.  
Transcutaneous Electric Nerve Stimulation (TENS) - TENS is a non-invasive 
pain control treatment, which involves applying electrical stimulation to an area of 
the feet or legs. A session typically lasts from five to fifteen minutes and treatment 
may be applied as often as necessary depending on the severity of the pain.  
Clinicians should also consider if certain medications (e.g. antidepressants, 
neuroleptic agents or dopamine-blocking antiemetics) are associated with initiation 
or worsening of RLS. Discontinuation of such medication should be considered, 
ensuring no harm is caused to patients. 
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1.10.2 Pharmocological Treatment 
If pharmacological treatment is necessary, the medication that is initially selected is 
based upon individual‟s specific RLS symptoms. It is recommended that medications 
should be initiated at a low dose and be taken an hour or two before bedtime, thus to 
allow sufficient absorption and commencement of a reaction. If symptoms cause 
awakening during the night, additional doses can be taken. To prevent development 
of tolerance to one drug, monthly rotation of two to three drugs may be effective. In 
severe cases, a combination of drugs may be favorable. It is important to recognize 
that a variety of medications may be prescribed and eventually discontinued before 
the most effective drug(s) – and the suitable dosage level(s) - are determined. It is 
accepted that dopamine is the neurotransmitter most closely associated with the 
pathophysiology of RLS based on the class effect of levodopa (L-dopa) and 
Dopamine Agonists against RLS symptoms Generally, physicians chose from 
dopaminergics, dopaminergic agonists, opioids and benzodiazepines.  
Dopaminergics – The first-line drug for most RLS patients are dopaminergic agents, 
which are largely used to treat Parkinson‟s disease. Treatment with levodopa plus 
carbidopa, have received positive results when used for RLS that occurs 
intermittently in the evening, at bedtime, or during specific activities such as airplane 
or lengthy car journeys. Studies have consistently shown that Levodopa reduces 
PLMS and nocturnal RLS symptoms (Stiasny, Wetter et al. 2001). For maximal 
absorption, it is recommended that levodopa be not taken with high-protein foods.  
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The manifestation of augmentation and rebound are the two most frequently 
encountered problems associated with Levodopa treatments.  
Rebound refers to the appearance of symptoms at a time coinciding with the end of 
the half-life period of the drug. The recurrence of RLS in the early morning occurs in 
20% to 35% of patients taking levodopa (Hening, Walters et al. 1999; Hening, 
Walters et al. 2004).  
Augmentation is the most important complication of dopaminergic therapy. It 
involves earlier onset of RLS symptoms during the day, commencement of 
symptoms during the day, an involvement of other body parts such as the arms, an 
increased severity, or a shorter latency to the beginning of RLS symptoms while at 
rest (Allen and Earley 1996). Up to 70% of patients, taking levodopa daily will 
develop augmentation, and the risk increases with daily doses of 200 mg or more. 
Augmentation, however, can start soon after therapy is begun or not until months or 
years later. The mechanisms causing the development of augmentation are still 
unknown. The main hypothesis is that a dopaminergic overstimulation of the striatal 
dopamine D1-receptors may play a role (Paulus and Trenkwalder 2006). Low serum 
ferritin levels may also enhance the symptoms of RLS (Trenkwalder, Hogl et al. 
2008). Furthermore, regardless of the difficulty of comparing augmentation rates 
from different studies it has become evident that higher dopaminergic doses must be 
considered as a risk factor for augmentation (Allen and Earley 1996). 
Tolerance to treatment has been described in some cases of dopaminergic therapy. It 
is the loss of therapeutic efficacy of an RLS treatment that had previously been 
efficacious. 
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Punding refers to an intense fascination with complex, stereotypical, purposeless, 
and repetitive behaviours e.g. sorting and hording of objects, cleaning and grooming. 
It has been previously described in high-dose psychostimulant users and patients 
with PD on dopamine agonists or levodopa. In October 2008, Evans and associates 
described two individuals with RLS who were treated with dopamine agonists and 
developed punding along with a variety of impulse control disorders (ICDs). 
Nevertheless, patients treated with agonists for RLS generally show a predisposition 
to punding (Evans and Stegeman 2009). Further studies are needed to fully evaluate 
punding and other ICDs with regards to RLS.  
Dopaminergic Agonists stimulate dopaminergic receptors. Generally, agonists 
which do not cross the blood-brain barrier have peripheral effects and agonists which 
penetrate well into the brain have mainly central effects. Agents such as mesylate, 
pramipexole, and roprinirole hydrochloride have proved to be effective in some 
patients. Although augmentation may be observed in some patients, it does not 
appear to be a major problem (Odin, Mrowka et al. 2002). 
Pergolide mesylate (Permax) is a potent, long acting dopamine agonist, which has 
been proven effective in RLS (Walters 1995). Pergolide was found to deliver better 
subjective relief and greater decreases in PLMS when compared with Levodopa 
(Staedt, Wassmuth et al. 1997). It was also found to be effective in patients who are 
unresponsive to levodopa (Earley and Allen 1996). However, some patients taking 
pergolide to treat the symptoms of Parkinson‟s disease have been shown to develop 
valvular heart disease, even though this is usually associated with higher doses than 
those used in RLS (Van Camp, Flamez et al. 2004). 
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Pramipexole (Mirapex) is a D3 and to a lesser extent a D2 dopaminergic receptor 
agonist. According to experimental studies, Pramipexole could have a 
neuroprotective effect. It can induce various adverse effects which include 
hallucinations and sudden onset of sleep. A recent study by Inoue and associates, 
was performed to evaluate the safety and efficacy of the long term use of 
Pramipexole in patients with primary RLS. The study was carried out in a cohort of 
141 Japanese patients. The IRLS score improved from 22.3 +/- 4.7 to 11.1+/-7.7 at 
week 8 and 4.9+/-5.9 at week 52. Adverse events were typical of nonergot 
dopmamine agonists, mild in intensity, and decreased in frequency as the study 
progressed. RLS augmentation was not observed. Overall the study found that 
Pramipexole showed good efficacy, particularly in patients with an IRLS total score 
<20 (Inoue, Kuroda et al. 2010). 
Bromocriptine mesylate (ParLODel), which was first reported in 1988, was reported 
to decrease PLMS and provide subjective relief in RLS patients.  
Cabergoline (Dostinex) is an ergot derivative, and a rather selective D2 receptor 
agonist. It is the strongest acting dopamine agonist available, with a half-life of at 
least 65 hours. It has the advantage of giving a 24-hour effect, which is useful for 
reducing/preventing the effects of augmentation.  
The action of dopamine agonists does not commence for 90 to 120 minutes after 
ingestion; thus, these agents cannot be used effectively once symptoms have started. 
In addition, agonists can cause nausea; therefore, slow dosage increase is important, 
especially for pergolide. 
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Opioids – These agents are usually recommended for the treatment of more severely 
affected patients, patients who are unresponsive to other medications or the 
uncommon patient with pain as a prominent symptom (Clark 2001). Although never 
formally investigated in large scale trials, opioids are often used following 
unsuccessful treatment with dopaminergic agents. Low-potency opioids include 
codeine and propoxyphen, and have proven to benefit patients with mild or 
intermittent symptoms. Higher-potency agents, such as methadone hydrochloride 
and oxycodone hydrochloride are thought to have a role in refractory cases. 
Oxycodone at an average dose of 15.9 mg reportedly decreases PLMS, and provides 
decreased arousals and improved sleep efficiency. Nevertheless, because of the 
recognized risk of addiction, most physicians are reluctant to use opioids. 
Benzodiazepines – Studies of benzodiazepines have focused on clonazepam 
therapy. Clonazepam has shown to ease the sensory symptoms and decrease PLMS. 
Other benzodiazepines include temazepam and alprazolam. Although this drug has 
been proven to be well tolerated in older patients, its long duration of action may 
cause effects that are more adverse. Such side effects include daytime drowsiness 
and confusion, unsteadiness and falls, and cognitive impairment in the morning. 
Gabapentin and other anticonvulsants - Anti-epileptic medications such as 
carbamazepine and gabapentin can also provide a therapeutic effect, especially in 
patients with painful RLS. Gabapentin has been shown to be an effective treatment, 
however, similar to opioids, large scale trials and long-term observations are 
minimal. Anticonvulsants such as carbamazepine and valproic acid, which have been 
previously investigated for the treatment of RLS, are no longer regarded as first-line 
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options due to their side effects. Dizziness, fatigue, and sleepiness are among the 
possible side effects (Happe, Klosch et al. 2001).  
Yokukansan (Herbal) – Yokukansan (YKS) was developed as a remedy for 
restlessness and agitiation. It has been approved for patients with insomnia in Japan, 
and in 2008, Shinno and associates reported that YKS improved sleep quality in 
patients with dementia (Shinno, Inami et al. 2008). In 2010, Shinno reported that 
three patients with RLS were successfully treated with YKS. It was speculated in the 
paper that actions on GABAergic, serotonergic and dopaminergic systems might 
account for some of the therapeutic effects of YKS in RLS patients (Shinno, 
Yamanaka et al. 2010). 
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1.10.3 Medications that may exacerbate RLS 
RLS as a side effect is ascribed to a number of drugs. Prior reports exist on RLS 
associated with drugs such as olanzapine (Kraus, Schuld et al. 1999), risperidone 
(Wetter, Brunner et al. 2002), and clozapine (Duggal and Mendhekar 2007). A 
number of case reports have been published on the provocation of RLS by “modern 
antidepressants (AD)” with specific receptor binding profile. One case was reported 
for each one of the selective serotonin reuptake inhibitors (SSRIs) sertraline, 
fluoxetine, paroxetine and citaloprame. For the nonadrenergic-specific serotenergic 
AD (NASSA) mirtazapine, a total of seven cases were reported (Rottach, Schaner et 
al. 2008). Some papers focused on the relationship between AD and RLS. Brown et 
al., investigated the possible association between RLS and AD, in 200 patients with 
sleep onset disturbance. Of these 200 patients, 45% met the diagnostic criteria of 
RLS, 56% suffered from depression, and 38% were on AD. A statistically significant 
association between RLS and AD was not demonstrable (Brown, Dedrick et al. 
2005).  
In 2007, Kang et al., reported that the prevalence of RLS was more than twofold 
higher (21.4%) in schizophrenics taking antipsychotics than in healthy individuals 
(Kang, Lee et al. 2007). However these reports are often disregarded or believed to 
be psychotic agitation or a somatic copmplaint because its symptoms are 
nonspecific, unclear and diverse, and are aggrevated or even happen exclusively at 
night time.  
In 2008, Kang et al., published another report in the Journal of Psychopharmacology 
in which five case studies were reported of RLS and PLMS that were probably 
associated with olanzapine. For example, the first case, a 36-year-old Korean female 
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with schizophrenia, showed a good response to olanzapine. However the RLS 
symptoms associated with olazapine resulted in poor long-term compliance, which 
ultimately led to the recurrence of psychotic symptoms. These report high-lights the 
fact that antipsychotic-induced RLS and PLMS are under-recognized side effects of 
antipsychotics, with the symptoms often misdiagnosed as psychotic agitation.  It also 
aims to make clinicians aware that although the antipsychotic olanzapine has few 
extrapyramidal symptoms, it can be the cause of RLS and PLMS and therefore affect 
a patients compliance with the medication and lead worsening of psychotic 
symptoms. Even though the cause of RLS and PLMS caused by antipsychotics has 
not been established, it is thought to be due to the dopamine receptor blocking of 
antipsychotics.  
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1.11 Prognosis and Impact of RLS 
1.11.1 Prognosis 
RLS is generally a lifelong condition. Symptoms tend to gradually progress with 
advancing age. At times individuals may experience spontaneous improvement, in 
which symptoms decrease or disappear for days, weeks, or months, although 
symptoms tend to recur. Improvement or resolution of symptoms is often observed 
in patients with RLS secondary to an underlying condition, if the underlying 
condition is treated.  
1.11.2 Impact on quality of life 
Depression is common in RLS patients and may be related to the chronic unrelenting 
nature of symptoms, to the persistent sleep loss or to the underlying brain 
abnormalities that cause RLS. In a study carried out on a headache and control 
groups, higher scores for depression and anxiety were more frequent in subjects with 
RLS compared to those without (d'Onofrio, Bussone et al. 2008). Treating 
depression patients with RLS may be difficult since, as mentioned above,  some of 
the antidepressants may individually exacerbate RLS symptoms.  
The most disturbing feature of RLS may be the social disruption which RLS 
sufferers experience. This is based on the need to decrease evening social or work 
engagements that involve inactivity. Social dinners, board meetings or theatre can be 
very challenging. Furthermore, individuals often have difficulty concentrating on 
daily tasks such as those demanded by their work. Problems with short term memory 
loss are often encountered, which can lead to cognitive deficits i.e. learning 
difficulties (Pearson, Allen et al. 2006). 
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RLS patients are more prone to headaches than healthy subjects. This is most likely 
secondary to the sleep disturbances and sleep loss. Headaches are usually 
comparable to migraine in character, though with an element of tension-type 
headache (d'Onofrio, Bussone et al. 2008). In  a study conducted between headache 
and control groups, headache patients with RLS reported sleep disturbances more 
frequently compared to those without RLS (50.0% vs. 32.7%; p<0.0001) (d'Onofrio, 
Bussone et al. 2008).  
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1.12 Linkage analysis 
1.12.1 Basic concepts in Genetics 
For centuries the hereditary basis of human disease has fascinated both scientists and 
the general public. An Austrian monk, Gregor Mendel provided the foundation for 
the study of human genetics. By carefully creating crossing experiments with peas 
and recording observations of the frequency of variable characteristics in the pea 
plant (e.g. seed texture, colour, plant height), he hypothesised what are now called 
Mendel‟s laws (Mendel 1866). Mendel‟s fundamental unit of inheritance is named 
the gene, which contains the information necessary for manufacturing proteins. DNA 
or deoxyribonucleic acid is the molecule that contains the gene and encodes 
information for producing both proteins and RNA. The locus is the physical location 
of a gene. Each individual carries two copies of each gene of which one was received 
from the mother and the other received from the father. At any particular locus there 
can exist a number of different forms of the gene, known as alleles. 
Normal chromosomes have a single centromere that is seen under the microscope as 
the central constriction. It separates the p (short) arm from the q (long) arm. It is 
essential for segregation during cell division. The normal human chromosome 
consists of 23 pairs of chromosomes, with one member of each pair inherited from 
each parent. Non-gamete cells are diploid as there are two copies of each 
chromosome in the cell. The first 22 pairs of chromosomes are called autosomes. 
The two remaining chromosomes, X and Y, are called sex chromosomes of which 
females carry two X and males carry one X and one Y.  
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Genes located on the same chromosome are said to be syntenic. Although two genes 
may be syntenic they may be far enough away from each other on the chromosome 
to segregate independently from one another i.e. unlinked. If two syntenic genes fail 
to be passed on to gametes independently from one another they are said to be 
linked. 
In sexual organisms such as humans the reproductive method involves the union of 
haploid gametes (sperm and egg cells). The process by which these haploid gametes 
are formed is termed as meiosis. Meiosis consists of meiosis I and meiosis II. In 
meiosis I each chromosome in the cell is replicated to generate two sets of duplicated 
homologous chromosomes. Each homologous chromosome therefore consists of two 
strands known as chromatids. Physical contact may occur between the chromatids, 
resulting in the formation of chiasmata. Chiasmata are a sign of the occurrence of 
crossing over (recombination) between two chromatids, thus leading to the exchange 
of DNA between two of the four chiasmata. A chiasma occurs at least once per 
chromosome pair, resulting in recombinant haplotypes. Meiosis II is identical to a 
mitotic division in which genetic material is transmitted equally and without 
recombination to daughter cells.  
As a consequence of the process of meiosis, gametes contain only a haploid set (one 
copy) of chromosomes. This explains why parents pass only a single gene onto their 
offspring. It also explains why the gender of an individual is determined by the 
father of the child. 
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1.12.2 The principles underlying 
linkage analysis 
In the accompanying figure (Figure 1.3), each 
bar represents a chromosome, paternal (P) and 
maternal (M). “D” represents the disease gene 
in a disorder with an autosomal dominant mode 
of inheritance and “d” is its normal 
correspondent. The numbers denote particular 
alleles at a series of genetic markers that span 
the chromosome (genetic markers will be 
explained later in section 1.11.3). 
When a gamete is produced, crossover events 
(recombinations) can occur at the points 
indicated with arrows during meiosis. (Four 
chromatids are formed during meiosis, but it is 
not shown here for the purpose of simplicity). 
The resulting offspring will inherit a “new” 
sequence of alleles. 
Subsequently a different pattern of marker 
alleles is seen in the next generation. Only the 
markers adjacent to the disease gene “D” 
(marked with a red bar) remain unchanged. 
During gamete formation in this individual, a 
 
 
Figure 1.3: The principles underlying 
linkage analysis 
Each bar represents a chromosome, 
paternal (p) and maternal (m). The 
numbers denote particular alleles at a 
series of genetic markers that span the 
chromosome. Crossover events 
(recombinations) have occured at the 
points indicated with arrows during 
meiosis. Thus, it is only the marker 
which are adjacent to the disease gene 
„D‟ which remain unchanged i.e. are 
inherited with the disease gene. 
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further recombination event may occur, thus separating some alleles from the disease 
gene.  
It is only the marker alleles closest to the disease gene “D” that remain unchanged. It 
is clear that allele 5 of the marker above the disease gene and allele 6 of the marker 
below the disease gene have remained “associated” with the disease gene “D”. 
These two markers are said to be linked to the disease gene because recombination 
events are not likely to isolate them from it. This is because of their close physical 
proximity. 
From figure 1.3 it can be perceived that if all the numbers in the bars were “2” it 
would be impossible to demonstrate the recombination events. This is an essential 
detail and indicates why genetic markers and in particular microsatellite markers are 
so valuable in linkage studies.  
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1.12.3 Genetic Markers 
If, in the above example the alleles were all numbered “2” i.e. if all individuals were 
homozygous for the allele 2, then no information on recombination events could be 
acquired. The rationale behind why the example shown above succeeds is that two 
different alleles are present at each locus, in other words the individuals are 
heterozygous. When individuals are heterozygous at these locations, recombination 
events can be identified and information can be obtained from the family. 
Genetic markers can be defined as sequences of DNA inherited in a mendelian 
manner. They demonstrate polymorphism, which means a difference in DNA 
sequence is observed among individuals, groups or populations that gives rise to 
different forms of the marker. Traditionally autosomal marker traits included the 
blood groups and the ability to taste phenylthiocarbamide (PTC). The X-linked 
marker groups include the Xg blood group and colour blindness. The demonstration 
of genetic linkage by pedigree studies was first described by Bell and Haldane in the 
1930‟s, when they showed that the locus for haemophilia was close to that for colour 
vision (Bell and Haldane 1986). 
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Microsatellite markers 
The genetic markers used in this study were polymorphic repeats which belong to a 
group of genetic markers called microsatellite repeats. Microsatellites were first 
described in 1989 as small blocks of tandemly repeated DNA in which the repeated 
element is usually a di-, tri-, or tetra-nucleotide sequence (e.g. [CA]n, [CAG]n, 
[CAGT]n, where n represents the number of repeats). The number of repeat elements 
in these blocks is often highly polymorphic, and show simple Mendelian inheritance. 
Information on several of thousands of microsatellite repeats is now electronically 
accessible to investigators through databases such as the Marshfield Institute, Entrez 
(at NCBI), the Whitehead Institute, the Genome Database and Généthon. Although 
these highly polymorphic microsatellites supply the investigator with important 
maps for linkage analysis, it is vital to remember that all genetic and physical maps 
are not constructed alike or with the same reliance. 
Dinucleotide Repeats  
The most common type of repeat is the dinucleotide CA (GT) repeat, occurring on 
average every 0.4 cM (Weber, 1990). The function of these repeats is unknown. A 
suggestion that they may be “hot-spots” for recombination is unlikely because of the 
linkage disequilibrium seen between them. Dinucleotide repeats have been used 
extensively as genetic markers. Two factors determine whether these repeats are 
polymorphic. Firstly the size of the repeat, and secondly whether it is an imperfect 
repeat (with interruptions) or a perfect repeat. A large percentage of the markers with 
15 or more perfect repeats are polymorphic. Dinucleotides while powerful have 
several technical disadvantages. Often dinucleotides have a “stutter” or “shadow 
band” that produces a background ladder of bands two base pairs apart. Also since 
72 
the alleles are only two base pairs apart, it can be difficult to make a distinction 
between one allele and the next.  
Tri- and Tetranucleotide repeats 
Trinucleotide repeats are approximately ten times less common than dinucleotides. 
They occur once every 300-500 kb. The most common form is [AAB]n (where B is 
C, G or T). Although certain trinucleotide repeats which are prone to expansion have 
warranted a lot of attention because of their disease causing characteristics (e.g. 
fragile X syndrome, Huntington‟s disease, myotonic dystrophy), the majority of 
trinucleotide repeats are not associated with disease and are very stable. 
Tetranucleotide are even more rare, and the most common form is [AAAB]n (where 
B= C,G,T]n. Tri- and Tetranucleotides have fewer stutter bands than dinucleotide 
repeats, typically generating unique PCR alleles without the laddering artefact. They 
are also easier to read when using fluorescently labelled primers and automated 
detectors such as the ABI 3130. Accurate allele identification is imperative, making 
these markers more favourable than their di-nucleotide match. However their lower 
occurrence in the genome restricts their extensive use. 
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1.12.4 Centre d‟Etude du polymorphisme Humain (CEPH)  
Centre d‟Etude du polymorphisme Humain (CEPH) is a centre for genetic studies in 
Paris, France. The primary URL for CEPH is http;//www.cephb.fr. This website 
provides information about CEPH and provides access to the CEPH genotype 
database which contains data on polymorphic markers. Researchers from over 100 
laboratories around the world have submitted genotyping data and from this CEPH 
have assembled a large panel of families to construct maps of genetic markers. These 
large families generally consist of pedigrees with three generations, living 
grandparents and an average sibship size of 8.5. The standard family set comprises 
of 40 families, while an extended family set of 64 families is available. These 
families are generally of European descent (Dausset, Cann et al. 1990). 
The CEPH database provides information on the marker including allele sizes and 
frequencies, and heterozygosity. It can also provide the actual genotypes for 
individuals in the CEPH pedigrees.  Blood from each member is stored at CEPH and 
can be made available to researchers around the world, therefore being able to access 
the actual genotypes of these individuals can greatly improve the consistency of 
allele calling between gels, projects and laboratories. CEPH however does not 
provide primer sequence data or the position of the marker on the chromosome in 
question. 
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1.12.5 Using Microsatellite Markers to find Disease-causing Genes 
When the disease causing gene in a family is unknown, a common technique used to 
find the gene is to genotype family members for a collection of microsatellite 
markers dispersed throughout the genome. If a distinct allele of one of these makers 
is found to be “linked” with the disease phenotype, then the disease gene is likely to 
be physically close to that marker. Complex statistical analyses are required to 
determine the level of linkage between the disease phenotype and the marker. A 
number of factors such as family structure, mode of inheritance and marker allele 
frequencies are all taken into account.  
Following sufficient evidence that the disease is linked to a given marker, other 
markers in that area need to be genotyped. When a set of alleles from adjacent 
microsatellite markers are found on a short segment of the same chromosome and 
tend to be transmitted together through a family, it is referred to as a haplotype. 
Within this haplotype there will be a number of candidate genes present, one of 
which will be the disease gene.  
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1.12.6 LOD scores 
By analysing the pattern of segregation of a gene and potential marker genes in 
families, it is possible to generate a mathematical measure of the likelihood of 
linkage, known as the LOD score or Z score. The LOD score was devised by Morton 
in 1955 and is defined as the logarithm of the odds (LOD) ratio (R) that the loci are 
linked rather than unlinked. The LOD score is therefore a statistical estimate that 
measures the probability of two loci being physically close together and thus being 
inherited together. 
The recombination fraction and genetic distance  
Recombination will rarely separate loci that lie very close together on a 
chromosome, as only a crossover located precisely in the small space between the 
two loci will produce recombinants. Thus sets of alleles on the same small 
chromosomal segment tend to be transmitted as a block through a pedigree. This 
block of alleles is known as a haplotype. The further apart two loci are on a 
chromosome the more likely it is that a crossover will separate them. The 
recombination is a measure of the distance between two loci. The further apart two 
loci are on a chromosome, the greater will be the frequency of recombination 
between them up to a maximum of 50%. Recombination fractions (θ) never exceed 
0.5, however far apart the loci. If there are no recombinants, the LOD score will be 
maximum at θ = 0.00. Recombination events can therefore be used as a measure of 
how close two loci are (genetic distance). Two loci that show 1% recombination are 
defined as being 1 centimorgan (cM) apart on a genetic map (Strachan and Read 
2003).  
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Genetic distance and physical distance are not equivalent. Genetic maps show the 
order of features along the chromosome and the chances that they will be separated 
by recombination; however, physical maps show the distance of features along the 
chromosome in kilobases (kb) or megabases (Mb). Areas such as the centromere 
show very few crossovers; therefore, genetic distances in these areas would be small 
in comparison to physical distance. In contrast, areas of equivalent physical size in 
crossover “hotspots” such as the telomeres would show large genetic distance. For 
large distances i.e. two loci that have a recombination value greater than Ө = 0.50, it 
is not possible to use the recombination fraction as an additive distance measure. It 
must therefore be transformed by a map function into a certain additive map 
distance, under the assumption of a certain level of genetic interference.  
Interference is thought of as the process whereby the presence of one cross-over in 
an interval inhibits the formation of another cross-over in the same region. 
Subsequently negative interference suggests that the presence of one cross-over will 
in turn encourage the formation of another cross-over event within an interval. 
Numerous levels of interference in humans have been hypothesized; however, the 
level of interference used in this study was the Kosambi (Kos) level. This method 
adopts an intermediate level of interference whereby double cross-over are seldom 
observed at small genetic distance, although the probability increases at greater 
distances (Keats, Ott et al. 1989). Another common map function employed to covert 
the estimated recombination fractions to map distances is the Haldane level, however 
it appears to produce less realistic values than does Kosambi‟s formula.  For example 
the Haldene map function converts Ө = 0.27 into 39 cM and the Kosambi map 
function translates Ө =27 into 0.30 Morgans (30 cM). Higher recombination rates 
are seen in the female than in the male. (Kosambi 1944) 
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Some allowance must therefore be made for the likely distance (in addition to 
recombination fraction) that may be present between a particular marker and the 
disease locus. Hence, it is normal practice to calculate all LOD scored at a range of 
recombination fractions. 
 
  
78 
1.12.7 Calculating LOD scores 
To find the odds of linkage it is necessary to calculate the overall likelihood that the 
two loci are linked (Ө = 0.00) compared to the likelihood that they are not linked (Ө 
= 0.50). The ratio of the latter probability to the former, expressed as a logarithm 
(base 10) is then the „LOD score‟ between those two markers. Therefore, the LOD 
score is a statistical estimate that measures the probability of two loci being 
physically close together and thus being inherited together. 
Each meiosis in the family is looked at in turn and the likelihood of the observed 
genotype and disease gene being transmitted together is calculated. This is 
moderately straightforward when all individuals are genotyped and recombinations 
are easily determined. Nonetheless problems do arise when recombinations cannot 
be easily identified and when gaps arise in a pedigree e.g. when individuals are 
unavailable for DNA sampling or perhaps deceased. Therefore when uncertainties 
like this arise the meiosis must be examined under the various alternatives that exist, 
and each alternative given an appropriate weighting. In order to calculate the full 
LOD score for a family various factors exist that need to be taken into account e.g. 
the genotypes of other individuals and population allele frequencies. Consequently 
this results in a large “branching tree” of genetic probabilities (Strachan and Read 
2003). Therefore, apart from very simplistic cases, human linkage analysis is 
completely dependent on computer programs.   
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1.12.8 LOD score values for linkage and exclusion 
The degree of linkage is a function of the distance between the disease gene locus 
and the maker locus. This can be measured by the number of crossovers between the 
two loci among the observed meioses (i.e., recombination fraction, θ). If there is no 
recombination, θ = 0.00, there is “complete linkage” and observed meiosis (θ < 
0.50). However if the observed recombination fraction is 50% (θ = 0.50), there is no 
linkage. LOD scores (θ) are usually recorded at θ = 0.00, 0.05, 0.10, 0.20, 0.30, 0.40 
and 0.50.  
If all chromosomes were of equal size and if two loci were picked randomly, the 
chance that they were found on the same chromosome would be 1 in 23. However 
the probability that two randomly picked loci would be close together and likely to 
be linked is estimated to be a one in fifty chance, thus the prior probability of 
linkage. Therefore, a large amount of evidence would be required to confirm linkage 
if there were only a one in fifty chance the two loci were actually linked.  
The LOD score is the logarithm of the odds that the loci are linked rather than 
unlinked, therefore, Log101000 = 3 represents the minimum LOD score required for 
statistical proof of linkage. 
As stated the conventional threshold for claiming linkage is a LOD score of 3.0, 
corresponding to 1000:1 odds that the loci are linked. LOD scores of -2.0 or less are 
indicative of nonlinkage (Morton, 1955). Values between -2.0 and 3.0 are 
inconclusive and require additional data before an assumption can be made. These 
criteria are based on the probability of type I and type II errors. Type I errors refers 
to the probability of concluding that there is linkage between the loci in question 
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when in fact there is no linkage (false-positive); and type II refers to assuming that 
there is no linkage when in fact there is (false-negative). A cautious value of z > 3.00 
for inferring linkage was chosen by Morton (1955) to prevent the risk of false 
positives. Therefore, if the total LOD score for one family or over all families is 3.0 
or more, one can conclude that there is extensive evidence for linkage. 
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1.12.9 Drawing family trees 
There are a number of computer programs available for pedigree drawing, and they 
have huge advantages over some of the older methods such as by hand. The pedigree 
drawing package used for this study was Cyrillic v2.01. Aside from being a drawing 
program Cyrillic v2.01 has a number of useful features. Such features include the 
ability to store vital information about individual patients and their families; to scale 
pedigree drawings to fit on one page; and to store up to 10000 individuals per 
family, up to 250 markers per chromosome and up to 150 alleles per marker. It can 
also colour haplotype bars to show inheritance and multiple crossovers. 
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1.13 Haplotype Analysis 
A haplotype is a set of alleles on the same small chromosomal segment that tends to 
be transmitted as a block through a pedigree. A haplotype may refer to as few as two 
loci or to an entire chromosome depending on the number of times recombination 
takes place between a given set of loci. Although a LOD score can point us in the 
direction of whether linkage has taken place or not, it is simply a statistical estimate 
and does not give us a mental picture of what is occurring. 
If a particular candidate locus is being examined with a series of markers, it is often 
useful to draw the haplotype at this locus for the family in the study. It can provide a 
visual explanation of the LOD score. (It may also be useful in identifying cases with 
possible reduced penetrance or other useful information.) Figure 1.4 explains this 
concept. Each individual in the pedigree has two columns of numbers, one column 
representing a paternal chromosome and the other representing a maternal 
chromosome. The numbers signify the set of alleles found using a series of adjacent 
markers. Therefore, each column is a haplotype and using colours for different 
haplotypes makes it easier to follow through the family. In the figure, one can see 
that the affected daughter has received the haplotype 2-1-5-7 from the father and 
haplotype 4-5-7-6 from the mother. Nonetheless there are times when it is not 
possible to determine which parent the haplotype has been passed on from. For 
example, for marker D in figure 1.4 the father is homozygous for allele 7, therefore, 
we are unable to determine if the allele 7 inherited by the affected son comes from 
the “red” chromosome or the “green” chromosome. 
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Figure 1.4: The concept of haplotypes and haplotye analysis 
This figure shows an affected father (filled square), an unaffected mother (circle) and 
an affected daughter. Four adjacent markers are examined here, marker A, B, C and 
D. The resultant allele for each marker is given by the numbers under each 
individual. The series of alleles (haplotypes) is given a coloured vertical bar. In this 
example, the daughter has inherited the red haplotype from the father and the blue 
haplotype from the mother. However for marker D, it is not possible to determine if 
the allele 7 inherited by the affected daughter comes from the fathers „red‟ 
chromosome or the „green‟ chromosome as the father is homozygous for this marker.  
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1.14 Summary  
Restless legs syndrome (RLS) is one of the most common neurological sensorimotor 
disorders in Western countries, affecting approximately 10% of the population. It is 
often associated with periodic limb movement during sleep (PLMS) leading to 
severe insomnia. However, it remains largely underdiagnosed and its underlying 
pathogenesis remains to be elucidated.  
RLS is generally idiopathic, with familial association in 40-60% of the cases, but 
may also be symptomatic of such associated conditions (secondary forms) as 
peripheral neuropathies, uremia, iron deficiency, diabetes, Parkinson‟s disease and 
pregnancy. In comparison to non-familial cases, familial RLS usually has a younger 
age at onset and a more slowly progressive course. The symptoms within a single 
RLS family can vary significantly, with some members displaying mild symptoms 
on only a few occasions during their life, while those more severely affected suffer 
from restlessness and sleep disturbances.  
Linkage studies in RLS families have revealed ten loci to date, however, no causally 
related sequence variant has yet been identified using this approach. Based on the 
hypothesis that RLS follows a recessive mode of inheritance, linkage to chromosome 
12q (RLS1) was identified in 2001 in a French-Canadian family. All of the nine 
other loci identified followed a dominant mode of inheritance. 
Genome wide association studies have identified variants within intronic or 
intergenic regions of MEIS1, BTBD9, PTPRD, MAP2K5/LBXCOR1, which has 
raised new pathological hypothesis for RLS. 
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Treatment options for RLS are advanced and have been investigated in large trials. 
In order to optimize treatment strategies, future studies should concentrate on the 
remaining problems of augmentation, rebound and its pathomechanism. 
Furthermore, genetic insights could reveal further specific treatment regiments other 
than the present therapeutic strategies.  
Notable progress has been made in distinguishing the diagnostic criteria of RLS 
from mimic conditions. However, much more must be done to fully elucidate the 
pathophysiology and etiologies of both primary and secondary forms of RLS.  
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Chapter 2 
Materials and Method 
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2.1 Family recruitment and clinical assessment 
In the University College Cork (UCC) Department of Pathology, research into the 
genetic features of RLS is continuous. Families for this ongoing study are recruited 
by various methods e.g. word of mouth, contact with GPs, and articles in the press. 
Contact was made with the department by one member of this family interested in 
participating in the study. Subsequently other family members were primarily 
contacted by phone, and those with interest in participating were visited individually 
in their homes located in various parts of Ireland. The requirements and aims of the 
study were explained to the members of the kindred and those willing to take part 
were asked to sign a consent form. Participants were then questioned as to the 
presence, frequency and severity of symptoms suggestive of RLS with particular 
reference to: 
 The presence of the revised essential diagnostic criteria proposed by the RLS 
epidemiology and diagnosis workshop with IRLSSG, 2002. 
 Obtaining RLS severity rating scale (proposed by IRLSSG). 
 Periodic limb movements during sleep and sleep disturbance. 
 The duration, frequency and severity of these symptoms. 
 The effect of pregnancy on symptoms (female patients). 
 Their past medical history. 
 Current medications and drug history. 
 Family history including anecdotal information on the affection status of 
deceased family members. 
Physical examination included a full neurological examination. Venous blood 
samples (approximately 20 mls) were obtained from affected and unaffected family 
members. Blood samples were collected in EDTA coated Vacutainers (to prevent 
clotting) and subsequently stored at -20 °C.  
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2.1.1 RLS3002 Pedigree 
The pedigree, name RLS3002, is outlined in figure 2.1 below. In this family RLS 
appears to follow an autosomal dominant mode of inheritance. Blood samples were 
collected from 18 members of the family, and following genomic extraction each 
family member was assigned their own unique “PATH” number. Of the 18 family 
members 11 are affected, all of whom met the essential diagnostic criteria. The age 
of onset was seen to vary from childhood, to teenage years and some early twenties. 
Although the majority of affected individuals did not endure sleep disturbances, one 
individual did experience severe disturbance and another had moderate disturbance. 
4 of the 14 family members remained unaffected. Table 2.1 lists the clinical data 
from all 11 affected members of RLS3002 
 
Figure 2.1: RLS3002 Pedigree 
This is a three generation family. Circles represent females, squares represent males. 
Coloured symbols represent affected members and symbols with the letter N 
represent unaffected members. The lines through the grandparents symbols indicate 
that they are deceased. Members of the family were each assigned their own unique 
PATH number.  
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Table 2.1: Clinical Features of RLS in the affected members of Family RLS3002. 
Individual Sex Age at 
study 
(yr) 
Age at 
onset 
(yr) 
Severity 
(IRLS) 
Parasthesia in 
legs 
Parasthesia 
in arms 
Symptom 
Prevalence 
PATH046 F 58 3 4 Yes No Night 
PATH048 F 31 10 14 Yes No Evening/ 
Night 
PATH050 F 21 11 13 Yes No Evening/ 
Night 
PATH051 M 57 20 15 Yes No Sitting for 
long 
periods/ 
Evening/ 
Night 
PATH053 F 25 13 17 Yes No Sitting for 
long 
periods/ 
Evening/ 
Night 
PATH054 M 23 15 11 Yes No Evening/ 
Night 
PATH055 M 53 10 10 
 
Yes 
(Lateralization 
of Symptoms; 
left leg) 
No Evening/ 
Night 
PATH083 M 27 13 10 Yes No Night 
PATH185 M 57 13 16 Yes No Evening/ 
Night 
PATH187 F 29 13 8 Yes No Evening/ 
Night 
PATH207 F 19 15 10 Yes No Sitting for 
long periods 
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2.2 DNA Extraction 
DNA was extracted from venous blood using a QIAamp Blood Kit from Qiagen. It 
involves cell lysis, nuclear lysis and protein salt presipitation stages. This method 
retains the DNA in a QIAamp spin column while contaminants are washed out and 
typically yields approximately 3-12 μg in 200 μl of final volume per 200 μl of whole 
blood. Before the extraction process the blood samples were allowed to thaw at room 
temperature, and a check was performed to ensure that the Buffer AL, Buffer AE and 
QIAGEN Protease were prepared correctly, according to the accompanying manual. 
The extraction was carried out according to the manual. The DNA was eluted with 
Buffer AE or distilled water and a NanoDrop was used to measure the DNA 
concentration. The DNA extraction was also confirmed by amplification using the 
polymerase chain reaction and efficient primers, then checked by agarose gel 
electrophoresis. The manufacturers state that the typical DNA yield from a 200 μl 
sample volume of Human Whole Blood is 3-12 µg of DNA in 200 µl water. The 
yield however depends on the quantity of white blood cells present and the 
performance of the procedure.  
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2.2.1 Determination of DNA Concentration 
A NanoDrop ND-1000 spectrophotometer was used to measure the DNA 
concentration following extraction. A NanoDrop is a cuvette-free spectrophotometer. 
It uses just 1 μl of sample and is accurate from 5 ng/μl up to 3,000 ng/μl. By 
eliminating the need to carry out dilutions, and thus reducing human error and 
variability factors, analyses can de done quickly and easily. The NanoDrop 
Spectrophotometer is linked to the computer that also runs the digital imaging 
system. 
The NanoDrop was blanked using buffer as the DNA was eluted with Buffer TE. 
When adding the sample it is essential that the liquid column is formed between the 
upper and lower measurement pedestals. 
Operation: A 1 μl sample is pipetted onto the lower pedestal (the receiving fiber). 
The second fiber or the upper pedestal is brought into contact with the liquid. A 
pulsed xenon flash lamp within the machine provides the light source and a 
spectrometer is used to analyse the light passing through the sample. As previously 
mentioned, the instrument is controlled by special software run from a PC. The data 
is then saved in an archive file on the PC. The sample concentration is recorded in 
ng/μl and is based on absorbance at 260 nm and 280 nm.  
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2.3 Polymerase Chain Reaction (PCR) 
The polymerase chain reaction is a rapid and versatile cell free procedure for in vitro 
enzymatic amplification of specific segment‟s of DNA. The template DNA is usually 
genomic DNA from a particular tissue or cultured cells, in which case the target 
DNA is typically a tiny fraction of the total DNA. In order to permit selective 
amplification of the target DNA, some prior DNA sequence information from the 
target sequence is required. This information is used to design two oligonucleotide 
primers, usually about 18-25 nucleotides long. These primers are specific for 
sequences flanking the target sequence. For the majority of PCR reactions, the goal 
is to amplify a single DNA sequence and so it is important to reduce the possibility 
of the primers binding to other locations in the DNA than the desired ones. 
Therefore, in order to avoid this a variety of considerations need to be factored into 
primer design e.g. the melting temperature (Tm) of the two primers should not differ 
by >5°c, self-complimentary sequences should be avoided, and the GC content 
should be between 40 and 60%.  
In addition to template DNA and primers, a PCR needs other reagents in order to be 
successful. A heat stable enzyme known as DNA polymerase, e.g. Taq polymerase, 
is employed. Small segments of DNA are generated when the polymerase adds 
complimentary deoxynucleotides (dNTPs) to the template DNA. The primers in this 
case are used as the starting point for the polymerase by providing double stranded 
DNA. During PCR, the DNA is heated and the double strands separate. Upon 
cooling, the primers bind to the template DNA thus providing a region of double 
stranded DNA from which the polymerase can begin to synthesise the new strand. 
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The PCR process usually consists of a series of twenty to thirty-five cycles. Each 
sequential cycle is composed of three steps: 
Denaturation: The double-stranded (template) DNA has to be heated to 94-96°C in 
order to separate the strands. This is referred to as denaturing; it breaks apart the 
hydrogen bonds that connect the two DNA strands. Also certain polymerases are 
activated at this time. 
Annealing: After separating the DNA strands, the temperature is lowered. This 
allows the oligonucleotide primers to bind to the single stranded DNA template. The 
two oligonucleotide primer sequences are specific for the taget DNA and are 
constructed using prior knowledge of the DNA sequence of the target sequence. The 
annealing temperature depends on the primers and is usually 5°C below their melting 
temperature (45-60°C). 
Extension: This is the final stage which involves the DNA polymerase copying the 
template DNA strand. The heat stable DNA polymerase initiates the synthesis of 
new DNA by adding the four bases, the deoxynucleoside triphosphates – dATP, 
dCTP, dGTP and dTTP, to the annealed primers in the order complimentary to the 
single stranded DNA template. The elongation (extension) temperature depends on 
the DNA polymerase. Taq polymerase elongates optimally at a temperature of 72°C. 
The thermostable DNA polymerase is possibly the most important component of the 
PCR technique as it remains active despite being repeatedly exposed to high 
denaturing temperatures. Taq polymerase isolated from the bacteria Thermus 
aquaticus, is thermostable up to 94°C. The Taq polymerase and buffers used in this 
study were obtained from Promega. 
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The newly synthesized DNA strands act as templates for further DNA synthesis in 
subsequent cycles. After about 30 successive cycles of DNA synthesis, the products 
of the PCR will lead to a 10
5
 - 10
6 
fold increase in the amount of target DNA. This 
amplification results in sufficient quantities of the target DNA for direct 
visualization by ultraviolet fluorescence after ethidium bromide staining. 
 
Figure 2.2: The PCR process 
Double-stranded DNA in the sample is heated to generate single strands. Sequence 
specific primers are added, which anneal to desired sites on the DNA. Nucleotides 
and heat-tolerant DNA polymerase allow for primer extension at elevated 
temperature. The result is two new copies of double-stranded DNA. The process is 
repeated to generate multiple specific dsDNA molecules (www.universe-review.ca). 
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2.3.1 Determination of optimal PCR conditions 
When carrying out a PCR reaction some variables may need to be optimized as 
conditions are specific to each primer pair. The most important variables are the 
MgCl2 buffer concentration and the cycling temperatures.  The number of cycles, 
amount of template DNA and the primer concentration may also need to be 
optimized. 
The selection of the annealing temperature is one of the most critical factors for 
optimizing the specificity of a PCR reaction. The higher the temperature the more 
stringent the base-pairing; hence, the more specific the PCR amplification. However, 
if the temperature is too low non-specific priming may occur. The choice of 
optimum annealing temperature for each primer depends on the Tm (melting 
temperature) of the expected duplex between primer and the DNA. This is the 
temperature in which half of the primer binding sites are occupied. The melting 
temperature increases with the length of the primer. The Tm is based on the 
nucleotide composition of the primer sequence and can be calculated using the 
following formula: 
Tm(°C) = 2(A+T) + 4(G+C).  
A preferred method of determining the optimum annealing temperature is when a 
temperature gradient is generated across a "gradient" block. This can be carried out 
on a thermocycler. A temperature gradient is built up across the thermoblock, where 
multiple reaction mixtures can be simultaneously run at temperatures that differ only 
slightly. With the aid of only one single PCR reaction an optimum temperature for 
the reaction can be quickly identified. 
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Lower salt concentration gives a higher degree of specificity by 1) affecting the 
primer annealing and 2) lowering the activity of the Taq polymerase, which in turn 
correlates with higher accuracy of the polymerase. 
PCR is a highly sensitive technique; therefore, it is important that sufficient 
measures are used to avoid contamination with other DNA (bacteria, viruses, own 
DNA etc.). Such measures include changing gloves for each PCR step; and storing 
aliquots separately from other DNA samples. A control reaction, omitting template 
DNA, should also be carried out, to ensure the absence of contamination. 
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2.3.2 PCR Method 
The Polymerase chain reactions were carried out in 15 μl reaction volumes. Genomic 
DNA at a concentration of 100 ng/μl was used as a template. The reagents required 
were gathered and thawed. The Taq polymerase was always kept on ice. Reagent 
volumes were calculated using the following table (Table 2.2), in order to prepare a 
premix solution covering the required number of samples (n). The table contains the 
name of the reagent, the stock concentration, the concentration used, and the amount 
of each reagent in a 15 µl reaction volume. 
Table 2.2: Reagents used for PCR in 15µl reaction volumes 
Reagent  Stock  Final n x (μl) 
DNA 20ngμl-1
 
100ng n x 1.5 
10x Buffer 10x 1x n x 1.5 
MgCl2 100mM 1.5mM n x 0.225 
dNTP 10mM 0.2mM n x 0.3 
F/R Primer 100ng μl-1 100ng n x 0.15 
Taq Polymerase 5 U μl-1 0.75 U n x 0.05 
H2O Variable Variable n x 11.35 
Final Vol (μl)   1 x 15 
 
The reagents (with the exception of the DNA) were added to a mastermix tube. The 
Taq polymerase was added last and kept on ice thereafter. Once a premix solution of 
reagents was prepared 13.5 μl of this solution was transferred into each 0.2 ml 
labelled PCR tube. The 1.5 μl DNA sample was then added to give the total 15 μl 
reaction volume.  
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PCR was carried out on a G-Storm Thermal cycler, under tube temperature control 
using the following program: 
 95°C X 5minutes 
 95°C X 30seconds 
 40-60°C X 30seconds 
 72°C X 45seconds 
 Incubate at 72°C X 5minutes 
 Hold at 4°C 
  
}30 cycles 
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2.4 Agarose Gel Electrophoresis 
Agarose gel electrophoresis is the easiest and most common way of separating and 
analysing DNA. An electric current is applied and due to the fact that DNA has a 
negative electric charge, the DNA molecules move across the agarose gel. The DNA 
fragments are therefore, separated according to their size. By adding ethidium 
bromide to the gel the DNA is visualised. The ethidium bromide is an intercalating 
dye which means it binds strongly to DNA. It is also fluorescent, therefore, capable 
of absorbing invisible UV light and transmitting the energy as visible orange light. 
Agarose gel electrophoresis was used after PCR had been performed on any given 
marker; the products from a number of samples together with the CEPH product and 
negative control were run on an agarose gel. This was to assess the success of that 
particular PCR and to confirm that there was no contamination of the reaction. 
2.4.1 Procedure 
A number of different gel concentrations were used (1.0 to 1.5%), however a 1.5% 
gel will be described as it was used most often. 
1. Molecular grade agarose (1.5g) was dissolved in100 ml of 1X TBE by 
heating in a microwave until the agarose was seen to have dissolved.  
2. The molten solution was poured into a gel plate and when set then tape and 
combs were removed. 
3. Each sample was assigned an electrophoresis lane/well. For each sample 5μl 
of PCR product was mixed with 2 μl of 2x gel loading buffer (Promega) and 
loaded into its well.  
4. A 100 bp ladder (Promega) was added allow determination of the PCR 
product size. The ladder contains multiple bands of known sizes, yielding 12 
bands suitable for use as molecular weight standards for agarose gel 
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electrophoresis. The digested DNA includes fragments ranging from 100-
1,517 bp. The 500 and 1,000 bp bands have increased intensity to serve as 
reference points (Figure 2.3). 
The DNA ladder also allowed for qualitative estimation of the level of 
staining and exposure of the gel that was independent of the PCR itself (i.e. if 
there were no bands seen in the sample lanes and the 100 bp ladder was seen 
to stain well, then this was due to the absence of the PCR product and not the 
under-exposure or under-staining of the gel). 
5. A voltage of between 100 and 150 volts was applied to the gel for between 
10 and 30 minutes.  
6. The gel was then immersed in a solution of ethidium bromide (0.5 ug/ml) for 
between 30 and 50 minutes, depending on the quality and age of the ethidium 
bromide solution. 
7. After staining the gel was examined with a UV transilluminator. (A UV 
protective visor was used when viewing to avoid eye injury caused by 
exposure to light from the UV light) Photographic record of the appearance 
of the gel was obtained and the gel was carefully disposed of.  
 
Figure 2.3: 100 bp DNA Ladder visualised by ethidium bromide staining on an 
agarose gel  
The 100 bp DNA Ladder consists of 10 blunt-ended fragments between 100 and 
1,000 bp in multiples of 100, plus additional fragments at 1,200 and 1,500 bp. The 
500 and 1,000 bp bands are approximately 2 to 3 times brighter than the other ladder 
bands, and these serve as reference bands.  
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2.5 Genotyping 
One of the essential components of any gene mapping study is obtaining the 
genotypes for the genetic markers used to test for linkage. Genotyping encompasses 
a range of applications used to analyse genetic differences between individuals. 
Amplification by PCR of microsatellite markers using oligonucleotide primers 
results in alleles of the microsatellite markers that differ by their number of integral 
repeat units. In this study, genotyping is used for analyzing the differences in 
microsatellite marker repeats between individuals. 
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2.5.1 ABI 3130 Genetic Analyser 
Genotyping was carried out by direct electrophoreses on an ABI 3130 sequencer 
analyser (Applied Biosystems). Instead of an agarose gel there is a capillary 
containing a gel matrix through which the samples are electrophoreised. The 
fragments of DNA (and all other negatively charged molecules) are attracted to the 
platinum cathode electrode attached to the end of the capillary (4 capillaries in total), 
which are filled with Performance optimized Polymer (POP). POP Polymers 
dynamically coat the capillary wall to control electro-osmotic flow and are 
specifically formulated to separate DNA fragments of a known size range at a 
desired resolution and run time. A current is applied to the DNA fragments which 
travel through the polymer. The capillary has a glass window through which laser 
light is passed. The fluorescent labels on the PCR product are excited by laser 
resulting in the emission of light of a particular wavelength (wavelength depends on 
the fluorescent label). The light is collected and separated according to wavelength 
by a spectrograph. It is collected onto a charge-coupled device camera. The ABI 
3130 has the ability to collect up to five types of fluorescent emissions 
simultaneously. Using software selectable filters, the data collection software gathers 
the emissions of light and stores them on the hard disk for eventual processing.  
Within each sample a size standard is also run. The internal-lane size standard 
permits accurate estimation of the peak sizes. The internal-lane size standard used is 
GeneScan
TM 
- 500 ROX
TM 
developed by Applied Biosystems, which allows accurate 
sizing of DNA fragment in the 35-500 bp range, and provides 16 single-stranded 
fragments of 35, 50, 75, 100, 139, 150, 160, 200, 250, 300, 340, 350, 400, 450, 490, 
and 500 bases.  These fragments are uniformly spaced to provide extremely accurate 
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base calling. Using this size standard for comparison, the analysis software 
assembles a graph with fragment size on the X-axis and coloured peaks 
complementary to the various fluorescent signals. The position of the peaks on the 
X-axis will depend on the time point these signals were detected in comparison to 
the time the size standards were detected. The smaller the DNA fragments the faster 
they will move through the gel and therefore, the earlier they will be detected. The 
height of the coloured peaks depend on the amplitude of the fluorescent signals, and 
therefore, on the quantity of the PCR product in the sample. Table 2.3 outlines the 
advantages of the ABI 3130. 
Table 2.3: A list of the advantages of the ABI3130 
Advantages of the ABI3130 
Continuous, unattended 24-hour operation, with fully automated delivery system, sample 
injection, separation and data analysis.  
Accurate determination of allele size. This is vital when dealing with dinucleotide or 
trinucleotide repeats, where some alleles may differ by only two or three base pairs.  
Capillary electrophoresis is used, which is a significant advantage over slab-gel based 
technologies. Samples can be re-run and the arrays are guaranteed for 100 runs (rather 
than one slab per gel). 
It is also less time consuming when compared with alternative techniques e.g. 
polyacrylamide gel electrophoresis succeeded by silver staining. 
Markers of similar size labelled with different fluorescent labels can be analysed 
together, thereby increasing the efficiency of sample analysis.  
The results may be saved, which allows easy review of previous ABI runs. 
 
As previously mentioned it is possible to distinguish between the different markers 
because they have colours on the graph (due to fluorescent markers) or have 
different size ranges. The operator can accurately view allele sizes for each marker. 
However interpretations of the graph and deciding which are the true alleles resides 
with the operator. 
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For each microsatellite marker, the DNA samples from the family members  was 
analysed  with two positive controls in order to accurately determine the correct 
allele sizes. These positive controls were individual 1 and individual 2 of the CEPH 
1331 family. These DNA samples were obtained from CEPH and amplified by PCR 
in the same manner as the family DNA. The genotypes of these CEPH samples is 
known for a large number of microsatellite markers and that data is available from 
the CEPH database. By comparing the known allele sizes with those obtained 
experimentally, corrections can be made to the allele sizes which ensures that the 
correct fequency data is applied in the statistical calculation of LOD scores. These 
controls were used for comparison when sizing the unknown alleles, as the genotype 
of the CEPH individual is known. The Foundation Jean Dausset-Centre d'Etude du 
Polymorphisme Humain (CEPH) maintains a database of genotypes for genetic 
markers that have been typed, and the allele sizes of the positive controls can be 
viewed on this database (section 1.11.4). 
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2.5.2 Preparing an ABI3130 run 
To analyse samples on the ABI3130, the samples need to be prepared and then a 
Genemapper software plate record is created in order to inform the of the location of 
each sample within the sample plate. 
1. Sample Preparation 
 For each analysis, a premix was prepared for all samples in the run allowing 
12 μl of de-ionised formamide and 0.5 μl of GeneScanTM - 500 ROXTM size 
standard for each sample. [To maximise use on the ABI3130, multiple 
markers were analysed simultaneously. For each family member, 1 μl of  
products from different PCR reactions were pooled together in one sample 
tube, making sure they were compatible i.e. if they could be distinguished 
from one another on the basis of different fluorescent primer labels, or 
different expected sizes.] 
 12.5 μl of the premix (step 1) was then added and mixed with the pooled 
PCR products. 
 All sample tubes were checked for air bubbles. Air bubbles can interfere with 
the injection step in the ABI analysis. 
 The samples were then denatured by heating to 95°C, for five minutes. After 
denaturing the samples were snap cooled by placing on ice before the 
samples were placed onto the autosampler tray of the machine. 
2. Plate Preparation 
 Before running the samples on the ABI3130 it was necessary to prepare a 
plate using GeneMapper softer, which told the machine the positions of the 
samples on the plate. To open a GeneMapper software plate information in 
the New Plate dialog must first be entered. This includes information on the 
name of the plate, description of the plate, the plate type (96-well or 384-
well), the name of the owner, and the name of the operator. This enables the 
operator to find and review previous ABI runs easily. Once this is completed 
the Genemapper software plate editor opens. 
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 Preparing a Genemapper software plate is simply a way of labelling each 
sample in the analysis software by indicating its position on the autosampler 
tray. The following information and conditions were also detailed: Sample 
Type (Positive control/Negative control/Sample), Size Standard and Analysis 
Method. 
3. Analysis of samples 
 When the ABI3130 run was finished, it was necessary to analyse the results 
and assign alleles to each individual. GeneMapper® Software was used to 
size and genotype the data. Fragment sizes were determined automatically 
relative to an the size standard. The software then allocated fragment sizes to 
the previously calibrated genotypes. The genotypes for each individual were 
then adjusted based on the two CEPH controls. The alleles for the family 
members were then recorded on an page which had the family pedigree. This 
was to ensure that each individual had been assigned the correct alleles, i.e. 
that a child had one allele from his/her father and one from the mother. Once 
alleles were assigned it was possible to generate LOD scores (Linkage 
analysis).  
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2.6 Programs for Linkage analysis 
LOD scores can easily be calculated on any desktop PC. The original LINKAGE 
program was compiled by J. Ott. (Ott 1985), and this is the program most commonly 
used for linkage analysis. This program accepts genotype data as a direct input or 
from the Cyrillic pedigree drawing software. LINKAGE calculates LOD scores 
between a chosen marker (a disease locus) and one or more other markers, and gives 
an output which indicates where the chosen marker lies relative to the others. The so 
called direct method of linkage analysis proceeds by directly observing and counting 
recombinants and non-recombinants. 
For this study two-point linkage analysis was performed using the subprogram 
MLINK of the Linkage program (version 5.0) as implemented in FASTLINK 
(ftp://linkage.rockefeller.edu/software/fastlink) (Lathrop et al., 1984: Lathrop et al., 
1985). MLINK calculates the likelihood of the pedigree under user-specified values 
of θ for two different loci (http://linkage.rockefeller.edu/soft/linkage/sec3.3.html). 
Subsequently, these likelihoods are used to calculate the LOD scores. In this case, 
analyses performed with MLINK involved a disease locus and a marker locus.  
Prior to running the MLINK program two input files are required; 
1. A pedigree (marker.ped) file. This file contains numeric representation of the 
family structure, disease affection status and details the alleles present in each 
individual.  
2. A parameter (marker.dat) file. This file includes information specific to the 
genetic model to be analyse such as disease and marker allele frequencies, 
and disease penetrance.  
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In this study, RLS was analysed as an autosomal dominant disease with the 
assumption of a disease-gene frequency of 0.001, and a penetrance rate of 95% 
(Bonati, Ferini-Strambi et al. 2003). Microsatellite maker allele frequencies were 
obtained from the CEPH database (www.cephb.fr). 
Using the above files, MLINK was used to generate LOD scores for specified θ 
values. The output from the two-point LOD score is put into the output (marker.out) 
file. 
While genemappers hope for a positive LOD score i.e. linkage, negative LOD scores 
are not without value. Such values are informative and show where the disease gene 
is not located, otherwise known as exclusion mapping. Consequently if enough of 
the genome is excluded only a few possible locations may remain. To find the 
genetic distance actually excluded when a negative LOD score < -2 is observed, a 
program called the map function (mapfun) is used. This program is available at URL 
ftp://linkage.rockefeller.edu/ott/linkutil.htm. A map function allows conversion 
between recombination frequencies (θ) and genetic distance in centimorgans (cM), 
under the assumption of a certain level of genetic interference (section 1.11.6).  
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2.6.1 Calculating sample size and power 
Before commencing linkage analysis, it is important to know whether the available 
pedigree information is sufficient to allow detection of gene(s) causing the disease of 
interest. Computer simulation methods are often employed to investigate this. The 
simulation method can also be helpful in determining if an observed maximum LOD 
score is significant for a pedigree. For example, if a LOD score of 2.0 was found in 
the pedigree in question with a given marker and disease, according to the 
established LOD-score-of-3 criterion this result is not significant. However, in a 
small pedigree with a sample size that is not sufficient to generate a LOD score of 3 
such a LOD score could be of interest. Such information can help the researcher 
decide whether or not to devote further time into typing more markers in this region, 
to try finding the disease causing gene in question. 
For this study we used the SLINK package to investigate if the RLS3002 pedigree 
was powerful enough to detect linkage. The program SLINK is a general computer 
program that uses a variation of the algorithm described by OTT (1989). It is based 
on the LINKAGE programs version 4.91 (Lathrop, Lalouel et al. 1984). The SLINK 
package consists not only of the simulation program (SLINK) but also of several 
analysis programs (MSIM, LSIM, ISIM, ELODHET). It is essential to remember 
that the data are simulated conditional on the phenotypes given in the pedigree file, 
at the recombination fraction(s) given in the data file.  
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2.7 Primer Design 
Primer design is aided greatly by software and includes checks for balanced 
annealing temperatures and for possible dimers and hairpins. There are many 
software packages available such as Primer Express (Applied Biosystems) and some 
can even be downloaded from the internet. All of the primers which were designed 
for this project were done so with the assistance of PrimerSelect, EditSeq and 
SeqBuilder, which are components of the DNAStar software package (Lasergene). 
This software supports a large number of criteria for primer design including checks 
for internal primer stability, energy profile, primer dimer and hairpin formation and a 
mismatch primer deign. 
The following points should be adhered to when designing primers regardless of the 
software used: 
 Primers should be between 16 and 24 bases long 
 Avoid long runs of any single base, particularly the tetranucleotide GGGG as 
it frequently occurs throughout the human genome. 
 If possible, the G and C content should be approximately 50% to prevent 
excessive primer dimer formation 
 Ensure that the ends of the primers are not complimentary, thus avoiding 
excessive primer dimer formation 
 Preferably the Tm of the two primers should be within 2°C of each other. 
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Primers had to be designed for this project for two different purposes; 
1. The first was when trying to minimize the RLS locus, by selecting repeats 
within specific areas of the locus in the hope that the number of repeats would differ 
between family individuals thus giving information. 
2. The second was when selecting a gene for screening within the RLS locus. 
 
When selecting an area for genotyping or a gene for screening: 
  UCSC (www.genome.ucsc.org), ensemble (www.ensembl.org) and NCBI 
(www.ncbi.nlm.nih.gov/) websites were consulted. 
 The location of interest was chosen and the DNA sequence was found using 
UCSC website.  
 Di-, tri-, or tetranucleotide repeats in the area of interest were identified. This 
area containing the repeat region was selected, with approximately 200 bp 
flanking either side 
 The sequence of interest was entered into EditSeq by a simple copy and paste 
procedure. The sequence became a (seq)-format when saved there. 
 The sequence was imported to PrimerSelect. 
 For each microsatellite marker primers were designed. Each of these primer 
files were saved as D(chromosome no.)S(physical position). 
 The primers were located on the original SeqBuilder File and it was ensured 
that the amplified region contains the repeated region. 
 The 5‟ end of one of the primers was tagged with a fluorescent dye such as 6-
FAM or HEX as genotyping was carried out on an ABI automated DNA 
analyser. 
 By using the PCR tool in UCSC or using BLAST from NCBI it was verified  
that the primer pairs were specific. It was vital to ensure that each primer 
would bind to  the correct genomic location. If both primers also bound a 
location on another chromosome, it was essential to investigate if a PCR 
product would be generated. 
 When all primers had been validated primers were ordered from 
www.biomers.net .  
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Or when selecting a gene for screening: 
 Once a candidate gene was chosen for screening the UCSC 
(www.genome.ucsc.org), Ensembl (www.ensembl.org) and NCBI 
(www.ncbi.nlm.nih.gov/) websites were searched for gene information. If 
more than one transcript existed it had to be ensured that all exons were 
screened. 
 The genomic DNA, mRNA and protein sequences for the gene was obtained, 
and saved using EditSeq. Looking at the genomic sequence the number of 
exons in the gene were confirmed i.e. the sequence in uppercase. 
 It was important to consult another commonly used genetic website such as 
Ensembl, and check that no additional transcripts or alternate exons existed. 
Also it was confirmed that the protein sequence corresponded with the UCSC 
protein. 
 Also it was examined if the exons found in the ensemble site were identical 
or different to the UCSC exons. 
 Each exon sequence was saved as a file named GENEx1. 
 All the exons were spliced together to make an in silico mRNA. This 
GENEspliced file was opened in MapDraw, the ORFs were found and the 
protein translated. It was confirmed that it was the expected protein.  
 Once the exons were confirmed, the UCSC genomic seq file was revisited 
and each exon with approximately 300bp flanking sequence was selected. 
Each of these files was saved as GENEx1 exonic region. 
 Using primerSelect and the exonic region files, primers were designed for 
each exon. The primers had to be positioned so that at least 50bp upstream of 
the start of the exon would be sequenced 
 If a large exon existed, a group of overlapping primer pairs was designed to 
ensure that the entire region was covered. These primers were labeled x3a, 
x3b, x3c etc  
 Each of these primer pairs were saved as GENEx1 primer files. 
 The primers were detected on the exonic region file.It was also confirmed 
that the exon was adequately covered. This file was saved with the sequence 
of the PCR product as a GENEx1 amplicon file. 
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 A word file of primers to be ordered was generated and the primers were 
copied from PrimerSelect. It was confirmed that the orientation of the 
primers was correct by comparing them with the amplification summary in 
PrimerSelect. 
 It was also confirmed that the primer pairs were specific for the selected gene 
by using the PCR tool in UCSC or using BLAST from NCBI selecting 
human only. It was important that each primer hit the correct location. If both 
primers also hit a location on another chromosome, it was necessary to 
investigate if a PCR product would be produced. 
 When all primers had been validated primers were ordered from 
www.biomers.net. 
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2.8 PCR Purification 
PCR Purification prior to sequencing was carried out using the JETQUICK PCR 
purification kit (Genomed). PCR purification kits provide rapid and efficient 
removal of short primers, dNTPs, enzymes, short-failed PCR products, and salts 
from PCR products. The kit contains two solutions: Solution H1 (binding) contains 
guanidine hydrochloride, isopropanol and Solution H2 (wash, reconstituted) contains 
ethanol, NaCl, EDTA and Tris/HCl. Before starting the procedure, the solution H2 is 
reconstituted in alcohol (96-100%) as indicated in the instructions. The kit also 
contains spin columns or „micro-spin units‟ which have a silica membrane in 
microcentrifugation units. These silica membranes initially trap the PCR products 
and during the final steps the PCR products are released from the membranes. All 
centrifugation steps are carried out at >12,000 RPM in a table-top microfuge. 
1. Sample Preparation 
400 µl of solution H1 was added to 100 µl of PCR assay and mixed thoroughly. 
2. Column Loading 
A JETQUICK spin column was placed into a 2 ml receiver tube. The mixture from 
step 1 was loaded into the prepared spin column and centrifuged at >12,000 RPM for 
1 min. The flowthrough was discarded. 
3. Column Washing 
The spin-column was inserted into an empty receiver tube. 500 µl of reconstituted 
solution H2 was added and centrifuged at >12,000 RPM for 1 min. The flowthrough 
was discarded. The JETQUICK column was placed back into the same receiver tube 
and centrifuged at maximum speed again for 1 min. 
4. DNA Elution 
The spin-column was inserted into a new 1.5 ml microfuge tube. 50 µl of sterile 
water (or TE buffer or 10 mM Tris/HCL, pH 8.0) was added directly onto the center 
of the silica matrix of the spin column. It was then centrifuged at >12,000 RPM for 2 
min. The eluted sample was stored at 1–5° C. 
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2.9 Sequencing Reaction 
Prior to sequencing the following steps were essential: 
 The fragment was amplified by PCR (50 µl).  
 Amplification was confirmed on an Agarose gel. 
 PCR product was purified (JETQUICK kit). 
 The purified product was then used as the template for sequencing. This step 
is based on Fred Sanger‟s dideoxy sequencing method which will be 
discussed in more detail in section 6.1/6.2. This will result in differently sized 
DNA fragments of the desired sequence with each base in the sequence 
tagged with a different fluorescent label.  
Table 2.4: Reagents used for PCR in 15µl reaction volumes 
Big Dye Ready Reaction mix  0.5 µl 
Buffer 1.0 µl 
Primer (100ng µl
-1
) 0.5 µl 
H2O 0.5 µl 
Template DNA (purified) 2.5 µl 
Total 5.0 µl 
 
Sequencing was carried out on a thermocycler, using the following sequence cycle 
programme: 
 93°C X 30 seconds 
 50°C X 15 seconds 
 60°C X 4 minutes 
 Incubate at 10°C X 15 minutes 
  
}x 25 cycles 
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2.10 Post-Sequencing Purification 
Purification of sequencing products was carried out using the AmpliPurify
TM
 
ExTerminator Kit (AME Biosciences). This optimised purification procedure will 
remove unincorporated dyes, dNTPs and excess salt. It will also remove the 
sequencing enzyme. All of these components, if not removed, will greatly reduce the 
quality of the capillary electrophoresis data.  
The post-sequencing purification was carried out as follows: 
1. 5 µl of Mix Blue was added to the sequencing reaction mixture (10-20 µl). 
2. 100 µl of bind/wash solution was added. 
3. The sample was loaded onto a minicolumn and spun at 3,000-4000 RPM for 
30 seconds. 
4. Another 400 µl of bind/wash solution was added to the minicolumn and spun 
at 12,000 – 14,000 RPM for 2 minutes. 
5. The minicolumn was transferred to a new 1.5ml tube and 25 µl of was 
applied directly to the membrane. 
6. The column and solution were incubated at room temperature for 2 minutes, 
and then spun again at 12,000 – 14,000 RPM for 1 minute. 
7. The samples were loaded directly onto the ABI3130 Sample Plate. 
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2.11 Sequencing analysis 
After loading the samples onto the ABI3130 plate, a Plate Record was created as for 
genotyping (section 2.5.2), however the application “Sequencing” was chosen 
instead. 
Following completion of the run, the generated sequences were analysed from raw 
data. This was carried out by opening the Sequence analysis software on the 
ABI3130 PC, adding the samples, and analysing. The success/failure of the ABI3130 
system run was recorded. It was noted if the run was completed correctly or if there 
had been an interruption to the run. The success of the sequencing for each 
individual sample was also noted, e.g. failed to sequence or sequence present but 
short/unreadable etc. 
2.11.1 Seqman Software 
After a sequence was run successfully on the ABI3130, it was necessary to compare 
generated sequences to each other, and also to generate a contig of sequences. 
DNAstar has a software tool available to do this, known as SeqMan. It allows users 
to perform alignments and discover variants, along with many other analyses on de 
novo or template assemblies. 
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Sequence assembly and Contig management 
 The Seqman program was opened from the Lasergene menu. 
 The sequences to be assembled were located and opened. 
The following options for assembly were chosen: 
1. Minimum match percentage = 80% 
2. Trace evidence  (compare) 95% 
3. Majority  (primary) 100% 
 To detect any variants between samples the traces were compared.  
 The sequences were examined carefully and any changes were recorded. It 
was important to see if any of the variants observed were in fact SNPs, and 
this was discovered by consulting with either the dbSNP or UCSC databases. 
 All files were saved so that additional sequences could be added as they were 
generated. 
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Chapter 3 Investigation of 
known RLS Loci and 
Associated Regions 
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3.1 Introduction 
Familial aggregation of RLS has been recognized since Ekbom formally described 
the condition in 1945 (Ekbom 1945). Since then genetic contribution to idiopathic 
RLS has been well-documented, is substantial, and has been consistently recognised 
from population and family studies. In 1960 Ekbom described familial aggregation 
in one-third of RLS patients (Ekbom 1960). A high concordance rate of 83% in 
monozygotic twins adds to the evidence(Ondo, Vuong et al. 2000).  
To date several major susceptibility loci for RLS (termed RLS1-5 and RLS7) have 
been proposed by linkage analysis. In addition 3 other loci on chromosome 16p, 4q 
and 17p were recently identified (table 3.1). A study of 25 individuals from a 
French-Canadian family was the first to identify a major genetic locus for the RLS 
phenotype. While findings were consistent with an autosomal recessive mode of 
inheritance, the researchers suggested a pseudodominant mode of inheritance may be 
more appropriate (Desautels, Turecki et al. 2001). Linkage to chromosome 12q was 
the only locus found under this model of inheritance. This locus has since been 
reported in several families as well as in the Icelandic population. According to 
Winkelmann et al the genetic traits found in these families could be explained by the 
described pseudominant model (described by Desautels et al) as well as by an 
autosomal dominant model (Desautels, Turecki et al. 2001; Winkelmann, Lichtner et 
al. 2006). Nonetheless, the susceptibility locus for RLS on chromosome 12q could 
not be confirmed in a study of 51 South Tyrolean family members or in two 
Northern Italian families affected by RLS (Ferini-Strambi, Bonati et al. 2004). 
Linkage in all other instances assumed an autosomal dominant inheritance model 
and is limited to single or a small number of kindreds. Further studies in Italian, 
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American, Canadian and German families showed linkage to chromosome 14q 
(RLS2), 9p (RLS3), 20p (RLS4), and 2q (RLS5). A study carried out in 2006 by 
Winkelmann and associates identified two loci in a single RLS family of German 
origin on chromosome 4q and 17p (Winkelmann J 2006). In 2008, suggestive 
evidence for linkage was found on chromosome 19p13 (Kemlink, Plazzi et al. 2008). 
Genome-wide association studies are also providing a better picture of how variants 
in the sequence of the human genome impact RLS. Association studies compare the 
frequencies of alleles in case and control populations. A higher frequency of the 
allele tested in cases is taken as confirmation that the allele or genotype is associated 
with an increased risk for the disease. Two such studies used a large-scale high 
density genome-wide approach. The first study was performed using the German and 
Canadian population in 1600 RLS cases and 2600 controls. Three genomic regions 
were identified. The first was RLS6 which was found to be associated with SNPs in 
the BTBD9 gene on chromosome 6p21 (Stefansson, Rye et al. 2007; Winkelmann, 
Schormair et al. 2007). Two other variants were found within intronic regions of 
MEIS1 and MAP2K5/LBXCOR1 (Winkelmann, Schormair et al. 2007). Individuals 
who carry one risk-allele have a 50% increased risk of developing RLS (Stefansson, 
Rye et al. 2007). Coincidently, in the same year a similar study was carried out in the 
Icelandic and US population, and an association was found to the identical variant in 
BTBD9 (RLS6) (Stefansson, Rye et al. 2007). In this study the presence of PLM was 
used to support the diagnosis of RLS and the association of BTBD9 was based on 
individuals being PLM-positive. However, none of these genes are located in any of 
the previously described loci (RLS1-RLS5). In 2008, an association study which 
included 2458 RLS cases and 4749 controls focused on the RLS3 linkage region, on 
chromosome 9p. Two independent signals within splice variants expressed in the 
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central nervous system of PTPRD showed genome-wide significant association to 
RLS. PTPRD located on chromosome 9p23-24 is the fourth locus associated with 
RLS (Schormair, Kemlink et al. 2008). Also in 2008, a further association study in 
two Caucasian RLS samples of 918 independent cases and controls focused on the 
RLS1 linkage region. A total of 1536 SNPs in 366 genes within the 21 Mb region of 
RLS1 were analysed. Association was observed with SNP rs7977109 which is in the 
neuronal nitric oxide synthase (NOS1) gene, and therefore, suggests the involvement 
of the NO/arginine pathway in the pathogenesis of RLS (Winkelmann, Lichtner et al. 
2008). These molecular findings suggest substantial genetic and clinical 
heterogeneity of RLS. 
Table 3.1 lists the previously known RLS loci and associated regions, the ancestry, 
the number of generations or number of cases/controls, the method used to locate the 
region, the chromosomal location and locus name. 
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Table 3.1:Known RLS loci and associated regions. 
Study Ancestry No. Of generations 
(No. of members) 
or No. of 
cases/controls 
Method Chromosomal 
location 
Locus 
 Irish 2 (29) Linkage 
analysis 
5q  
Desautels et al. 
(2001) 
French-
Canadian  
1 (25) Linkage 
analysis 
12q12-q21  RLS1 
Bonati et al. 
(2003) 
Italian 1 (30) Linkage 
analysis 
14q13-q31 RLS2 
Chen et al. (2004)  United 
States 
2 (23) Linkage 
analysis 
9p24-22 RLS3 
Pichler et al. 
(2006) 
South 
Tyrolean 
Population Isolate 
(530) 
Linkage 
analysis 
2q33 RLS4 
Levchenko et al. 
(2006) 
French-
Canadian 
1 (59) Linkage 
analysis 
20p13 RLS5 
Winkelmann et al 
(2006) 
German Unknown Linkage 
analysis 
4q  
Winkelmann et al 
(2006) 
German Unknown Linkage 
analysis 
17p  
Winkelmann et al 
(2007)  
German and 
Canadian 
case/controls 
1600 cases and 2000 
controls 
Association 
study 
6p21 RLS6 
Stefansson et al 
(2007) 
Icelandic 429 cases and 16,866 
controls 
Association 
studies 
6p21 RLS6 
Winkelmann et al 
(2007) 
German and 
Canadian 
case/controls 
1600 cases and 2000 
controls 
Association 
studies 
2p14 RLS7 
Winkelmann et al 
(2007) 
German and 
Canadian 
case/controls 
1600 cases and 2000 
controls 
Association 
studies 
15q  
Schormair et al 
(2008) 
German, 
Austrian, 
Czech, 
Canadian 
2458 RLS cases and 
4749 controls  
Association 
studies 
9p23-24  
Winkelmann et al 
(2008) 
Caucasian 918 independent 
cases 
A three-
stage 
association 
study 
12q  
Levchenko et al 
(2008) 
French-
Canadian 
4 (46) Linkage 
analysis 
16p  
Kemlink et al. 
(2008) 
Italian 3 (12) Linkage 
analysis 
19p  
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The newly recruited Irish family RLS3002 had been previously examined for linkage 
to known loci. At the time of the initial research there were only four known loci: 
chromosome 12q, 14q, 9p and 5q and hence only these loci were examined. The 
research successfully excluded the entire chromosome 14 locus. However, although 
the other three loci were excluded for linkage to RLS in this pedigree by haplotype 
analysis, gaps still remained which required further investigation.  
Therefore, the aim of part one of this study was to completely exclude linkage from 
the three loci already examined, and to examine the newly identified loci and 
associated regions.  
  
125 
3.2 Materials and methods 
DNA extraction 
The same QIAamp Blood Kit from Qiagen described in section 2.2 was used to 
extract DNA from peripheral venous blood samples. 
Primer selection 
Polymorphic markers from the regions of RLS loci and associated SNPs were 
selected. Primer information was accessible from the UCSC genome browser 
(www.genome.ucsc.edu) and from the NCBI website (www.ncbi.nlm.nih.gov). 
Primers were ordered from biomers.net and the forward primer of each pair was 
fluorescently tagged to allow detection by the ABI 3130 system. The microsatellite 
markers for each of the RLS loci and associated SNPs examined are outlined in the 
tables below. 
Polymerase Chain Reaction (PCR) 
For this section of the study and for the purpose of genotyping, Polymerase chain 
reaction was carried out in 15 µl reaction volumes. Table 3.2 provides details of the 
reagents used.  
Table 3.2: Reagents used for PCR reaction 
Reagent [Stock] [Final] 1 sample (µl) 
10x buffer 10x 1x 1.5 
MgCl2 25mM 1.5mM 0.9 
dNTP 10mM 0.2mM 0.3 
Forward Primer 100ng/µl 100ng 0.5 
Reverse Primer 100ng/µl 100ng 0.5 
Taq polymerase 5U/µl 0.05U 0.1 
H2O   6.2 
DNA  50-100ng 5.0 
Total Volume   15.0 
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Once the samples were prepared, each 15 µl reaction was placed in a 0.2 ml capped 
PCR tube and placed on the GStorm Thermal Cycler PCR machine. A temperature 
gradient was initially used to discover the optimal annealing temperature for each 
individual marker (as outlined in section 2.3.1). The success of PCR was verified by 
agarose gel electrophoresis (as outlined in section 2.4). 
Genotyping and Linkage analysis were successfully performed for all markers under 
investigation (as per section 2.5 to 2.7). Figure 3.1 below is an example of ABI 
analysis reading of genotyping for two parents and two children for marker 
D13S218.  
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Figure 3.1: An example of ABI genotyping of related individuals 
Marker D13S218 using samples PATH046 (mother), PATH047 (father), PATH83 
(child1) and PATH199 (child 2). The red peaks refer to the internal size standard 
(ROX) used to determine allele sizes. These size standards are labelled for 
PATH083, at 139 bp, 150 bp and 160 bp respectively. The alleles are shown as blue 
peaks. The colour of the peaks correspond to the colour of the fluorescent label, 
which in this example is 6-FAM. The mother (PATH046) is homozygous for this 
marker (one peak at 147 bp) and the father (PATH047) is heterozygous (two peaks at 
147 bp and 153 bp). The positions of the peaks corresponds to the size of the allele 
which in this case is 141-153 bp. Child 1 (PATH083) is heterozygous and the alleles 
can be traced through the generations. He receives the 147 bp allele from his mother 
and the 153 bp allele from his father. Subsequently child 2 (PATH199) is 
homozygous for this marker (one single peak) with the inheritance of one 147 bp 
allele from the mother and another 147 bp from the father.  
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The allele fragment sizes obtained from genotyping were correlated with the allele 
numbers according to the CEPH database (www.cephb.fr). LOD scores were 
generated and distances excluded were determined. In addition, when gaps remained 
to be excluded in a locus, haplotype analysis was performed.  
Chromosomes 5q, 12q, and 9p had been analysed previously and needed some 
further work; therefore, they were examined first. The Linkage analysis result of 
each locus and associated region is described separately. 
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3.3 Results 
3.3.1 Chromosome 5 locus 
A novel locus for autosomal dominant RLS was previously mapped to chromosome 
5q. Based on linkage analysis and haplotype analysis of the large Irish family, the 
locus was placed in an 11.50 cM region between D5S2507 and D5S2042. Marker 
D5S2507 is located at 66.81 cM and marker D5S2042 is located at 78.31 cM. This 
locus had been previously examined for linkage for our RLS3002 Irish pedigree; 
however, linkage was not excluded from the entire locus. These previous results 
almost excluded the chromosome 5 locus but a small 3.08 cM gap remained between 
72.53 cM and 75.61 cM. When this initial study was being carried out, only 11 
family members were available. A number of other family members became 
available at a later date; therefore, it was necessary to genotype these members for 
the markers already examined. This was done in the hope that the additional family 
members would give more power to the study, giving a greater LOD score and 
thereby reduce or remove the remaining gap. Table 3.3 lists all the markers 
examined and outlines their positions (cM), the maximum LOD scores obtained at 
theta equal to zero and the corresponding maximum excluded distances in cM. Five 
of the six markers had been previously examined (Abdulrahim 2008). These markers 
are shown in blue. The results of the original data is shown in italics and the updated 
data is shown in regular text underneath. 
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Table 3.3: Markers used to examine chromosome 5 locus.  
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D5S418 58.55 -11.04 13.63 44.92 72.18 
D5S2500 69.23 -5.51 
-6.89 
3.30 
6.94 
65.93 
62.29 
72.53 
76.17 
D5S2072 73.35 0.17 
0.57 
0.00 
0.00 
- 
- 
- 
- 
D5S647 74.07 0.78 
1.38 
0.00 
0.00 
- 
- 
- 
- 
D5S2036 74.68 -1.98 
-1.94 
0.00 
0.00 
- 
- 
- 
- 
D5S2003 78.31 -5.51 
-5.44 
4.70 
4.92 
73.61 
73.39 
83.01 
83.23 
 
As mentioned, five markers which had been examined previously were genotyped 
for the remaining members of the RLS3002 family (PATH185, PATH186, 
PATH187, PATH199, PATH200, PATH207 and PATH208) which had been 
unavailable at the initial investigation of this locus. An additional marker, D5S418 
was also examined for this locus. Following investigation with the additional family 
members the 3.08 cM gap was removed. Figure 3.2 illustrates the positions of the 
markers, and the corresponding regions of exclusion on chromosome 5. The total 
area excluded spans from 44.92 cM to 83.23 cM. 
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Figure 3.2: Illustration of areas of exclusion for chromosome 5 locus 
Black arrow with scale represents a portion of chromosome 5. The black bar to the 
left of chromosome 5 represents the RLS locus spanning 11.50 cM. The regions 
excluded by the markers D5S418, D2S2500 and D2S2003 are represented by the 
coloured bars to the right of chromosome 5. The dark green bar on the far left 
illustrates the total area excluded combining results from all three markers. 
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3.3.2 Chromosome 12 locus (RLS1; MIM 102300) 
Chromosome 12 locus is flanked by markers D12S1044 and D12S78, located at 
97.16 cM and 111.87 cM respectively. The distance between these markers is 14.17 
cM (Desautels, Turecki et al. 2001). This locus was already examined for family 
RLS3002; however these results did not totally exclude the locus. There was a gap of 
0.10 cM which remained to be excluded. Seven markers were previously examined 
for the chromosome 12 locus. During this study an additional four markers were 
examined at this locus. Table 3.4 lists all the markers examined during the initial 
study (blue text) and the four additional markers examined, the LOD scores obtained 
at theta equal to zero, the distance of excluded regions, and the corresponding region 
of exclusion. Marker D12S1300 was repeated for the seven additional markers, 
similar to the chromosome 5 markers. The results of the original data is shown in 
italics and the updated data is shown in regular text underneath. 
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Table 3.4: Markers used to examine chromosome 12 RLS1 locus. 
(Original data is shown in italics and updated data is shown in regular text.) 
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D12S1052 83.19 -3.50 0.00 83.19 83.19 
D12S326 86.40 -6.75 3.20 83.20 89.60 
D12S1064 95.03 -3.22 1.20 93.83 96.23 
D12S351 95.56 -4.51 9.72 85.84 105.28 
D12S1044 103.90 -6.10 4.92 98.98 108.82 
D12S1300 104.12 -1.70 
-2.82 
0.00 
2.20 
- 
101.92 
- 
106.32 
D12S346 104.65 -10.90 11.82 92.83 116.47 
D12S1030 109.47 0.01 0.00 - - 
D12S318 109.47 -2.78 0.90 108.57 110.37 
D12S78  111.87 -2.78 -1.40 105.67 118.07 
 
In the previous study five markers obtained statistically significant LOD scores and 
excluded various regions of the chromosome 12 locus. The marker D12S1052 
showed a significant LOD score however it was only significant at θ=0.00. Hence 
there was no area of exclusion except at the position of the marker itself. Four 
additional markers D12S326, D12S351, D12S1300 and D12S346 were examined for 
this locus, to attempt to exclude the remaining 0.10 cM gap which was positioned 
between 110.37 cM and 110.47 cM. Marker D12S346 was successful at excluding 
this gap, excluding from 92.83 cM to 116.47 cM. Figure 3.3 illustrates the positions 
of the markers, and the corresponding regions of exclusion on chromosome 12. The 
total area excluded expands from to 83.19 cM to 118.07 cM. 
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Figure 3.3: Illustration of areas of exclusion on chromosome 12 locus 
Black arrow with scales represents a portion of chromosome 12 . The black bar to 
the left of chromosome 12 represents the chromosome 12 locus spanning 14.17 cM. 
The regions excluded by the markers D12S1064, D12S351, D12S1044, D12S1300 
D12S346, D12S318, and D12S78 are represented by the coloured bars to the right of 
chromosome 12. The dark green bar on the far left illustrates the total area excluded 
combining results from all markers. 
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3.3.3 Chromosome 9 locus (RLS3; MIM 610438) 
The chromosome 9 RLS locus is the largest found to date, and is located on the small 
arm of chromosome 9. The candidate region is defined by markers D9S1779 (0.00 
cM) and D9S162 (34.42 cM) in a region covering a 34.42 cM. Five markers had 
been previously examined, of which four obtained a statistically significant LOD 
score. However, two gaps remained to be excluded on the chromosome 9 locus. The 
first gap was located at the telomeric end of chromosome 9 and was 15.00 cM in 
length, and the second was located between 21.36 cM and 24.81 cM, 3.4 cM in 
length. Two new markers, D9S1813 and D9S1810, located at the telomeric end were 
ordered for the 15.00 cM gap. Marker D9S274 was re-examined with the remaining 
members of the RLS3002 family which had been unavailable at the initial 
investigation of this locus. Table 3.5 lists the markers investigated and summarizes, 
their positions, the LOD scores obtained at theta equal to zero, the distance of 
excluded regions, and the corresponding region of exclusion. 
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Table 3.5: Markers used to examine chromosome 9 locus.  
(Original data is shown in italics and updated data is shown in regular text.) 
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D9S917 0.00 -0.11 0.00 - - 
D9S1779 0.00 -2.20 0.00 - - 
D9S1871 8.37 0.43 0.00 - - 
D9S1813 9.83 -5.80 6.30 3.50 16.16 
D9S288 9.83 -8.35 7.45 2.38 17.28 
D9S1810 12.78 -3.4 4.90 7.88 17.68 
D9S286 18.06 -3.23 3.30 - - 
D9S274 28.42 -3.10 
-5.60 
3.61 
8.89 
- 
19.53 
- 
37.31 
D9S162 34.42 -3.30 5.02 - - 
 
The results for each marker on the initial examination are highlighted in blue in table 
3.5 above. The results which were achieved after genotyping the additional family 
members are in the unshaded lines below their corresponding marker. The two 
additional markers examined are included in this family. Following investigation 
with the additional family members the 3.40 cM gap located between 21.36 cM and 
24.81 cM was removed. The 14.76 cM gap was partially removed; however a 2.38 
cM gap remains at the top of chromosome 9. Figure 3.4 illustrates the positions of 
the markers, and the corresponding regions of exclusion on chromosome 9.  
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Figure 3.4: Illustration of areas of exclusion on chromosome 9 locus 
Black arrow with scales represents chromosome 9 (scales in cM). The black bar to 
the left of chromosome 9 represents the chromosome 9 locus spanning 34.42 cM 
between markers D9S1779 and D9S162. The regions excluded by the markers 
D9S1813, D9S1810, D9S286, D9S274 and D9S162 are represented by the light 
blue, purple, dark blue, green and pink bars to the right of chromosome 9. The green 
bar on the far left illustrates the total area excludeds. 
 
The results almost exclude the chromosome 9 locus, however a small 2.38 cM gap 
remains to be excluded at 0.00 cM to 2.38 cM. A haplotype analysis was carried out 
at this locus. It is clear from this analysis that there is no haplotype that is present in 
all the affected individuals and not present in the unaffected individuals. Therefore, 
due to the fact that the gap is small and that the haplotype analysis confirms 
exclusion of the locus, it can be assumed that the chromosome 9 locus is not linked 
to RLS in the pedigree.  
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Figure 3.5: Haplotype analysis of RLS3002 pedigree for the chromosome 4 
locus 
A list of the examined markers is present on the left hand side. The alleles for each 
individual obtained from genotyping using these markers are listed below each 
individual. Each haplotype formed from the series of alleles is given a coloured bar 
so it can be recognised easily. All the coloured haplotypes are present in both 
affected (filled squares and circles) and unaffected (squares and circles containing 
the letter N) individuals. Hence there is no one shared haplotype between all the 
affected individuals that is absent in normal individuals. 
 
This data, coupled with the LOD score results provides evidence that there is no 
linkage between RLS and the chromosome 9 locus in this family. 
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3.3.4 Chromosome 2 locus (RLS4; MIM 610439) 
The chromosome 2 RLS locus is located on 2q33. The candidate region is located 
between markers D2S311 (196.85 cM) and D2S2208 (205.06 cM), with a distance of 
8.21 cM between them. At this locus four markers were examined. Each of the 
markers showed negative LOD scores of <-2, all of which excluded variable 
distances. Table 3.6 lists the markers investigated and summarises their relative 
positions, the LOD scores obtained at theta equal to zero, the distance of excluded 
regions, and the corresponding region of exclusion. 
Table 3.6: Markers used to examine chromosome 2 locus. 
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D2S311 196.85 -5.6 2.20 194.65 199.05 
D2S2289 199.18 -3.4 2.60 196.58 201.78 
D2S2358 203.46 -3.2 2.60 200.86 206.06 
D2S2208 205.06 -5.6 9.90 195.16 214.96 
 
Four markers were examined within and surrounding the chromosome 2 locus, each 
of which obtained statistically significant LOD scores and excluded distinct regions 
of the RLS4 locus. Figure 3.4 illustrates the positions of the markers, and the 
corresponding regions of exclusion on chromosome 2.  
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Figure 3.6: Illustration of areas of exclusion on chromosome 2 locus 
Black arrow with scales represents a portion of chromosome 2. The black bar to the 
left of chromosome 2 represents the RLS4 locus spanning 8.21 cM between markers 
D2S311 and D2S2208. The regions excluded by the markers D2S311, D2S2289, 
D2S2358, and D2S2208 are represented by the coloured bars to the right of 
chromosome 2. The green bar on the far left illustrates the total area excluded 
combining all four markers. 
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3.3.5 Chromosome 20 locus (RLS5; MIM 611242) 
The chromosome 20 locus, referred to as RLS5, is located at 20p13. The region is 
flanked by the telomeric end of chromosome 20p (above marker D20S1155 at 0.00 
cM) and by a 1.07 cM interval between markers D20S849 (13.98 cM) and D20S835 
(15.05 cM). According to the Marshfield map the candidate region spans 
approximately 15.05 cM (http://research.marshfieldclinic.org/genetics/home/index.asp). It 
is important to note that the RLS5 locus paper estimates a locus of 16.00 cM 
(Levchenko, Provost et al. 2006). However, Levchenko and associates used the 
Decode map to estimate the positions of the microsatellite markers 
(http://www.decode.com). 
Six markers were examined at this locus, all of which showed negative LOD scores 
of <-2. Each excluded varying distances on the chromosome 20 locus. Table 3.7 lists 
all of the six markers investigated and describes, their positions, the LOD scores 
obtained at theta equal to zero, the distance of excluded regions, and the 
corresponding region of exclusion. 
 
Table 3.7: Markers used to examine chromosome 20 locus. 
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D20S199 6.25 -5.75 7.66 0.00 13.91 
D20S842 8.97 -5.61 9.33 2.79 21.45 
D20S181 9.53 -3.02 0.20 9.33 9.73 
D20S116 11.2 -2.8 2.20 9.00 13.40 
D20S849 13.98 -3.08 0.70 13.28 14.68 
D20S882 15.05 -3.28 3.10 11.95 18.15 
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Six markers obtained statistically significant LOD scores and excluded various 
regions of the chromosome 20 locus, RLS5. The marker D20S842 showed a 
significant LOD score, -5.61 at θ=0.00, and excluded from 0.00 cM to 21.45 cM, 
thereby excluding the entire chromosome 20 locus. Figure 3.7 illustrates the 
positions of the markers, and the corresponding regions of exclusion on chromosome 
20. 
 
  
Figure 3.7: Illustration of areas of exclusion on chromosome 20 locus 
Black arrow with scales represents a portion of chromosome 20. The black bar to the 
left of chromosome 20 represents the chromosome 20 locus spanning 8.20 cM 
between markers D20S311 and D20S2208. The regions excluded by the markers 
D20S199, D20S842, D20S181, D20S116, D20S849, and D20S882 are represented 
by the coloured bars to the right of chromosome 20. The green bar on the far left 
illustrates the total area excluded combining results of all markers. 
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3.3.6 Chromosome 16p locus 
The chromosome 16 locus is flanked by markers 16p_m30 (43.21 cM) and 16p_m11 
(44.36 cM), and 16p_m31 (47.01 cM) and D16S3068 (48.53 cM). This locus is split 
into two linked regions of ~830 and ~350 Kb. In genetic distance the locus is split 
into two regions; the first which is 1.16 cM, spanning from 43.21 cM to 44.36 cM, 
and the second which is 0.83cM spanning from 47.01 cM to 47.84 cM. Three 
markers (D16S3046, D16S403 and D16S3068), which were used in the initial study 
by Levchenko and associates, were examined for our pedigree (Levchenko, 
Montplaisir et al. 2008). Table 3.8 lists the three markers examined and outlines their 
positions, the LOD scores obtained at θ=0.00 and the equivalent excluded regions for 
the statistically significant scores. 
Table 3.8: Markers used to examine chromosome 2 locus.  
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D16S3046 40.65 -8.37 6.03 34.62 46.68 
D16S403 43.89 -2.05 0.00 - - 
D16S3068 48.53 -8.35 10.66 37.87 59.19 
 
All three markers obtained statistically significant LOD scores. Markers D16S3046 
and D16S3068 both excluded various regions of the chromosome 16 locus. The 
marker D16S403 showed a significant LOD score, however it was only significant at 
θ=0.00. Therefore, there was no distance of exclusion except at the position of the 
marker. Figure 3.8 illustrates the positions of the markers, and the corresponding 
regions of exclusion on chromosome 16. The total area excluded spans from 34.62 
cM to 59.19 cM.  
144 
 
Figure 3.8: Illustration of areas of exclusion for the chromosome 16 locus  
Black arrow with scales represents a portion of chromosome 16. The two black bars 
to the left of chromosome 16 represent the chromosome 16 locus spanning 1.16 cM 
and 0.83 cM respectively. The regions excluded by the markers D16S3046 and 
D16S3068 are represented by the coloured bars to the right of chromosome 16. The 
green bar on the far left illustrates the total area excluded. 
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3.3.7  Chromosome 19p locus 
Suggestive evidence for linkage on chromosome 19p has been reported. The locus is 
flanked by SNP markers rs754292 and rs273265, and was further mapped within a 
1.90 cM (0.30 Mb) interval between microsatellite markers D19S429 and D19S915. 
The locus is positioned at 45.38 cM to 47.31 cM on chromosome 19. Three markers 
were examined at this locus, and two of these markers, D19S226 and D19S414, were 
used in the initial study (Kemlink, Plazzi et al. 2008). All three markers showed 
negative LOD scores of <-2, each excluding variable distances. Table 3.9 lists the 
markers used to examine the chromosome 19 locus, their positions (cM), maximum 
obtained LOD scores at theta equal to zero, and the corresponding maximum 
excluded distances (cM). 
Table 3.9: Markers used to examine the chromosome 19 locus. 
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D19S226 42.28 -7.44 1.80 40.48 44.08 
D19S410 45.48 -5.02 2.40 43.08 47.88 
D19S414 53.81 -7.66 8.89 44.92 62.70 
 
All three markers examined obtained statistically significant LOD scores and 
excluded various regions of the chromosome 19p locus. The marker D19S414, 
which had been used in the initial study, showed a significant LOD score of -7.66 at 
θ=0.00, and excluded from 44.92 cM to 62.70 cM, thus excluding the entire 
chromosome 19p locus. Similarly for marker D19S410, it excluded the 1.90 cM 
locus as it excludes from 43.08 cM to 47.88 cM.  
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Figure 3.9 illustrates the positions of the three markers and the corresponding 
regions of exclusion on chromosome 19p. 
 
 
Figure 3.9: Illustration of areas of exclusion the chromosome 19 locus 
Black arrow with scales represents a portion of chromosome 19. The black bar to the 
left of chromosome 19 represents the chromosome 19 locus spanning 1.90 cM. The 
regions excluded by the markers D19S226, D19S410, and D19S414 are represented 
by the coloured bars to the right of chromosome 19. The green bar on the far left 
illustrates the total area excluded combining all three markers. 
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3.3.8  Chromosome 4q locus 
The Chromosome 4q locus is flanked by markers D4S406 and D4S402, located at 
117.06 cM and 124.45 cM respectively. Three markers were examined at this locus, 
and all three markers showed negative LOD scores of <-2, each excluding variable 
distances.Table 3.10 lists the three markers examined and outlines, their positions, 
the LOD scores obtained at θ=0.00 and the equivalent excluded regions for the 
statistically significant scores.  
Table 3.10: Markers used to examine chromosome 4 locus. 
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded 
fom to (cM) 
D4S2989 117.06 -8.38 3.61 113.45 120.67 
D4S407 117.06 -8.68 4.51 112.55 121.57 
D4S1575 132.05 -11.17 8.87 123.18 140.92 
 
All three markers obtained statistically significant LOD scores. Markers D4S2989 
and D4S407 excluded various regions of the chromosome 4 locus from 113.45 cM to 
121.57 cM. Marker D4S1575 excluded from 123.18 cM to 140.92 cM. Therefore, a 
1.62 cM gap remains to be excluded from the chromosome 4 locus. Figure 3.10 
illustrates the positions of the markers, and the corresponding regions of exclusion 
on chromosome. 
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Figure 3.10: Illustration of areas of exclusion on chromosome 4 locus 
Black arrow with scales represents a portion chromosome 4. The black bar to the left 
of chromosome 4 represents the chromosome 4 locus spanning 7.39 cM between 
markers D4S406 and D4S402. The regions excluded by the markers D4S2989, 
D4S407 and D4S1575 are represented by the coloured bars to the right of 
chromosome 4. The green bar on the far left illustrates the total area excluded 
combining all four markers. 
 
The results almost exclude the chromosome 4 locus, however a small 1.62 cM gap 
remains to be excluded. A haplotype analysis was carried out at this locus. It is clear 
from this analysis that there is no haplotype that is present in all the affected 
individuals and not present in the unaffected individuals. Therefore, due to the fact 
that the gap is small and that the haplotype analysis confirms exclusion of the locus, 
it can be assumed that the chromosome 4 locus is not linked to RLS in the pedigree.  
  
149 
 
 
Figure 3.11: Haplotype analysis of RLS3002 pedigree for the chromosome 4 
locus 
A list of the examined markers is present on the left hand side. The alleles for each 
individual obtained from genotyping using these markers are listed below each 
individual. Each haplotype formed from the series of alleles is given a coloured bar 
so it can be recognised easily. Unfortunately PATH187, PATH207 and PATH208 
could not be assigned a second bar as only one marker defined the two bars for 
PATH185 (their mother), and that marker information was not available for the three 
children.  All the coloured haplotypes are present in both affected (filled squares and 
circles) and unaffected (squares and circles containing the letter N) individuals. 
Hence there is no one shared haplotype between all the affected individuals that is 
absent in normal individuals. It is therefore possible to conclude that there is no 
linkage between RLS and the chromosome 4 locus in this family.  
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3.3.9  Chromosome 17p locus 
The chromosome 17p RLS locus extends from D17S1857 (43.01 cM) to D17S1294 
(50.74 cM) spanning a distance of 7.73 cM (Winkelmann J 2006). Four markers 
were examined at this locus. Three of the four markers showed a negative LOD 
score of <-2, each excluding variable distances. Table 3.11 lists the markers that 
were examined, the LOD scores obtained at θ=0.00 and the corresponding excluded 
regions. 
Table 3.11: Markers used to examine chromosome 17 locus.  
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D17S1857 43.01 -1.51 0.00 - - 
D17S2196 44.62 -8.52 7.76 36.86 52.38 
D17S1294 50.74 -6.01 6.03 44.71 56.77 
D17S798 53.41 -6.50 5.52 47.89 58.93 
 
The area excluded by the three markers, D17S2196, D17S1294 and D17S798, 
extends from 36.86 cM to 58.93 cM. The chromosome 17p locus extends from 43.01 
cM to 50.74 cM; therefore, it is possible to conclude that there is no linkage between 
RLS and the chromosome 17p locus in this family. Figure 3.12 illustrates the 
position of the three markers that obtained significant negative LOD scores and the 
corresponding regions of exclusion. 
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Figure 3.12: Illustration of areas of exclusion on chromosome 17 locus 
Black arrow with scales represents a portion of chromosome 17. The black bar to the 
left of chromosome 17 represents the chromosome 17 locus spanning 7.73 cM 
between markers D17S1857 and D17S1294. The regions excluded by the markers 
D17S2196, D17S1294 and D17S798 are represented by the coloured bars to the right 
of chromosome 17. The green bar on the far left illustrates the total area excluded . 
  
153 
3.3.10 Association within the BTBD9 gene (RLS6; MIM 611185) 
Association with several SNPs in the BTBD9 gene has been confirmed by a number 
of independent studies since 2007. Three SNPs in particular; rs9296249, rs9357271, 
and rs3922809, have been reported to be associated with susceptibility to RLS. 
These SNPs are located at 53.80-53.82 cM on chromosome 6. Two microsatellite 
markers were examined in this area; D6S1610 and D6S1607. Both showed 
significant LOD scores of <-2, excluding varied distances. Table 3.12 lists the two 
markers in questions, showing the LOD score obtained at θ=0.00 and the 
corresponding excluded regions. 
Table 3.12: Markers used to examine SNPs within the BTBD9 gene.  
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D6S1610 53.81 -2.71 1.20 52.61 55.01 
D6S1607 59.34 -8.54 6.64 52.70 65.98 
 
The two markers examined for this region both obtained significantly significant 
LOD scores, and excluded the area containing the associated SNPs. The markers 
D6S1610 showed a significant LOD score of -2.71 at θ=0.00, excluding 1.20 cM 
either side. The marker D6S1607 showed a significant LOD score of -8.54 at θ=0.00, 
excluding 6.64 cM either side, thereby overlapping with the area excluded by marker 
D6S1607. Figure 3.13 illustrates the positions of the two markers and the regions 
excluded on chromosome 6. 
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Figure 3.13: Illustration of areas of exclusion for variants within the BTBD9 
gene 
Black arrow with scales represents a portion of chromosome 2. The black arrow at 
approximately 53.80 cM represents the area where the SNPs are located. The regions 
excluded by the markers D6S1610 and D6S1607 are represented by the coloured 
bars to the right of chromosome 6. The green bar on the far left illustrates the total 
area excluded combining the two markers. 
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3.3.11  Association within the MEIS1 gene (RLS7; MIM 612853) 
A significant association was found between RLS and rs2300478 in the MEIS1 gene 
(601739) on the short arm of chromosome 2; 2p14-p13. This SNP is located at 
approximately 84.42 cM. Seven markers were selected and examined in this region. 
Six of the seven markers showed negative LOD scores of <-2. However, only three 
of these markers excluded variable distances. Table 3.13 lists all of the markers 
investigated and shows their positions (cM), the LOD scores obtained at θ=0.00 and 
the regions excluded for the markers with statistically significant LOD scores. 
Table 3.13: Markers used to examine SNP within the MEIS1 gene.  
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D2S2739 73.61 -5.59 7.56 66.05 81.17 
D2S337 80.60 -5.59 3.00 77.60 83.60 
D2S290 84.42 -2.17 0.00 - - 
D2S166 84.42 -3.23 0.00 - - 
D2S285 86.02 -2.41 0.00 - - 
D2S2113 88.15 0.22 0.00 - - 
D2S2110 90.82 -5.12 8.27 82.55 99.09 
 
Seven markers were examined in this region, however only three of these obtained a 
statistically significant LOD score, and excluded various regions surrounding the 
SNP rs2300478. The markers D2S290, D2S166, and D2S285 showed a significant 
LOD score of <-2, however it was only significant at θ=0.00. Therefore, there was 
no distance of exclusion aside from the position of the marker itself. The marker 
D2S2113 did not show a significant LOD score, and yielded an inconclusive LOD 
score of 0.22 at θ=0.00.   
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Figure 3.14 illustrates the positions of the markers, and the corresponding regions of 
exclusion on chromosome 2. The total area excluded spans from 66.05 cM to 99.09 
cM. 
 
 
Figure 3.14: Illustration of areas of exclusion for the SNP within the MEIS1 
gene  
Black arrow with scales represents a portion of chromosome 2. The black arrow at 
approximately 84.42cM to the left of chromosome 2 represents the region which the 
SNP is located. The regions excluded by the markers D2S273, D2S337, and D2S211 
are represented by the coloured bars to the right of chromosome 2. The dark green 
bar on the far left illustrates the total area excluded. 
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3.3.12  Association between RLS and variants in the 
MAP2K5/LBXCOR1 gene 
Highly significant associations were found between RLS and a number of variants in 
a locus containing the genes MAP2K5 and LBXCOR1 on the long arm of 
chromosome 15. These associations were located at approximately 66.90 cM. Four 
markers were selected and examined in this region. All four of the markers showed 
negative LOD scores of <-2, each excluding variable distances, depending on the 
LOD scores obtained. Table 3.14 displays the markers investigated and outlines their 
positions (cM), the LOD score obtained at θ=0, and the corresponding excluded 
regions.  
Table 3.14: Markers used to examine variants within the MAP2K5 and LBXCOR1 
genes.  
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D15S1015 66.90 -3.91 1.10 65.80 68.00 
D15S153 68.10 -5.51 3.71 64.39 71.81 
D15S131 71.28 -9.82 12.03 59.25 83.31 
D15S211 75.85 -5.92 7.45 68.40 83.30 
 
Four markers were examined in this region, all of which obtained significantly 
significant LOD scores, each excluding varying distances on chromosome 15. The 
marker D15S131 obtained a LOD score of -9.82 at θ=0.00, excluding a large 
distance of 12.03 cM either side of the marker, thus overlapping with the regions 
excluded by the other three markers. Figure 3.15 illustrates the positions of the 
markers, and the corresponding regions of exclusion on chromosome 15. The total 
area excluded spans from 59.25 cM to 83.31 cM.  
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Figure 3.15: Illustration of areas of exclusion for variants within the 
MAP2K5/LBXCOR1 genes 
Black arrow with scales represents a portion of chromosome 15. The black arrow at 
approximately 66.90 cM to the left of chromosome 15 represents the region which 
the SNP is located. The regions excluded by the markers D15S1011, D15S153, 
D15S211, and D15S131 are represented by the coloured bars to the right of 
chromosome 15. The dark green bar on the far left illustrates the total area excluded 
combining the four markers. 
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3.3.13  Protein tyrosine phosphatase, receptor type, D (PTPRD) 
Protein tyrosine phosphatase, receptor type, D (PTPRD) is a member of the protein 
tyrosine phosphatase (PTP) family. A significant association was found between 
RLS and two independent SNPs, rs1975917 and rs4626664, in the PTPRD gene 
(5789) on the short arm of chromosome 9; 9p23-p24.3 (Schormair, Kemlink et al. 
2008). Two markers were selected and examined in this region. Both of these 
markers showed negative LOD scores of <-2, thereby excluding variable distances. 
Table 3.15 lists all of the markers investigated and shows their positions, the LOD 
scores obtained at θ=0.00 and the regions excluded for the markers with statistically 
significant LOD scores. 
Table 3.15: Markers used to examine SNPs within the PTPRD gene.  
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from 
Area 
Excluded to 
D9S286 18.06 -5.06 7.56 10.50 25.62 
D9S274 28.42 -5.61 3.00 19.53 37.31 
 
Two markers were examined in this region, and both excluded the region 
surrounding the SNPs rs1975917 and rs4626664. Figure 3.16 illustrates the positions 
of the markers, and the corresponding regions of exclusion on chromosome 9. The 
total area excluded spans from 10.50 cM to 37.31 cM. 
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Figure 3.16: Illustration of areas of exclusion for SNPs within the PTPRD gene 
Black arrow with scales represents a portion of chromosome 9. The two black arrows 
at approximately 19.17 cM and 20.12 cM to the left of chromosome 9 represent the 
regions which the SNPs are located. The regions excluded by the markers D9S286 
and D9S274 are represented by the coloured bars to the right of chromosome 9. The 
dark green bar on the far left illustrates the total area excluded combining all three 
markers. 
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3.3.14 Association of variants in the NOS1 gene and RLS 
Highly significant associations were found between RLS and a number of variants in 
the neuronal nitric oxide synthase (NOS1) gene on the long arm of chromosome 12. 
Association was observed with SNP rs7977109 which is located at a genetic distance 
of 129.30 cM on chromosome 12 (Winkelmann, Lichtner et al. 2008). Two markers 
were selected and examined in this region. The two markers, D12S2082 and 
D12S366, both showed negative LOD scores of <-2, each excluding variable 
distances, depending on the LOD scores obtained. Table 3.16 displays the markers 
investigated and outlines their positions (cM), the LOD score obtained at θ=0.00 and 
the corresponding excluded regions. 
Table 3.16: Markers used to examine variants within the NOS1 gene.  
Marker Position (cM) Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D12S2082 130.94 -6.63 2.20 128.74 133.14 
D12S366 133.33 -8.56 2.20 131.13 135.53 
 
Two markers were examined in this region, both of which obtained significant LOD 
scores, each excluding varying distances on chromosome 12. Marker D12S2082 
obtained a LOD score of -6.63 at θ=0.00 and marker D12S366 obtained a LOD score 
of -8.56 at θ=0.00, however both excluded 2.20 cM either side of the position in 
which it is located. Figure 3.17 illustrates the positions of the markers, and the 
corresponding regions of exclusion on chromosome 12. The total area excluded 
spans from 128.74 cM to 135.53 cM. 
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Figure 3.17: Illustration of areas of exclusion for variants within the NOS1 gene 
Black arrow with scales represents a portion of chromosome 12. The black arrow at 
129.30 cM to the left of chromosome 12 represents the region which the SNP 
rs7977109 is located. The regions excluded by the markers D12S2082 and D12S366 
are represented by the orange and blue bars to the right of chromosome 12. The dark 
green bar on the far left illustrates the total area excluded.  
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3.4 Conclusion 
A new Irish family RLS3002 which consisted of 18 members had been previously 
recruited (Figure 2.1). This is a three generation family. Unfortunately the affected 
grandmother and unaffected grandfather were deceased at the time of the study, and 
DNA samples were unavailable. In the second and third generation, there are 11 
affected individuals, three unaffected spouses and four unaffected children. Although 
the chromosome 12q locus mapped by Desautels and associates in a French-
Canadian family displayed autosomal recessive inheritance (Desautels, Turecki et al. 
2001), this Irish pedigree displayed and autosomal dominant pattern of inheritance as 
reported in all the other RLS loci. This is evident as all the affected individuals have 
only one parent who is affected. 
At the time the previous study was carried out only four loci had been described, 
chromosome 12q, 14p, 9p and 5q. RLS linkage was successfully excluded for the 
entire RLS2 locus (chromosome 14q) in this family. Due to time constraints the 
other three loci were not fully excluded; therefore, further work had to be carried out 
for these loci. A further six RLS loci and five associated regions had been identified 
since the initial study was performed. It was therefore necessary to investigate if 
pedigree RLS3002 was linked to any of these regions.  
When the previous study was carried out only 11 family members were available to 
participate in this study. However, over the years following, physical examination 
and questionnaires were administered for the remaining seven individuals, and 
subsequently these additional blood sample were collected. The addition of these 
seven members would add considerable power to the study. Therefore, this study 
began by re-investigating the markers used for the chromosome 5p, 12q and 9p loci, 
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and genotyping was performed for any individuals who hadn‟t been previously 
available. This was in the hope that the addition of the genotypes would increase  the 
power of the study and generate stronger LOD scores for specific markers and 
therefore, exclude any gaps remaining in the loci.  
The chromosome 5 locus was examined first. A 1.10 cM gap remained in this locus 
which was not excluded. Following investigation with the additional family member 
the LOD score of marker D5S2500 decreased from -5.51 at θ=0.00 to -6.89 at 
θ=0.00. Previously it had been excluded from 65.93 cM to 72.53 cM, however it 
now excluded from 62.29 cM to 76.17 cM, thereby excluding the gap which was 
positioned between 72.53 cM to 73.61 cM. The chromosome 5 locus was 
successfully excluded for RLS3002.  
Chromosome 12 locus (RLS1) was next examined. A small gap of 0.10 cM remained 
to be excluded for this locus. Four additional markers were examined at this locus 
and marker D12S346 which gave a LOD score of 10.90 at θ=0.00 was successful at 
excluding the gap which was positioned between 110.37 cM and 110.47 cM. The 
chromosome 12 locus was successfully excluded for RLS3002. 
The chromosome 9 locus, which was found in an Italian population, is a very large 
locus, and two gaps remained to be investigated for pedigree RLS3002. The two 
gaps spanned 14.76 cM at the telomeric end of chromosome 9 and the other 3.40 cM 
gap was located between 21.36 cM and 24.81 cM. Following investigation with the 
additional family members and marker D9S274, which was used in the previous 
study, the 3.40 cM gap was removed. Two additional markers were investigated at 
the telomeric end, D9S1813 and D9S1810. The 14.76 cM gap was partially excluded 
for linkage, however there is still a small area where the markers failed to cover and 
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a 3.53 cM gap remains. The haplotye analysis provides evidence to confirm 
exclusion of linkage to this locus. Examination of further markers in the region of 
the area not excluded would confirm this further. 
The chromosome 2 locus (RLS4) was next examined for linkage in this Irish 
pedigree. Four evenly spaced markers were chosen and examined, each of which 
obtained statistically significant LOD scores and successfully excluded the RLS4 
locus for linkage to this pedigree. The markers D2S311 and D2S2208 which flank 
the locus and were used in the initial study by Pichler and associates were used in 
this study also. It is interesting that marker D2S2208 could solely exclude this locus 
for linkage to our Irish pedigree. It excluded 9.90 cM either side of where it was 
positioned, the locus only being 8.20 cM in length. 
The RLS5 locus which was located in a French-Canadian population is located on 
the short arm of chromosome 20. Six markers were examined for this locus and each 
one excluded varying distances on the chromosome 20 locus, successfully excluding 
the entire chromosome 20 locus. 
The chromosome 16p locus which was also found in a French-Canadian family is 
unusual as it is split into two linked regions of ~830 and ~350 Kb (Levchenko, 
Montplaisir et al. 2008). It is unusual to see a locus split into two linked regions 
caused by an unusual and rare double recombination in just one family member. 
Genotyping errors and DNA contamination was ruled out, so therefore the tight 
double recombination was either a consequence of a recombination event without 
crossover interference or due to the fact a very rare event occurred. Three markers 
were examined for this locus. All three gave a statistically significant LOD score, 
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however only two of the markers excluded various regions of the chromosome 16 
locus. These markers were sufficient to fully exclude linkage for pedigree RLS3002. 
There was suggestive linkage to chromosome 19p13. Three markers were examined 
at this locus, two of which were used in the initial study by Kemlink and associates 
(Kemlink, Plazzi et al. 2008). All three markers examined obtained a statistically 
significant LOD score, and RLS linkage was successfully excluded for the 
chromosome 19p13 locus in the family. 
A relatively new approach used to find regions associated with RLS is the genome-
wide association study or GWAS; this is a high-throughput approach which scans 
the entire genome in an unbiased manner, using statistical methods to determine 
associations between chromosomal loci and a given phenotype. It requires a large 
number of cases and a large number of controls which is often difficult to collect. 
Association studies don‟t always have to scan the entire genome and they can be 
used for specific regions, such as the explorative study carried out by Winkelmann 
and associates in a 21 Mb region encompassing the RLS1 critical region on 
chromosome 12 (Winkelmann, Lichtner et al. 2008).   
Two recent studies used a large-scale high-density genome-wide approach. In the 
first study which was conducted in the German and Canadian population, three 
genomic regions were identified encoding the genes MEIS1, BTBD9 and a third 
region encoding the genes MAP2K5 and LBXCOR1 (Winkelmann, Schormair et al. 
2007). Coincidently a similar study was carried out in the Icelandic and US 
population, and an association was found in the identical variant in BTBD9 
(Stefansson, Rye et al. 2007).  
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Three SNPs were found to be associated in the BTBD9 gene, RLS6. Two markers 
were examined for linkage in this area on chromosome 6, both excluding varying 
distances, and specifically the region in which the variants are located. Therefore the 
SNPs associated with the BTBD9 gene are not linked to our family and can be 
excluded. 
The MEIS1 gene is located on chromosome 2p14. Seven genes needed to be 
examined for this region. Four of the seven genes did not give any exclusion; 
therefore it was necessary to examine a further three markers. These markers 
excluded varying overlapping distances and subsequently excluded the region 
containing the associated SNP. 
Highly significant associations were found between RLS and a number of variants in 
the locus containing the genes encoding MAP2K5 and LBXCOR1 on chromosome 
15q. Four markers in this region were chosen and examined for linkage to RLS3002. 
All four markers obtained significant LOD scores, enabling the exclusion of this 
region. 
Two independent signals within splice variants expressed in the CNS of PTPRD 
showed genome-wide significant association to RLS (Schormair, Kemlink et al. 
2008). Two markers were chosen in this region and linkage analysis was performed 
for family RLS3002. Markers were successful in excluding the associated region for 
linkage to the family.  
The association of variants in the NOS1 gene and RLS implies an involvement of the 
NO/arginine pathway in the pathogenesis of RLS. Two markers were chosen in this 
region and following examination of our family with these markers, the associated 
region was excluded for linkage to our family. 
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Our analysis shows that the disease is not linked to any of the known RLS loci or 
risk-associated genes. Hence it can be assumed that members of the family may 
carry a gene mutation in a novel genetic locus. Therefore a new unidentified locus 
awaits discovery and provides further evidence for the genetic heterogeneity of RLS. 
In order to identify a novel-locus a genome-wide scan is required.  
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Chapter 4 
Genome-wide Scan 
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4.1 Introduction 
Initial work showed that pedigree RLS3002 is not linked to any of the known RLS 
loci or risk associated genes. Therefore it can be assumed that a new locus awaits 
identification in this pedigree, a locus which carries a gene mutation. In order to look 
for this novel locus a genome-wide scan was performed. This approach tests for 
linkage of the trait to anonymous polymorphic markers spread throughout the 
genome. A good genome-wide scan will attempt to cover the entire human genome 
using a set of markers evenly spaced across a given genetic map. The polymorphic 
markers used are generally chosen for their ease of genotyping and their position 
within a genetic map. An advantage of doing such a scan is that no previous 
knowledge of the function of any genes is required. Another huge advantage of this 
method, particularly for RLS, is that knowledge of the biology of the trait or disease 
in question is not a requirement. Genome-wide scans rely on a standard set of 
markers which are generally termed a “mapping set.” For this study, two mapping 
set were used. 
The first mapping set used was the Research Genetics Inc. mapping set (Appendix I). 
It comprised of 146 microsatellite markers, which were spaced at approximately 20 
cM intervals throughout the genome. The markers were predominantly 
tetranucleotide repeats, although the set did contain some dinucleotide and 
trinucleotide markers also. The markers were fluorescently labelled with 6-FAM 
(blue), HEX (green) or TET (yellow) labels. 
The second mapping set used was the Applied Biosystems Linkage mapping set 
version 2.5 (Appendix II). This mapping set comprises of 28 panels of fluorescently 
labeled primer pairs selected to amplify informative microsatellite loci from the 
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Généthon human linkage map. All markers in this set are dinucleotide repeats, and 
are fluorescently labeled with either 6-FAM (blue), VIC (green) or NED (yellow). 
There is exactly 400 microsatellite markers in this mapping set and the set has a 
resolution of 10 cM. Each of the 28 panels consists of a group of markers that can be 
loaded into one capillary or into one lane in a gel. Therefore no one marker in any 
panel has the same fluorescent dye or is in the same size range as another marker in 
that panel. Panels sometimes contain markers from more than one chromosome in 
order to gain the most efficiency. The allele size range for this mapping set is based 
on the range of sizes seen for a particular marker in the CEPH database. However, 
Applied Biosystems optimised and tailed the markers, and the primers used for this 
set are often different to those recommended by the standard databases e.g. NCBI 
and Ensembl. Therefore it is often necessary to correct the genotyping results by 
adding/subtracting values up to 150 bp in order to adjust them to CEPH values.  
It was important to find the total length of each chromosome before starting the 
genome-wide scan. By knowing the total genetic length of a chromosome it was 
possible to tell whether or not the telomere at the end of the chromosome was totally 
excluded or if another marker was required to exclude this area. The total sex 
averaged genetic length of the 22 autosomes is 3488 cM (Broman, Murray et al. 
1998). Table 4.1 lists the genetic length of each individual chromosome Each of the 
22 autosomes and its corresponding genetic distance (in cM) is given.  
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Table 4.1: The genetic length of each chromosome  
Chromosome  Length (cM) Chromosome  Length (cM) 
1 289.66 12 168.79 
2 269.07 13 114.99 
3 228.14 14 138.19 
4 211.66 15 122.15 
5 197.54 16 134.13 
6 193.14 17 126.46 
7 181.97 18 126.00 
8 167.91 19 105.02 
9 168.98 20 101.22 
10 173.13 21 57.78 
11 147.78 22 62.32 
As previously discussed (section 1.12) LOD scores of 3.00 (1000:1 odds in favour of 
linkage) or more are evidence of linkage and -2.00 or less are indicative of non-
linkage/exclusion (Haines J.L 1998). Values between -2.00 and 3.00 are inconclusive 
and require further examination. Power calculation for linkage analysis based on 
family RLS3002 was performed using SLINK 
(http:/linkage.rockefeller.edu/soft/slink.html). SLINK simulation analysis indicated 
that the maximum LOD score achievable for this family is 3.41 at θ = 0.01. This 
value is very informative in that it allows the investigator to gain insight into the full 
information content of the available pedigree material. The true maximum LOD 
score is the highest potential LOD score when all meiosis are fully informative under 
the assumed model and allele frequencies (Haines J.L 1998). It is important to 
consider that when carrying out two-point linkage analysis the maximum LOD score 
may not be attained even if there is linkage. When considering the significance of a 
particular LOD score it is important to note whether all the available linkage 
information has been captured. The observed maximum LOD score may not match 
the attainable maximum LOD score for several reasons, including lack of 
informativeness of key individuals or a difference in allele frequencies from 
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simulated results. Therefore when performing linkage analysis for RLS3002 any 
microsatellite marker which resulted in a maximum LOD score of approximately 
1.00 or more was investigated further. 
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4.2 Materials and Methods  
DNA extraction 
The QIAamp Blood Kit from Qiagen described in section 2.2 was used to extract 
DNA from peripheral venous blood samples. 
 
Polymerase Chain Reaction (PCR) 
For this section of the study, two different recipes for PCR were used, depending on 
the mapping set in question.  
Research Genetics Inc. mapping set 
The first mapping set used was the Research Genetics Inc. mapping set, and PCR 
was carried out in 15 µl reaction volumes. Table 4.2 provides details of the reagents 
used. The table contains the name of the reagent, the stock concentration, the 
concentration used, and the amount of each reagent in a 15 µl reaction volume.  
Table 4.2 Reagents used for PCR in 15 µl reaction volumes.  
Reagent [Stock] [Final] 1 sample (µl) 
5x buffer Promega 5x 1x 1.50 
MgCl2 Promega 25 mM 1.5 mM 0.90 
dNTP 10 mM 0.2 mM 0.30 
Forward Primer 100 ng/µl 100 ng 0.50 
Reverse Primer 100 ng/µl 100 ng 0.50 
Taq polymerase 
Promega 
5 U/µl 0.05 U 0.10 
H2O   6.20 
DNA  50-100 ng 5.00 
Total Volume   15.0 
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Once the samples were prepared, each 15 µl reaction was placed in a 0.2 ml capped 
PCR tube and placed on the GStorm Thermal Cycler PCR machine. A temperature 
gradient was initially used to discover the optimal annealing temperature for each 
individual marker (as outlined earlier in section 3.2). The success of PCR was 
verified by agarose gel electrophoresis (as outlined in section 2.4).  
Applied Biosystems Linkage mapping set version 2.5 
The second mapping set, the Applied Biosystems Linkage mapping set version 2.5, 
required a different recipe for PCR. For this mapping set True Allele® PCR Premix 
was used. This is a PCR master mix that contains AmpliTaq Gold® DNA 
polymerase, dNTPs, MgCl2, and buffer. True Allele® PCR Premix had been 
optimized for strong, specific PCR amplification of microsatellite markers in the 
ABI PRISM® Linkage Mapping Set. The reaction consisted of premix, primers, 
DNA and water and was performed in 15 µl reaction volumes. Table 4.3 provides 
details of the reagents used. The table contains the name of the reagent, the 
concentration used, and the amount of each reagent in a 15µl reaction volume. 
Table 4.3. Reagents used for PCR using the PCR premix from Applied Biosystems.  
Reagent [Final] 1 sample (µl) 
True Allele® PCR Premix  9.00 
Primer mix 5 pmol 0.60 
H2O  3.00 
DNA 50-100 ng 2.40 
Total Volume  15.00 
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PCR was carried out on a GStorm Thermal cycler, under temperature control using 
the following program: 
95°C for 12 min (Denaturation) 
94°C for 15 s 
55°C for 15 s 
72°C for 30 s 
89°C for 15 s 
55°C for 15 s 
72°C for 30 s 
72°C for 10 min (Extension) 
The success of PCR was verified by agarose gel electrophoresis (as outlined in 
section 2.4). 
Genotyping and Linkage analysis were successfully performed for all markers under 
investigation (as per section 2.5 to 2.7). Figure 4.2 below is an example of ABI 
analysis reading of genotyping for two parents and two children. The marker used in 
this example is D10S597, a marker which was used in the genome-wide scan, and 
part of the Applied Biosystems Linkage mapping set version 2.5. 
} 10 cycles 
} 32 cycles 
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Figure 4.1: An example of ABI genotyping of related individuals 
Marker D10S597 using samples PATH046 (mother), PATH047 (father), PATH048 
(child1) and PATH049 (child 2). The red peaks refer to the internal size standard 
used to determine allele sizes. The alleles are shown as green peaks. The colour of 
the peak corresponds to the colour of the fluorescent label, which in this example is 
HEX. The positions of the peaks correspond to the size of the allele which in this 
case is 273-297 bp.  The mother (PATH046) is homozygous for this marker (one 
peak), and carries two copies of the 292 bp allele.  The father (PATH047) is 
heterozygous (two peaks) and carries a copy of the 292 bp allele and a copy of the 
294 bp allele. Child 1 (PATH048) is heterozygous and the alleles can be traced 
through the generations. The 292 bp allele is passed from the mother and the 294 bp 
allele is passed from the father. Child 2 (PATH049) is homozygous for this marker 
(one single peak) with the inheritance of one 292 bp allele from the mother and 
another 292 bp from the father.  
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4.3 Results 
The results for each chromosome will be given individually, combining the results 
from the two mapping sets. Markers which had been previously ordered for 
examination of RLS loci and associated regions, and which have been previously 
discussed in chapter 3, have been included in these results also in order to identify 
regions that have been excluded. 
4.3.1 Chromosome 1  
The Research Genetics Inc. mapping set contained eight markers for chromosome 
one, five of which were tetranucleotide repeats and the remaining three were 
trinucleotide. The Applied Biosystems mapping set contained 31 markers for 
chromosome 1. Table 4.4 lists the markers that were examined from both mapping 
sets, their positions, the LOD scores obtained at θ=0.00 the corresponding maximum 
excluded distances in cM, and the regions excluded. Markers highlighted in blue 
represent markers from the Research Genetics Inc. mapping set. Markers highlighted 
in pink represent markers from the Applied Biosystems mapping set. 
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Table 4.4: Markers used to examine chromosome 1.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D1S468 4.22 -5.52 1.90 2.32 6.12 
D1S214 14.04 -5.31 2.40 11.64 16.44 
D1S450  20.61  -6.79  3.61  17.00 24.22  
D1S2667 24.68 -5.49 1.70 22.98 26.38 
D1S2697 37.05 -5.55 6.33 30.72 43.38 
D1S199 45.33 -8.21 2.00 43.33 47.33 
D1S234 55.10 -8.24 9.00 46.10 64.10 
D1S1622  56.74  -5.31  2.50  54.24  59.24  
D1S255  65.47  -5.09  0.40  65.07  65.87  
D1S2797  75.66  -2.08  0.00  -  -  
D1S2890 85.68 -6.61 3.10 82.57 88.78 
D1S3728  89.49  -5.43  1.60  87.89  91.09  
D1S230 95.31 -6.58 2.40 92.91 97.71 
D1S2841 106.45 -8.36 12.13 94.32 118.58 
D1S1728  109.04  -2.55  0.40  108.64  109.44  
D1S2868 126.16 0.60 0.00 - - 
D1S206  134.20  -4.25  4.31  129.89  138.51  
D1S3723  140.39  -5.59  7.35  133.04  147.74  
D1S2726  144.28  -5.08  5.32  138.96  149.6  
D1S498 155.89 -7.22 1.90 153.99 157.79 
D1S484 169.69 1.69 0.00 - - 
D1S2878 177.86 -10.62 9.51 168.35 187.37 
D1S196 181.49 -7.37 5.62 175.87 187.11 
D1S1589  192.05  -3.24  3.10  188.95  195.15  
D1S413 212.42 -3.34 4.81 207.61 217.23 
D1S249  222.65  -1.86  0.00  -  -  
GATA124F08  226.16  -8.57  10.14  216.02  236.30  
D1S425 231.11 -1.79 0.00 - - 
D1S213  242.23  -7.65  9.31  232.92  251.54  
D1S3462  247.23  -5.27  1.30  245.93  248.53  
D1S2800  252.12  -7.64  7.45  244.67  259.57  
D1S2785 266.27 -5.88 1.50 264.77 267.77 
D1S547  267.51  0.34  0.00  -  -  
D1S2842 273.96 -1.79 0.00 - - 
D1S2836 285.75 -5.24 1.50 284.25 287.25 
Thirty-five markers from the two mapping sets were examined for chromosome 1. 
Twenty-eight of these markers obtained a statistically significant LOD score, and 
excluded various regions on the chromosome. Marker D1S2797 showed a significant 
LOD score of <-2, however it was only significant at θ=0.00. Therefore, there was 
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no distance of exclusion aside from the position of the marker itself. Markers 
D1S2868, D1S484, D1S249, D1S425, D1S547 and D1S2842 did not show 
significant LOD scores, and yielded inconclusive LOD scores of 0.60 at θ=0.00, 1.69 
at θ=0.00, -1.86 at θ=0.00, -1.79 at θ=0.00, 0.34 at θ=0.00 and -1.79 at θ=0.00 
respectively. Figure 4.1 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 1. 
 
Figure 4.2: Illustration of areas of exclusion for Chromosome 1 
Black vertical line with scales represents chromosome 1 (scale in cM). The red bars 
on the right illustrates the total areas excluded combining all markers from the two 
linkage sets. The marker(s) which contributed to these exclusion values are also 
indicated.  
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The results of the genome-wide scan exclude a substantial area of chromosome 1. A 
number of gaps remain on chromosome 1 however the majority of these gaps are 
small. The largest gap is seen between 65.87 cM and 82.58 cM. A total of 196.14 cM 
of chromosome 1 was excluded, which equates to 67.7% of the entire chromosome. 
The highest LOD score seen for this chromosome was for D1S484 at169.69 cM, 
which presented with a LOD score of 1.69 at θ=0.00. Although this LOD score was 
less than the +3 required for evidence of linkage, it was one of the highest LOD 
scores observed, therefore it required further investigation (section 4.4.1). 
  
182 
4.3.2 Chromosome 2  
The Research Genetics Inc. mapping set contained eleven markers for chromosome 
2, nine of which were tetranucleotide repeats. The Applied Biosystems mapping set 
contained 30 markers for chromosome 2. Table 4.5 lists the markers that were 
examined from both mapping sets, their positions, the LOD scores obtained at 
θ=0.00, the corresponding maximum excluded distances in cM, and the regions 
excluded. Markers highlighted in blue represent markers from the Research Genetics 
Inc. mapping set. Markers highlighted in pink represent markers from the Applied 
Biosystems mapping set.  
Eight markers from the Research Genetics Inc mapping set were completed for 
chromosome two and eighteen makers from the Applied Biosystems Mapping set 
were completed. Eleven additional markers on chromosome 2 had been ordered 
previously to examine the chromosome 2 locus (Section 3.3.4) and to examine the 
association between RLS and a variation within the MEIS1 gene (section 3.3.11). 
Figure 4.2 illustrates the total areas excluded from chromosome 2 when markers 
from both mapping sets and previously examined markers have been combined. 
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Table 4.5: Markers used to examine chromosome 2.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D2S2211 15.61 0.03 0.00 - - 
D2S2952 17.88 -3.08 6.84 11.04  24.72  
D2S168 27.6 -5.56 3.10 23.96 30.16 
D2S405 47.97 -1.78 0.00 -  -  
D2S367 54.96 -8.28 11.71 43.25 66.67 
D2S2259 64.29 -8.11 8.48 55.81 72.77 
D2S1356 64.29 -5.86  3.10  61.19  67.39  
D2S391 70.31 -7.05 8.89 61.42 79.20 
D2S2739 73.61 -5.59 7.56 66.05  81.17  
D2S337  80.6  -5.59  3.00  77.6  83.6  
D2S290  84.42  -2.17  0.00  -  -  
D2S166  82.42  -3.23  0.00  -  -  
D2S285  86.02  -2.41  0.00  -  -  
D2S327  88.15  -5.17  1.90  86.25  90.05  
D2S2113  88.15  0.22  0.00  -  -  
D2S2110  90.82  -5.12  8.27  82.55  99.09  
D2S286 94.05 -6.07 10.55 83.50 104.60 
D2S1777 99.41 0.22 0.00 -  -  
D2S329  101.02  -2.79  2.20  98.82  103.22  
D2S2333 103.16 -8.18 6.54 96.62 109.70 
D2S160 122.96 -4.69 4.11 118.85 127.07 
D2S112 141.62 -8.54 1.20 140.42 142.82 
D2S1334 145.08 -5.62 9.93 135.15  155.01  
D2S151 152.04 -8.36 7.35 144.69 159.39 
D2S142 161.26 -6.51 1.80 159.46 163.06 
D2S117 194.45 -7.66 6.64 187.81 201.09 
D2S311  196.90  -5.61  4.40 192.50  201.30  
D2S2289  199.20  -3.43  4.00 195.20  203.20  
D2S2358  203.50  -3.16  5.20 198.30  208.70  
D2S325 204.53 -5.49 7.97 196.56 212.50 
D2S2208  205.10 -5.55  9.90 196.56 212.50 
D2S2382 213.50 -7.67 5.22 208.28 218.72 
D2S434  215.73 -3.57 0.60 215.13  216.33  
D2S126 221.13 0.48 0.00 - - 
D2S206 240.79 -0.22 0.00 - - 
D2S2968 251.94 0.52 0.00 -  -  
D2S125 260.63 -5.97 7.97 252.66 268.60 
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Figure 4.3: Illustration of areas of exclusion for Chromosome 2 
Black vertical line with scales represents chromosome 2 (scales in cM). The red bars 
on the right illustrates the total areas excluded combining all markers from the two 
linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
 
The results of the genome-wide scan exclude a substantial area on chromosome 2. A 
number of gaps remain on chromosome 2; the largest gap present is between 218.72 
cM and 252.66 cM. A total of 168.55 cM of chromosome 2 was excluded, which 
equates to 62.6% of the entire chromosome. The highest LOD score seen for this 
chromosome was for D1S2968 at 251.94 cM, which presented with a LOD score of 
0.52 at θ=0.00. This LOD score was not high enough to require further investigation.  
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4.3.3 Chromosome 3  
The Research Genetics Inc. mapping set contained nine markers for chromosome 3, 
five of which were tetranucleotide repaeats and the remaining three were 
trinucleotide. The Applied Biosystems mapping set contained 16 markers for 
chromosome one. Table 4.6 lists the markers that were examined from both mapping 
sets, their positions, the LOD scores obtained at θ=0.00, the corresponding 
maximum excluded distances in cM, and the regions excluded. Markers highlighted 
in blue represent markers from the Research Genetics Inc. mapping set. Markers 
highlighted in pink represent markers from the Applied Biosystems mapping set. 
Markers highlighted in green represent markers which were found in both mapping 
sets. 
Table 4.6: Markers used to examine chromosome 3.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded 
to (cM) 
D3S1304 22.33 -2.07 0.00 - - 
D3S1263 36.10 -8.58 8.89 27.21 44.99 
D3S2338 42.10 -3.69 0.20 41.90 42.30 
D3S3038 44.81 -5.64 9.00 35.81 53.81 
D3S1266 52.60 -3.12 0.20 52.40 52.80 
D3S1277 61.52 0.49 0.00 - - 
D3S1289 71.41 -11.08 7.15 64.26 78.56 
D3S1300 80.32 -6.91 3.10 77.22 83.42 
D3S1285 91.18 -6.34 3.91 87.27 95.09 
D3S2406 102.64 -5.45 2.70 99.94 105.34 
D3S1271 117.76 -3.98 1.30 116.46 119.06 
D3S3045 124.16 -5.75 2.70 121.46 126.86 
D3S1278 129.73 -8.21 6.84 122.89 136.57 
D3S1303 136.32 -5.84 3.40 132.92 139.72 
D3S1267 139.12 -7.92 10.55 128.57 149.67 
D3S1292 146.60 -4.08 11.18 135.42 157.78 
D3S1569 158.38 -5.85 10.45 147.93 168.83 
D3S3053 181.87 -8.54 11.30 170.57 193.17 
D3S1565 186.04 -6.02 1.80 184.24 187.84 
D3S1262 201.14 -3.04 1.00 200.14 202.14 
D3S1580 207.73 -4.96 9.10 198.63 216.83 
D3S3023 (deCode) 0.26 0.00 - - 
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Twenty-two markers from the two mapping sets were examined for chromosome 3. 
Nineteen of these markers obtained a statistically significant LOD score, and 
excluded various regions on the chromosome. Marker D3S1304 showed a significant 
LOD score of <-2, however it was only significant at θ=0.00. Therefore there was no 
distance of exclusion aside from the position of the marker itself. Markers D3S1277 
and D3S3023 did not show significant LOD scores, and yielded inconclusive LOD 
scores of 0.49 at θ=0.00 and 0.26 at θ=0.00 respectively. Marker D3S3023 was part 
of the Research Genetics Inc mapping set, however the position of the marker on the 
Marshfield map was not available. A genetic position was only available from the 
deCODE map (www.decode.com/). The marker did not give a significant LOD score 
and therefore the position on the Marshfield map was not needed per se. Figure 4.3 
illustrates the positions of the markers that obtained significant negative LOD scores 
and the corresponding regions of exclusion on chromosome 3. 
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Figure 4.4: Illustration of areas of exclusion for Chromosome 3 
Black vertical line with scales represents chromosome 3 (scales in cM). The red bars 
on the right illustrates the total areas excluded combining all markers from the two 
linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
These results exclude a large area of chromosome 3. A number of gaps remain on 
chromosome 3, the largest gap present at the telomere between 0.00 cM and 27.21 
cM. A total of 154.25 cM of chromosome three was excluded, which equates to 
67.6% of the entire chromosome. The highest LOD score seen for this chromosome 
was for D3S1277 at 61.52 cM, which presented with a LOD score of 0.49 at θ=0.00. 
This LOD score was not high enough to deserve further investigation.  
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4.3.4 Chromosome 4  
The Research Genetics Inc. mapping set contained eight markers for chromosome 4, 
six of which were tetranucleotide repeats. The Applied Biosystems mapping set 
contained 29 markers for chromosome four. Table 4.7 lists the markers that were 
examined from both mapping sets. The positions (cM), maximum obtained LOD 
scores at theta equal to zero, the corresponding maximum excluded distances in cM, 
and the regions excluded are listed here. Markers highlighted in blue represent 
markers from the Research Genetics Inc. mapping set. Markers highlighted in pink 
represent markers from the Applied Biosystems mapping set. Markers highlighted in 
green represent markers which were found in both mapping sets. Markers which 
have not been highlighted were ordered previously for investigation of linkage to the 
chromosome 4 locus (section 3.3.7). 
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Table 4.7: Markers used to examine chromosome 4.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D4S412 4.74 0.33 0.00 - - 
D4S403 25.9 -8.64 12.24 13.66 38.14 
D4S2632 50.53 -5.61 10.35 40.18 60.88 
D4S3248 72.52 -3.21 0.90 71.62 73.42 
D4S3243 88.35 -1.75 0.00 - - 
D4S1534 95.09 -5.94 6.13 88.96 101.22 
D4S414 100.75 -8.57 3.41 97.34 104.16 
D4S1647 104.94 -5.08 3.00 101.94 107.94 
D4S1572 107.95 -1.78 0.00 - - 
D4S406 117.06 -8.38 2.90 114.16 119.96 
D4S2989 117.06 -8.38 3.61 113.45 120.67 
D4S407 117.06 -8.68 4.51 112.55 121.57 
D4S402 124.45 -5.69 0.00 - - 
D4S1575 132.05 -11.18 8.87 123.18 140.92 
D4S424 144.56 -5.79 7.45 137.11 152.01 
D4S1629 157.99 -5.31 3.00 154.99 160.99 
D4S413 157.99 -5.32 0.20 157.79 158.19 
D4S1539 176.19 -2.51 0.80 175.39 176.99 
D4S415 181.36 -5.85 4.31 177.05 185.67 
D4S2417 181.93 -2.06 0.00 - - 
D4S408 195.06 -2.05 0.70 194.36 195.76 
D4S1535 195.06 -2.85 0.20 194.86 195.26 
D4S426 206.98 -10.98 13.63 193.35 220.61 
Twenty-one markers from the two mapping sets were examined for chromosome 4. 
Two markers had been ordered previously for investigation of the chromosome 4 
locus (included in the table above). Eighteen of the markers from the mapping sets 
obtained a statistically significant LOD score, and excluded various regions on the 
chromosome. Markers D4S402 and D4S2417 showed significant LOD scores of <-2, 
however they were only significant at θ=0.00. There was no distance of exclusion 
aside from the position of the marker itself. Markers D4S412, D4S3243 and 
D4S1572 did not show significant LOD scores, and yielded inconclusive LOD 
scores of 0.33 at θ=0.00, -1.75 at θ=0.00 and -1.78 at θ=0.00 respectively.  
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Figure 4.4 illustrates the positions of the markers that obtained significant negative 
LOD scores and the corresponding regions of exclusion on chromosome 4. 
 
Figure 4.5: Illustration of areas of exclusion for Chromosome 4 
Black vertical line with scales represents chromosome 4 (scales in cM). The red bars 
on the right illustrates the total areas excluded combining all markers from the two 
linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
 
These results exclude a large area of chromosome 4. A number of gaps remain on 
chromosome 4, the largest gap present at the telomere between 0.00 cM and 13.66 
cM. A total of 147.29 cM of chromosome four was excluded, which equates to 
69.6% of the entire chromosome. The highest LOD score seen for this chromosome 
was for D4S412 at 4.74 cM, which presented with a LOD score of 0.33 at θ=0.00. 
This LOD score was not high enough to deserve further investigation.  
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4.3.5 Chromosome 5  
The Research Genetics Inc. mapping set contained seven markers for chromosome 5, 
five of which were tetranucleotide repeats. The Applied Biosystems mapping set 
contained 22 markers for chromosome 5. Table 4.8 lists the markers that were 
examined from both mapping sets, their positions (cM), maximum obtained LOD 
scores at theta equal to zero, the corresponding maximum excluded distances in cM, 
and the regions excluded. Markers highlighted in blue represent markers from the 
Research Genetics Inc. mapping set. Markers highlighted in pink represent markers 
from the Applied Biosystems mapping set. Markers which have not been highlighted 
were ordered previously for investigation of linkage to the chromosome 5 locus 
(section 3.3.1). 
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Table 4.8: Markers used to examine chromosome 5.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D5S1981 1.72 -8.37 8.38 0.00 10.10 
D5S406 11.85 -5.53 2.10 9.75 13.95 
D5S630 19.67 -5.59 6.13 13.94 25.80 
D5S817 22.88 -2.87 0.20 22.68 23.08 
D5S416 28.76 -5.32 3.61 25.15 32.37 
D5S419 39.99 -7.19 10.55 29.44 50.54 
D5S1470 45.34 -5.43 5.02 40.32 50.36 
D5S426 51.99 -13.46 10.55 41.44 62.54 
D5S418 58.55 -11.04 13.63 44.92 72.18 
D5S2500 69.23 -6.86 6.94 62.29 76.17 
D5S2122 78.31 -5.23 2.70 75.60 81.01 
D5S2003 78.31 -5.44 4.92 73.39 83.23 
D5S424 81.95 -4.09 1.50 80.45 83.45 
D5S641 92.38 -11.19 4.41 87.97 96.79 
D5S428 95.40 -11.18 3.61 91.79 99.01 
D5S1725 97.82 -3.31 6.74 91.08 104.56 
D5S644 104.76 -8.35 11.29 93.47 116.05 
D5S2027 119.50 -6.11 2.60 116.90 122.10 
D5S1505 129.83 -5.63 4.31 125.52 134.14 
D5S471 129.83 -7.76 7.66 122.17 137.49 
D5S2115 138.64 -10.70 7.35 131.29 145.99 
D5S436 147.49 -8.37 12.03 135.46 159.52 
D5S1480 147.49 -3.16 4.31 143.18 151.80 
D5S410 156.47 -5.09 4.51 151.96 160.98 
D5S400 174.80 -7.91 4.11 170.69 178.91 
D5S211 182.89 -5.78 4.41 178.48 187.30 
D5S408 195.49 -1.51 0.00 - - 
 
Twenty-five markers from the two mapping sets were examined for chromosome 5. 
Two additional markers, which have been included in table 4.8, had been ordered 
previously for investigation to the chromosome 5 locus. Twenty-four of the markers 
from the mapping sets obtained a statistically significant LOD score, and excluded 
various regions on the chromosome. Marker D5S408 did not show a significant LOD 
score, and presented with an inconclusive LOD score of -1.51 at θ=0.00.  
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Figure 4.5 illustrates the positions of the markers that obtained significant negative 
LOD scores and the corresponding regions of exclusion on chromosome 5. 
 
Figure 4.6: Illustration of areas of exclusion for Chromosome five 
Black vertical line with scales represents chromosome 5 (scales in cM). The red bars 
on the right illustrates the total areas excluded combining all markers from the two 
linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
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These results exclude a large area of chromosome 5. Only four gaps remain on 
chromosome five. These are positioned at 83.23 cM to 87.97 cM, 116.05 cM to 
116.90 cM, 160.98 cM to 170.69 cM and 187.30 cM to 197.54 cM. A total of 172 
cM of chromosome five was excluded, which equates to 87.1% of the entire 
chromosome. The highest LOD score seen for this chromosome was for D5S408 at 
195.49 cM, which presented with a LOD score of -1.51 at θ=0.00. This LOD score 
did not need any warrant further investigation. 
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4.3.6 Chromosome 6  
The Research Genetics Inc. mapping set contained five markers for chromosome 6, 
five which were tetranucleotide repeats and the remaining one a trinucleotide. The 
Applied Biosystems mapping set contained 20 markers for chromosome six. Table 
4.9 lists the markers that were examined from both mapping sets, the LOD scores 
obtained at θ=0.00 and the corresponding excluded regions. Markers highlighted in 
blue represent markers from the Research Genetics Inc. mapping set. Markers 
highlighted in pink represent markers from the Applied Biosystems mapping set. 
Markers which have not been highlighted were ordered previously for investigation 
of linkage to the chromosome 6 locus (section 3.3.10). 
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Table 4.9: Markers used to examine chromosome 6.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D6S1574 9.81 -6.02 3.41 6.40 13.22 
D6S470 18.22 -11.02 11.71 6.51 29.93 
D6S2434 25.08 -5.32 1.80 23.28 26.88 
D6S289 29.93 -8.10 6.64 23.29 36.57 
D6S422 35.66 -8.64 9.72 25.94 45.38 
D6S2439 42.27 -2.05 0.08 42.19 42.35 
D6S1051 50.75 -3.12 0.20 50.55 50.95 
D6S1610 53.81 -3.69 3.71 50.10 57.52 
D6S1607 59.34 -8.54 6.64 52.70 65.98 
D6S2410 73.13 -2.77 0.00 - - 
D6S257 79.92 -8.27 1.80 78.12 81.72 
D6S460 89.93 -5.01 0.70 89.13 90.53 
D6S462 99.01 -5.32 1.60 97.41 100.61 
D6S287 121.97 -8.62 10.66 111.31 132.63 
D6S1040 128.93 -8.54 3.81 125.12 132.74 
D6S262 130.00 -5.43 3.20 126.80 133.20 
D6S292 136.97 -6.40 4.71 132.26 141.68 
D6S308 144.46 0.35 0.00 - - 
D6S441 154.1 -6.23 1.00 153.10 155.10 
D6S2436 154.64 -5.84 5.22 149.42 159.86 
D6S1581 164.78 0.29 0.00 - - 
D6S264 179.07 -5.96 5.62 173.45 184.69 
D6S446 189.00 0.16 0.00 - - 
D6S281 190.14 -4.19 0.10 190.04 190.24 
 
Twenty-two markers from the two mapping sets were examined for chromosome 6. 
Two additional markers, which have been included in table 4.8, had been ordered 
previously for investigation to the chromosome 6 locus. Eighteen of the markers 
from the mapping sets obtained a statistically significant LOD score, and excluded 
various regions on the chromosome. Marker D6S2410 showed a significant LOD 
scores of <-2, however it was only significant at θ=0.00. Therefore there was no 
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distance of exclusion aside from the position of the marker itself. Markers D6S308, 
D6S1581, and D6S446 did not show significant LOD scores, and produced 
inconclusive LOD scores of 0.35 at θ=0.00, 0.29 at θ=0.00 and 0.16 at θ=0.00 
respectively. Figure 4.6 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 6. 
 
 
Figure 4.7: Illustration of areas of exclusion for Chromosome 6 
Black vertical line with scales represents chromosome 6 (scales in cM). The red bars 
on the right illustrates the total areas excluded combining all markers from the two 
linkage set. The marker(s) which contributed to these exclusion values are also 
indicated.  
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These results exclude a large area of chromosome 6. A number of gaps remain on 
chromosome 6, the largest gap of 13.59 cM present between 159.86 cM and 173.45 
cM. A total of 115.31 cM of chromosome 6 was excluded, which equates to 59.7% 
of the entire chromosome. The highest LOD score seen for this chromosome was for 
D6S308 at 144.46 cM, which presented with a LOD score of 0.35 at θ=0.00. This 
LOD score was not high enough to require further investigation. 
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4.3.7 Chromosome 7  
The Research Genetics Inc. mapping set contained eight markers for chromosome 7, 
five of which were tetranucleotide repeats. The Applied Biosystems mapping set 
contained 22 markers for chromosome 7. Table 4.10 lists the markers that were 
examined from both mapping sets, the LOD scores obtained at θ=0.00 and the 
corresponding excluded regions. Markers highlighted in blue represent markers from 
the Research Genetics Inc. mapping set. Markers highlighted in pink represent 
markers from the Applied Biosystems mapping set. Markers highlighted in green 
represent markers which were found in both mapping sets. 
Table 4.10: Markers used to examine chromosome 7.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D7S517 7.44 -5.61 1.20 6.24 8.64 
D7S513 17.74  -5.59  7.54  10.20  25.28  
D7S3051 29.28  -3.47  0.50  28.78  29.78  
D7S493 34.69 -8.38 3.81 30.88 38.50 
D7S516 41.69 -1.79 0.00 - - 
D7S484 53.70 -1.92 0.00 - - 
D7S2846 57.59  -3.31  1.10  56.49  58.69  
D7S519 69.03 -5.77 7.56 61.47 76.59 
D7S3046 78.65  -2.69  0.10  78.55  78.75  
D7S669 90.42 -3.51 2.90 87.52 93.32 
D7S821 109.12  -5.61  11.30  97.82  120.42  
D7S530 134.55 -6.41 6.74 127.81 141.29 
D7S1804  136.95  -1.31  0.00  -  -  
D7S640 137.83 -7.21 8.07 129.76 145.90 
D7S684 147.22 -5.43 4.71 142.51 151.93 
D7S661 155.10 -8.01 9.31 145.79 164.41 
D7S1823/ 
D7S3058  
173.71  -5.35  0.40  173.31  174.11  
  
200 
Seventeen markers from the two mapping sets were examined for chromosome 7. 
Fourteen of the markers from the mapping sets obtained a statistically significant 
LOD score, and excluded various regions on the chromosome. Markers D7S516, 
D7S484, and D7S1804 did not show significant LOD scores, and produced 
inconclusive LOD scores of -1.79 at θ=0.00, -1.92 at θ=0.00 and -1.31 at θ=0.00 
respectively. Figure 4.7 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 7. 
 
Figure 4.8: Illustration of areas of exclusion for Chromosome 7 
Black vertical line with scales represents chromosome 7 (scales in cM). A number of 
gaps remain on chromosome 7, the largest which is seen between 38.50 cM and 
56.49 cM. The red bars on the right illustrates the total areas excluded combining all 
markers from the two linkage set. The marker(s) which contributed to these 
exclusion values are also indicated.  
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These results of the genome-wide scan exclude a large area of chromosome 7. A 
total of 109.42 cM of chromosome 7 was excluded, which equals 60.1% of the entire 
chromosome. There were three markers which resulted in an inconclusive LOD 
score none of which were high enough to require further investigation and the 
marker(s) which contributed to these exclusion values. 
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4.3.8 Chromosome 8  
The Research Genetics Inc. mapping set contained ten markers for chromosome 8, 
five of which were tetranucleotide repeats. The Applied Biosystems mapping set 
contained 14 markers for chromosome 8. Table 4.11 lists the markers that were 
examined from both mapping sets, the LOD scores obtained at θ=0.00 and the 
corresponding excluded regions. Markers highlighted in blue represent markers from 
the Research Genetics Inc. mapping set. Markers highlighted in pink represent 
markers from the Applied Biosystems mapping set. Markers highlighted in green 
represent markers which were found in both mapping sets. 
Table 4.11: Markers used to examine chromosome 8.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D8S264 0.73 -0.25 0.00 - - 
D8S1130 22.41 -3.24  5.83  16.58  28.24  
D8S549 31.73 -4.37 5.42 26.31 37.15 
D8S258 41.55 -6.19 4.51 37.04 46.06 
D8S136 43.96 0.58  0.00  -  -  
D8S1771 50.05 -6.62 5.93 44.12 55.98 
D8S505 60.87 -4.67 5.42 55.45 66.29 
D8S532 64.75 -8.19  10.35  54.40  75.10  
D8S285 71.00 -5.69  2.80  68.20  73.80  
D8S260 79.36 -4.57  7.25  72.11  86.61  
D8S2324 94.08 -5.91  11.08  83.00  105.16  
GAAT1A4 110.20 0.33  0.00  -  -  
D8S1784 118.15 0.37 0.00 - - 
D8S514 130.00 -5.95 0.40 129.6 130.4 
D8S1179  135.08 -5.89  3.81  131.27  138.89  
D8S284 143.82 -6.03 3.61 140.21 147.43 
D8S256  148.12 -0.02  0.00  -  -  
D8S272 154.02 -6.21 4.71 149.31 158.73 
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Eighteen markers from the two mapping sets were examined for chromosome 8. 
Two of these markers were found in both mapping sets, D8S185 and D8S260. 
Thirteen of the markers from the mapping sets obtained a statistically significant 
LOD score, and excluded various regions on the chromosome. Markers D8S264, 
D8S136, GAAT1A4, D8S1784 and D8S256 did not show significant LOD scores, 
and produced inconclusive LOD scores of -0.25 at θ=0.00, 0.58 at θ=0.00, 0.33 at 
θ=0.00, 0.37 at θ=0.00 and -0.02 at θ=0.00 respectively. Figure 4.8 illustrates the 
positions of the markers that obtained significant negative LOD scores and the 
corresponding regions of exclusion on chromosome 8. 
 
Figure 4.9: Illustration of areas of exclusion for Chromosome 8 
Black vertical line with scales represents chromosome 8 (scales in cM). The red bars 
on the right illustrates the total areas excluded combining all markers from the two 
linkage set. The marker(s) which contributed to these exclusion values are also 
indicated.  
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The results of the genome-wide scan exclude a substantial area of chromosome 8. 
The largest gap which remains is between 105.16 cM and 129.60 cM. A large area of 
exclusion was observed between 16.58 cM and 105.16 cM. A total of 113.62 cM of 
chromosome 8 was excluded, which equates to 67.7% of the entire chromosome. 
The highest LOD score seen for this chromosome was for D8S136 at 43.96 cM, 
which presented with a LOD score of 0.58 at θ=0.00. This LOD score was not high 
enough to deserve further investigation and the marker(s) which contributed to these 
exclusion values. 
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4.3.9 Chromosome 9  
The Research Genetics Inc. mapping set contained seven markers for chromosome 9, 
five of which were tetranucleotide repeats, one a trinucleotide, and the remaining 
two markers were dinucleotide. The Applied Biosystems mapping set contained 20 
markers for chromosome nine. Table 4.12 lists the markers that were examined from 
both mapping sets, the LOD scores obtained at θ=0.00 and the corresponding 
excluded regions. Markers highlighted in blue represent markers from the Research 
Genetics Inc. mapping set. Markers highlighted in pink represent markers from the 
Applied Biosystems mapping set. Markers which have not been highlighted were 
ordered previously for investigation of linkage to the chromosome 9 locus (section 
3.3.3). 
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Table 4.12: Markers used to examine chromosome 9. 
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D9S917 0 -0.11 0.00 - - 
D9S1779 0 -2.20 0.00 - - 
D9S1871 8.37 0.43 0.00 - - 
D9S288 9.83 -8.35 7.45 2.38 17.28 
D9S1813  9.83  -5.81  6.33  3.50  16.16  
D9S1810  12.78  -3.39  4.90  7.88  17.68  
D9S286  18.06  -3.23  3.30  14.76  21.36  
D9S274  28.42  -5.61  8.89  19.53  37.31  
D9S285 29.52 -8.37 9.72 19.80 39.24 
D9S157 32.24 -8.37 12.24 20.00 44.48 
D9S162 34.42  -3.32  5.02  29.40  39.44  
D9S171 42.73 -3.35 4.31 38.42 47.04 
D9S1679  44.28  -7.66  9.72  34.56  54.00  
D9S1121  44.28  -0.05  0.00  -  -  
D9S169  49.20  -7.65  6.94  42.26  56.14  
D9S161 51.87 -5.72 6.94 44.93 58.81 
D9S1118  58.26  -5.31  2.70 55.56  60.96  
D9S273 65.79 -2.06 0.70 65.09 66.49 
D9S175 70.33 -5.31 2.70 67.63 73.03 
D9S1122  75.88  0.32  0.00  -  -  
D9S167 83.41 -4.98 9.51 73.90 92.92 
D9S257  91.87  0.00  0.00  -  -  
D9S287 103.42 -8.37 9.82 93.60 113.24 
D9S1690 106.63 -7.79 6.23 100.40 112.60 
D9S1677 117.37 -5.42 0.60 116.77 117.97 
D9S1776 123.33 -5.43 4.21 119.12 127.54 
D9S1682 132.09 -1.77 0.00 - - 
D9S282  136.47  -1.79  0.00  -  -  
D9S290 140.86 -3.49 2.80 138.06 143.66 
D9S1826 159.61 -5.84 0.20 159.41 159.81 
 
Twenty-one markers from the two mapping sets were examined for chromosome 9. 
Nine additional markers, which have been included in table 4.12, had been ordered 
previously for investigation to the chromosome 9 locus. Sixteen of the markers from 
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the mapping sets obtained a statistically significant LOD score, and excluded various 
regions on the chromosome. Markers D9S1121, D9S1122, D9S257, D9S1682 and 
D9S282 did not show significant LOD scores, and yielded inconclusive LOD scores 
of -0.05 at θ=0.00, 0.32 at θ=0.00, 0.00 at θ=0.00, -1.77 at θ=0.00 and -1.79 at 
θ=0.00 respectively. Figure 4.9 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 9. 
 
Figure 4.10: Illustration of areas of exclusion for Chromosome 9 
Black vertical line with scales represents chromosome 9 (scales in cM). The red bars 
on the right illustrates the total areas excluded combining all markers from the two 
linkage set. The marker(s) which contributed to these exclusion values are also 
indicated.  
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These results exclude a large area of chromosome 9. A number of gaps remain on 
chromosome 9, the largest gap of 15.75 cM present between 143.66 cM and 159.41 
cM. A total of 122.27 cM of chromosome 9 was excluded, which equates to 72.4% 
of the entire chromosome. The highest LOD score seen for this chromosome was for 
D9S1122 at 75.88cM, which presented with a LOD score of 0.32 at θ=0.00. This 
LOD score was not high enough to warrant further investigation. 
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4.3.10 Chromosome 10  
The Research Genetics Inc. mapping set contained eight markers for chromosome 
10, four of which were tetranucleotide repeats, two were trinucleotide repeats, and 
the remaining two markers were dinucleotide. The Applied Biosystems mapping set 
contained 19 markers for chromosome 10. Table 4.13 lists the markers that were 
examined from both mapping sets, the LOD scores obtained at θ=0.00 and the 
corresponding excluded regions. Markers highlighted in blue represent markers from 
the Research Genetics Inc. mapping set. Markers highlighted in pink represent 
markers from the Applied Biosystems mapping set. Markers highlighted in green 
represent markers which were found in both mapping sets. 
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Table 4.13: Markers used to examine chromosome 10.  
Marker Position 
(cM) 
Max 
LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D10S249 2.13 -5.39 0.20 1.93 2.33 
D10S189  19.00 -5.61 11.18  7.82  30.18  
D10S547 29.15 -5.56 6.54 22.61 35.69 
D10S1653 40.36 -5.84 0.30 40.06 40.66 
D10S548 45.70 1.71 0.00 - - 
D10S1423  46.23 -5.67 6.84  39.39  53.07  
D10S197 52.10 -7.18 3.81 48.29 55.91 
D10S1208  63.30 0.45 0.00  -  -  
D10S196 70.23 -6.82 6.84 63.39 77.07 
GATA121A08  88.41 -3.11 4.31  84.10  92.72  
D10S537 91.13 -5.92 7.90 83.23 99.03 
D10S2327  100.92 -2.86 1.70  99.22  102.62  
D10S1686 105.04 -7.71 6.23 98.81 111.27 
D10S185 116.34 -6.65 2.50 113.84 118.84 
D10S192 124.27 0.24 0.00 - - 
D10S1239  125.41 -2.61 6.13  119.28  131.54  
D10S597 128.73 -5.98 1.73 127 130.46 
D10S1693 137.39 -5.57 4.21 133.18 141.6 
D10S1230  142.78 -5.86 5.83  136.95  148.61  
D10S587 147.57 -5.97 8.69 138.88 156.26 
D10S217 157.89 -5.71 0.20 157.69 158.09 
D10S1651 168.77 -3.94 2.40 166.37 171.17 
D10S212  170.94 -11.34 14.71  156.23  185.65  
Twenty-three markers from the two mapping sets were examined for chromosome 
10. Twenty of the markers from the mapping sets obtained a statistically significant 
LOD score, and excluded various regions on the chromosome. Markers D10S548, 
D10S1208 and D10S192 did not show significant LOD scores, and yielded 
inconclusive LOD scores of 1.71 at θ=0.00, 0.48 at θ=0.00 and 0.24 at θ=0.00 
respectively. Figure 4.10 illustrates the positions of the markers that obtained 
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significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 10. 
 
Figure 4.11: Illustration of areas of exclusion for Chromosome 10 
Black vertical line with scales represents chromosome 10 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
These results exclude a substantial area of chromosome 10. A number of small gaps 
remain on chromosome 10, the largest gap only 7.48 cM, located between 55.91 cM 
and 63.39 cM. A total of 143.66 cM of chromosome 10 was excluded, which equates 
to 83% of the entire chromosome. The highest LOD score seen for this chromosome 
was for D10S548 at 45.70 cM, which presented with a LOD score of 1.71 at θ=0.00. 
This LOD score required further investigation (section 4.4.2).  
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4.3.11 Chromosome 11  
The Research Genetics Inc. mapping set contained seven markers for chromosome 
11, five of which were tetranucleotide repeats, one a trinucleotide, and the remaining 
two markers were dinucleotide. The Applied Biosystems mapping set contained 20 
markers for chromosome 11. Table 4.14 lists the markers that were examined from 
both mapping sets, the LOD scores obtained at θ=0.00 and the corresponding 
excluded regions. Markers highlighted in blue represent markers from the Research 
Genetics Inc. mapping set. Markers highlighted in pink represent markers from the 
Applied Biosystems mapping set. Markers highlighted in green represent markers 
which were found in both mapping sets. 
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Table 4.14: Markers used to examine chromosome 11.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D11S4046 2.79 -6.22 8.48 0.00 11.27 
D11S1338 12.92 -5.57 5.22 7.70 18.14 
D11S902 21.47 -4.29 0.10 21.37 21.57 
D11S1981 21.47 -1.46 0.00  -  -  
D11S904 33.57 -7.08 3.41 30.16 36.98 
D11S935 45.94 -5.54 5.11 40.83 51.05 
D11S905 51.95 -1.77 0.00 - - 
D11S4191 60.09 -8.06 4.81 55.28 64.90 
D11S987 67.48 -7.66 2.50 64.98 69.98 
D11S1314 73.64 -2.06 0.00 - - 
D11S2371 76.13 -2.48 0.00  -  -  
D11S937 79.98 -4.89 0.60 79.38 80.58 
D11S901 85.48 -2.05 0.00 - - 
D11S4175 91.47 -6.56 0.60 90.87 92.07 
D11S898 98.98 -5.83 3.10 95.88 102.08 
D11S2000 100.62 -3.51 4.41  96.21  105.03  
D11S4090 105.74 -5.42 2.90  102.84  108.64  
D11S908 108.59 -5.31 5.62 102.97 114.21 
D11S1998 113.13 -2.05 0.00  -  -  
D11S925 118.47 -4.29 5.83 112.64 124.30 
D11S912 131.26 -5.74 8.38  122.88  139.64  
D11S1320 141.91 -4.42 3.61 138.30 145.52 
D11S968 147.77 0.44 0.00 - - 
 
Twenty-three markers from the two mapping sets were examined for chromosome 
11. Sixteen of the markers from the mapping sets obtained a statistically significant 
LOD score, and excluded various regions on the chromosome. Markers D11S1314, 
D11S2371, D11S901 and D11S1998 showed significant LOD scores of <-2, 
however they were only significant at θ=0.00. Therefore there was no distance of 
exclusion aside from the position of the marker itself. Markers D11S1981, D11S905 
and D11S968 did not show significant LOD scores, and yielded inconclusive LOD 
214 
scores of -1.46 at θ=0.00, -1.77 at θ=0.00 and 0.44 at θ=0.00 respectively. Figure 
4.11 illustrates the positions of the markers that obtained significant negative LOD 
scores and the corresponding regions of exclusion on chromosome 11. 
 
Figure 4.12: Illustration of areas of exclusion for Chromosome 11 
Black vertical line with scales represents chromosome eleven (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
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These results exclude a considerable area of chromosome 11. A number of gaps 
remain on chromosome 11, the largest gap being 10.29 cM, located between 80.58 
cM and 90.87 cM. A total of 101.52 cM of chromosome 11 was excluded, which 
equates to 68.7% of the entire chromosome. The highest LOD score seen for this 
chromosome was for marker D11S968 located at 147.77 cM, which presented with a 
LOD score of 0.44 at θ=0.00. This LOD score is inconclusive and is not high enough 
to require further investigation.  
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4.3.12 Chromosome 12  
The Research Genetics Inc. mapping set contained four markers for chromosome 12, 
three of which were tetranucleotide repeats, and the remaining marker a trinucleotide 
repeat. The Applied Biosystems mapping set contained 19 markers for chromosome 
12. Table 4.15 lists the markers that were examined from both mapping sets, the 
LOD scores obtained at θ=0.00 and the corresponding excluded regions. Markers 
highlighted in blue represent markers from the Research Genetics Inc. mapping set. 
Markers highlighted in pink represent markers from the Applied Biosystems 
mapping set. Markers which have not been highlighted were ordered previously for 
investigation of linkage to the chromosome 12 locus (section 3.3.2) and the NOS1 
associated region (section 3.3.14). 
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Table 4.15: Markers used to examine chromosome 12.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D12S352 0.00 -1.38 0.00 - - 
D12S99 12.60 -1.75 0.00 - - 
D12S1617 44.03 -5.95 3.81 40.22 47.84 
D12S345 53.09 -6.33 2.60 50.49 55.69 
D12S368 66.03 -5.94 7.35 58.68 73.38 
D12S398 68.16 -5.64 5.02  63.14  73.18  
D12S83 75.17 -7.07 14.6 60.57 89.77 
D12S326 86.40 -6.75 3.20 83.20 89.60 
D12S1064 95.03 -3.22 1.20 93.83 96.23 
D12S351 95.56 -4.51 9.72 85.84 105.28 
D12S1044  103.90 -6.10  4.90  99.0 0 108.8  
D12S1300 104.12 -2.82 2.20  101.92  106.32  
D12S346 104.65 -10.91 11.82 92.83 116.47 
D12S318  109.40  -2.80  0.90  108.5 0 110.3  
D12S78  111.80  -6.65 6.20  105.67  118.07  
D12S2070 125.30 0.24 0.00  -  -  
D12S79 125.31 -4.51 5.32 119.99 130.63 
D12S2082 130.94 -7.58 2.20 128.74 133.14 
D12S366 133.33 -6.63 2.20 131.13 135.53 
D13S86 134.54 -11.22 9.93 124.61 144.47 
D12S324 149.17 -8.67 6.54 142.63 155.71 
D12S2078 149.60 -8.56 7.45  142.15  157.05  
D12S1659 155.94 -7.76 5.93 150.01 161.87 
D12S1723 164.63 -3.60 3.10 161.53 167.73 
 
Nineteen markers from the two mapping sets were examined for chromosome 12. 
Five markers had been ordered and investigated previously for investigation of the 
chromosome 12 locus and associated region. These markers are included in the table 
above. Sixteen of the markers from the mapping sets obtained a statistically 
significant LOD score, and excluded various regions on the chromosome. Markers 
D12S352, D12S99 and D12S2070 did not show significant LOD scores, and yielded 
inconclusive LOD scores of -1.38 at θ=0.00, -1.75 at θ=0.00 and 0.24 at θ=0.00 
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respectively. Figure 4.12 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 12. 
 
 
Figure 4.13: Illustration of areas of exclusion for Chromosome 12 
Black vertical line with scales represents chromosome 12 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
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These results exclude a considerable area of chromosome 12. A number of gaps 
remain on chromosome 12, the most substantial being that at the telomeric end of 
chromosome 12 where a gap of 40.22 cM remains between 0.00 cM and 40.22 cM. 
A total of 119.95 cM of chromosome ten was excluded, which equates to 71.1% of 
the entire chromosome. The highest LOD score seen for this chromosome was for 
marker D12S2070 located at 125.30 cM, which presented with a LOD score of 0.24 
at θ=0.00. This LOD score is inconclusive and is not high enough to require further 
investigation. 
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4.3.13 Chromosome 13  
The Research Genetics Inc. mapping set contained four markers for chromosome 13, 
three of which were tetranucleotide repeats and the remaining one a trinucleotide 
repeat. The Applied Biosystems mapping set contained 14 markers for chromosome 
13. Table 4.16 lists the markers that were examined from both mapping sets, their 
positions (cM), the LOD scores obtained at θ=0.00, the corresponding maximum 
excluded distances in cM, and the regions excluded. Markers highlighted in blue 
represent markers from the Research Genetics Inc. mapping set. Markers highlighted 
in pink represent markers from the Applied Biosystems mapping set. 
Table 4.16: Markers used to examine chromosome 13.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D13S175 6.03 -7.03 5.52 0.51 11.55 
D13S217 17.21 -5.38 10.40 6.81 27.61 
D13S171 25.08 0.38 0.00 - - 
D13S1493 25.80 -2.13 0.00  -  -  
D13S218 32.90 0.00 0.00 - - 
D13S263 38.82 -4.73 0.10 38.72 38.92 
D13S153 45.55 -8.13 2.90 42.65 48.45 
D13S800 55.31 -5.52 0.60  54.71  55.91  
D13S156 55.85 -3.22 5.52 50.33 61.37 
D13S170 63.90 -10.16 9.62 54.28 73.52 
D13S793 76.26 -5.74 4.01 72.25 80.27 
D13S779 82.93 -5.52 4.61  78.32  87.54  
D13S173 93.52 -5.51 7.76 85.76 101.28 
D13S1265 98.82 -7.09 10.24 88.58 109.06 
 
Fourteen markers from the two mapping sets were examined for chromosome 13. 
Eleven of the markers from the mapping sets obtained a statistically significant LOD 
score, and excluded various regions on the chromosome. Marker D13S1493 
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presented with a significant LOD score of <-2, however it was only significant at 
θ=0.00. Therefore there was no distance of exclusion aside from the position of the 
marker itself. Markers D13S171 and D13S218 did not show significant LOD scores, 
and yielded inconclusive LOD scores of 0.38 at θ=0.00 and 0.00 at θ=0.00 
respectively. Figure 4.13 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 13. 
 
Figure 4.14: Illustration of areas of exclusion for Chromosome 13 
Black vertical line with scales represents chromosome 13 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated.  
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These results exclude a considerable area of chromosome 13. A number of small 
gaps remain on chromosome 13, the largest being 11.11 cM located between 27.61 
cM and 38.72 cM. A total of 91.83 cM of chromosome 13 was excluded, which 
equates to 79.9% of the entire chromosome. The highest LOD score seen for this 
chromosome was for marker D13S171 located at 25.08 cM, which presented with a 
LOD score of 0.38 at θ=0.00. This LOD score is inconclusive and is not high enough 
to require further investigation. 
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4.3.14 Chromosome 14  
The Research Genetics Inc. mapping set contained eleven markers for chromosome 
14, six of which were tetranucleotide repeats, two trinucleotides, and the remaining 
markers were dinucleotide. The Applied Biosystems mapping set contained 14 
markers for chromosome 14. Table 4.17 lists the markers that were examined from 
both mapping sets, their positions (cM), the LOD scores obtained at θ=0.00, the 
corresponding maximum excluded distances in cM, and the regions excluded. 
Markers highlighted in blue represent markers from the Research Genetics Inc. 
mapping set. Markers highlighted in pink represent markers from the Applied 
Biosystems mapping set. Markers which have not been highlighted were ordered 
previously for investigation of linkage to the chromosome 14 locus (Abdulrahim 
2008). 
Table 4.17: Markers used to examine chromosome 14 
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D14S608 28.01 0.08 0.00 - - 
D14S283 13.89 -4.96 8.58 5.31 22.47 
D14S70 40.11 -5.91 4.31 35.80 44.42 
D14S599 40.68 0.39 0.00 - - 
D14S1049 40.94 -3.44 5.93 35.01 46.87 
D14S1048 45.12 -3.23 1.10 44.02 46.22 
D14S301 45.12 -2.95 0.10 45.02 45.22 
D14S288 47.51 -3.17 0.90 46.61 48.41 
D14S1013 47.51 -6.07 4.51 43.00 52.02 
D14S1068 50.50 -6.14 4.61 45.89 55.11 
D14S587 55.82 -1.75 0.00 - - 
D14S592 66.80 -5.43 1.90 64.9 68.7 
D14S63 69.18 -11.33 12.88 56.3 82.06 
D14S588 75.61 -8.57 7.76 67.85 83.37 
D14S258 76.28 -7.96 10.55 65.73 86.83 
D14S53 86.29 -2.92 1.20 85.09 87.49 
D14S1279 95.89 -5.61 1.70 94.19 97.59 
D14S65 117.30 -6.35 4.31 112.99 121.61 
D14S985 126.61 -3.72 3.00 123.61 129.61 
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Fourteen markers from the two mapping sets were examined for chromosome 14. 
Five markers had been ordered, investigated and previously discussed for the 
investigation of the chromosome 14 locus. These markers are included in the table 
above. Eleven of the markers from the mapping sets obtained a statistically 
significant LOD score, and excluded various regions on the chromosome. Markers 
D14S608, D14S599 and D14S587 did not show significant LOD scores, and yielded 
inconclusive LOD scores of 0.08 at θ=0.00, 0.39 at θ=0.00 and -1.75 at θ=0.00 
respectively. Figure 4.12 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 14. 
 
Figure 4.15: Illustration of areas of exclusion for Chromosome 14 
Black vertical line with scales represents chromosome 14 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated.  
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These results exclude a substantial area of chromosome 14. A number of gaps 
remain on chromosome 14, the largest being 15.40 cM located between 97.59 cM 
and 112.99 cM. A total of 86.47 cM of chromosome 14 was excluded, which equates 
to 62.6% of the entire chromosome. The highest LOD score seen for this 
chromosome was for marker D14S599 located at 40.68 cM, which presented with a 
LOD score of 0.39 at θ=0.00. This LOD score is inconclusive and is not high enough 
to require further investigation.  
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4.3.15 Chromosome 15  
The Research Genetics Inc. mapping set contained sixteen markers for chromosome 
15; however three markers were only available at the time. Two of these markers 
were tetranucleotides, and the third marker a trinucleotide. The Applied Biosystems 
mapping set contained 13 markers for chromosome 15. Table 4.18 lists the markers 
that were examined from both mapping sets, their positions (cM), maximum 
obtained LOD scores at theta equal to zero, the corresponding maximum excluded 
distances in cM, and the regions excluded. Markers highlighted in blue represent 
markers from the Research Genetics Inc. mapping set. Markers highlighted in pink 
represent markers from the Applied Biosystems mapping set. The marker which has 
not been highlighted was ordered previously for investigation of linkage to the 
variants containing the genes encoding MAP2K5 and LBXCOR1 (section 3.3.12). 
Table 4.18: Markers used to examine chromosome 15.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D15S128 6.11 -4.95 1.30 4.81 7.41 
D15S1002 14.58 -6.21 1.40 13.18 15.98 
D15S1007 25.86 -10.98 12.77 13.09 38.63 
D15S994 40.25 -10.84 8.69 31.56 48.94 
D15S978 45.62 -11.22 9.51 36.11 55.13 
D15S117 51.21 -11.11 12.45 38.76 63.66 
D15S1507 60.17 -5.59 3.00 57.17 63.17 
D15S1015 66.9 -3.91 1.10 65.80 68.00 
D15S153 68.1 -5.50 3.71 64.39 71.81 
D15S131 71.28 -9.82 12.03 59.25 83.31 
D15S211 75.85 -5.92 7.45 68.40 83.30 
D15S205 78.92 -6.50 4.41 74.51 83.33 
D15S127 86.81 -8.08 8.58 78.23 95.39 
D15S816 100.59 -3.28 0.40 100.19 100.99 
D15S130 100.59 -0.05 0.00 - - 
D15S120 112.58 -1.15 0.00 - - 
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Fifteen markers from the two mapping sets were examined for chromosome 15. A 
separate marker had been ordered, investigated and previously discussed for the 
investigation of variants within chromosome 15. This marker is included in the table 
above. Thirteen of the markers from the mapping sets obtained a statistically 
significant LOD score, and excluded various regions on the chromosome. Markers 
D15S130 and D15S120 did not show significant LOD scores, and yielded 
inconclusive LOD scores of -0.05 at θ=0.00 and -1.15 at θ=0.00 respectively. Figure 
4.12 illustrates the positions of the markers that obtained significant negative LOD 
scores and the corresponding regions of exclusion on chromosome 15. 
 
Figure 4.16: Illustration of areas of exclusion for Chromosome 15 
Black vertical line with scales represents chromosome 15 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated.  
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These results exclude a large amount of chromosome 15. Only four gaps remain on 
chromosome 15. The largest and most significant of these gaps is seen between 
100.99 cM and the telomere (122.15 cM). A substantial area of exclusion can be 
observed between 13.18 cM and 95.39 cM. A total of 85.61 cM of chromosome 
thirteen was excluded, which equals 70.1% of the entire chromosome. There was no 
considerably high LOD score observed for any of the markers on chromosome 15.  
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4.3.16 Chromosome 16  
The Research Genetics Inc. mapping set contained two markers for chromosome 16, 
one which was a tetranucleotide repeat, and the other a trinucleotide repeat. The 
Applied Biosystems mapping set contained 13 markers for chromosome 16. Table 
4.19 lists the markers that were examined from both mapping sets, their positions 
(cM), maximum obtained LOD scores at theta equal to zero, the corresponding 
maximum excluded distances in cM, and the regions excluded. Markers highlighted 
in blue represent markers from the Research Genetics Inc. mapping set. Markers 
highlighted in pink represent markers from the Applied Biosystems mapping set. 
Table 4.19: Markers used to examine chromosome 16.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D16S404 18.07 -8.51 6.64 11.43 24.71 
D16S3075 23.28 -6.21 1.80 21.48 25.08 
D16S3046 40.65 -8.37 6.03 34.62 46.68 
D16S403 43.89 -2.05 0.00 - - 
D16S3068 48.53 -8.36 10.66 37.87 59.19 
D16S3136 62.11 -0.22 0.00 - - 
D16S415 67.62 -7.33 2.70 64.92 70.32 
D16S3253 71.77 -0.96 0.00 - - 
D16S503 83.55 0.19 0.00 - - 
D16S515 92.1 -1.35 0.00 - - 
D16S516 100.39 -1.77 0.00 - - 
D16S3091 111.12 -5.71 2.00 109.12 113.12 
D16S520 125.82 -2.98 0.60 125.22 126.42 
 
Thirteen markers from the two mapping sets were examined for chromosome 16. 
Only seven of these markers from the mapping sets obtained a statistically 
significant LOD score, and excluded various regions on the chromosome. Marker 
D16S403 presented with a significant LOD scores of <-2, however it was only 
significant at θ=0.00. Therefore there was no distance of exclusion aside from the 
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position of the marker itself. Markers D16S3253, D16S503, D16S515 and D16S516 
did not show significant LOD scores, and yielded inconclusive LOD scores of -0.96 
at θ=0.00, 0.19 at θ=0.00, -1.35 at θ=0.00  and -1.77 at θ=0.00 respectively. Figure 
4.16 illustrates the positions of the markers that obtained significant negative LOD 
scores and the corresponding regions of exclusion on chromosome 16. 
 
 
Figure 4.17: Illustration of areas of exclusion for Chromosome 16 
Black vertical line with scales represents chromosome 16 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
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This result for the scan of chromosome 16 was not as successful as the other 
chromosomes. A large number of substantial gaps remain on chromosome 16. The 
largest gap is 38.80 cM and located between 70.32 cM and 109.12 cM. Five of the 
markers obtained an inconclusive LOD score and the other markers showed quite 
small areas of exclusion. Therefore a large number of gaps remain to be investigated 
further. A total of 48.82 cM of chromosome 16 was excluded, which equals 36.4% 
of the entire chromosome. There was no considerably high LOD score observed for 
any of the markers on chromosome 16. 
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4.3.17 Chromosome 17 
The Research Genetics Inc. mapping set contained six markers for chromosome 17, 
two which were tetranucleotide repeats, two which were trinucleotide repeats, and 
the remaining two markers were dinucleotide. The Applied Biosystems mapping set 
contained 15 markers for chromosome 17. Table 4.20 lists the markers that were 
examined from both mapping sets. Markers highlighted in blue represent markers 
from the Research Genetics Inc. mapping set. Markers highlighted in pink represent 
markers from the Applied Biosystems mapping set. Markers highlighted in green 
represent markers which were found in both mapping sets. The marker which has not 
been highlighted was ordered previously for investigation of linkage to the 
chromosome seventeen locus (section 3.3.9). 
Table 4.20: Markers used to examine chromosome 17.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D17S849 0.63 -8.49 8.48 -7.85 9.11 
D17S831 6.60 -5.96 5.52 1.08 12.12 
D17S938 14.69 -7.93 5.42 9.27 20.11 
D17S974 22.24 -5.61 6.23 16.01 28.47 
D17S1852 22.24 -6.34 7.97 14.27 30.21 
D17S799 31.96 -5.41 3.10 28.86 35.06 
D17S921 36.14 -4.11 1.80 34.34 37.94 
D17S1857 43.01 -1.51 0.00 - - 
D17S2196 44.62 -8.52 7.76 36.86 52.38 
D17S1294 50.74 -6.01 6.03 44.71 56.77 
D17S798 53.41 -6.50 5.52 47.89 58.93 
D17S1868 64.16 -5.83 9.62 54.54 73.78 
D17S2180 66.85 0.44 0.00 - - 
D17S787 74.99 -9.59 4.61 70.38 79.60 
D17S944 82.56 1.36 0.00 - - 
D17S2193 89.32 -3.78 0.00 - - 
D17S949 93.27 -5.86 0.40 92.87 93.67 
D17S785 103.53 -8.91 8.48 95.05 112.01 
D17S784 116.86 -3.27 3.30 113.56 120.16 
D17S928 126.46 -1.19 0.00 - - 
233 
Nineteen markers from the two mapping sets were examined for chromosome 17. A 
separate marker had been ordered, investigated and previously discussed for the 
investigation of the chromosome 17 RLS locus. This marker is included in the table 
above. Fifteen of the markers from the mapping sets obtained a statistically 
significant LOD score, and excluded various regions on the chromosome. Marker 
D17S2193 presented with a significant LOD scores of <-2, however it was only 
significant at θ=0.00. Therefore there was no distance of exclusion aside from the 
position of the marker itself.  Markers D17S1857, D17S2180, D17S944 and 
D17S928 did not show significant LOD scores, and yielded inconclusive LOD 
scores of -1.51 at θ=0.00, 0.44 at θ=0.00, 1.36 at θ=0.00 and -1.19 at θ=0.00 
respectively. Figure 4.17 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 17. 
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Figure 4.18: Illustration of areas of exclusion for Chromosome 17 
Black vertical line with scales represents chromosome 17 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated.  
These results exclude a large amount of chromosome 17. The largest gap which 
remains on chromosome 17 is located between 79.60 cM and 92.87 cM. A 
substantial area of exclusion can be observed between 0.00 cM and 79.60 cM. A 
total of 103.96 cM of chromosome seventeen was excluded, which equals 82.2% of 
the entire chromosome. The highest LOD score seen for this chromosome was for 
D17S944 at 82.56 cM, which presented with a LOD score of 1.36 at θ=0.00. 
Although this LOD score was less than the +3.00 required for evidence of linkage, it 
was one of the highest LOD scores observed, therefore it required further 
investigation (section 4.4.2).  
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4.3.18 Chromosome 18  
The Research Genetics Inc. mapping set contained five markers for chromosome 18, 
three of which were tetranucleotide repeats, and the remaining two markers were 
dinucleotide. The Applied Biosystems mapping set contained 20 markers for 
chromosome 18. Table 4.21 lists the markers that were examined from both mapping 
sets, their positions (cM), maximum obtained LOD scores at theta equal to zero, the 
corresponding maximum excluded distances in cM, and the regions excluded. 
Markers highlighted in blue represent markers from the Research Genetics Inc. 
mapping set. Markers highlighted in pink represent markers from the Applied 
Biosystems mapping set. Markers highlighted in green represent markers which were 
found in both mapping sets. The marker which has not been highlighted was ordered 
previously for investigation of linkage to the chromosome 18 locus (section 3.3.9). 
Table 4.21: Markers used to examine chromosome 18.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D18S59 0.00 -5.63 0.60 -0.60 0.60 
D18S63 8.30 -5.57 1.50 6.80 9.80 
D18S976 12.88 -5.81 4.11 8.77 16.99 
D18S452 18.70 -2.07 0.00 - - 
D18S464 31.17 -4.81 7.45 23.72 38.62 
D18S53 41.24 -1.79 0.00 - - 
D18S542 41.24 -1.82 0.00 - - 
D18S877 54.40 -1.49 0.00 - - 
D18S1102 62.84 -6.95 4.01 58.83 66.85 
D18S64 84.80 -6.01 3.91 80.89 88.71 
D18S1357 88.62 0.68 0.00 - - 
D18S68 96.48 -4.57 1.32 95.16 97.80 
D18S61 105.03 -8.38 6.74 98.29 111.77 
ATA82B04 106.81 -1.49 0.00 - - 
D18S1161 114.26 -8.60 6.94 107.32 121.20 
D18S462 120.05 -8.58 10.66 109.39 130.71 
D18S70 126.00 -5.79 8.27 117.73 134.27 
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Seventeen markers from the two mapping sets were examined for chromosome 18. 
Twelve of the markers from the mapping sets obtained a statistically significant LOD 
score, and excluded various regions on the chromosome. Markers D18S452 
presented with a significant LOD scores of <-2, however it was only significant at 
θ=0.00. Therefore there was no distance of exclusion aside from the position of the 
marker itself. Marker D18S53, D18S542, D18S877, D18S1357 and ATA82B04 did 
not show significant LOD scores, and yielded inconclusive LOD scores of -1.79 at 
θ=0.00 -1.82 at θ=0.00 , -1.49 at θ=0.00, 0.68 at θ=0.00 and -1.49 at θ=0.00. Figure 
4.18 illustrates the positions of the markers that obtained significant negative LOD 
scores and the corresponding regions of exclusion on chromosome 18. 
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Figure 4.19: Illustration of areas of exclusion for Chromosome 18 
Black vertical line with scales represents chromosome 18 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
These results exclude a substantial area of chromosome 18. A number of small gaps 
remain on chromosome 18, the largest gap only 7.48 cM, located between 38.62 cM 
and 58.83 cM. A total of 72.38 cM of chromosome 18 was excluded, which equates 
to 57.4% of the entire chromosome. The highest LOD score seen for this 
chromosome was for D18S1357 at 57.44 cM, which presented with a LOD score of 
0.68 at θ=0.00. Although this LOD score was less than the +3.00 required for 
evidence of linkage, it was one of the highest LOD scores observed, therefore it 
required further investigation.  
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4.3.19 Chromosome 19  
The Research Genetics Inc. mapping set contained seven markers for chromosome 
19, five of which were tetranucleotide repeats, one a trinucleotide, and the remaining 
two markers were dinucleotide. The Applied Biosystems mapping set contained 20 
markers for chromosome 19. Table 4.22 lists the markers that were examined from 
both mapping sets, their positions (cM), maximum obtained LOD scores at theta 
equal to zero, the corresponding maximum excluded distances in cM, and the regions 
excluded. Markers highlighted in blue represent markers from the Research Genetics 
Inc. mapping set. Markers highlighted in pink represent markers from the Applied 
Biosystems mapping set. The marker which has not been highlighted was ordered 
previously for investigation of linkage to the chromosome 19 locus (section 3.3.6). 
Table 4.22: Markers used to examine chromosome 19.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D19S209 10.97 -0.71 0.00 - - 
D19S216 20.01 -2.62 0.00 - - 
D19S1034 20.75 -5.95 1.00 19.75 21.75 
D19S884 26.37 -4.88 0.20 26.17 26.57 
D19S586 32.94 -2.84 0.00 - - 
D19S221 36.22 0.48 0.00 - - 
D19S226 42.28 -7.44 1.80 40.48 44.08 
D19S410 45.48 -5.03 2.40 43.08 47.88 
D19S414 54.01 -5.44 8.89 45.12 62.9 
D19S220 62.03 -5.68 9.10 52.93 71.13 
D19S420 66.30 -8.36 14.06 52.24 80.36 
D19S178 68.08 -5.59 6.64 61.44 74.72 
D19S902 72.72 -9.16 7.86 64.86 80.58 
D19S589 87.66 -2.56 0.40 87.26 88.06 
D19S210 100.01 -6.406 6.60 93.41 106.61 
 
Fourteen markers from the two mapping sets were examined for chromosome 19. A 
separate marker had been ordered, investigated and previously discussed for the 
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investigation of the chromosome 19 RLS locus. This marker is included in the table 
above. Ten of the markers from the mapping sets obtained a statistically significant 
LOD score, and excluded various regions on the chromosome. Markers D19S216 
and D19S586 presented with a significant LOD scores of <-2; however they were 
only significant at θ=0.00. Therefore there was no distance of exclusion aside from 
the position of the marker itself. Marker D19S209 and D19S221 did not show 
significant LOD scores, and yielded inconclusive LOD scores of -0.71 at θ=0.00 and 
0.47 at θ=0.00. Figure 4.19 illustrates the positions of the markers that obtained 
significant negative LOD scores and the corresponding regions of exclusion on 
chromosome 19. 
 
Figure 4.20: Illustration of areas of exclusion for Chromosome 19 
Black vertical line with scales represents chromosome 19 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated.  
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These results exclude substantial areas on chromosome 19. A number of gaps remain 
on chromosome 19, the largest gap located between 0.00 cM and 19.75 cM. A total 
of 56.50 cM of chromosome 19 was excluded, which equates to 53.8% of the entire 
chromosome. The highest LOD score seen for this chromosome was for D19S209 at 
10.97 cM, which presented with a LOD score of 2.01 at θ=0.67. Although this LOD 
score was less than the +3.00 required for evidence of linkage, it was the highest 
LOD score seen during the process of the genome-wide search and therefore further 
investigation of the region surrounding marker D19S209 was required. 
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4.3.20 Chromosome 20  
The Research Genetics Inc. mapping set contained two markers for chromosome 20, 
one which was a tetranucleotide repeat, and one which was a dinucleotide repeat. 
The Applied Biosystems mapping set contained 20 markers for chromosome 20. 
Table 4.23 lists the markers that were examined from both mapping sets, their 
positions (cM), maximum obtained LOD scores at theta equal to zero, the 
corresponding maximum excluded distances in cM, and the regions excluded. 
Markers highlighted in blue represent markers from the Research Genetics Inc. 
mapping set. Markers highlighted in pink represent markers from the Applied 
Biosystems mapping set. The markers which have not been highlighted were ordered 
previously for investigation of linkage to the Chromosome 20 locus (section 3.3.5). 
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Table 4.23: Markers used to examine chromosome 20.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D20S864 0.00 -1.75 0.00 - - 
D20S117 2.83 -1.87 0.00 - - 
D20S199 6.25 -5.72 7.66 -1.41 13.91 
D20S113 8.97 0.14 0.00 - - 
D20S842 8.97 -5.61 9.33 -0.36 18.30 
D20S181 9.53 -3.02 0.20 9.33 9.73 
D20S193 9.53 0.00 0.00 - - 
D20S116 11.20 -2.80 2.20 9.00 13.40 
D20S889 11.20 -8.20 11.60 0.00 22.80 
D20S482 12.12 -5.61 9.33 2.79 21.45 
D20S849 13.98 -3.08 0.70 13.28 14.68 
D20S895 13.98 0.00 0.00 - - 
D20S882 15.05 -3.28 3.10 11.95 18.15 
D20S115 21.15 -6.19 4.41 16.74 25.56 
D20S851 24.70 -3.12 0.30 24.4 25.00 
D20S186 32.30 -8.52 10.24 22.06 42.54 
D20S112 39.25 -8.63 8.07 31.18 47.32 
D20S107 55.74 -5.68 7.76 47.98 63.50 
D20S119 61.77 -8.53 8.17 53.6 69.94 
D20S178 66.16 -6.19 4.01 62.15 70.17 
D20S196 75.01 -11.33 8.07 66.94 83.08 
D20S100 84.78 -2.07 0.00 - - 
D20S171 95.70 -8.97 5.62 90.08 101.32 
D20S173 98.09 -2.99 1.40 96.69 99.49 
 
Fourteen markers from the two mapping sets were examined for chromosome 20. 
Ten separate markers had been ordered, investigated and previously discussed for the 
investigation of the chromosome twenty RLS locus. These markers are included in 
the table above. Twelve of the markers from the mapping sets obtained a statistically 
significant LOD score, and excluded various regions on the chromosome. Marker 
D20S100 presented with a significant LOD scores of <-2, however it was only 
significant at θ=0.00. Therefore there was no distance of exclusion aside from the 
position of the marker itself. Marker D20S928 did not show significant LOD scores, 
and yielded an inconclusive LOD scores of -1.87 at θ=0.00. Figure 4.20 illustrates 
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the positions of the markers that obtained significant negative LOD scores and the 
corresponding regions of exclusion on chromosome 20. 
 
Figure 4.21: Illustration of areas of exclusion for Chromosome 20 
Black vertical line with scales represents chromosome 20 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
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The results of the genome-wide scan exclude a large amount of chromosome 20. 
Only two small gaps remain on the chromosome and these are positioned from 47.32 
cM to 47.98 cM and from 83.08 cM to 101.32 cM. A total of 93.56 cM of 
chromosome 20 was excluded, which equals 92.4% of the entire chromosome. The 
highest LOD score seen for this chromosome was for D20S113 at 8.97 cM, which 
presented with a LOD score of 0.14 at θ=0.00. This LOD score was not high enough 
to require further investigation. 
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4.3.21 Chromosome 21 
The Research Genetics Inc. mapping set contained only one marker for chromosome 
21, which was a GATA tetranucleotide repeat. The Applied Biosystems mapping set 
contained five markers for chromosome 21. Table 4.24 lists the markers that were 
examined from both mapping sets, their positions (cM), maximum obtained LOD 
scores at theta equal to zero, the corresponding maximum excluded distances in cM, 
and the regions exclude. Markers highlighted in blue represent markers from the 
Research Genetics Inc. mapping set. Markers highlighted in pink represent markers 
from the Applied Biosystems mapping set. 
Table 4.24: Markers used to examine chromosome 21.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D21S1914 19.39 -8.38 11.50 7.89 30.89 
D21S263 27.40 -8.68 6.84 20.56 34.24 
D21S1252 35.45 -8.68 9.93 25.52 45.38 
D21S2055 40.49 -5.23 5.62 34.87 46.11 
D21S266 45.87 -5.49 4.01 41.86 49.88 
 
Five markers were examined for chromosome 21. All five markers from the two 
mapping sets obtained statistically significant LOD scores. Figure 4.21 illustrates the 
positions of the markers that obtained significant negative LOD scores and the 
corresponding regions of exclusion on chromosome 21. 
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Figure 4.22: Illustration of areas of exclusion for Chromosome 21 
Black vertical line with scales represents chromosome 21 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
 
The results of the genome-wide scan excluded a large section of chromosome 21, 
between 7.89 cM and 49.88 cM. A 7.89 cM gap remains at the telomeric end of the 
short arm of chromosome 21. A 7.90 cM gap remains at the opposite end of 
chromosome 21 also. A total of 41.99 cM of chromosome 21 was excluded, which 
equates to 72.7% of the entire chromosome.  
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4.3.22 Chromosome 22  
The Research Genetics Inc. mapping set contained only one marker for chromosome 
22, which was a GCT trinucleotide repeat. The Applied Biosystems mapping set 
contained seven markers for chromosome 22. Table 4.25 lists the markers that were 
examined from both mapping sets, their positions (cM), maximum obtained LOD 
scores at theta equal to zero, the corresponding maximum excluded distances in cM, 
and the regions excluded are listed here. Markers highlighted in blue represent 
markers from the Research Genetics Inc. mapping set. Markers highlighted in pink 
represent markers from the Applied Biosystems mapping set. 
Table 4.25: Markers used to examine chromosome 22.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D22S420 4.06 -8.68 8.38 -4.32 12.44 
D22S539 14.44 0.19 0.00 - - 
GCT10C10 18.10 -0.66 0.00 - - 
D22S315 21.47 -4.79 6.33 15.14 27.80 
D22S280 31.30 -1.48 0.00 - - 
D22S283 38.62 -7.39 9.10 29.52 47.72 
D22S423 46.42 -7.55 9.10 37.32 55.52 
D22S274 51.54 -1.47 0.00 - - 
 
Four out of the eight markers from the two mapping sets obtained statistically 
significant LOD scores. Figure 4.22 illustrates the positions of the markers that 
obtained significant negative LOD scores and the corresponding regions of exclusion 
on chromosome 22.  
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Figure 4.23: Illustration of areas of exclusion for Chromosome 22 
Black vertical line with scales represents chromosome 22 (scales in cM). The red 
bars on the right illustrates the total areas excluded combining all markers from the 
two linkage set. The marker(s) which contributed to these exclusion values are also 
indicated. 
 
These results exclude a large area of chromosome 22. Three gaps are present on the 
chromosome and are positioned between: 12.44 cM and 15.14 cM; 27.80 cM and 
29.52 cM; and 55.52 cM and 62.32 cM. A total of 55.10 cM of chromosome 22 was 
excluded, which equates to 82% of the entire chromosome. The highest LOD score 
seen for this locus was for D22S539, which presented with a LOD score of 0.19 at 
θ=0.00. This LOD score was not high enough to require further investigation. 
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4.4 Areas of further Investigation  
4.4.1 Chromosome 1 
Marker D1S484 (169.69 cM) which was part of the Applied biosystems mapping set 
obtained a positive LOD score of 1.69 at θ=0.00. Although this LOD score is 
inconclusive, it was one of the highest LOD scores seen throughout the genome-
wide scan; therefore it was necessary to investigate the region further. Marker 
D1S2878 (177.86 cM) which was also part of the Applied biosysystems mapping set 
is positioned 8.17 cM away from D1S484. Marker D1S2878 obtained a LOD score 
of -10.62 at θ=0.00, and excluded linkage from 168.35 cM to 187.37 cM. Therefore 
the region where D1S484 is positioned was excluded for linkage to RLS. 
Nevertheless to ensure that RLS is not linked to this region a haplotye analysis was 
carried out. The haplotype analysis was carried out using three other markers from 
the mapping sets. One marker was positioned distal to D1S484 and the other two 
were positioned further along chromosome 1. From looking at the haplotype analysis 
(figure 4.23), it becomes clear that there is no haplotype that is present in all the 
affected patients and not present in the unaffected individuals. So due to the fact that 
there is exclusion of the region and that haplotype analysis confirms exclusion of this 
region on chromosome 1, it can be safely assumed that the region surrounding 
marker D1S484 is not linked to RLS in this family. 
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Figure 4.24: Haplotype analysis of RLS3002 pedigree for chromosome 1 region 
A list of the examined markers is present on the left hand side. The alleles for each 
individual obtained from genotyping using these markers are listed below each 
individual. Each haplotype formed from the series of alleles is given a coloured bar 
so it can be recognised easily. All the coloured haplotypes are present in both 
affected (filled squares and circles) and unaffected (squares and circles containing 
the letter N) individuals. Hence there is no one shared haplotype between all the 
affected individuals that is absent in normal individuals. It is therefore possible to 
conclude that there is no linkage between RLS and the region surrounding marker 
D1S484 on chromosome 1. 
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4.4.2 Chromosome 10 
Marker D10S548 (45.70 cM) which was part of the Applied biosystems mapping set 
showed a LOD score of 1.71 at θ=0.00. This LOD score was inconclusive however it 
was necessary to investigate it further as it was close to the value which would 
suggest linkage. Marker D10S548 is positioned at 45.70 cM on chromosome 10. 
This region was later excluded by marker D10S1423, which was also part of the 
Applied Biosystems mapping set. Marker D10S1423 (46.23 cM) is positioned only 
0.53 cM away from marker D10S548, and showed a LOD score of -5.67 at θ=0.00, 
excluding from 39.39 cM to 53.07 cM. Therefore the position at which D10S548 is 
situated was excluded for linkage. To ensure that RLS is not linked to this region a 
haplotye analysis was carried out. Looking at the haplotype analysis (figure 4.24), it 
becomes clear that there is no haplotype that is present in all the affected patients and 
not present in the normal individuals. So due to the fact that there is exclusion of the 
region and that haplotype analysis confirms exclusion of this region on chromosome 
10, it can be safely assumed that the region surrounding marker D10S548 is not 
linked to RLS in this family. 
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Figure 4.25: Haplotype analysis of RLS3002 pedigree for chromosome 10 region 
A list of the examined markers is present on the left hand side. The alleles for each 
individual obtained from genotyping using these markers are listed below each 
individual. Each haplotype formed from the series of alleles is given a coloured bar 
so it can be recognised easily. All the coloured haplotypes are present in both 
affected (filled squares and circles) and unaffected (squares and circles containing 
the letter N) individuals. Hence there is no one shared haplotype between all the 
affected individuals that is absent in normal individuals. It is therefore possible to 
conclude that there is no linkage between RLS and the region surrounding marker 
D10S548 on chromosome 10. 
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4.4.3 Chromosome 17 
Marker D17S944 (83.56 cM) which was part of the Applied Biosystems mapping set 
yielded a LOD score of 1.36 at θ=0.00. This area was not excluded by any other 
marker in the mapping sets. To ensure that RLS is not linked to this region a 
haplotye analysis was carried out. From looking at the haplotype analysis (figure 
4.25), it becomes clear that there is no haplotype that is present in all the affected 
patients and not present in the normal individuals. Therefore, due to the fact that 
haplotype analysis confirms exclusion of this region on chromosome 17, it can be 
safely assumed that the region surrounding marker D17S944 is not linked to RLS in 
this family. 
 
Figure 4.26: Haplotype analysis of RLS3002 pedigree for chromosome 17 region 
A list of the examined markers is present on the left hand side. The alleles for each 
individual obtained from genotyping using these markers are listed below each 
individual. Each haplotype formed from the series of alleles is given a coloured bar 
so it can be recognised easily. All the coloured haplotypes are present in both 
affected (filled squares and circles) and unaffected (squares and circles containing 
the letter N) individuals. Therefore, there is no one shared haplotype between all the 
affected individuals that is absent in normal individuals.  
254 
4.4.4 Chromosome 18 
Marker D18S1357 (88.62 cM) which was part of the Research Inc. mapping set 
yielded a LOD score of 0.68 at θ=0.00. This area was not excluded by any other 
marker in the mapping sets; therefore it was necessary to investigate this area further. 
Four additional markers in the area were chosen and ordered. Table 4.26 lists the 
markers that were ordered. Their positions (cM), size (bp), and the fluorescent tags 
with which they were labelled are listed here. 
Table 4.26: Markers used to examine the area surrounding D18S1357.  
Marker Position (cM) Size (bp) Fluorescent label 
D18S1134 88.62 204-232 6-FAM 
D18S1148 90.60 132-154 6-FAM 
D18S1147 90.60 207-219 HEX 
D18S465 100.11 232-251 6-FAM 
The four microsatellite markers surrounding marker D18S1357 were examined. Two 
of the four markers did not yield a statistically significant LOD score (i.e. <-2 or >3). 
Table 4.27 lists the markers that were examined, the LOD scores obtained at θ=0.00 
and the corresponding excluded regions. Their positions (cM), maximum obtained 
LOD scores at theta equal to zero, the corresponding maximum excluded distances 
in cM, and the regions excluded are listed here. 
Table 4.27: Markers used to examine the area surrounding D18S1357.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D18S1134 88.62 -2.04 0.10 88.52 88.72 
D18S1148 90.60 -4.96 0.00 - - 
D18S1147 90.60 -1.49 0.00 - - 
D18S465 100.11 -1.76 0.00 - - 
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The markers were not successful in excluding the area in question. The marker 
D18S1134 (88.62 cM) showed a significant LOD score of -2.04 at θ=0.00 and 
excluded 0.10 cM either side. The marker D18S1148 showed a significant score 
however it was only significant at θ=0.00. Hence there was no distance of exclusion 
except at the position of the marker. Therefore the region in question has not been 
excluded by the extra markers ordered in this area. However by looking at the 
haplotype analysis (figure 4.26), it becomes clear that there is no haplotype that is 
present in all the affected patients and not present in the normal individuals. So due 
to the fact that there is exclusion of D18S1148 at the exact position it is located and 
that haplotype analysis confirms exclusion of this region on chromosome 18, it can 
be safely assumed that the region surrounding marker D18S1357 is not linked to 
RLS in this family. 
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Figure 4.27: Haplotype analysis of RLS3002 pedigree for chromosome 18 region 
A list of the examined markers is present on the left hand side. The alleles for each 
individual obtained from genotyping using these markers are listed below each 
individual. Each haplotype formed from the series of alleles is given a coloured bar 
so it can be recognised easily. All the coloured haplotypes are present in both 
affected (filled squares and circles) and unaffected (squares and circles containing 
the letter N) individuals. There is no one shared haplotype between all the affected 
individuals that is absent in normal individuals. Therefore, there is no linkage 
between RLS and the region surrounding marker D18S1357 on chromosome 18. 
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4.4.5 Chromosome 19 
Marker D19S209 (10.97 cM) on chromosome 19, which was part of the Applied 
Biosystems mapping set yielded a LOD score of 2.01 at θ=0.67. This was the highest 
LOD score seen during the process of the genome-wide search and suggested linkage 
of RLS to the region. The nearest marker D19S216 (20.01 cM) was positioned 
almost 10.00 cM away and although it showed a significant LOD score of -2.62 at 
θ=0.00, it was only significant at this point. Hence, there was no distance of 
exclusion except at the position of the marker. The area surrounding D19S209 was 
not excluded by any other marker; therefore it was necessary to investigate this area 
further. 
The highest LOD score for D19S209 was observed at θ=0.67. This indicates that the 
area of interest is approximately 6.00 cM away from the marker, which is positioned 
at 10.97 cM. Therefore our area of interest was at approximately 5.00 cM or at 17.00 
cM. This was important information for ordering additional markers. Four additional 
markers in the area were chosen; the first positioned at 6.57 cM, the second 
positioned at 15.55 cM, a third positioned close to D19S209 at 9.84 cM and a final 
marker positioned at the telomere of chromosome 19. Table 4.28 lists the markers 
that were ordered. Their positions (cM), size (bp), and the fluorescent tags with 
which they were labelled are also listed. 
Table 4.28: Markers used to examine the area surrounding marker D19S209.  
Marker Position (cM) Size (bp) Fluorescent label 
D19S886 0.00 134-158 6-FAM 
D19S878 6.57 208-230 6-FAM 
D19S591 9.84 96-112 6-FAM 
D19S894 15.55 144-168 HEX 
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The four markers surrounding marker D18S1357 were examined. Only one of the 
four markers yielded a statistically significant LOD score (i.e. <-2 or >3). Table 4.29 
lists the markers that were examined Their positions (cM), maximum obtained LOD 
scores at theta equal to zero, the corresponding maximum excluded distances in cM, 
and the regions excluded. 
Table 4.29: Markers used to examine the area surrounding D18S1357.  
Marker Position 
(cM) 
Max LOD 
(θ=0) 
Excluded 
(cM) 
Area 
Excluded 
from (cM) 
Area 
Excluded to 
(cM) 
D19S886 0.00 1.87 0.00 - - 
D19S878 6.57 3.59 0.00 - - 
D19S591 9.84 1.81 0.00 - - 
D19S894 15.55 -5.44 0.60 14.95 16.15 
These results provide evidence of linkage to chromosome 19. Marker D19S878 
yielded a maximum LOD score of 3.59 at θ=0.00. A LOD score of >3 is required to 
be statistically significant. It was proposed that the locus would be positioned 
approximately 6.00 cM away from marker D19S209, which is located at 10.97 cM. 
Marker D19S878 is positioned 4.40 cM from D19S209 which is in the approximate 
location estimated. The marker D19S894 chosen to be 6.00 cM in the other direction 
away from D19S209, yielded a LOD score of -5.44 and excluded 0.60 cM either side 
of the position of the marker. The other two markers examined did not show 
statistically significant LOD scores, however both had LOD scores of approximately 
1.80 at θ=0.00, which would have been questioned if found independently. 
Furthermore, by looking at the haplotype analysis (figure 4.27), it becomes obvious 
that there is one haplotype (red bar) that is present in all the affected individuals and 
not present in the unaffected individuals. Therefore following further investigation, it 
can be concluded that this region on chromosome 19 is linked to RLS in our Irish 
RLS3002 pedigree.   
259 
Figure 4.28: Haplotype analysis of RLS3002 pedigree for chromosome 19 region 
A list of the examined markers is present on the left hand side. The alleles for each 
individual obtained from genotyping using these markers are listed below each 
individual. Each haplotype formed from the series of alleles is given a coloured bar 
so it can be recognised easily. The red bar (haplotype) is in all affected individuals 
(filled squares and circles) and a green or blue bar (haplotype) is present in the 
unaffected (squares and circles containing the letter N) individuals. Hence there is a 
shared haplotype between all the affected individuals that is absent in normal 
individuals. It is therefore possible to conclude that there is linkage between RLS 
and the region on chromosome 19. 
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4.5 Discussion 
Following exclusion of pedigree RLS3002 to all known RLS loci and associated 
regions it was necessary to conduct a genome-wide search. The aim of this approach 
was to find out the rough location of the causative gene relative to a microsatellite 
marker, which has it position already known. The first mapping set used was the 
Research Genetics Inc. mapping set. This mapping set consisted of microsatellite 
markers spaced approximately every 20 cM along the entire genome. The majority 
of the markers in this set were tetranucleotide. Following completion of this mapping 
set, no positive LOD score of >3.00 was observed. Therefore it was necessary to 
continue the genome-wide search. 
For the second mapping set, it was decided that a mapping set with greater coverage 
was necessary. Therefore the Applied Biosystems mapping set version 2.5-MD10 
was used. This mapping set has approximately 400 microsatellite markers spaced at 
10 cM intervals along the genome. This mapping set also had an average 
heterozygosity of 0.79. 
Subsequently four areas of interest were found and required further investigation. 
The first region of interest was observed on chromosome 1 where marker D1S484 
showed a LOD score of 1.69 at θ=0.67. This region was excluded for linkage by 
marker D1S2878, and a haplotype analysis confirmed that RLS3002 was not linked 
to this region.  
The second area of interest was on chromosome 10, where a LOD score of 1.71 at 
θ=0.00 was observed for marker D10S548. This region had also been excluded by 
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marker D10S1423, however a haplotype analysis confirmed pedigree RLS3002 was 
not linked to this region.  
The third area which was investigated further was a region on chromosome 18. 
Marker D18S1357 showed a LOD score of 0.68 at θ=0.00, and although this value 
was inconclusive, a large area surrounding the marker was not excluded for linkage 
and therefore required further investigation. Four additional markers surrounding 
D18S1357 were ordered and investigated. The markers were mostly inconclusive, 
however following haplotype analysis it was clear that pedigree RLS3002 was not 
linked to this. 
A positive LOD score of 2.01 at θ=0.67 obtained for marker D19S209 suggested 
linkage of RLS to the region on chromosome 19. This was the fourth area which 
required investigation. Four adjacent markers were ordered and examined. Linkage 
analysis of marker D19S878 yielded a LOD score of 3.59 at θ=0.00, thereby 
providing evidence of linkage to this region. SLINK simulation analysis indicates 
that the maximum LOD score achievable with this pedigree is 3.41 at θ=0.01. To 
confirm that this region on chromosome 19 is linked to RLS in pedigree RLS3002, a 
haplotype analysis was performed. For the haplotype analysis the four newly ordered 
markers and two markers from the Applied Biosystems mapping set were used. 
These markers were located between 0.00 cM and 20.01 cM on chromosome 19. 
Haplotype analysis of the genotype data revealed a disease haplotype that was 
present in all 11 affected members. Therefore the haplotype analysis confirmed that 
this region was linked to RLS in our Irish pedigree.  
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Chapter 5 
Fine-Mapping Chromosome 19 
RLS locus 
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5.1 Introduction 
Linkage to RLS in our Irish pedigree RLS3002 was confirmed to chromosome 19p. 
Marker D19S878 yielded a LOD score of 3.59 at θ=0.00, thereby providing evidence 
of linkage to this region. Haplotype analysis of the region also confirmed linkage. 
Initial detection of a genetic locus generally does not yield much precision on its 
location, thus leaving too vast an area to explore for candidate genes. It is therefore 
necessary to refine the location of the genetic determinants. Localisation or fine-
mapping is the process of refining the location. Studies which have an increased 
number of meiosis between individuals, narrowing the expected preserved segment 
lengths and thus increasing the resolution, are most advantageous. Fine-mapping of a 
region can be achieved in a number of ways, the most common being; increasing 
marker density within the chromosomal area of interest or by increasing the number 
of individuals for which phenotype information can be obtained. Since all known 
members of the RLS3002 have been recruited and used for this study, it was 
necessary to identify microsatellite markers that were very tightly linked to the 
targeted area and thereby used to further refine the susceptibility region. 
The region in question was a marker poor region; therefore, it was necessary to 
identify novel microsatellite markers in the region. This was essential for generation 
of a more detailed haplotype. In order to design more microsatellite markers it was 
necessary to examine DNA sequences in databases for clusters of short tandemly 
repeated nucleotide bases. The areas which were targeted were areas in which no 
known microsatellite markers were present. For this study repeats which were 
greater than 10 units long were considered for fine-mapping. Following 
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identification of short tandem repeats in the desired area, primers were designed 
flanking the area of interest (see section 2.7 for primer design).  
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5.2 Materials and Methods 
5.2.1 Microsatellite marker selection 
The area on chromosome 19 which was found to be linked to RLS in this Irish 
family required further examination in order to refine the region.  
Known Microsatellite Markers 
Following a search of genetic databases www.ncbi.nlm.nih.gov and 
www.genome.ucsc.org, only five other microsatellite markers in the region were 
identified. These microsatellite markers were D19S883, D19S565, D19S247, 
D19S120 and D19S424. The marker located nearest to the telomere was D19S883, 
which is located at 5.54 cM. There was no microsatellite marker in the databases 
between the telomere and 5.54 cM. In an attempt to refine this novel region it was 
necessary to design novel microsatellite markers.  
Novel Microsatellite Markers 
This region is a marker poor region, and it was therefore necessary to create 
additional microsatellite markers in the region. The regions which were marker poor 
and had no documented microsatellite markers were identified. The main region was 
located between the telomere and marker D19S883 (5.54 cM). Figure 5.1 shows this 
region (1 – 1,454,490 bp). The map shows genetic STS markers which have a red 
line beside their name, and radiation hybrid markers which have a black line beside 
their name. Only two genetic markers were observed in this map, and they were 
AFMA319WD9 (D19S886) and AFMA299YC1 (D19S883), which is highlighted in 
the figure. Microsatellite marker D19S886 had been previously used (chapter 4). 
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D19S886 is located at 998,664 bp on chromosome 19, therefore there was nearly a 
1,000,000 bp region which was devoid of microsatellite markers. The aim was to 
attempt to design novel microsatellite markers in this region. 
 
Figure 5.1:. Chromosome 19p13.3. microsatellite poor regions 
This figure shows chromosome 19 ideogram with a red box indicating the location of 
the area shown. The area shown is 1-1,454,490 bp. Below the ideogram is a list of all 
STS genetic marker (red) and radiation hybrids (black). The highlighted marker is 
AFMA299YC1, also known as D19S883. There is a microsatellite poor region 
between the telomere and marker AFMA310WD9 (D19S886). UCSC Genome 
Browser on Human, Feb 2009 Assembly (http://genome.ucsc.edu). 
 
Furthermore, the highest LOD score to date was 3.59 at θ=0.00 for Microsatellite 
marker D19S878 (section 4.4.2). A recombination event was observed in PATH053 
between marker D19S878 and D19S209 (10.97 cM) (figure 4.27). Therefore it was 
necessary to investigate the region proximal to microsatellite marker D19S878 in the 
hope of reducing the locus further (Fig. 5.2). 
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Figure 5.2: Region proximal to marker D19S878 on Chromosome 19p13.3. 
This figure shows chromosome 19 ideogram with a red box indicating the location of 
the area shown. The area shown is 12,290,900-2,768,109 bp. Below the ideogram is 
a list of all STS genetic markers (red) and radiation hybrids (black). Two 
microsatellite markers are observed, AFMA282VE9 (D19S878) and AFMA052WB9 
(D19S565). It is the region proximal to D19S878 which requires further 
investigation. UCSC Genome Browser on Human, Feb 2009 Assembly 
(http://genome.ucsc.edu). 
 
The sequence of the microsatellite poor regions of interest were copied and pasted 
into EditSeq and the sequence was searched for multiple GA, GATA, CA, and CAG 
etc repeats. If a repeat was located the number of repeats were counted and if it 
consisted of more than ten repeats, it was accepted. One could not be certain it these 
regions were polymorphic but it was assumed that if there were at least 10 repeat 
units there was some evidence that the region might be polymorphic. Primers were 
designed for these region as per primer design (section 2.8).  
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5.2.2 Calculation of Genetic position  
A method was required to calculate the genetic position of microsatellite markers 
which were not found in the database and were designed by relying on the position 
of known microsatellite repeats in the region. Linear interpolation based on physical 
positions was used to estimate the genetic position (Levchenko, Montplaisir et al. 
2008). Figure 5.3 represents the genetic map and the physical map where the new 
microsatellite marker (B) is located. Microsatellite markers A and C are known 
microsatellite markers for which their genetic and physical position is known. The 
physical location of marker B is known, however the genetic position requires 
calculation.  
 
Figure 5.3: Genetic and physical maps required when determining the genetic 
distance of marker B 
The black vertical lines represent a chromosome, with relative positions at markers 
A, B and C. A1, B1 and C1 represent the genetic positions of markers A, B and C 
indicated. A2, B2 and C2 represent the physical positions of markers A, B and C 
respectively. Marker B represents the microsatellite marker with an unknown genetic 
location. Using the known locations of the other markers and the known physical 
location of marker B, a formula is used to find the genetic position of marker B. 
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To find the genetic location of marker B, the following formula was used: 
22
22
AC
AB


=
11 AC
x

,  where 11 ABx   
The relative genetic distance „x‟ is then added to the known genetic position of 
marker A1.  
5.2.3 Genotyping 
Genotyping of novel and known microsatellite markers to fine-map the chromosome 
19 RLS locus was performed as per section 2.5. 
5.2.4 Haplotype analysis 
Haplotype analysis of the novel chromosome 19 locus was carried out according to 
section 2.7.  
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5.2.5 Multipoint Linkage Analysis 
Multipoint linkage analysis is commonly used to evaluate linkage of a disease to 
multiple markers in a small region. It is an extension of two-point linkage analysis, 
where linkage of the disease trait is tested not to just a single microsatellite marker, 
but to a map of markers. The analysis usually involves three or more linked markers. 
In general multipoint linkage analysis is not used in the testing phase of a study, i.e. 
when using highly polymorphic markers to find linkage. Multipoint Linkage analysis 
is more beneficial when estimating the location of a linked disease gene. 
In multipoint analysis, linkage analysis is carried out for a set of markers that are 
linked to each other against a disease. It is assumed that the marker order and the 
intermarker distances are known. The disease is then placed in each marker interval, 
as well as left and right of the leftmost and right most markers. Subsequently, the 
likelihood is computed for all possible positions of the trait locus in the considered 
chromosomal region. One can then estimate the position of the disease gene along a 
chromosomal region (Ziegler A 2010). Multipoint linkage analysis is more complex 
than two-point analysis. The order of the loci now matters. Furthermore the number 
of parameters, haplotypes, and genotypes increases drastically with the number of 
loci considered.  
As before, the disease gene is an autosomal dominant disease with disease allele 
frequency of 0.01 and disease allele frequency of 0.95. For this study, LINKMAP 
was used for multipoint linkage analysis 
(ftp://linkage.rockefeller.edu/software/linkage). LINKMAP performs the 
calculations by allowing the user to fix the order and spacing of two or more of the 
markers. Likelihoods of the pedigree data are then calculated allowing the locus 
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whose position is unknown to be placed in all possible intervals. The software 
MAPFUN was utilized to convert between recombination fractions and morgans. A 
graph is used to interpret the results. From the graph it is possible to estimate the 
location of the disease gene.  
Multipoint Linkage analysis requires a number of essential steps: 
1. A batch file is prepared using LCP. 
2. Recompile the LINKMAP program if necessary. The constants may need to 
be modified to suit the problem which is under consideration.  
3. The analysis is performed. 
4. The program does not produce the actual multipoint LOD scores, therefore it 
is necessary to calculate the multipoint LOD scores. The program 
LINKLODS will perform this calculation. 
5. Convert the recombination fractions to map distance using MAPFUN. 
6. Graph the results. The y axis is the multipoint lod score and the x axis is the 
map distance.  
7. The graph is used to interpret the location of the disease gene.  
There are two major advantages to multipoint LOD score analysis. The first is that it 
offers an opportunity to impute the genotype information at an original 
uninformative locus via haplotype information. Consequently, the linkage results are 
less sensitive to the uninformative or missing genotype at any given marker. 
Secondly, multipoint linkage analysis can be extremely useful to pintpoint a disease 
gene location in the fine-mapping of a Mendelian disorder (Haines J.L 1998). This 
can be accomplished by evaluating many positions Z(x) on a fixed map. At a certain 
location (x), any true recombinant will contribute a strongly negative LOD score and 
decrease the possibility that his location contains a candidate locus. Thus this will 
help to further define the candidate region. On the other hand, the position where the 
272 
maximum multipoint LOD score is observed can pinpoint the location of the 
causative gene and can be used as a guide for selecting candidate genes. 
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5.3 Results 
5.3.1 Novel Microsatellite Markers 
The newly designed primers, their location (bp), the forward and reverse primer 
used, the fluorescent tag used to label the forward primer, and the expected size of 
the product are detailed in Table 5.1. Their physical positions (bp), primers used for 
amplification, the fluorescent tag, and the annealing temperature are listed here. 
Table 5.1. List of newly designed microsatellite markers used to fine-map the 
chromosome 19 RLS locus.  
Marker Location 
(bp) 
Primers  Fluorescent 
Tag 
Product 
Size 
(bp) 
Annealing 
Temp °C 
CA19S322F 322,195 agacgctttcaaaactcaccact HEX 326 * 
CA19S322R  gggcacccacctcagacat    
AC19S189F 189,592 taagtgatccccatgcctctgtct 6-FAM 407 * 
AC19S189R  aacatggtgaaaccccgtctctac    
CA19S872F 872,286 acagtgcaaatgcccatcaatcaa 6-FAM 411 67 
CA19S872R  gtggcgccgtctcacctgaa    
GT19S949F 949,752 ctccctccgtccctccccagtc 6-FAM 271 68 
GT19S949R  ctcccgacggtgtctccccagat    
ATA19S1001F 1,001,575 cctggctaacatggtgaaacagtg 6-FAM 409 67 
ATA19S1001R  gacgtcgtggcccaggatgaag    
AC19S1117F 1,117,411 ccctccacatggattgaagacaca 6-FAM 414 67 
AC19S1117R  cagggtggtgcggctttctgt    
CA19S2310F 2,310,554 cttcccgggcaacatggtgagac 6-FAM 270 67 
CA19S2310R  agggcgttttctagggcactggtg    
ATA19S2359F 2,359,877 aaaaataaagttgccgggtgtggt 6-FAM 436 * 
ATA19S2359R  ctcaggaggctaaggcaggagaat    
GT19S2518F 2,518,246 ttggccgtgatcattcctgtagtg HEX 290 68 
GT19S2518R  cctgggcaaaatggcgaaacc    
* represents markers which failed to amplify, therefore the annealing temperature 
remains unknown. 
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5.3.2  Calculation of Genetic positions 
Using the formula described above, the genetic positions were calculated for the new 
microsatellite marker. Below is an example of how this formula was used to 
calculate the genetic distance of marker AC19S1117 located at 1,117,411bp on 
chromosome 19. 
 
Figure 5.4: Calculating the genetic position of marker AC19S1117  
The black horizontal lines represent chromosome 19. A1, B1 and B2 represent the 
genetic positions of markers D19S886, AC19S1117 and D19S883 respectively. A2, 
B2 and B3 represent the physical positions of markers D19S886, AC19S1117 and 
D19S883 respectively. Marker B represents the microsatellite marker AC19S1117 
with an unknown genetic location. Using the known locations of the other markers 
and the known physical location of marker AC19S1117, a formula is used to find the 
genetic position of AC19S1117. 
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Using the formula the genetic position of marker AC19S1117 is calculated. 
22
22
AC
AB


=
11 AC
x

,   where 11 ABx   
1,117,411 bp - 949,644 bp = X  
1,364,757 bp- 949,644 bp 5.54 cM– 0.00 cM 
167,767 bp=  X 
415,113 bp 5.54 cM 
X = 2.23cM 
The relative genetic distance „X‟ is then added to the known genetic position of 
marker A1. 
0.00 cM (A1) + 2.23 cM (X) = 2.23 cM 
Therefore marker AC19S1117 is located at 2.23 cM on chromosome 19. The 
remaining new markers were calculated for genetic position. Table 5.2 lists the 
known markers that were used to calculate the genetic position (cM) of the novel 
microsatellite markers. As this was a marker poor region, there were no 
microsatellite markers located at the region distal to  markers CA19S322, AC19S189 
and CA19S872. Therefore a superficial marker „X‟ was used which had a physical 
location at 0.00 bp and a genetic position at 0.00 cM. In table 5.2, Marker B 
represents the novel microsatellite marker for which the genetic location is unknown 
and the physical location (B2) is known. Markers A and B represent known marker 
for which the genetic location (A1 and B1) and the physical location (A2 and B2) is 
known. Marker „X‟ represents the superficial marker used to calculate the genetic 
position of novel microsatellite markers CA19S322, AC19S189 and CA19S872. 
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Table 5.2: Known markers used for calculating the genetic position of novel 
microsatellite markers used for fine mapping the chromosome 19 locus.  
Marker (B) Known 
Marker 
A 
Known 
Marker 
C 
A1 
(cM) 
A2 (bp) B2 (bp) C1 
(cM) 
C2 (bp) 
CA19S322 X D19S886 0.00 0 322,195 0.00 949,644 
AC19S189 X D19S886 0.00 0 872,284 0.00 949,644 
CA19S872 X D19S886 0.00 0 872,390 0.00 949,644 
GT19S949 D19S886 D19S883 0.00 949,644 949,752 5.54 1,364,757 
ATA19S1001 D19S886 D19S883 0.00 949,644 1,001,575 5.54 1,364,757 
AC19S1117 D19S886 D19S883 0.00 949,644 1,117,411 5.54 1,364,757 
CA19S2310 D19S883 D19S878 5.54 1,364,757 2,310697 6.57 2,310,697 
GT19S2359 D19S878 D19S565 6.57 2,310,697 2,359,877 6.57 2,518,075 
GT19S2518 D19S565 D19S591 6.57 2,518,075 2,518,246 9.84 3,026,844 
 
The genetic positions of the novel microsatellite markers were calculated using the 
figures in Table 5.2. The results of these calculations, along with the physical and 
genetic positions of known microsatellite markers are detailed in Table 5.3. This 
table lists their physical position (bp) and Genetic position (cM). 
Table 5.3: Genetic positions of known and novel microsatellite markers examined 
for fine-mapping chromosome 19 RLS locus.  
Marker Physical position (bp) Genetic position (cM) 
CA19S322 322,195 0.00 
AC19S189 872,284 0.00 
CA19S872 872,390 0.00 
GT19S949 949,644 0.00 
ATA19S1001 1,001,575 0.69 
AC19S1117 1,117,411 2.23 
D19S883 1,413,918 5.54 
CA19S2310 2,310,554 6.57 
GT19S2359 2,359,877 6.57 
GT19S2518 2,518,246 6.57 
D19S565 2,567,233 6.57 
D19S247 3,139,982 9.84 
D19S120 3,189,343 10.97 
D19S424 3,226,373 10.97 
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5.3.3 Genotyping results  
Fourteen microsatellite markers were ordered for fine-mapping the chromosome 19 
locus, nine of which were novel microsatellite markers. These microsatellites were 
newly designed. It was not known if these markers were polymorphic and therefore 
if they were going to be informative. Six of the nine novel microsatellite markers 
were amplified, all of which were polymorphic, and provided LOD scores. This was 
a fantastic result, as these were newly designed primers, and it was not known if the 
novel microsatellite markers would firstly amplify and secondly be polymorphic. Of 
the known microsatellite markers four out of five amplified and provided LOD 
scores. Four out of the fourteen known and novel markers ordered for fine-mapping 
the chromosome 19 locus were not informative: CA19S322, AC19S189, D19S883 
and ATA19S2359. These microsatellite marker did not produce specific bands on 
agarose gel electrophoresis. Standard procedures were carried out to attempt to 
amplify these markers e.g. range of annealing temperatures, range of Mg
2+ 
concentrations, and primers were re-suspended. Nonetheless, these markers failed to 
amplify.   
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As previously mentioned ten of the fourteen microsatellite markers were successfully 
amplified for the chromosome 19 RLS locus. Table 5.3 lists all the markers 
examined and outlines their genetic positions (cM), the LOD score obtained at 
θ=0.00, the corresponding maximum excluded distances in cM. 
Table 5.4: Markers used to fine-map the chromosome 19 RLS locus.  
Marker Position (cM) Max LOD (θ=0) Excluded cM 
CA19S872 0.00 2.47 0.00 
GT19S949 0.00 2.12 0.00 
ATA19S1001 0.69 2.16 0.00 
AC19S1117 2.23 2.46 0.00 
CA19S2310 6.57 3.46 0.00 
D19S565 6.57 -0.78 0.00 
GT19S2518 6.57 -0.89 0.00 
D19S247 9.84 0.92 0.00 
D19S120 10.97 -1.66 0.00 
D19S424 10.97 -1.72 0.00 
 
Of the ten microsatellite markers which worked, one of them obtained a statistically 
significant LOD score of >3, thereby confirming linkage. None of the microsatellite 
markers showed a negative LOD score of <-2, therefore there was no area of 
exclusion. 
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5.3.4 Haplotype Analysis 
From these results it is not possible to determine the refined candidate region. In 
order to determine this region a haplotype for the chromosome 19 locus was 
reconstructed with the new microsatellite markers added. All 11 affected individuals 
carried a common haplotype which was identified by markers CA19S872, D19S886, 
GT19S949, AC19S1117, CA19S2310, and D19S878. Although individual 
PATH208 is unaffected, he does share part of the affected haplotype (figure 5.6). 
A recombination event between markers D19S878 and D19S565 in individual 
PATH053 allowed for the defining of the RLS region. Both marker D19S878 and 
D19S565 are located at 6.57 cM, however D19S878 is located at 2.3 Mb and 
D19S565 is located at 2.5 Mb on chromosome 19. Therefore a recombination event 
took place somewhere within this 0.2 Mb region. Haplotype reconstruction allowed 
determination of the overall candidate region which is flanked by the telomere and 
microsatellite marker D19S565. This candidate region has a genetic distance of 6.57 
cM and corresponds to a physical distance of 2.5 Mb on chromosome 19p13.3. 
Figure 5.5 represents the newly reconstructed haplotype for the chromosome 19 RLS 
locus. 
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Figure 5.5: Haplotype analysis of RLS3002 pedigree for chromosome 19 region 
A list of the examined markers is present on the left hand side. The alleles for each 
individual obtained from genotyping using these markers are listed below each 
individual. Each haplotype formed from the series of alleles is assigned a coloured 
bar so it can be recognised easily. The red bar (haplotype) is in all affected 
individuals (filled squares and circles), and it is assumed that this red bar is inherited 
from the affected grandmother in generation I. The unaffected (squares and circles 
containing the letter N) individuals do not inherit a red bar, and it is assumed they 
inherit their haplotype from the unaffected grandfather (generation I). Hence there is 
a shared haplotype between all the affected individuals that is absent in normal 
individuals. A recombination event was observed in individual PATH053 and the 
point of recombination is marked with an asterix (*). This recombination event 
defined the critical RLS gene location as distal to marker D19S565. 
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5.3.5 Multipoint Linkage analysis 
Once linkage has been detected, multipoint linkage analysis can help localize the 
position of the gene more precisely (Elston and Olson 2002). Multipoint linkage 
analysis is the analysis of linkage data involving three or more linked loci. 
Multipoint linkage analysis was performed for this region for a number of different 
marker combinations. However the combination of markers which gave the highest 
LOD score was: D19S886 (0.00 cM), D19S878 (6.57 cM) and D19S591 (9.84 cM). 
A maximum multipoint LOD score of 3.77 was obtained at a position of 6.64 cM on 
chromosome 19, the nearest marker to this being D19S878 which is positioned at 
6.57cM. This maximum multipoint LOD score is illustrated in figure 5.6 which also 
shows the surrounding markers. A number of markers are located at the same genetic 
position on chromosome 19, these markers are represented with a + sign. 
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Figure 5.6: Graph of Multipoint parametric LOD scores for family RLS3002 on 
chromosome 19p 
Genetic distance (cM) are plotted on the x axis and LOD score [ Z (θ)] is plotted on 
the y axis. Multipoint Linkage analysis was performed with markers D19S886, 
D19S878 and D19S591, which are shown in red. Names of a number of 
microsatellite markers are not shown on the graph as a number of the markers share 
the same genetic position. The markers which generated the highest LOD scores are 
shown on this map.  
 
Multipoint Linkage analysis can help localize the position of the gene more 
precisely. However, it can also support the findings of the genome-wide scan. The 
results of the multipoint linkage analysis in figure 5.6 support the findings that 
family RLS3002 is linked to chromosome 19 for RLS. A maximum multipoint LOD 
score of 3.77 was obtained at a position of 6.64 cM on chromosome 19. 
From a multipoint LOD score graph it is usually possible to determine a support 
interval for the likely placement of the disease locus. Current Protocols of Human 
Genetics suggest that in order to do this , a horizontal line is to be drawn across the 
graph at a value equal to the highest LOD score minus 3 LOD units. All points on 
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the map that are above this horizontal line are included within the 3-LOD-unit 
support interval and cannot be entirely excluded. For two-point linkage analysis 
graph only a 1-LOD unit support is required, however the 3-LOD-unit support is 
needed for multipoint analysis to ensure a higher degree of confidence in locus 
placement for multipoint situation (Speer 2006). Unfortunately it is not possible to 
use this approach for our study. The maximum LOD score is equal to 3.77, which 
would indicate that a horizontal line be drawn at Z(θ=0.77). This line would not 
cross the LOD score curve at any point, therefore no support interval can be inferred.  
Nevertheless, the graph can be used to interpret the location of the disease gene. The 
highest LOD score was obtained just proximal to microsatellite marker D19S878. 
The value of the maximum LOD score is equal to 3.77. Therefore the most likely 
location of the causative gene is in close proximity to microsatellite marker 
D19S878. This information should be considered when selecting candidate genes for 
screening.  
.  
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5.4 Discussion  
Following confirmation of linkage to chromosome 19 it was necessary to refine the 
region. Refining the region will help to the smallest possible area will reduce the 
candidate region and will help locate the gene. Initial detection of a genetic locus 
generally does not yield much precision on its location, thus leaving too vast a region 
for choosing candidate genes. Fine-mapping refines the genetic region, thereby 
reducing the number of genes within the candidate region. Fine mapping is therefore 
an essential step before beginning candidate gene selection in order to reduce the 
number of potential candidate genes. 
To fine map the chromosome 19 candidate region it was necessary to locate other 
microsatellite markers in the region. Only four other microsatellite markers were 
available in this region, (www.ncbi.nih.nlm, and www.ensembl.org). These markers 
were: D19S565, D19S247, D19S120 and D19S424. This region is a microsatellite 
poor region; therefore it was necessary to find additional microsatellite repeats in the 
region and to design primers to amplify these regions. An additional 10 
microsatellite markers were ordered. Linkage analysis results of these markers 
obtained a maximum LOD score of 3.46 for marker CA19S2310 which is located at 
6.57 cM. 
Haplotype reconstruction revealed that all 11 affected individuals carried a common 
haplotype. A recombination event between markers D19S878 and D19S565 in 
individual PATH053 allowed for the defining of the 19p13.3 RLS region flanked by 
the telomere and microsatellite marker D19S565. Therefore an overall candidate 
region of 6.57 cM corresponding to 2.5 Mega bases (Mb) on chromosome 19p13.3 
has been identified.  
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Individual PATH208, is unaffected, however shares part of the affected haplotype. 
Two theories can explain this individual‟s phenotype. In the first scenario, individual 
PATH208 is a carrier of only a portion of the overall candidate region, spanning 1.1 
Mb on the physical map. The gene responsible for RLS in this family may be 
positioned elsewhere on the chromosome 19p13.3 locus. The second theory is that 
PATH208 is a non-symptomatic member. He may carry the affected haplotype but 
symptoms and genetic traits are not being expressed (incomplete penetrance). It has 
been previously noted that incomplete penetrance is seen in one third of cases with 
autosomal dominant RLS (Hamet and Tremblay 2006). 
A maximum multipoint LOD score of 3.77 was obtained at a position of 6.64 cM on 
chromosome 19, the nearest marker being D19S878 which is positioned at 6.57 cM. 
This confirmed linkage to the chromosome 19p13.3 region and also localises the 
position of the gene more precisely. It is probably not a coincidence that the highest 
two-point LOD score was also observed at this microsatellite marker, D19S878 
(LOD=3.59 at θ=0.00). Therefore the multipoint analysis shows that the most likely 
map location for the RLS gene is close to D19S878. Multipoint LOD scores are 
potentially more informative than two point LOD scores as they have the ability to 
pinpoint a disease gene location in the fine-mapping of a Mendelian disorder. 
Nonetheless, as seen in this study multipoint LOD scores will not produce a higher 
absolute value at a specific marker if the marker itself is already fully informative for 
linkage. In this study a maximum LOD score of 3.77 (θ=0.00) was observed, which 
was only slightly higher than that seen for the two-point LOD score (3.59 at θ=0.00).  
In conclusion a novel locus for RLS has been identified on chromosome 19p13.3. 
The next step is to search the region for candidate genes. It can be anticipated that 
286 
the detection of the underlying gene defect at 19p13.3 will add to our current 
understanding of the underlying pathophysiology of RLS. 
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Chapter 6 
Sequencing  
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6.1 Introduction  
The novel RLS locus which was identified spanned a region of 6.57 cM 
corresponding to 2.5 Mb on chromosome 19p13.3. The next obvious step was to 
search the region for candidate genes in the hope of finding the underlying gene 
defect.  
The first stage of this part of the study was to select candidate genes from within thes 
novel locus. Due to the fact that no causative gene had yet been identified in any of 
the previously described loci, it was not possible to choose candidate genes based on 
known genes. The candidate genes therefore were selected on the rationale that the 
pathophysiology of RLS may be closely linked to the dopaminergic system and/or 
iron metabolism. As previously mentioned (section 1.6), the pharmacological data 
that strongly lend support to a dopaminergic abnormality and iron depletion is 
regarded as the most relevant additional factor for the clinical manifestations of the 
syndrome. The chromosome 19p13.3 locus is flanked by the telomere and 
microsatellite marker D19S565. The region is 6.57 cM (genetic length) 
corresponding to 2.5 Mb (physical length). There are approximately 100 genes in 
this region and were identified using the human genome public database websites 
http://genome.ucsc.edu/ and www.ensembl.org. Many of the genes had known 
functions, for example MADCAM1, which is a cell adhesion leukocyte receptor 
expressed by mucosal venules; and PPAP2C, which is a member of the phosphatidic 
acid phosphatise family and is found mainly in the brain and placenta. Other genes 
were expressed in tissues unlikely to be related to RLS, for example C19orf22 which 
is expressed in whole blood, B cells and T cells. The genes within the chromosome 
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19p13.3 locus were narrowed down to 8 possible candidate genes, and from this two 
of the more promising genes within the candidate interval were chosen for screening. 
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6.1.1. KLF16 
The first gene selected for screening was KLF16 (Krueppel-like factor 16) otherwise 
known as Transcription factor BTEB4 (Basic transcription element-binding protein 
4) and DRRF (dopamine receptor regulating factor). Transcriptional regulation is 
governed by the coordinated action of regulatory factors that bind to specific DNA 
elements. KLF16 (DRRF) binds to GC and GT boxes in the D1 and D2 dopamine 
receptor promoters and effectively displaces Sp1 and Sp3 from these sequences. 
Subsequently, DRRF can modulate the activity of these dopamine receptor 
promoters. In a study published in 2001, it was reported that mice treated with drugs 
that increase extracellular striatal dopamine levels (cocaine), block dopamine 
receptors (haloperidol), or destroy dopamine terminals (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) show significant alterations in DRRF mRNA (Hwang, D'Souza 
et al. 2001). KLF16, therefore, is an excellent candidate gene for RLS as it is 
important for modulating dopaminergic transmission in the brain. 
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6.1.2 GAMT 
The second gene selected for screening was GAMT (guanidinoacetate N-
methyltransferase. It is also known as PIG2 and TP53I2. GAMT supplies instructions 
for making the enzyme guanidinoacetate methyltransferase. It is active in the 
pancreas, liver and kidneys. This enzyme participates in the two-step synthesis of the 
compound creatine from the amino acids glycine, arginine and methionine. GAMT 
gene mutations impair the ability of the guanidinoacetate methyltransferase enzyme 
to participate in creatine synthesis (http://ghr.nlm.nih.gov/). The effects of 
guanidinoacetate methyltransferase deficiency are most severe in organs and tissues 
that require large amounts of energy, such as the brain and muscles. Increased serum 
concentration of muscle creatine phosphokinase is observed in the majority of 
affected individuals with choreoacanthocytosis (ChAc) (Hiersemenzel, Johannes et 
al. 1996). Choreoacanthocytosis is characterised by a progressive movement 
disorder. Although the movement disorder is mostly limb chorea, some individuals 
present with a parkinsonian syndrome 
(http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&part=chac).  
  
292 
6.1.3 DNA sequencing 
The principles of DNA sequencing is based on the dideoxy sequencing method 
developed by Fred Sanger. The DNA is present in a single stranded form and acts as 
a template for making a new complementary DNA strand in vitro using a suitable 
DNA polymerase. Cycle sequencing is similar to PCR as it includes denaturation, 
annealing and DNA synthesis and it uses a heat stable DNA polymerase. In addition, 
however, it uses dideoxynucleotide triphosphates (ddNTPs), and only a single 
oligonucleotide primer is required. The ddNTPs are closely related to the normal 
dNTPs; they differ only in that they lack a hydroxyl group at the 3‟ carbon position 
as well as the 2‟ carbon. Due to the fact that ddNTPs lack a 3‟ hydroxyl group, any 
ddNTP that is incorporated into a growing DNA chain cannot participate in 
phosphodiester bonding at it 3‟ carbon atom. This thereby causes abrupt termination 
of chain synthesis. By setting the concentration of the ddNTP to be much lower than 
that of the dNTPs, there will be competition between a specific ddNTP molecule and 
an surplus of analogous dNTP molecules for incorporation into the growing DNA 
chain. Therefore if a dNTP is incorporated, chain extension will continue; however if 
a ddNTP is (occasionally) included it causes chain termination. Thus, each reaction 
is only a partial reaction, as chain termination will take place randomly at one of the 
possible choices for a specific type of base in any one DNA strand. The sequence 
cycle will therefore result in the synthesis of differently sized labelled DNA 
fragments. Figure 6.1 demonstrates the dideoxy DNA sequencing with the random 
incorporation of ddNTP causing a chain termination (Strachan and Read 2003). 
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Figure 6.1: A schematic diagram explaining Sanger’s dideoxy DNA sequencing 
The sequencing primer binds to a region 3′ of the desired DNA sequence and primes 
synthesis of a complementary DNA strand in the indicated direction. Four parallel 
base-specific reactions are carried out, each with all four dNTPs and with one 
ddNTP. Competition for inclusion into the growing DNA chain between a ddNTP 
and its normal dNTP analog results in a population of fragments of different lengths. 
The fragments will have a common 5′ end (defined by the sequencing primer) but 
variable 3′ ends, depending on where a dideoxynucleotide (shown with a filled circle 
above) has been inserted. For example, in the A-specific reaction chain, extension 
occurs until a ddA nucleotide (shown as A with a filled black circle above) is 
incorporated. This will lead to a population of DNA fragments of lengths n + 2, n + 
5, n + 13, n + 16 nucleotides, etc. 
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6.2 Materials and Methods 
6.2.1 Primer design 
KLF16 
According to the UCSC Genome Browser (Feb. 2009), two versions (A and B) of 
GAMT exist (figure 6.2). Introns are depicted as lines with arrows indicating the 
direction of transcription. The arrows are pointing to the left, therefore transcription 
occurs on the negative strand. Version A of KLF16 has two exons in total. The 
second exon, which is the one to the far right, is quite large, spanning approximately 
2 kb. Version B of KLF16 has three exons in total. Exon one is identical to that seen 
in version A. Exons two and three are located in the same location as the second 
exon in version A, the only difference being there is approximately 1.0 kb of an 
intronic region dividing the two exons. To ensure comprehensive screening of 
KLF16, both versions of the gene required screening. Exon 1 was identical in both 
versions and was designated x1. By screening the second exon of version A, exons 
two and three of version B was also covered.  
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Figure 6.2: Chromosome 19 and KLF16 gene 
This figure shows the chromosome 19 ideogram, with a red vertical bar indicating 
the position of KLF16 on the chromosome. A represents the UCSC version of the 
KLF16 gene. The two exons are represented by the blue filled rectangles. The introns 
are represented by the arrowed lines in between the exons, with the arrows indicating 
the direction of transcription. The arrows are pointing to the left, therefore 
transcription occurs on the negative strand. B is a representation of the KLF16 gene 
based on another database. This version only has three exons. UCSC Genome 
Browser, February2009 Assembly (http://genome.ucsc.edu). 
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GAMT (Primer Design) 
According to the UCSC Genome Browser (Feb. 2009), two versions of GAMT exist. 
These two versions can be observed in figure 6.3 below. Introns are depicted as lines 
with arrows indicating the direction of transcription. In this case intron orientation is 
negative, therefore arrows point to the left. Version A of GAMT has six exons (black 
rectangles). Version B of GAMT has only five exons, however. Exons 1 to 4 
(represented by the blue rectangles) are identical to exons 1-4 in version A. 
Nonetheless, exon 5 is somewhat larger than that of version A, and exon 6 does not 
exist. Hence, to ensure comprehensive screening of GAMT, both versions of the gene 
required screening. Exons 1 to 4 were identical and were therefore designated x1, x2, 
x3, x4. By screening the fifth exon of version B, exon 5 of version A was also 
covered. The fifth exon of version B was designated x5. Exon 6 of version A was 
designated x6. According to ensembl (www.ensembl.org) only one version of GAMT 
exists, and this is identical to version A (http://genome.ucsc.edu).  
 
Figure 6.3: Chromosome 19 and GAMT gene 
This figure shows the chromosome 19 ideogram, with a red vertical bar indicating 
the position of GAMT on the chromosome. A represents the UCSC version of the 
GAMT gene. The six exons are represented by the black filled rectangles. The introns 
are represented by the arrowed lines in between the exons, with the arrows indicating 
the direction of transcription. The arrows are pointing to the left, therefore 
transcription occurs on the negative strand. B is a representation of the GAMT gene 
based on another database. This version only has five exons. UCSC Genome 
Browser, February2009 Assembly (http://genome.ucsc.edu).  
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6.2.2 Pedigree RLS3002 
When carrying out the genome-wide scan it was necessary to genotype all members 
of the RLS3002 family. However, when sequencing a candidate gene, it is not 
necessary to screen every member of the family. For the purpose of screening the 
two candidate genes KLF16 and GAMT, DNA from one unaffected and two affected 
members of the pedigree were screened. The two affected members screened were 
first cousins, PATH048 and PATH054. One unaffected member of the family was 
screened, PATH047. This individual is the father of individual PATH048, which 
would mean that any variant observed in the daughter (PATH048) and not in the 
father would have been inherited from the affected mother or less likely, it would be 
a novel mutation. PATH047 is married into pedigree RLS3002, which also means 
that any variation he has is unlikely to be disease causing. The three members chosen 
for screening the candidate gene can be observed in figure 6.4. 
 
Figure 6.4: Members of RLS3002 chosen for candidate gene screening 
Only three members of RLS3002 were used for screening the candidate genes. Two 
affected members, PATH048 and PATH054, who are first cousins, were screened. 
PATH047, father of PATH048 is an unaffected member and was also screened. The 
three individuals used for this part of the study are indicated by the red boxes.  
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6.2.3 PCR 
PCR was carried out in 50 µl reactions. A total of 5 µl of genomic DNA was used as 
a template for amplification reactions. Table 6.1 provides details of the reagents 
used. The table contains the name of the reagent, the stock concentration, the 
concentration used, and the amount of each reagent in a 50 µl reaction volume. 
Table 6.1 Reagents used for PCR in 50µl reaction volumes. 
Reagent [Stock] [Final] 1 sample (µl) 
10x buffer 10x 1x 5.00 
MgCl2 25 mM 1.5 mM 3.00 
dNTP 10 mM 0.2 mM 1.00 
Forward Primer 100 ng/µl 100 ng 1.00 
Reverse Primer 100 ng/µl 100 ng 1.00 
Taq polymerase 5 U/µl 0.05 U 0.15 
H2O   33.85 
DNA  50-100 ng 5.00 
Total Volume   50.0 
 
Once the samples were prepared, each 50 µl reaction was placed in a 0.2 ml capped 
PCR tube and placed on the GStorm Thermal Cycler PCR machine. A temperature 
gradient was initially used to discover the optimal annealing temperature for each 
individual marker (as outlined earlier in section 3.2). The success of PCR was 
verified by agarose gel electrophoresis (as outlined in section 2.4).  
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6.2.4 DNA sequencing 
Automated DNA sequencing requires 1) fluorescence labelling of DNA and 2) a 
detection system. Dideoxynucleotides to which fluorophores (chemical groups 
capable of fluorescing) are attached are used. This results in each nucleotide base 
being attached to a specific fluorophore. Since a different label is used for each 
nucleotide, the cycle sequencing will produce differently sized DNA fragments of 
the desired sequence with each base in the sequence tagged with a different 
fluorescent label. During electrophoresis, using the ABI3130 Genetic Analyser, the 
fluorescence signal is detected and recorded as the DNA passes through a fixed point 
in the capillary. The output is in the form of intensity profiles for each of the 
differently coloured fluorophores and the information is simultaneously stored 
electronically (Strachan and Read 2003). 
Following amplification of the desired region by PCR (section 6.2.2 above), the 
sequencing protocol used for this study comprises of the following steps: 
a. PCR purification; 
b. Sequencing reaction; 
c. Post-sequencing purification; 
d. Detection of sequences using the ABI3130 genetic analyser. 
a. PCR purification 
To achieve good quality sequence data using the Sanger dideoxy sequencing method 
and fluorescently labelled nucleotides, it is necessary to remove the excess primer 
and dNTPs from the initial PCR reaction performed (section 6.2.2). JETQUICK Spin 
Columns were used according to the manufacturer‟s guidelines as described in 
section 2.8.  
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b.  Sequencing reaction 
The purified PCR products were then sequenced. As previously mentioned this 
technique is based on Fred Sanger‟s dideoxy sequencing method (section 6.1.3). 
This will result in differently sized DNA fragments of the desired sequence with 
each base in the sequence tagged with a different fluorescent label. The reaction was 
carried out according to the protocol detailed in section 2.9. 
 
c. Post-Sequencing Purification 
Purification of sequencing products was carried out using the AmpliPurify
TM
 
ExTerminator Kit. This optimised purification procedure removes unincorporated 
dyes, dNTPs and excess salt. It also removes the sequencing enzyme. This was 
performed according to the protocol outlined in section 2.10. 
 
d. Detection of sequences using the ABI3130 genetic analyser 
The instrument is used to perform the electrophoresis step and to monitor the 
different fluorophores (colours) as they pass by and are detected by the laser. The 
samples are run on the ABI3130 according to guidelines outlined in section 2.11.1. 
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6.2.5 Sequence Analysis 
The sequences acquired from the ABI3130 were analysed using SeqMan programme 
from DNAstar software. SEQMAN provides a number of useful tools for 
simplifying the process of assembling data from a sequencing project. It allows the 
user to perform alignments and discover variants, along with many other analyses on 
de novo or template assemblies. SeqMan allows the user to assemble anything from 
two sequences to tens of thousands of sequences into contigs (figure 6.5). 
 
 
Figure 6.5: DNA sequence data from the Seqman programme 
A series of peaks are seen each of which corresponds to a specific base. Blue = C 
(Cytosine), black = G (Guanine), green = A (Adenine) and red = T (Thymine). X 
points to the position of the sequence (bp), Y points to the consensus sequence and Z 
points to the sequence of the sample. The example illustrated here shows a section of 
sequence from GAMT exon 6a, sample PATH054. 
 
Sequences were compared with the expected amplicon and with other samples. Any 
variation present was recorded and both affected and unaffected individuals were 
compared for the presence or absence of variations. For a variation to be significant 
within this family, it must be present in samples from both of the affected individuals 
(PATH048 and PATH054) and not present in the unaffected individual (PATH047). 
If a variation was detected in both affected individuals, various websites 
(http://genome.ucsc.edu, http://www.ensembl.org and http://www.ncbi.nlm.nih.gov/) 
should be searched to determine whether these variations are known single 
nucleotide polymorphisms (SNPs).   
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6.3. Results 
6.3.1 Primer Design 
KLF16 
As described in section 6.2.1, two versions of KLF16 exist according to UCSC 
Genome Browser, February2009 Assembly (http://genome.ucsc.edu). However, by 
screening version A of KLF16, version B is included within this. Therefore, two 
exons in total required screening.  
The first exon (KLF16x1) was 524 bp long. Initially, only one set of primers was 
designed to amplify this exon. However, after numerous attempts to amplify this 
fragment, another set of primers were designed. One of the main limitation within a 
sequencing reaction is sequence length, therefore this exon was divided into smaller 
overlapping fragments. Exon 1 was divided into four overlapping fragments, x1a, 
x1b, x1c, and x1d. Only a forward primer was ordered for x1c, as the reverse of x1d 
was to be used to amplify this inner region of exon 1.  
The second exon, KLF16x2, was a large exon, encompassing 2,362 bp. Similar to 
exon 1 this exon was also divided into smaller overlapping fragments. Exon 2 was 
divided into five overlapping fragments, which were designated: x2a, x2b, x2c, x2d 
and x2e (illustrated in figure 6.6).  
As work progressed, a further three sets of primers were ordered. This was because 
gaps remained between sequences after analysis of the sequences using the original 
primers and so a complete sequence of exon 2 was not obtained. One gap was 
located between x2b and x2c. In total, two more pairs of primers (KLF16x2gap1 and 
KLF16x2bgap) were required to obtain sequences to close this gap. 
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A second gap of sequence was present between x2d and x2e. It was necessary to 
design and order an additional set of primers (KLF16x2gap2) to cover this gap. 
The primer sequences, annealing temperatures, and expected sizes of all the KLF16 
fragments are shown in table 6.2. A number of the fragments failed to amplify, 
therefore an asterix (*) represents unknown annealing temperature in Table 6.2. 
Figure 6.6 shows KLF16 and its the positions of the fragments used to sequence the 
gene. 
Table 6.2: Features of primer fragments used to screen KLF16. 
Fragment Forward Primer Sequence Reverse Primer Sequence Annealing 
Temp (°C) 
Size 
(bp) 
KLF16x1 CCCCACGCGCCACGCA
GTTT 
GGGCGGGGCGGGCTGT
G 
* 761 
KLF16x1a AGAGGCCCAGCAGGAG
CAGGAAC 
AGCACGTCGGCGGCGA
AGTAATC 
* 186
5 
KLF16x1b TCGCCGCCGACGTGCT
CAT 
TCAATCCCGCCCGCAG
ACCTC 
* 691 
 
KLF16x1c GCGCGGCTCGGAGAGT
GGTG 
 * * 
KLF16x1d CCGTGGCGTGCGTGGA
TTACTT 
CTGGCGGGGGAGGGGT
CTC 
* 509 
KLF16x2a GGGGGCGGGTAAGGGT
TGTATTCT 
GGGGGCAGGGGTGTCT
TCAGG 
67 600 
KLF16x2b GCCCTCGTGCAGCCCA
CCCTGAC 
CGCTGCCCCACTCCTG
GCTCTACC 
70 630 
KLF16x2c CCACCGAAAGCCATGG
GAGTAGTT 
CACAGCCAGCCCTCTG
CTTCCAGT 
70 657 
KLF16x2d CCGCCGGGGTTGCAGG
CTCTT 
TCCCCCACCCACCCCC
ACAGACTA 
69 766 
KLF16x2e GGGGGCTTTGGATGGC
ACTG 
CCCTCCGCGGGGCTTA
GG 
69 750 
KLF16x2gap
1 
GGGTGACGGGGGCTTG
TGTCTGTA 
CATCCTAACGCTGCCC
CACTCCTG 
70 447 
KLF16x2gap
2 
GTTGGCTGCAGGAGGT
TTTTG 
GAGGGGCCCAGTTATA
GAGTTCTG 
63 413 
KLF16x2bga
p 
GGGTGGAGTGGACTTC
TGG 
TCAACCCCCGACTCCT
CT 
66 105 
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Figure 6.6: KLF16 gene, its exons and amplicons (primer fragments) 
The horizontal line with arrows at the base of the picture represents the KLF16 gene 
to be sequenced. The two blue rectangles at either end represent exon 1 and exon 2. 
The fragments to be sequenced using the primers which were previously described 
(Table 6.2 ) are represented by the black rectangles. The name of each fragment is 
indicated. Both exons are covered by the fragments and from the diagram it is clear 
that many of the exons overlap. This is to ensure that all nucleotides are examined.  
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GAMT 
As previously mentioned (section 6.2.1), two versions of the GAMT gene exist. To 
ensure comprehensive screening of GAMT, it was necessary to screen both versions 
of the gene. GAMT had six exons which required screening and they were designated 
x1, x2, x3, x4, x5 and x6. Initially five sets of primers were designed using the 
PrimerSelect program, and were ordered from Biomers (http://biomers.net). Exons 1 
and 6 had one set of primers each (GAMTx1 and GAMTx6). Three sets of primers 
were designed to cover exons 2 to 3 (x2-3) and exons 4 to 5 (x4-5a and x4-5b). As 
work progressed, a further two sets of primers were required to obtain sequences not 
detected by the original primer products. The first additional set which was designed 
included primers for fragments to cover x1 (GAMTx1a and GAMTx1b), and primers 
for fragments to cover x6 (GAMTx6a and GAMTx6b). It was later necessary to 
design and order an additional set of primers (GAMTx1.2) to cover a large gap which 
remained in x1. The primer sequences, annealing temperatures, and expected sizes of 
the GAMT fragments are shown in Table 6.3.  
Table 6.3: Features of primer fragments used to screen GAMT. (*) represents 
unknown annealing temperatures. 
Fragment Forward Primer Sequence Forward Primer 
Sequence 
Annealing 
Temp (°C) 
Size 
(bp) 
GAMTx1 CCGACCCCACTCCCGCCACC
TCTC 
GCCCCCACCTGCAGCCCC
ACTTC 
* 509 
GAMTx1a GTAAGCGGCAAGGCGGGGA
TTC 
CAGCGCGTGCATATAGG
GGGTCTC 
* 465 
GAMTx1b CCCAGCGCGACCCCCATCTT GGACCCGGTTCCACCCAG
TTTCA 
63 477 
GAMTx1.2 AGCGCCTGGAAGATCCTCAG
AT 
CAGCCCCGGCCTCAGTTT 53 631 
GAMTx2-3 CGCCCCCTCCTCCAGGCAGT
CT 
CGCCCCCTCCTCCAGGCA
GTCT 
63 701 
GAMTx4-
5a 
GGGTGTGGGCCTGGCTGTGG CACCCCCATCCAAGGTCA
CTTCCT 
70 555 
GAMTx4-
5b 
GGAGGCCCTCGGGGAAGCG TACCCAGGCTGGAGTGC
AGTGGTT 
70 702 
GAMTx6 CCCGCACTGGGGAGCTGGA
GATTC 
CTCCAGGTTTCTGAGCGG
CCCCAG 
* 615 
GAMTx6a CACTGGGGAGCTGGAGATTC
C 
AGCGCCGGCGTTTACTTC
AC 
69 574 
GAMTx6b CCGCTACTACGCCTTCCC GGGGCCGCTCAGAAACC 69 422 
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Figure 6.7 illustrates the positions of the fragments used to sequence the GAMT 
gene. 
 
Figure 6.7. GAMT gene, its exons and amplicons (primer fragments) 
The two horizontal lines with arrows at the base of the picture represents the two 
versions of GAMT to be sequenced. The black and blue rectangles located at 
intervals along these lines represent exons 1 to 6. From the figure, it can be seen that 
two versions of exon 5 exist. The larger exons was screened. The fragments to be 
sequenced using the primers which were previously described (Table 6.3) are 
represented by the black rectangles. The name of each fragment is indicated to the 
left hand side. All six exons are covered by the fragments and from the diagram it is 
clear that many of the exons overlap. This is to ensure that all nucleotides are 
examined.  
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6.3.2 PCR 
As mentioned for the purpose of screening KLF16 and GAMT for mutations, three 
individuals from RLS3002 were selected, two affected individuals (PATH048 and 
PATH054) and one unaffected individual (PATH047). DNA was amplified for all 
fragment following PCR optimisation.  
 
Figure 6.8: Agarose gel electrophoresis of PCR products of GAMT x2-3 
Samples used are PATH047, PATH048, PATH054 and H2O (negative control). The 
100 bp ladder is to the far left of the gel and the 500 bp, 700 bp and 1,000 bp bands 
are indicated. The ladder allows assessment of size of the products and also the 
quality of gel staining. The three samples (PATH047, PATH048 and PATH054) 
have one single band each, which is located at approximately 700 bp. This is 
consistent with the expected PCR product size of 701 bp. 
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KLF16 
All fragments for KLF16x2 (KLF16x2a, KLF16x2b, KLF16x2c, KLF16x2d, 
KLF16x2e) were amplified successfully. An additional three sets of primers 
(KLF16x2gap1, KLF16x2gap2, KLF16x2bgap) were ordered to cover gaps in the 
sequence. Fragment KLF16x1 failed to amplify. A number of approaches were 
applied to attempt to amplify the fragment, e.g. altering annealing temperature, 
increasing/decreasing MgCl2, however none of these approaches were successful. 
Upon examining the content of the region, the reason that the fragment was failing to 
amplify became clear. The region has a very high GC content (81%), and 
amplification of these regions is usually very difficult. Problems usually observed 
with GC-rich DNA are constraint of template amplification by stable secondary 
structures that stall or reduce the DNA polymerase progress, and the presence of 
secondary annealing sites giving rise to nonspecific amplified bands. Four additional 
primer sets were designed and ordered for exon 1 (KLf16x1a, KLf16x1b, KLf16x1c, 
KLf16x1d). When designing these primers, it was ensured that the primers 
themselves did not have a high GC content. Unfortunately, these four primer pairs 
failed to amplify also. Therefore, exon 1 of KLF16 was not sequenced. 
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GAMT 
Following determination of PCR conditions, GAMTx1b, GAMTx2-3, GAMTx4-5a 
and GAMTx4-5 were amplified successfully. GAMTx1a and GAMTx6 did not 
amplify successfully. Upon examining the content of GAMTx1, it was discoved that 
this region has a high GC content (79%) and was possibly the reason GAMTx1a 
failed to amplify. After several attempts to amplify this region e.g increasing 
annealing temperature, adjusting MgCl2 concentration, and using betaine, the 
fragment failed to amplify. An additional set of primers was designed and ordered 
for this region (GAMTx1.2). These primers were successful in amplifying the 
remaining region on exon 1. GAMTx6 also failed to amplify after several attempts. 
Two new sets of primers were ordered for this region (GAMTx6a and GAMTx6b). 
These primers allowed successful amplification of exon 6.  
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6.3.3 DNA sequencing and Sequencing analysis 
The next step was DNA sequencing and sequence analysis of all three individuals to 
check for variation in the exons of KLF16 and GAMT. Sequences were compared 
with the expected amplicon and with one another. Any variation present was 
recorded and examined for presence/absence on the affected and unaffected 
individuals. For a variation to be significant with respect to RLS within this family, 
it must be present in the affected individuals (PATH048 and PATH054), and not in 
the unaffected one (PATH047).  
KLF16 
Three variants were detected in KLF16x2. Table 6.4 lists these variations, the 
chromosome position, the variant type, and the SNP title.  
Table 6.4: Variants found in gene KLF16. 
Exon Chromosome 19 
Position (bp) 
[UCSC Genome 
Browser Feb. 
2009] 
Variant type Comment SNP title 
KLF16x2b 1,805,159 C→G Present in an unaffected 
individual (PATH107) and 
affected family members. 
rs12972720 
KLF16x2b 1,805,260 GG Insertion Present in unaffected 
(PATH047) and affected 
family members (PATH048 
and PATH054) 
New 
variant 
KLF16x2d 1,853,667 G→C (Het) Present only in unaffected 
(PATH047) 
rs3746043 
 
  
311 
The first SNP detected was rs12972720 in exon 2b of KLF16. The SNP is a known C 
to G change in the coding sequence if KLF16 exon 2. The unaffected member 
PATH047 was homozygous C/C; his affected son PATH048 was heterozygous 
(C/G) at that position; and the affected individual PATH054 was homozygous G/G. 
Therefore both affected individuals carry at least one G, while the unaffected sample 
has no G. An additional unaffected control PATH107 (which has been used for other 
RLS studies in the Dept. of Pathology) was sequenced; this was to ensure that the 
SNP was not significant with respect to RLS within this family. PATH107 was also 
homozygous G/G.  
Although the two affected individuals (PATH048 and PATH054) do not have the 
same genotype at this position, both do carry at least one G while the unaffected 
sample has no G (PATH047). Furthermore, the G in PATH048 must have been 
inherited from her affected parent as the unaffected parent is CC at this position. 
Another unaffected sample (PATH107) was screened and was determined to be GG 
at this position. This individual does not have RLS; therefore, the genotype is not the 
causative variant. Furthermore, the frequency data on the SNP website 
www.ncbi.nlm.gov/projects/SNP/ published data for four populations for this SNP 
rs12972720. The European data (pilot.1.CEU) found that 54.2% of the population 
have a C at this position, while 45.8% of the population have a G. 
One can conclude that this SNP is not a disease causing variant for two reasons.  Due 
to the fact that the SNP was also seen in PATH107, an unaffected control, and that it 
is a known variant common in the European population, one can conclude that this is 
not disease causing variant. 
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Figure 6.9: A segment of DNA sequence data demonstrating C→G 
heterozygous change  
Exon 2b of GAMT. The four individuals screened for the variant are identified in the 
figure. The unaffected individual has a single blue peak at this position, and is 
therefore homozygous (C/C). Instead for PATH048 two overlapping peaks (black 
and blue) are present representing a C→G heterozygous change. Furthermore, a 
C→G homozygous change is present in PATH054 and PATH107, represented by a 
single black peak. This change is present in both an affected individual and an 
unaffected control. Blue = C (Cytosine), black = G (Guanine), green = A (Adenine) 
and red = T (Thymine). 
 
The second variant detected in KLF16x2 was a single nucleotide insertion seen in 
both the affected and unaffected family members. PATH054 is homozygous for a 
single insertion of a G. The insertion was also observed in PATH048, however this 
sample is heterozygous, carrying one copy of the fragment with the insertion and one 
copy of the fragment without the insertion. This results in non-identical sequences 
downstream of the insertion point and this is observed in sequence data when there 
are two peaks at each nucleotide position. The position is 507bp from the beginning 
of exon 2 in an untranslated region (UTR). The consensus sequence has 5 Guanines 
(ggggg); however, PATH054 has 6 Guanines (gggggg) in both copies of sequence. 
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PATH048 has one copy of each. A number of other affected and unaffected family 
members were sequenced for this region to determine if they also had this insertion 
(Table 6.5). Both affected and unaffected family members have a heterozygous 
insertion and a homozygous G insertion. Hence, it is non-disease segregating. 
 
Figure 6.10: A segment of DNA sequence data demonstrating an insertion  
The arrows point to positions on PATH047, PATH052 and PATH054 where 
according to the database sequence there should be a single blue peak representing 
the base C. However, PATH048 has a G (heterozygous) insertion at this position, 
represented by the blue and black peak. PATH052 and PATH054 both have a G 
(homozygous) insertion at this position represented by the single black peak. This 
inserion is present in both affected and unaffected members of Pedigree RLS3002. 
Blue = C (Cytosine), black = G (Guanine), green = A (Adenine) and red = T 
(Thymine). 
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Table 6.5: Results of family members tested for the G/G insertion in KLF16 x2. 
Individual  Status Insertion 
PATH046 Affected G/G (Hom) 
PATH048 Affected G (Het) 
PATH053 Affected G/G (Hom) 
PATH054 Affected G/G (Hom) 
PATH047 Unaffected Not present 
PATH052 Unaffected G/G (Hom) 
PATH199 Unaffected G (Het) 
PATH200 Unaffected G (Het) 
 
The third variant detected was a G (Guanine) to C (Cytosine) heterozygous shift, in 
the coding sequence of KLF16 exon 2. This variant was detected in the 
control/unaffected family member, PATH047 (figure 6.9). The variant was not 
present in either of the two affected family members. A number of other family 
members were sequenced for this SNP, two affected members (PATH053, 
PATH055) and two unaffected members (PATH052, PATH186). This variant was 
not detected in any of the other family members. Therefore this is not the disease 
causing mutation. It was only detected in one „married in‟ family member. 
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Figure 6.11: A segment of DNA sequence data demonstrating G→C 
heterozygous change.  
Exon 2bc of GAMT . The arrow points to a position (PATH047) where according to 
the amplicon should have a single black peak representing the base G, but instead 
two overlapping peaks (black and blue) are present representing a G→C 
heterozygous change. This is only present in PATH047 (unaffected parent) and not 
present in the affected individuals. Blue = C (Cytosine), black = G (Guanine), green 
= A (Adenine) and red = T (Thymine). 
 
KLF16x1 failed to amplify therefore it could not be sequenced. 
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GAMT 
GAMT was successfully sequenced and analysed. No variants were detected within 
any of the amplicons. The UCSC genome browser database (www.genome.ucsc.edu) 
was used to investigate if there were any known SNPs within the regions amplified 
for GAMT. Figure 6.10 illustrates the SNPs located within the amplified regions of 
GAMT.  
 
Figure 6.12: SNPs within the GAMT amplicons 
The amplicons are represented by the black rectangles. Each amplicon has its own 
unique name e.g. GAMTx6a, which indicates the exon the fragment is incorporating. 
The SNPs are shown below the two versions of GAMT. There are 25 SNPs within 
these amplified regions. The SNPs are represented by colours. Black represents 
Unknown, Untranslated, Locus and Intron SNPs. Green represents 
Coding/Synonymous SNPs. Red represents Splice sites and Coding/Non-
synonymous SNPs. UCSC Genome Browser, February2009 Assembly 
(http://genome.ucsc.edu). 
 
None of the above known SNPs or no new variant was detected within the three 
investigated members of pedigree RLS3002 for the gene GAMT.   
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6.4 Discussion 
This part of the study examined two candidate genes within the novel RLS locus on 
chromosome 19p13.3. The first candidate gene which was studied was KLF16. 
Although this candidate region was not very near to the area which gave the highest 
multipoint LOD score, it was an excellent candidate gene. KLF16 is important for 
modulating dopaminergic transmission in the brain. The pathophysiology of RLS is 
thought to be closely linked to the dopaminergic system and iron metabolism.  
Exon 2 of KLF16 was large and therefore had to be divided into five overlapping 
fragments of sizes suitable for sequencing. Amplification and sequencing of this 
exon was successful and three variants were detected. The first SNP detected was 
rs12972720. This is a synonymous SNP present in the untranslated region of exon 2. 
The C→G change was observed in both unaffected individuals PATH048 and 
PATH054. However a second unaffected control for RLS was sequenced and was 
found to also have this variation. This SNP was a known variant, and according to 
the population data both the C and G are common in the European population. 
Therefore this disease most likely has no role in the pathogenesis of RLS. 
The second variant was a G insertion in the untranslated region of exon 2. A number 
of additional family members were examined for this variation and it was found that 
both affected and unaffected family members carry either a heterozygous or 
homozygous G insertion. It did not have an effect on amino acid as it is in an 
untranslated region. This was an unknown SNP; therefore no frequency data was 
available. Due to the fact the variation was seen in both affected and unaffected 
family members, this variation was not disease segregating and most likely has no 
role in the pathogenesis of RLS.   
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The third variation that was observed in exon 2 of KLF16 was a G to C change in the 
unaffected individual, PATH047. This is a known SNP (rs3746043), and is a 
synonymous SNP, therefore it does not have any effect on the resulting amino acid. 
A number of additional affected and unaffected family members were examined for 
this variation, and it was not detected in these samples. The frequency data on the 
SNP website www.ncbi.nlm.gov/projects/SNP/ published data for five studies for 
this SNP rs3746043. The European data (pilot.1.CEU) found that 26.4% of the 
population have a C at this position, while 73.6% of the population have a G. 
Subsequently, the variant rs3746043 detected in exon 2 of KLF16 is common within 
the European population and is unlikely to have a role in the pathogenesis of RLS in 
this family. 
Exon 1 of KLF16 is not a very large exon, howver it has a high GC content (81%). 
This exon proved very difficult to amplify, and after several attemps including trying 
to amplify the fragment with betaine and reordering new primers it failed to amplify. 
Therefore, KLF16 cannot be fully excluded as to having a role in the aetiology of 
RLS in this pedigree. 
The second candidate gene which was investigated was GAMT. GAMT is required 
for producing the enzyme guanidinoacetate methyltransferase. A deficiency in this 
enzyme mainly affects organs and tissues that require large amounts of energy, such 
as the brain and muscles. RLS is a neurological disorder which is characterised by 
cramps in the lower limbs and often accompanied with muscle spasms.  
Exon 1 of GAMT was difficult to amplify as it has a high GC content. Additional 
primers were ordered for this region, and were designed avoiding the GC rich areas. 
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All of the GAMT fragments were amplified successfully for the three family 
members PATH047, PATH048 and PATH 054. 
No SNP or new variant was detected within any of the amplicons analysed for the 
members of pedigree RLS3002. Firstly there were not many SNPs within the 
amplicons. Figure 6.12 confirms that there were a total of 25 SNPs within these 
amplified regions. One of these SNPs, rs73525059, was deleted from the database on 
May 13, 2010. Therefore there are a total of 24 SNPs within the amplicons of 
GAMT. Furthermore, when the database of these SNPs were investigated further, it 
was became clear that many of these SNPs are not common in people of European 
descent. For example, SNP rs266811 had frequency data for two populations. The 
first was for pilot.1.YRI (Nigerian population) which found an allele frequency of 
0.24 for C and an allele frequency of 0.76 for G. The CEPH data (European 
population), also for SNP rs266811, found an allele frequency of 1.00 for G. Another 
SNP, rs1050914, found an allele frequency of 1.00 for G. In addition to this, a 
number of SNPs had only been detected in non-European populations. For example, 
rs76461299 and rs73515058, had only been detected in Chinese/Japanese and 
Nigerian population respectively. Therefore it is not unusual that any of the known 
variants were not detected in the members of pedigree RLS3002. The SNPs within 
the amplified region were seen mostly within non-European populations, and are not 
common within the European population.  
All six exons of GAMT were analysed including splice sites. No mutation was found 
within the exons of GAMT when comparing the two affected members (PATH047 
and PATH054) to the unaffected member (PATH047). Sequencing of the candidate 
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gene GAMT did not identify mutations, however variants in either the promoter 
region or the intronic regulatory elements cannot be excluded. 
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Chapter 7 
Discussion 
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7.1 Introduction 
Restless Legs Syndrome is one of the most common disorders seen in sleep clinics. 
It is a sensorimotor disorder, characterised by the desire to move the lower limbs due 
to unpleasant sensations that are worse at rest and in the evenings and are relieved, at 
least temporarily, by movement. It can be either primary (genetic/idiopathic) or 
secondary (caused by other conditions). RLS causes tremendous distress and affects 
the quality of life of those affected. Generally speaking, RLS is not well understood 
in terms of pathophysiology and symptomatology. Ironically, RLS can be described 
as one of the most common conditions one has never heard of. 
In order to find the causative gene for primary RLS, several genome wide studies 
have been completed and 10 loci have been identified on chromosomes 5q, 12q, 14q, 
9p, 2q, 20p, 4q, 17p, 16p and 19p. Several association studies have also been 
performed and to date five genomic regions associated with RLS have been 
identified on chromosomes 6p, 2p, 15q, 9p and 12q. 
The UCC Pathology lab has identified and collected Irish families with RLS. In one 
large autosomal dominant (AD) family, a novel RLS locus has been determined. The 
research lab also identified and recruited a second Irish AD RLS family (RLS3002). 
Previous research on this family had partially excluded four of the known loci 
(Abdulrahim 2008). The aim of this study was to examine all known loci and 
associated regions for linkage to this family, and if linkage was not found to perform 
a genome-wide search to map and identify the causative gene in this RLS family 
.  
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7.2 Discussion 
RLS is a difficult to define condition that is possibly more prevalent than previously 
thought. Public and professional awareness of RLS has certainly increased in the last 
number of years, but questions, even skepticism about the very existence of the 
condition, persist (Varga, Ako-Agugua et al. 2009). According to Professor Richard 
P. Allen, Secretary of the World Association of Sleep Medicine and Committee 
Member of World Sleep Day 2009 he has “ conducted medical research in the field 
of RLS for over 30 years, but still encounter many misconceptions about the 
condition.”  
In 2005 Requip (ropinirole) became the first drug approved by the FDA for 
treatment of RLS. This was followed, in 2006, by Mirapex (pramipexole). In 2006 
an article published in the Public Library of Science Medicine Journal, discussed the 
issue of “disease mongering” in relation to RLS. This is the effort by pharmaceutical 
companies (or others with similar financial interests) to enlarge the market for a 
treatment by convincing people that they are sick and need medical intervention. 
They state that “the restless legs campaign has developed into a multimillion dollar 
international effort to push restless legs syndrome into the consciousness of doctors 
and consumers alike” (Woloshin and Schwartz 2006). 
Although there are a number of negative claims regarding RLS, scientific evidence 
proves this is a “real” syndrome. The oldest reference of „Restless Legs syndrome‟ 
syndrome on PubMed (www.ncbi.nlm.nih.gov/pubmed), dates back to 1960 (Ekbom 
1960). Ekbom also published and presented eight cases in a paper published in 1945, 
titled „Restless Legs.‟ It was claimed that Mirapex and Requip were in fact failed 
sleep medications, however, both of these medications were also approved by the 
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FDA as treatments for Parkinson ‟s disease. The drugs are dopamine agonists, which 
means they act in the brain mimicking the neurotransmitter dopamine, which is 
lacking in PD patients. The pathophysiology of RLS is thought to be closely linked 
to dopamine dysfunction; L-dopa ( a precursor to dopamine) relieves the symptoms 
of RLS. Furthermore akathisia, which is present in PD patients, is similar in 
character to RLS. It was therefore understandable why dopamine agonists, such as 
Mirapex and Requip, were considered for the treatment of RLS. It was not surprising 
that such drugs helped relieve symptoms of RLS. 
RLS is a known disorder known for over four decades, it fits well within our 
knowledge of movement disorders and the role of dopamine agonists in treating 
them. 
The UCC Pathology lab recruited pedigree RLS3002 in 2004/2005. There was a 
strong family history seen in this family, the grandmother (generation I), all of her 
four children (generation II) and seven of her grandchildren (generation III) being 
affected with RLS. Suggestive family history is therefore consistent with an 
autosomal mode of inheritance. All 18 family members answered a questionnaire 
and all affected individuals undertook a neurological examination. Age of onset in 
most affected individuals in this family ranged from 3 years of age to the teens. 
Although most RLS patients have lower extremity symptoms, arm restlessness 
occurs in up to 49% of patients with RLS (Freedom and Merchut 2003). In pedigree 
RLS3002, most of the individuals experienced symptoms confined to the lower 
limbs bar one who reported upper limb and trunk symptoms as well. Of the 11 
affected individuals, five were affected mildly and the remaining six individuals 
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were moderately affected according to the IRLSSG rating scale for RLS severity 
(section 1.3.2). 
Iron deficiency and chronic renal failure can play a part in the pathophysiology of 
RLS and basic biochemical tests such as serum iron and renal function can be carried 
out on affected individuals to rule out secondary RLS. Such tests were not performed 
on affected individuals of pedigree RLS3002 as the familial pattern, the early age of 
onset and the absence of any clinical history of other disease indicates 
primary/familial RLS in this family.  
Mode of inheritance refers to the way in which genes are passed down from 
generation to generation (e.g. autosomal dominant, autosomal recessive, X-linked, 
multifactorial and mitochondrial inheritance). By analysing mode of inheritance, 
researchers can estimate the relative risk for and penetrance of a disease. 
Determining the mode of inheritance was crucial for this study. In order to perform 
linkage analysis and to compute a LOD score it is necessary to specify the mode of 
genetic transmission of the family being investigated. RLS has been identified as a 
Mendelian autosomal dominant disease with variable expressivity and high 
penetrance ((Winkelmann, Muller-Myhsok et al. 2002; Bonati, Ferini-Strambi et al. 
2003; Levchenko, Montplaisir et al. 2004; Pichler, Marroni et al. 2006). An 
autosomal dominant mode of inheritance was displayed in pedigree RLS3002 as was 
reported in the other loci. This was evident by the fact that all the affected 
individuals have one parent who is affected. The chromosome 12q locus mapped by 
Desautels et al in a French-Canadian (FC) family was the only exception to an 
autosomal dominant mode of inheritance in an RLS pedigree. This family displayed 
autosomal recessive inheritance (Desautels, Turecki et al. 2001). However, Desautels 
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and associates explained the autosomal recessive mode of inheritance in their family 
as pseudodominant mode of inheritance. This means that the real transmission of the 
gene is autosomal recessive but given a high frequency of the disease allele(s) there 
is a higher proportion of affected individuals, thus giving the appearance of a 
dominant pattern of inheritance. Desautels et al supported their pseudodominant 
mode of transmission, by stating that 1) the occurrence of RLS in the FC population 
was one of the highest in the world; 2) only FC families were linked to that locus at 
that time; and 3) that a founder effect has been well described in the FC population. 
The paper also maintained that RLS may be similar to Parkinson disease, where the 
presence of intrafamilial allelic heterogeneity is highly possible. After the original 
report of recessive juvenile Parkinsonism, a number of other studies later identified 
further mutations in the same gene and have also identified a mixed mode of 
inheritance of different mutations within and between families (Desautels, Turecki et 
al. 2005). 
Linkage analysis of pedigree data is a powerful tool for mapping genomic regions 
that are likely to contain genes influencing human diseases. It is assumed that the 
phenotype arises from a single major gene effect with almost full (95%) penetrance 
i.e. it is expressed regardless of other genetic or environmental factors. It has been 
successful in mapping hundreds of Mendelian diseases including Huntington‟s 
disease and cystic fibrosis. However for many common diseases with high 
prevalence, their penetrance are often incomplete. Also, phenocopies may exist. It is 
therefore difficult to specify the genetic model parameters in these circumstances. 
Misspecification of the model parameters as a result of incomplete penetrances 
and/or phenocopies may lead to a reduction in power to detect linkage. The reason 
there may be a reduction in linkage power is, incomplete penetrances have the ability 
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to reduce evidence for linkage. Furthermore, phenocopies can give false information 
about recombination patterns. For linkage calculations in this study, RLS was 
modelled as an autosomal dominant
 
trait with a 95% penetrance as used in other RLS 
linkage studies (Chen et al, 2004). The
 
reported value varies from 86% to full 
penetrance in most families;
 
Trenkwalder et al., 1996 ; Lazzarini et al., 1999 ).  
For many years, genetic mapping was limited by the lack of available markers. In 
1980, it was suggested that restriction-fragment length polymorphisms (RFLPs) be 
used as simple Mendelian co-dominant genetic markers. Although RFLPs generally 
did not lie within a gene of interest, they had the advantage of requiring no prior 
knowledge about the sequence of DNA in which they lie, or of its function. Since the 
1980‟s the field of molecular biology has grown rapidly, and there are currently a 
number of dense genetic maps available. Microsatellite markers are now more 
commonly used, and were therefore employed for this study. While this was efficient 
and powerful for the gene mapping part of this study, once linkage was estabished 
fine-mapping of our RLS locus was hampered by the lack of available markers in the 
area. Novel microsatellite markers were identified and primers were designed for 
these areas. It was not known if these novel microsatellites would be polymorphic, 
and subsequently, informative. Despite the great advances in genomic technology, 
the availability of microsatellite markers for fine-mapping the chromosome 19p13.3 
region was limited.  
Apart from a number of microsatellite markers failing to amplify i.e. those used for 
fine-mapping (section 5.3.3), no problems with genotyping was encountered 
throughout the study. I found it was best to attain the alleles without reference to the 
pedigree, and then to consider the results in the context of the family tree. This 
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avoided the subconscious bias of results. If there was doubt over a particular 
individual or a number of individuals in the family, these samples were re-analysed 
together with parent samples if available. This made it much easier to determine 
whether or not they all share the same allele. When genotyping, it is important to 
bear in mind that an inconsistency can arise through mutation of the microsatellite 
from one generation to the next. This is the process of how microsatellite 
polymorphisms occur over time. This, however, was not observed during this study.  
When this study was initiated only four loci were identified. It was postulated that 
the newly recruited Irish family might share the same disease locus as the other Irish 
family in which the chromosome 5 locus was identified rather than being linked to 
the other loci identified in families of other origins. Hence, the remaining gap on 
chromosome 5 was examined first. A total area of 38.31 cM was excluded extending 
from 44.92 cM (flanked by the marker D5S418) and 83.23 cM (flanked by the 
marker D5S2003). The results exclude a large area which included the locus. All 
other nine loci identified by linkage analysis studies were examined for linkage to 
RLS3002. Linkage to all nine loci was successfully examined and excluded in this 
RLS family. 
In 2007 the first RLS association studies were published. To date four RLS regions 
have been identified by association studies. This is a high-throughput approach 
which scans the entire genome or a specific region in an unbiased manner, using 
statistical methods to determine associations between chromosomal loci and a given 
phenotype. It requires a large number of cases and a large number of controls which 
is often difficult to collect, therefore would not have been a suitable method to use 
for our family. However, it was important to investigate if pedigree RLS3002 was 
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linked to any of these novel RLS regions. Following linkage analysis, our analysis 
shows that RLS3002 is not linked to any of these known risk-associated genes. 
The RLS3002 pedigree must therefore carry a mutation in a novel genetic locus. 
Two microsatellite marker sets were used during the genome wide scan of family 
RLS3002. The first marker set used was the Research Genetics Inc. mapping set. 
When this panel of markers was completed and no linkage had been found, there 
were many questions raised as to whether another microsatellite marker set should be 
used or if another route should be taken. Two possible options to locate the RLS 
locus were considered. The first option was another microsatellite marker set with a 
higher density of markers. The second options considered was using microarray-
based single nucleotide polymorphism (SNP) data. The second option was becoming 
more widely used as markers for linkage analysis in the identification of loci for 
disease-associated genes. Both options were considered. Although microarray based 
SNP analyses have markedly reduced genotyping time and cost compared with 
microsatellite-based analyses, applying these enormous data to linkage analysis 
programs is a time-consuming step. The Microsatellite marker set which was 
considered was the Applied Biosystems Linkage mapping set version 2.5, which has 
a resolution of 10 cM. The first mapping, Research Genetics Inc. has a resolution of 
approximately 20 cM.  
Furthermore, since the beginning of the initial genome-wide scan an additional seven 
members of the RLS3002 family had been examined and had blood samples taken 
which significantly increase the power of the study. The maximum possible positive 
LOD score with initial eleven individuals in the study was calculated to be 1.86. In 
order to detect linkage reliably, the family size must be large enough to give a 
330 
statistically significant answer. This means that in practice there must be at least ten 
potentially informative meiosis (those in which potential cross-overs could be 
recognised) within a family in order to give a LOD score > 3.00. With the addition 
of the seven other members, power analysis with the SLINK software was performed 
again and it was found that the maximum possible LOD score for this family was 
now 3.41. This was sufficient to prove linkage as a LOD score of > 3.00 is required 
to prove linkage. It was therefore decided that the Applied Biosystems Linkage 
mapping set version 2.5 would be used to continue the investigation of RLS in 
pedigree RLS3002.  
Several epidemiological investigations have shown a female preponderance of 
RLS(Berger, Luedemann et al. 2004). This could indeed be a result of reporting bias. 
As pedigree RLS3002 is quite small it is difficult to say if there is a female 
prevalence. There are six affected females (seven if the grandmother is included), 
and there are five affected males.  
There are considerable geographical variations in the prevalence of RLS. The cause 
of these variations are not well understood. The majority of these prevalence studies 
have also been performed on Caucasian populations. Prevalence estimates in East 
Asians include 0.1% in a Singapore survey (Tan, Seah et al. 2001) and 12% in a 
Korean survey (Kim, Choi et al. 2005). This study on an Irish Caucasian family is 
consistent with these findings. 
The racial differences in RLS have yet to be understood. The prevalence of RLS in 
some ethnic groups may have been underestimated due to their under-representation 
in RLS speciality clinics. In a study by Lee et al. (2006) the prevalence of RLS in 
African-Americans and Caucasians were compared in a biracial community sample. 
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The prevalence of RLS in the overall population was 4.1%. The rates were similar 
for African–Americans (4.7%) and Caucasians (3.8%). After adjustment for age, 
gender, medical comorbidities, and socioeconomic status, no difference in the 
prevalence of RLS was found between African–Americans and Caucasians. It is 
quite possible that under-representation difficulties are present in prevalence studies 
in countries such as India where access to speciality clinics may also be a problem. 
Barriers affecting access to care settings for RLS patients worldwide should be 
investigated in the future. Further investigations into the geographical and racial 
differences in RLS need to be carried out also. 
Two candidate genes within the novel RLS locus 19p13.3 were screened. Exon 1 of 
KLF16 failed to sequence; however the results show no disease causing mutations in 
the exons and exon-intron junction regions of KLF16 exon 2 and GAMT. There is a 
possibility that the mutation is one which is not detectable using current sequencing 
techniques, for example, large deletions.  
In order to exclude mutations in the remaining introns of KLF16 and GAMT further 
work is needed. There may be possible mutations within the introns of these genes 
that cause a cryptic splice site. These mutations would not have been detected by the 
approaches used in this study.  
Further research is needed to screen other candidate genes within the disease gene 
interval. Genes which play a role in iron and dopamine pathways will be identified 
and prioritised for mutation screening. Failing to find a disease causing mutation in 
these genes, all other genes within the locus need to be screened as many do not have 
a known function as yet. Furthermore new mechanisms which have not yet been 
described may be involved in the pathophysiology. Reducing the size of the RLS 
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locus would reduce the number of genes to be examined. A number of approaches 
could be used to potentially decrease the size of the locus. Since all family members 
of RLS3002 have been recruited this approach is not an option. One approach to 
narrow
 
the linkage region is to add more markers to the region
 
to find additional 
recombinants. Although all known microsatellite markers in the region were 
examined, there is a possibility new markers may be identified in the future. 
Additional
 
clinically defined RLS families could also be studied to determine
 
whether any might be linked to the RLS 19p13.3 locus. This might allow for 
reduction of the locus 
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7.3 Conclusion and Future work 
The results obtained in the Irish pedigree RLS3002 with autosomal dominant RLS 
showed evidence of a new RLS locus located on chromosome 19p13.3. To date 
linkage studies in RLS families have revealed 11 loci but no causally related 
sequence variant has yet been identified using this approach. Replication of RLS 
linkage studies has met with limited success. The first RLS locus, reported on 
chromosome 12q in a study of a single French-Canadian family, was confirmed in an 
additional 5 of 18 families (Desautels, Turecki et al. 2005) , and extended to a study 
of 100 families in Iceland (Hicks AA 2005). RLS2, the second susceptibility locus 
identified on chromosome 14q was initially seen in two large families from South 
Tyrol (Bonati, Ferini-Strambi et al. 2003) and subsequently identified in a single 
French-Canadian family (Levchenko, Montplaisir et al. 2004). This suggests that 
RLS is a genetically highly-heterogeneous disorder thus presenting a challenge to 
researchers hoping to unravel its pathophysiology. Further confirmation of existing 
RLS loci in different ethnic groups would be important as these might help prioritise 
and promote efforts to identify potential causative genes.  
Symptoms of RLS are quite common. The prevalence of RLS severe enough to 
cause impairment in quality of life (QOL) and warrant medical treatment is probably 
around 2-3%. This makes clinically significant RLS 2 to 6 times as common as 
epilepsy in developed countries (estimated prevalence of epilepsy is 0.5-1.0%) 
(Natarajan). RLS can cause significant impairment of sleep and about 94% of 
patients report sleep disturbance due to RLS. As a result patients have daytime 
fatigue, reduced motivation, emotional stress, anxiety and difficulty accomplishing 
their jobs and participating in social activities. Studies have shown that RLS patients 
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are more prone to headaches than healthy subjects. Headaches are similar to 
migraine in character, though with an element of tension-type headache (d'Onofrio, 
Bussone et al. 2008). In addition, RLS may be linked to cardiovascular disease 
(Winkelman, Shahar et al. 2008) Currently, RLS is diagnosed solely on the clinical 
history, there are four essential criteria and all of them must be established to make a 
definite diagnosis. In addition there are three supportive criteria that are not 
necessary for a diagnosis of RLS but are admittedly helpful in the differential 
diagnosis. No other method has yet been discovered to diagnose RLS as effectively 
as the clinical criteria. The treatment of RLS is mainly symptomatic. Many 
therapeutic measures have been considered, some less effective than others. At 
present dopaminergic receptor agonists are considered the first choice in treating 
moderate to severe cases of RLS. However they can often be problematic, causing 
side effects such as augmentation; where in some patients the symptoms begin in late 
afternoon or in early evening as a result of treatment. Patients should also realize that 
pharmacological treatment is life-long in most cases. Ultimately if the causative 
gene(s) for RLS is identified, it would be a stepping stone to unravelling the 
etiology, and the development of therapeutic drugs to treat, prevent, and hopefully to 
cure this chronic distressing condition.(Garcia-Borreguero, Allen et al. 2007). 
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Appendix I: Restless Legs Syndrome Rating Scale 
 
The patient rated his/her symptoms for the ten questions listed below. Ratings range from: none (0); mild (1); moderate (2); severe (3); and very 
severe (4). Ratings for question 3 include: none (0); mild (1 day a week or less) (1); moderate (2 to 3 days per week) (2); severe (4 to 5 days per 
week) (3); and very severe (6 to 7 days per week) (4). Ratings for question 4 include: none (0); mild (less than 1 hour per 24 hour day) (1); moderate 
(1 to 3 hours per 24 hour day) (2); severe (3 to 8 hours per 24 day) (3); and very severe (8 hours per 24 hour day or more) (4). 
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1. Overall, how would you rate the RLS 
discomfort in your legs or arms? 
1 2 2 2 3 2 2 1 1 1 2 
2. Overall, how would you rate the need to 
move around because of your RLS 
symptoms? 
0 3 2 2 4 3 4 3 4 2 3 
3. Overall, how much relief of your RLS 
arm or leg discomfort do you get from 
moving around? 
1 1 1 2 1 1 2 2 
1-2 
(1.5) 
1 1 
4. Overall, how severe is your sleep 
disturbances from your RLS symptoms? 
0 2 3 0 0 1 0 0 1 1 0 
5. How severe is your tiredness or 
sleepiness from your RLS symptoms? 
0 1 1 0 0 0 0 0 0 0 0 
6. Overall, how severe is your RLS as a 
whole? 
1 2 1 1 2 2 1 1 3 1 2 
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7. How often do you get RLS symptoms? 1 2 1 1 1 4 1 2 
1-2 
(1.5) 
1 1 
8. When you have RLS symptoms, how 
severe are they on an average day? 
0 1 1 2 1 4 1 1 1 1 1 
9. Overall, how severe is the impact of your 
RLS symptoms on your ability to carry out 
your daily affairs, for example carrying out 
a satisfactory family, home, social, school, 
or work life? 
0 0 0 0 1 0 0 0 1 0 0 
10. How severe is your mood disturbance 
from your RLS symptoms – for example 
angry, depressed, sad, anxious or irritable? 
0 0 1 0 2 0 0 0 1 0 0 
Total score: 4 14 13 10 15 17 11 10 16 8 10 
 
Scoring criteria are: None = 0 points; mild = 1 – 10 points; moderate = 11 – 20 points; severe = 21 – 30 points; and Very severe = 31-40 points. 
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Appendix II: Research Genetics Inc. mapping set 
 
Chromosome 
Microsatellite 
Marker Fluorescent Label 
Position 
(cM) Repeat Type 
 
Heterozygosity Size Range (bp) 
1 D1S1622 FAM 56.74 ATA 0.73 249-273 
1 D1S3728 HEX 89.49 GATA 0.63 244-268 
1 D1S1728 HEX 109.04 GATA 0.58 158-174 
1 D1S3723 HEX 140.39 GATA 0.67 142-206 
1 D1S1589 TET 192.05 ATA 0.69 201-214 
1 GATA124F08 FAM 226.16 GATA 0.79 229-245 
1 D1S3462 TET 247.23 ATA 0.75 256-271 
1 D1S547 TET 267.51 GATA 0.87 282-308 
2 D2S2952 TET 17.88 GATA 0.77 177-209 
2 D2S1400 FAM 27.60 GGAA 0.50 111-140 
2 D2S405 TET 47.97 GATA 0.68 240-256 
2 D2S1356 TET 64.29 ATA 0.95 218-262 
2 D2S2739 FAM 73.61 GATA 0.94 281-329 
2 D2S1777 FAM 99.41 GATA 0.64 196-208 
2 D2S1334 HEX 145.08 GATA 0.71 266-310 
2 D2S1776 TET 173.00 GATA 0.88 288-312 
2 D2S434 FAM 215.78 GATA 0.82 262-286 
2 D2S2968 HEX 251.94 GATA 0.59 171-195 
2 D2S125 HEX 260.63 AC 0.86 96-100 
3 D3S1304 HEX 22.33 AC 0.86 253-269 
3 D3S3038 HEX 44.81 GATA 0.81 187-219 
3 D3S4542 FAM 89.91 GATA 0.68 236-260 
3 D3S2406 HEX 102.64 GGAT 0.92 306-350 
3 D3S3045 FAM 124.16 GATA 0.99 170-211 
3 D3S1303 FAM 136.32 AC 0.93 196-220 
3 D3S3053 TET 181.87 GATA 0.68 226-238 
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3 D3S1262 FAM 201.14 AC 0.78 112-126 
3 D3S3023 TET 126.98 ATA 0.82 228-249 
4 D4S403 TET 25.90 AC 0.61 217-231 
4 D4S2632 FAM 50.53 GATA 0.82 124-164 
4 D4S3248 FAM 72.52 GATA 0.65 233-257 
4 D4S3243 TET 88.35 GATA 0.61 162-174 
4 D4S1647 TET 104.94 GATA 0.79 132-156 
4 D4S1629 HEX 157.99 GATA 0.68 137-157 
4 D4S2417 TET 181.93 GATA 0.67 251-271 
4 D4S408 HEX 195.06 AC 0.85 229-243 
5 D5S817 TET 22.88 GATA 0.62 260-272 
5 D5S1470 TET 45.34 GATA 0.85 163-207 
5 D5S2500 FAM 69.23 GATA 0.75 149-181 
5 D5S1725 FAM 97.82 GATA 0.86 188-212 
5 D5S1505 FAM 129.83 GATA 0.74 243-275 
5 D5S1480 TET 147.49 ATA 0.86 208-249 
5 D5S211 HEX 182.89 AC 0.79 186-204 
6 D6S2434 TET 25.08 ATA 0.57 224-236 
6 D6S2439 FAM 42.27 GATA 0.76 218-258 
6 D6S2410 HEX 73.13 GATA 0.56 238-254 
6 D6S1040 TET 128.93 GATA 0.74 257-285 
6 D6S2436 TET 154.64 GATA 0.63 121-149 
7 D7S513 FAM 17.74 AC 0.84 173-201 
7 D7S3051 HEX 29.28 GATA 0.68 146-182 
7 D7S2846 TET 57.79 GATA 0.85 172-196 
7 D7S3046 FAM 78.65 GATA 0.69 318-346 
7 D7S821 FAM 109.12 GATA 0.82 238-270 
7 D7S3061 FAM 128.41 GGAA 0.82 114-146 
7 D7S1804 TET 136.95 GATA 0.86 250-290 
7 D7S1823 HEX 173.71 GATA 0.76 207-235 
8 D8S1130 HEX 22.41 GATA 0.78 132-156 
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8 D8S136 TET 43.96 AC 0.79 71-80 
8 D8S1477 FAM 60.34 GGAA 0.89 139-179 
8 D8S532 FAM 64.75 AC 0.86 239-255 
8 D8S285 FAM 71.00 AC 0.81 108-124 
8 D8S260 HEX 79.36 AC 0.81 187-213 
8 D8S2324 HEX 94.08 GATA 0.74 196-216 
8 GAAT1A4 TET 110.20 GAAT 0.67 140-160 
8 D8S1179 TET 135.08 GATA 0.91 162-194 
8 D8S256 FAM 148.12 AC 0.81 210-232 
9 D9S921 HEX 21.88 GATA 0.87 175-232 
9 D9S1121 FAM 44.28 GATA 0.71 184-212 
9 D9S1118 TET 58.26 GATA 0.85 142-178 
9 D9S1122 TET 75.88 GATA 0.79 186-217 
9 D9S257 HEX 91.87 AC 0.93 259-285 
9 D9S282 FAM 136.47 AC 0.74 233-242 
9 D9S2157 TET 146.83 ATA 0.82 132-173 
10 D10S189 HEX 19.00 AC 0.85 175-195 
10 D10S1423 FAM 46.23 GATA 0.83 218-238 
10 D10S1208 FAM 63.30 ATA 0.83 179-200 
10 ATA5A04 FAM 88.41 GATA 0.63 184-200 
10 D10S2327 HEX 100.92 GGAT 0.58 204-228 
10 D10S1239 TET 125.41 GATA 0.78 160-184 
10 D10S1230 TET 142.78 ATA 0.71 113-140 
10 D10S212 TET 170.94 AC 0.65 189-201 
11 D11S1981 FAM 21.47 GATA 0.84 134-178 
11 D11S2371 FAM 76.13 GATA 0.64 188-220 
11 D11S2000 HEX 100.62 GATA 0.92 199-235 
11 D11S4090 FAM 105.74 CA 0.80 167-191 
11 D11S1998 HEX 113.13 GATA 0.69 129-169 
11 D11S912 TET 131.26 AC 0.93 101-123 
12 D12S398 FAM 68.16 GGAT 0.71 120-144 
360 
 
12 D12S1300 TET 104.12 GATA 0.68 112-136 
12 D12S2070 TET 125.30 ATA 0.89 89-107 
12 D12S2078 TET 149.60 GATA 0.89 250-282 
13 D13S1493 FAM 25.80 GGAA 0.92 215-260 
13 D13S800 HEX 55.31 GATA 0.74 295-319 
13 D13S793 TET 76.26 GATA 0.74 253-273 
13 D13S779 TET 82.93 ATA 0.50 175-210 
14 D14S608 HEX 28.01 GATA 0.78 188-224 
14 D14S599 FAM 40.68 ATA 0.85 98-133 
14 D14S978 HEX 53.19 CA 0.89 228-258 
14 D14S989 FAM 55.29 CA 0.57 161-185 
14 D14S587 HEX 55.82 GGAA 0.81 254-274 
14 D14S592 TET 66.80 ATA 0.78 220-250 
14 D14S588 TET 75.61 GGAA 0.68 110-145 
14 D14S53 FAM 86.29 CA 0.66 144-161 
14 D14S610 FAM 95.89 GATA 0.73 360-376 
14 D14S1279 TET 95.89 GATA 0.68 107-143 
14 D14S617 FAM 105.53 GGAA 0.76 141-173 
15 D15S1507 TET 60.17 GATA 0.65 205-221 
15 D15S211 HEX 75.85 AC 0.95 207-261 
15 D15S816 FAM 100.59 GATA 0.56 130-150 
16 D16S403 HEX 43.89 AC 0.86 120-160 
16 D16S3253 TET 71.77 GATA 0.78 167-199 
17 D17S974 FAM 22.24 GATA 0.82 201-217 
17 D17S947 FAM 31.96 AC 0.82 250-280 
17 D17S2196 FAM 44.62 GATA 0.87 139-163 
17 D17S2180 HEX 66.85 ATC 0.64 116-128 
17 D17S2193 TET 89.32 ATA 0.71 88-123 
17 D17S784 TET 116.86 AC 0.78 226-238 
18 D18S976 HEX 12.81 GATA 0.92 171-198 
18 D18S542 FAM 41.24 GATA 0.75 178-205 
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18 D18S877 TET 54.40 GATA 0.75 110-150 
18 D18S1357 HEX 88.62 ATA 0.82 126-147 
18 ATA82B02 TET 106.81 ATA 0.86 172-196 
19 D19S1034 FAM 20.75 GATA 0.71 216-232 
19 D19S586 HEX 32.94 GATA 0.79 222-250 
19 D19S178 FAM 68.08 AC 0.77 155-189 
19 D19S589 HEX 87.66 GATA 0.64 161-181 
20 D20S482 TET 12.12 GATA 0.75 151-167 
20 D20S851 HEX 24.70 AV 0.73 128-150 
21 D21S2055 HEX 40.49 GATA 0.85 119-199 
22 GCT10C10 FAM 18.10 GCT 0.68 192-210 
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Appendix III: Applied Biosystems Linkage mapping set version 2.5 
 
Panel Chromosome Microsatellite Marker Fluorescent Label Position (cM) Het Size Range (bp) 
1 1 D1S2797 FAM 75.66 0.74 97-135 
1 1 D1S249 FAM 220.65 0.87 160-190 
1 1 D1S2800 FAM 252.12 0.77 205-221 
1 1 D1S234 FAM 55.1 0.81 262-284 
1 1 D1S450 FAM 20.61 0.81 315-341 
1 1 D1S255 VIC 65.47 0.75 85-107 
1 1 D1S2667 VIC 24.68 0.82 122-152 
1 1 D1S2785 VIC 266.27 0.76 171-185 
1 1 D1S2890 VIC 85.68 0.81 211-235 
1 1 D1S484 VIC 169.68 0.64 272-286 
1 1 D1S196 VIC 181.49 0.74 321-337 
1 1 D1S213 NED 242.34 0.86 103-129 
1 1 D1S2878 NED 177.86 0.84 148-176 
1 1 D1S206 NED 134.2 0.82 205-223 
1 1 D1S2836 NED 285.75 0.79 242-256 
1 1 D1S2726 NED 144.38 0.75 280-294 
1 1 D1S2842 NED 273.46 0.76 336-358 
2 1 D1S199 FAM 45.33 0.83 94-120 
2 1 D1S207 FAM 113.69 0.84 146-176 
2 1 D1S2868 FAM 126.16 0.76 206-220 
2 1 D1S413 FAM 212.44 0.76 249-265 
2 1 D1S238 FAM 202.73 0.86 292-326 
2 1 D1S252 VIC 150.27 0.81 86-112 
2 1 D1S230 VIC 95.31 0.78 150-164 
2 1 D1S468 VIC 4.22 0.76 191-211 
2 1 D1S2841 VIC 106.45 0.78 230-250 
2 1 D1S2697 VIC 37.05 0.70 286-302 
2 1 D1S214 NED 14.04 0.78 117-147 
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2 1 D1S498 NED 155.89 0.82 187-209 
2 1 D1S218 NED 191.52 0.83 265-291 
2 1 D1S425 NED 231.11 0.81 332-358 
3 2 D2S286 FAM 94.05 0.66 80-102 
3 2 D2S165 FAM 47.43 0.85 141-175 
3 2 D2S160 FAM 122.96 0.78 206-224 
3 2 D2S2211 FAM 15.61 0.74 236-258 
3 2 D2S367 FAM 54.96 0.86 306-340 
3 2 D2S125 VIC 260.63 0.82 87-109 
3 2 D2S206 VIC 240.79 0.8 125-163 
3 2 D2S117 VIC 194.45 0.82 190-220 
3 2 D2S142 VIC 161.26 0.76 235-255 
3 2 D2S2333 NED 103.16 0.82 79-101 
3 2 D2S126 NED 221.13 0.82 113-145 
3 2 D2S325 NED 204.53 0.82 154-184 
3 2 D2S364 NED 186.21 0.80 230-256 
3 2 D2S337 NED 80.69 0.88 291-315 
4 2 D2S112 FAM 141.62 0.71 73-89 
4 2 D2S162 FAM 20.03 0.75 119-148 
4 2 D2S2330 FAM 169.41 0.81 166-186 
4 2 D2S2216 FAM 111.21 0.76 208-224 
4 2 D2S347 FAM 131.51 0.80 267-299 
4 2 D2S2259 FAM 64.29 0.79 321-341 
4 2 D2S319 VIC 7.6 0.73 128-140 
4 2 D2S168 VIC 27.06 0.82 156-180 
4 2 D2S151 VIC 152.04 0.82 224-252 
4 2 D2S2382 VIC 213.49 0.81 296-336 
4 2 D2S2368 NED 85.48 0.83 93-117 
4 2 D2S391 NED 70.31 0.79 143-159 
4 2 D2S335 NED 175.91 0.79 183-205 
4 2 D2S396 NED 232.9 0.83 232-250 
4 2 D2S338 NED 250.54 0.81 264-288 
4 2 D2S305 NED 38.87 0.72 314-336 
5 4 D4S392 FAM 78.97 0.82 79-109 
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5 3 D3S1311 FAM 224.88 0.83 133-159 
5 3 D3S1565 FAM 186.04 0.64 178-194 
5 4 D4S406 FAM 117.06 0.87 242-268 
5 4 D4S1575 FAM 132.05 0.65 287-305 
5 3 D3S1271 VIC 117.76 0.73 84-104 
5 3 D3S3681 VIC 109.22 0.83 121-161 
5 4 D4S414 VIC 100.75 0.89 231-249 
5 4 D4S405 VIC 56.95 0.86 281-309 
5 3 D3S1614 NED 177.75 0.83 101-125 
5 3 D4S1534 NED 95.09 0.77 147-169 
5 3 D3S1263 NED 36.1 0.86 191-211 
5 3 D3S1285 NED 91.18 0.73 233-251 
5 3 D4S1597 NED 169.42 0.76 274-300 
6 3 D3S1262 FAM 201.14 0.80 110-132 
6 3 D3S1569 FAM 158.38 0.80 150-174 
6 4 D4S1572 FAM 107.95 0.84 195-213 
6 3 D3S1300 FAM 80.32 0.82 230-262 
6 4 D4S413 FAM 157.99 0.85 282-334 
6 4 D4S2935 VIC 13.96 0.62 85-105 
6 4 D4S1592 VIC 69.53 0.72 113-141 
6 4 D4S391 VIC 43.59 0.85 150-170 
6 3 D3S1304 VIC 22.33 0.80 254-276 
6 3 D3S1601 VIC 214.45 0.85 298-330 
6 3 D3S1297 VIC 8.31 0.82 351-369 
6 3 D3S1292 NED 146.6 0.85 111-145 
6 4 D4S426 NED 206.98 0.76 160-180 
6 4 D4S419 NED 33.42 0.77 225-245 
6 4 D4S415 NED 181.36 0.80 264-300 
7 4 D4S402 FAM 124.45 0.91 106-146 
7 4 D4S403 FAM 25.9 0.77 170-186 
7 4 D3S1580 FAM 207.73 0.84 215-235 
7 4 D3S1279 FAM 169.6 0.85 268-286 
7 4 D4S1539 FAM 176.19 0.68 316-326 
7 4 D3S2338 VIC 42.1 0.86 89-109 
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7 4 D4S2964 VIC 88.35 0.76 119-143 
7 4 D4S412 VIC 4.74 0.77 158-176 
7 4 D4S424 VIC 144.56 0.83 194-212 
7 4 D3S1278 VIC 129.73 0.87 232-260 
7 4 D3S1266 VIC 52.6 0.73 289-305 
7 4 D3S1267 NED 139.12 0.88 93-131 
7 4 D3S1566 NED 97.75 0.84 155-177 
7 4 D3S1289 NED 71.41 0.81 202-224 
7 4 D4S1535 NED 195.06 0.77 248-262 
7 4 D3S1277 NED 61.52 0.82 289-311 
8 5 D5S407 FAM 64.67 0.86 82-110 
8 6 D6S289 FAM 29.93 0.79 160-182 
8 6 D6S1610 FAM 53.81 0.84 200-214 
8 6 D6S1581 FAM 164.78 0.72 257-271 
8 6 D6S422 FAM 35.66 0.77 298-320 
8 5 D5S644 VIC 104.76 0.85 82-112 
8 6 D6S281 VIC 190.14 0.68 131-151 
8 6 D6S262 VIC 130 0.82 169-189 
8 5 D5S424 VIC 81.95 0.76 212-234 
8 5 D5S419 VIC 39.99 0.81 255-287 
8 5 D5S433 NED 111.97 0.86 63-93 
8 5 D5S422 NED 164.19 0.84 113-135 
8 5 D5S406 NED 11.85 0.79 164-192 
8 5 D5S400 NED 174.8 0.82 217-239 
8 6 D6S309 NED 14.07 0.83 304-330 
9 6 D6S264 FAM 179.07 0.70 108-130 
9 6 D6S1574 FAM 9.18 0.84 146-172 
9 6 D6S276 FAM 44.41 0.83 201-233 
9 5 D5S408 FAM 195.49 0.73 249-285 
9 6 D6S308 FAM 144.46 0.75 326-354 
9 6 D6S287 VIC 121.97 0.85 105-139 
9 6 D6S292 VIC 136.97 0.83 155-177 
9 6 D6S434 VIC 109.19 0.86 202-246 
9 5 D5S426 VIC 51.99 0.80 275-299 
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9 5 D5S1981 NED 1.72 0.73 115-125 
9 6 D6S257 NED 79.92 0.87 167-195 
9 6 D6S446 NED 189 0.62 217-229 
9 5 D5S641 NED 92.38 0.77 299-339 
10 5 D5S2027 FAM 119.5 0.78 180-202 
10 5 D5S436 FAM 147.49 0.83 238-258 
10 6 D6S460 FAM 89.83 0.81 279-303 
10 5 D5S410 FAM 156.47 0.79 329-351 
10 6 D6S462 VIC 99.01 0.68 104-121 
10 5 D5S2115 VIC 138.64 0.76 142-170 
10 5 D5S418 VIC 58.55 0.80 208-228 
10 5 D5S428 VIC 95.4 0.76 241-259 
10 5 D5S630 VIC 19.67 0.89 283-393 
10 6 D6S470 NED 18.22 0.80 120-140 
10 6 D6S441 NED 154.1 0.86 162-196 
10 5 D5S471 NED 129.83 0.76 235-255 
10 5 D5S416 NED 28.76 0.77 285-297 
10 5 D5S647 NED 74.07 0.82 326-365 
11 7 D7S484 FAM 53.5 0.74 97-115 
11 8 D8S264 FAM 0.73 0.83 136-160 
11 8 D8S260 FAM 79.36 0.81 191-217 
11 7 D7S517 FAM 7.44 0.83 243-261 
11 8 D8S1784 FAM 118.15 0.67 276-292 
11 7 D7S2465 FAM 180.24 0.83 319-343 
11 8 D8S549 VIC 31.73 0.63 73-83 
11 7 D7S530 VIC 134.55 0.78 105-123 
11 8 D8S258 VIC 41.55 0.70 142-156 
11 7 D7S669 VIC 90.42 0.80 172-194 
11 8 D8S272 VIC 154.02 0.81 211-261 
11 7 D7S502 VIC 78.65 0.84 289-309 
11 7 D7S630 VIC 98.44 0.73 327-355 
11 7 D7S510 NED 59.93 0.77 79-95 
11 7 D7S640 NED 137.83 0.85 110-150 
11 7 D7S513 NED 17.74 0.83 168-198 
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11 8 D8S514 NED 130 0.77 212-232 
11 7 D7S657 NED 104.86 0.81 244-270 
11 7 D7S516 NED 41.69 0.76 306-326 
11 8 D8S1771 NED 50.05 0.75 343-367 
12 7 D7S507 FAM 28.74 0.89 81-109 
12 7 D7S515 FAM 112.32 0.82 139-201 
12 7 D7S486 FAM 124.08 0.81 221-235 
12 7 D7S519 FAM 69.03 0.81 257-284 
12 7 D7S661 FAM 155.1 0.75 305-337 
12 7 D7S798 VIC 168.98 0.84 71.26-93 
12 8 D8S505 VIC 60.87 0.79 110-124 
12 8 D8S277 VIC 8.34 0.73 151-185 
12 7 D7S493 VIC 34.69 0.88 203-235 
12 8 D8S284 VIC 143.82 0.83 272-306 
12 7 D7S684 VIC 147.22 0.81 341-363 
12 8 D8S270 NED 103.69 0.79 101-117 
12 7 D7S636 NED 162.33 0.90 136-172 
12 8 D8S550 NED 21.33 0.87 187-217 
12 7 D7S531 NED 5.28 0.77 276-294 
12 8 D8S285 NED 71 0.78 314-330 
13 11 D11S987 FAM 67.48 0.82 94-134 
13 11 D11S937 FAM 79.98 0.88 144-180 
13 11 D11S935 FAM 45.94 0.73 196-218 
13 9 D9S1677 FAM 117.37 0.81 229-255 
13 11 D11S1314 VIC 73.64 0.78 93-121 
13 11 D11S902 VIC 21.47 0.80 148-170 
13 11 D11S904 VIC 33.57 0.83 183-213 
13 11 D10S547 VIC 29.15 0.74 236-257 
13 11 D11S905 VIC 51.95 0.75 269-297 
13 9 D9S285 NED 29.52 0.78 80-110 
13 10 D10S249 NED 2.13 0.74 117-139 
13 9 D9S171 NED 42.73 0.79 160-186 
13 9 D9S273 NED 65.79 0.74 202-222 
13 10 D10S192 NED 124.27 0.77 238-264 
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13 11 D11S4175 NED 91.47 0.89 288-340 
14 9 D9S161 FAM 51.81 0.78 122-139 
14 10 D10S197 FAM 52.1 0.75 166-180 
14 10 D10S185 FAM 116.34 0.77 201-219 
14 9 D9S175 FAM 70.33 0.85 255-289 
14 11 D11S901 FAM 85.48 0.82 311-327 
14 10 D10S1653 VIC 40.36 0.77 118-132 
14 10 D10S212 VIC 170.94 0.71 189-207 
14 10 D10S1686 VIC 105.04 0.86 243-281 
14 9 D9S287 VIC 103.42 0.67 295-315 
14 11 D11S4046 NED 2.79 0.86 101-125 
14 9 D9S288 NED 9.83 0.84 132-154 
14 10 D10S208 NED 60.64 0.79 173-193 
14 9 D9S157 NED 32.24 0.84 225-249 
14 9 D9S167 NED 83.41 0.87 304-338 
15 9 D9S164 FAM 147.91 0.80 84-102 
15 9 D9S286 FAM 18.06 0.88 136-170 
15 9 D9S1690 FAM 106.63 0.78 226-240 
15 11 D11S1320 FAM 141.91 0.68 259-277 
15 11 D11S4151 FAM 127.33 0.79 331-345 
15 11 D11S4191 VIC 60.09 0.87 89-119 
15 11 D11S968 VIC 147.77 0.81 140-162 
15 9 D9S1776 VIC 123.33 0.84 172-210 
15 11 D11S1338 VIC 12.92 0.74 253-271 
15 10 D10S591 VIC 13.49 0.71 309-339 
15 10 D10S587 NED 147.57 0.80 92-114 
15 10 D10S537 NED 91.13 0.83 139-165 
15 10 D10S189 NED 19 0.72 179-197 
15 11 D11S925 NED 118.47 0.84 260-290 
16 10 D10S217 FAM 157.89 0.81 96-120 
16 11 D11S898 FAM 98.98 0.85 141-165 
16 10 D10S548 FAM 45.7 0.70 182-198 
16 9 D9S1826 FAM 159.61 0.69 215-231 
16 9 D9S290 FAM 140.86 0.83 240-262 
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16 9 D91817 FAM 59.34 0.88 279-315 
16 9 D9S158 FAM 161.71 0.69 330-356 
16 10 D10S196 VIC 70.23 0.77 103-115 
16 9 D9S1682 VIC 132.09 0.68 147-159 
16 11 D11S908 VIC 108.59 0.76 172-190 
16 10 D10S1693 VIC 137.39 0.80 213-227 
16 10 D10S597 VIC 128.73 0.64 273-297 
16 9 D9S283 NED 94.85 0.80 89-115 
16 10 D10S1651 NED 168.77 0.80 206-230 
16 10 D10S1652 NED 80.77 0.78 269-295 
17 12 D12S83 FAM 75.17 0.81 102-122 
17 13 D13S218 FAM 32.9 0.66 141-153 
17 12 D12S78 FAM 111.87 0.91 174-212 
17 13 D13S217 FAM 17.21 0.68 242-262 
17 12 D12S1659 FAM 155.94 0.78 290-316 
17 13 D13S285 VIC 110.55 0.81 89-115 
17 13 D13S170 VIC 63.9 0.90 143-173 
17 12 D12S1723 VIC 164.63 0.67 198-216 
17 13 D13S175 NED 6.03 0.76 101-119 
17 13 D13S263 NED 38.32 0.84 146-174 
17 12 D12S346 NED 104.65 0.84 188-214 
17 12 D12S1617 NED 44.03 0.80 245-265 
18 12 D12S85 FAM 61.34 0.67 99-131 
18 12 D12S351 FAM 95.56 0.75 147-169 
18 12 D12S368 FAM 66.03 0.81 202-222 
18 13 D13S1265 FAM 98.82 0.80 275-305 
18 12 D12S86 VIC 134.54 0.89 129-169 
18 13 D13S156 VIC 55.85 0.80 277-297 
18 12 D12S336 NED 19.68 0.82 111-129 
18 12 D12S79 NED 125.31 0.87 160-186 
18 12 D12S345 NED 53.09 0.87 211-247 
18 12 D12S99 NED 12.6 0.83 264-296 
19 13 D13S158 FAM 84.87 0.82 116-133 
19 13 D13S159 FAM 79.49 0.90 154-196 
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19 13 D13S173 FAM 93.52 0.82 232-252 
19 12 D12S364 FAM 30.6 0.87 298-326 
19 13 D13S265 VIC 98.82 0.70 89-127 
19 12 D12S352 VIC 0 0.73 154-174 
19 12 D12S326 VIC 86.4 0.80 207-233 
19 12 D12S310 VIC 36.06 0.69 244-252 
19 13 D13S153 NED 45.55 0.81 89-121 
19 13 D13S171 NED 25.08 0.73 177-205 
19 12 D12S324 NED 147.17 0.69 233-255 
20 14 D14S292 FAM 134.3 0.73 83-100 
20 14 D14S275 FAM 28.01 0.70 145-159 
20 14 D14S258 FAM 76.28 0.79 192-213 
20 14 D14S280 FAM 105 0.68 237-258 
20 14 D14S70 VIC 40.11 0.75 98-114 
20 14 D14S283 VIC 13.89 0.81 127-158 
20 14 D14S63 VIC 69.18 0.76 177-195 
20 14 D14S985 VIC 126.61 0.76 240-255 
20 14 D14S74 VIC 87.36 0.79 297-321 
20 14 D14S65 NED 117.3 0.79 124-156 
20 14 D14S288 NED 47.51 0.83 192-215 
20 14 D14S276 NED 56.36 0.76 236-249 
20 14 D14S261 NED 6.46 0.75 273-305 
20 14 D14S68 NED 95.89 0.91 318-346 
21 16 D16S3075 FAM 23.28 0.79 76-94 
21 16 D16S3136 FAM 62.11 0.69 173-185 
21 16 D16S3068 FAM 48.53 0.77 219-235 
21 15 D15S130 FAM 100.59 0.66 285-299 
21 16 D16S515 FAM 92.1 0.80 325-357 
21 15 D15S1002 VIC 14.58 0.78 104-134 
21 16 D16S520 VIC 125.82 0.84 149-165 
21 15 D15S165 VIC 20.24 0.79 182-213 
21 15 D15S131 VIC 71.28 0.83 240-281 
21 16 D16S503 VIC 83.55 0.81 299-319 
21 15 D15S127 NED 86.81 0.86 118-154 
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21 16 D16S3091 NED 111.12 0.73 166-182 
21 15 D15S153 NED 62.4 0.87 240-274 
21 15 D15S117 NED 51.21 0.78 321-339 
22 16 D16S3046 FAM 40.65 0.74 83-109 
22 15 D15S205 FAM 78.92 0.88 126-166 
22 16 D16S415 FAM 67.62 0.72 213-241 
22 15 D15S1012 VIC 35.95 0.72 94-112 
22 16 D16S423 VIC 10.36 0.73 137-161 
22 15 D15S978 VIC 45.62 0.83 184-212 
22 16 D16S404 VIC 18.07 0.80 261-281 
22 16 D16S3103 VIC 32.07 0.81 315-343 
22 15 D15S1007 NED 25.86 0.86 84-108 
22 15 D15S120 NED 112.58 0.73 155-183 
22 15 D15S128 NED 6.11 0.78 197-215 
22 16 D16S516 NED 100.39 0.73 245-267 
22 15 D15S994 NED 40.25 0.73 303-315 
23 18 D18S70 FAM 126 0.83 111-131 
23 17 D17S949 FAM 93.27 0.80 210-228 
23 18 D18S478 FAM 52.86 0.64 242-256 
23 17 D17S1852 FAM 22.24 0.87 279-310 
23 17 D17S831 VIC 6.6 0.82 107-129 
23 17 D17S1857 VIC 43.01 0.64 164-174 
23 17 D17S799 VIC 31.96 0.68 186-208 
23 17 D17S1868 VIC 64.16 0.73 254-268 
23 17 D17S798 VIC 53.41 0.80 298-322 
23 18 D18S1102 NED 62.84 0.79 90-102 
23 17 D17S787 NED 74.99 0.81 138-174 
23 18 D18S61 NED 105.03 0.87 209-239 
23 17 D17S849 NED 0.63 0.67 253-267 
23 18 D18S462 NED 120.05 0.70 296-318 
24 18 D18S474 FAM 71.32 0.82 121-143 
24 18 D18S53 FAM 41.24 0.79 152-182 
24 17 D17S938 FAM 14.69 0.76 238-258 
24 18 D18S464 FAM 31.17 0.65 298-314 
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24 18 D18S63 VIC 8.3 0.79 74-100 
24 18 D18S59 VIC 0 0.81 152-174 
24 17 D17S921 VIC 36.14 0.72 193-211 
24 17 D17S784 VIC 116.86 0.77 230-244 
24 18 D18S64 VIC 84.8 0.74 319-345 
24 17 D17S928 NED 126.46 0.76 68-102 
24 18 D18S452 NED 18.7 0.83 126-144 
24 17 D17S785 NED 103.53 0.83 165-193 
24 18 D18S1161 NED 114.26 0.82 211-237 
24 18 D18S68 NED 96.48 0.68 269-295 
24 17 D17S944 NED 82.56 0.75 318-334 
25 20 D20S889 FAM 11.2 0.83 87-123 
25 20 D20S117 FAM 2.83 0.84 151-187 
25 20 D20S112 FAM 39.25 0.81 213-237 
25 19 D19S220 FAM 62.03 0.84 267-291 
25 19 D19S221 VIC 36.22 0.86 87-110 
25 20 D20S171 VIC 95.7 0.78 127-155 
25 19 D19S210 VIC 100.01 0.74 172-192 
25 20 D20S100 VIC 84.78 0.76 209-235 
25 19 D19S420 NED 66.3 0.79 95-117 
25 19 D19S414 NED 54.01 0.78 164-194 
25 20 D20S115 NED 21.15 0.66 234-246 
25 20 D20S196 NED 75.01 0.81 259-295 
26 20 D20S119 FAM 61.77 0.82 103-123 
26 21 D21S266 FAM 45.87 0.59 156-178 
26 20 D20S107 FAM 55.74 0.80 197-221 
26 19 D19S902 FAM 72.72 0.79 237-273 
26 20 D20S186 VIC 32.3 0.86 113-139 
26 22 D22S420 VIC 4.06 0.77 153-169 
26 22 D22S280 VIC 31.3 0.82 213-225 
26 19 D19S216 VIC 20.01 0.76 256-274 
26 22 D22S423 VIC 46.42 0.82 287-309 
26 19 D19S884 NED 26.37 0.86 93-113 
26 21 D21S1252 NED 35.45 0.80 144-176 
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26 22 D22S539 NED 14.44 0.58 199-217 
26 22 D22S274 NED 51.54 0.77 276-298 
27 20 D20S195 FAM 50.81 0.81 128-154 
27 22 D22S315 FAM 21.47 0.78 180-210 
27 19 D19S209 FAM 10.97 0.77 238-254 
27 19 D19S418 VIC 92.56 0.66 87-107 
27 20 D20S173 VIC 98.09 0.67 128-182 
27 21 D21S263 VIC 27.4 0.75 194-229 
27 21 D21S1914 VIC 19.39 0.86 258-280 
27 21 D21S1256 NED 9.72 0.65 96-116 
27 22 D22S283 NED 38.62 0.89 127-155 
27 20 D20S178 NED 66.16 0.83 179-195 
27 19 D19S226 NED 42.28 0.85 238-270 
27 19 D19S571 NED 84.08 0.81 287-319 
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Appendix IV: Corrected CEPH sizes for microsatellite markers and corresponding members of RLS3002 
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127 
123,
125 
125,
129 
123,
125 
  
D2S2113 
88.1
5 
194,
194 
194,
200 
194,
200 
194,
200 
194,
194 
194,
200 
  
194,
194 
194,
194 
194,
194 
194,
194 
188,
194 
194,
194 
194,
200 
194,
200 
  
D2S2110 
90.8
2 
139,
141 
133,
139 
133,
141 
133,
141 
139,
141 
133,
139 
133,
139 
133,
141 
139,
141 
133,
139 
139,
139 
133,
141 
133,
139 
139,
141 
139,
141 
133,
141 
  
D2S286 
94.0
5 
136,
144 
136,
136 
136,
144 
136,
144 
136,
144 
136,
136 
136,
136 
 
136,
144 
136,
136 
136,
136 
144,
136 
130,
136 
136,
144 
136,
136 
136,
136 
136,
144 
136,
144 
D2S1777 
99.4
1 
200,
200 
200,
204 
200,
204 
200,
204 
200,
200 
200,
200 
  
200,
200 
204,
208 
200,
208 
200,
204 
200,
200 
200,
200 
200,
204 
200,
200 
  
D2S329 
101.
02 
244,
244 
236,
238 
238,
244 
238,
244 
236,
244 
238,
244 
238,
244 
238,
244 
242,
244 
244,
244 
242,
244 
244,
244 
242,
248 
244,
244 
242,
242 
242,
244 
  
D2S2333 
103.
16 
254,
260 
254,
256 
254,
256 
254,
260 
254,
254 
256,
260 
256,
260 
254,
256 
254,
256 
248,
254 
254,
256 
248,
254 
254,
256 
254,
256 
254,
258 
256,
258 
254,
258 
254,
254 
D2S160 
122.
96 
212,
214 
212,
214 
214,
214 
212,
214 
212,
214 
212,
214 
212,
214 
214,
214 
212,
214 
208,
214 
208,
212 
208,
214 
212,
212 
212,
214 
210,
210 
210,
212 
 
210,
214 
D2S1334 
145.
08 
286,
290 
286,
298 
290,
298 
298,
86 
286,
286 
286,
286 
  
290,
294 
286,
298 
286,
294 
286,
290 
286,
298 
290,
294 
286,
294 
   
378 
 
D2S151 
152.
04 
221,
227 
221,
221 
221,
227 
221,
221 
221,
221 
221,
221 
221,
227 
221,
227 
221,
227 
225,
225 
221,
225 
225,
227 
221,
225 
 
221,
227 
 
227,
231 
221,
227 
D2S142 
161.
26 
254,
254 
260,
262 
254,
262 
254,
260 
254,
262 
254,
262 
254,
260 
254,
260 
254,
254 
260,
260 
254,
260 
 
254,
264 
254,
262 
258,
264 
254,
264 
258,
262 
258,
262 
D2S117 
194.
45 
204,
206 
 
206,
206 
206,
206 
206,
206 
204,
208 
206,
208 
206,
206 
192,
204 
188,
192 
192,
192 
192,
204 
192,
204 
192,
192 
206,
208 
192,
208 
192,
206 
192,
206 
D2S325 
204.
53 
200,
206 
 
206,
206 
204,
206 
206,
206 
200,
204 
204,
206 
206,
206 
200,
206 
198,
198 
198,
206 
198,
200 
200,
200 
200,
200 
198,
200 
200,
200 
200,
200 
200,
200 
D2S2382 
213.
49 
251,
261 
251,
259 
259,
261 
259,
261 
 
251,
251 
259,
261 
259,
261 
261,
273 
279,
279 
261,
279 
273,
279 
273,
285 
251,
285 
251,
256 
  
255,
285 
D2S434 
215.
78 
270,
274 
266,
278 
266,
274 
266,
274 
274,
278 
270,
278 
  
274,
274 
270,
282 
274,
282 
274,
282 
274,
274 
270,
274 
270,
274 
274,
274 
  
D2S126 
221.
13 
141,
151 
 
151,
153 
141,
153 
141,
151 
141,
151 
151,
153 
141,
153 
141,
151 
153,
155 
151,
155 
151,
153 
151,
155 
141,
151 
153,
155 
151,
155 
151,
155 
151,
155 
D2S2968 
251.
94 
183,
187 
183,
187 
183,
187 
187,
187 
183,
187 
183,
187 
  
183,
183 
183,
183 
183,
183 
183,
183 
183,
183 
183,
187 
183,
179 
179,
183 
  
D2S125 
260.
63 
98,9
8 
98,1
04 
98,9
8 
98,9
8 
98,1
04 
98,1
04 
98,9
8 
98,1
04 
104,
106 
 
98,1
04 
98,1
06 
98,1
06 
98,1
04 
92,9
4 
94,1
04 
 
92,1
04 
D3S1304 
22.3
3 
263,
263 
267,
267 
263,
267 
263,
267 
263,
267 
263,
267 
  
263,
263 
265,
267 
263,
267 
263,
265 
263,
263 
263,
267 
253,
267 
253,
267 
  
D3S1263 
36.1
0 
233,
239 
 
239,
247 
 
233,
239 
239,
247 
239,
247 
239,
247 
233,
239 
233,
237 
233,
239 
233,
237 
233,
239 
237,
239 
231,
235 
235,
237 
231,
239 
231,
239 
D3S2338 
42.1
0 
179,
179 
183,
189 
179,
189 
179,
183 
179,
183 
179,
189 
179,
189 
179,
189 
179,
179 
189,
189 
179,
189 
179,
189 
 
179,
195 
 
193,
195 
179,
191 
 
D3S3038 
44.8
1 
199,
203 
195,
203 
195,
199 
203,
203 
203,
203 
195,
203 
  
199,
215 
199,
199 
199,
199 
199,
215 
199,
203 
199,
215 
199,
199 
199,
215 
  
D3S1266 
52.6
0 
291,
291 
289,
291 
289,
291 
291,
291 
291,
291 
289,
291 
289,
291 
289,
291 
291,
297 
289,
297 
297,
297 
291,
297 
 
291,
291 
291,
297 
291,
291 
291,
297 
291,
297 
D3S1277 
61.5
2 
274,
274 
266,
268 
268,
274 
268,
274 
268,
274 
266,
274 
266,
274 
266,
274 
 
268,
268 
268,
274 
268,
274 
 
274,
274 
 
264,
274 
274,
274 
274,
274 
379 
 
D3S1289 
71.4
1 
211,
215 
205,
215 
205,
211 
211,
215 
211,
215 
205,
215 
205,
211 
205,
215 
209,
217 
209,
209 
209,
209 
209,
217 
211,
215 
211,
217 
 
211,
217 
211,
217 
217,
217 
D3S1300 
80.3
2 
229,
241 
235,
237 
235,
241 
239,
237 
239,
237 
237,
241 
239,
235 
 
235,
237 
217,
217 
 
217,
235 
229,
241 
229,
235 
237,
237 
235,
237 
235,
237 
235,
237 
D3S4542 
89.9
1 
                  
D3S1285 
91.1
8 
232,
232 
238,
238 
 
232,
238 
232,
238 
232,
238 
232,
238 
232,
238 
232,
238 
238,
238 
238,
238 
232,
238 
232,
232 
232,
240 
232,
238 
 
232,
240 
232,
240 
D3S2406 
102.
64 
346,
350 
314,
318 
314,
350 
314,
350 
318,
250 
318,
350 
  
346,
350 
306,
330 
330,
346 
330,
350 
334,
350 
334,
346 
306,
330 
330,
334 
  
D3S3681 
109.
22 
                  
D3S1271 
117.
76 
156,
158 
156,
156 
156,
158 
156,
158 
156,
158 
156,
158 
156,
156 
156,
156 
156,
158 
156,
156 
156,
156 
156,
158 
 
156,
158 
154,
156 
154,
156 
154,
158 
 
D3S3045 
124.
64 
187,
195 
183,
191 
191,
195 
191,
195 
183,
195 
183,
195 
  
191,
195 
179,
195 
191,
195 
195,
195 
195,
191 
187,
195 
203,
203 
187,
203 
  
D3S1278 
129.
73 
203,
217 
209,
225 
203,
225 
203,
225 
203,
209 
203,
209 
217,
225 
203,
225 
203,
227 
207,
207 
207,
227 
203,
207 
 
203,
217 
221,
221 
217,
221 
203,
221 
203,
221 
D3S1303 
136.
32 
196,
202 
202,
202 
202,
202 
202,
202 
202,
202 
202,
202 
  
202,
210 
196,
202 
202,
210 
202,
202 
202,
210 
196,
202 
206,
214 
196,
214 
  
D3S1267 
139.
12 
153,
167 
145,
149 
145,
153 
149,
153 
145,
167 
 
149,
167 
149,
167 
149,
153 
155,
157 
149,
155 
153,
155 
149,
153 
153,
167 
147,
149 
149,
167 
147,
167 
147,
153 
D3S1292 
146.
60 
160,
166 
144,
156 
156,
166 
144,
160 
156,
160 
156,
166 
156,
160 
144,
160 
160,
166 
156,
156 
156,
160 
156,
166 
156,
166 
148,
160 
144,
156 
156,
160 
144,
160 
148,
156 
D3S1569 
158.
38 
283,
287 
277,
291 
283,
291 
277,
287 
277,
283 
283,
291 
283,
291 
277,
287 
277,
291 
281,
287 
277,
287 
281,
291 
 
277,
287 
 
277,
277 
277,
277 
277,
289 
D3S3053 
181.
87 
234,
242 
226,
234 
226,
242 
226,
242 
226,
234 
226,
242 
  
226,
242 
226,
238 
226,
238 
226,
226 
234,
238 
226,
238 
226,
238 
238,
238 
234,
238 
 
D3S1565 
186.
04 
239,
241 
239,
245 
239,
241 
239,
241 
239,
239 
239,
241 
239,
241 
239,
239 
239,
241 
241,
241 
239,
241 
239,
241 
239,
241 
239,
241 
241,
241 
241,
241 
239,
241 
241,
241 
380 
 
D3S1262 
201.
14 
112,
112 
118,
128 
112,
128 
112,
128 
112,
128 
112,
128 
  
116,
116 
116,
122 
116,
122 
116,
116 
112,
116 
116,
124 
116,
124 
112,
124 
  
D3S1580 
207.
73 
139,
155 
139,
143 
139,
155 
139,
155 
139,
155 
139,
155 
143,
155 
 
145,
145 
153,
155 
145,
155 
145,
153 
139,
155 
145,
155 
143,
157 
143,
155 
143,
145 
143,
155 
D3S3023 
(deC
ode) 
234,
234 
234,
246 
234,
234 
234,
234 
234,
246 
234,
246 
  
234,
234 
243,
246 
234,
246 
234,
246 
234,
234 
234,
324 
234,
240 
234,
240 
  
D4S412 4.74 
245,
245 
237,
237 
237,
245 
237,
245 
237,
245 
237,
245 
237,
245 
237,
245 
243,
245 
245,
245 
245,
245 
  
245,
245 
245,
247 
245,
247 
245,
245 
245,
247 
D4S403 
25.9
0 
225,
227 
217,
219 
219,
225 
219,
225 
217,
227 
217,
225 
  
217,
227 
217,
227 
217,
217 
227,
227 
217,
225 
217,
227 
225,
227 
227,
227 
  
D4S3248 
75.5
2 
241,
245 
241,
237 
241,
241 
241,
245 
237,
245 
237,
241 
  
241,
241 
237,
237 
241,
237 
241,
237 
237,
245 
241,
245 
237,
245 
237,
241 
  
D4S3243 
88.3
5 
174,
174 
170,
174 
170,
174 
170,
174 
174,
174 
174,
174 
  
162,
170 
162,
174 
170,
174 
162,
170 
174,
174 
174,
174 
174,
178 
178,
174 
  
D4S1534 
95.0
9 
146,
156 
158,
156 
146,
148 
148,
156 
146,
156 
156,
156 
148,
156 
146,
148 
146,
156 
146,
146 
146,
156 
 
156,
156 
146,
156 
154,
158 
154,
156 
156,
158 
154,
156 
D4S414 
100.
75 
231,
236 
236,
241 
231,
241 
231,
241 
236,
241 
236,
236 
236,
241 
231,
241 
241,
246 
234,
236 
 
234,
241 
231,
236 
231,
236 
236,
238 
236,
238 
236,
236 
236,
238 
D4S1647 
104.
94 
140,
148 
148,
148 
148,
148 
148,
148 
148,
148 
140,
148 
  
144,
148 
144,
132 
144,
144 
144,
132 
140,
148 
140,
148 
132,
140 
140,
140 
  
D4S1572 
107.
95 
147,
147 
141,
143 
143,
147 
143,
147 
141,
147 
141,
147 
143,
147 
143,
147 
141,
147 
147,
149 
141,
147 
141,
149 
147,
147 
147,
147 
147,
147 
147,
147 
147,
147 
147,
147 
D4S407 
117.
06 
117,
125 
111,
121 
111,
117 
111,
117 
117,
121 
121,
125 
111,
117 
111,
117 
127,
127 
117,
129 
127,
129 
117,
127 
117,
125 
125,
127 
119,
125 
125,
125 
125,
125 
125,
125 
D4S2989 
203,
211 
207,
209 
207,
211 
207,
211 
207,
211 
209,
211 
203,
209 
207,
211 
 
205,
209 
201,
207 
205,
207 
201,
205 
203,
211 
203,
209 
201,
213 
203,
213 
203,
213 
203,
213 
D4S406 
117.
06 
234,
246 
248,
250 
234,
248 
234,
248 
234,
250 
246,
250 
234,
248 
234,
248 
250,
254 
234,
252 
234,
250 
250,
252 
234,
246 
246,
254 
248,
250 
246,
248 
246,
248 
246,
248 
D4S402 
124.
45 
289,
309 
287,
319 
309,
319 
309,
319 
 
289,
319 
309,
319 
309,
319 
289,
309 
287,
315 
 
289,
315 
289,
309 
289,
319 
297,
315 
289,
315 
289,
315 
289,
315 
381 
 
D4S1575 
132.
05 
221,
223 
223,
225 
223,
225 
221,
223 
223,
223 
221,
225 
   
219,
221 
221,
221 
221,
223 
221,
221 
219,
221 
221,
221 
221,
221 
219,
221 
219,
221 
D4S424 
144.
56 
188,
190 
180,
190 
188,
190 
188,
190 
180,
188 
180,
190 
190,
190 
190,
190 
188,
190 
182,
190 
190,
190 
190,
190 
199,
190 
199,
190 
190,
190 
188,
190 
190,
190 
190,
190 
D4S1629 
157.
99 
141,
149 
145,
157 
141,
145 
145,
149 
141,
147 
149,
157 
  
141,
149 
145,
153 
145,
149 
141,
153 
145,
153 
141,
149 
141,
153 
141,
153 
  
D4S413 
157.
99 
128,
166 
130,
140 
140,
166 
128,
140 
130,
166 
128,
130 
128,
140 
128,
140 
128,
166 
   
128,
166 
128,
166 
134,
140 
134,
166 
128,
140 
128,
134 
D4S1539 
176.
19 
225,
227 
223,
225 
223,
225 
223,
227 
225,
225 
225,
225 
223,
227 
223,
227 
225,
227 
225,
227 
225,
227 
225,
225 
223,
227 
225,
227 
225,
225 
225,
225 
225,
227 
225,
225 
D4S415 
181.
36 
174,
196 
174,
194 
194,
196 
194,
196 
174,
174 
174,
174 
194,
196 
194,
196 
174,
196 
174,
198 
196,
198 
174,
198 
196,
196 
174,
196 
194,
194 
174,
194 
194,
196 
194,
196 
D4S2417 
181.
93 
255,
255 
263,
263 
255,
263 
255,
263 
255,
263 
255,
263 
255,
263 
255,
263 
255,
255 
263,
263 
255,
263 
255,
263 
259,
263 
255,
255 
255,
259 
255,
259 
  
D4S2417 
181.
92 
255,
255 
263,
263 
255,
263 
255,
263 
255,
263 
255,
263 
  
255,
255 
263,
263 
255,
263 
255,
263 
259,
263 
255,
255 
255,
259 
255,
259 
  
D4S1535 
195.
06 
185,
185 
183,
185 
183,
185 
183,
185 
185,
185 
185,
185 
183,
185 
183,
185 
185,
185 
185,
185 
185,
187 
185,
187 
   
187,
191 
 
187,
191 
D4S408 
195.
06 
229,
229 
233,
242 
229,
243 
229,
243 
229,
233 
229,
233 
  
229,
229 
229,
233 
229,
229 
229,
229 
233,
233 
229,
233 
229,
239 
229,
233 
  
D4S426 
206.
98 
179,
181 
177,
191 
177,
181 
181,
191 
181,
191 
179,
191 
177,
179 
177,
181 
181,
191 
179,
191 
 
191,
191 
189,
191 
 
181,
187 
187,
189 
187,
189 
187,
189 
D5S1981 1.72 
262,
266 
262,
268 
 
262,
266 
262,
268 
266,
268 
262,
268 
262,
266 
268,
272 
262,
266 
262,
268 
262,
268 
262,
272 
262,
266 
268,
278 
266,
268 
266,
278 
266,
278 
D5S406 
11.8
5 
178,
180 
168,
178 
 
168,
178 
178,
180 
178,
178 
178,
180 
168,
178 
178,
180 
168,
180 
168,
178 
178,
180 
178,
180 
178,
180 
168,
180 
178,
180 
178,
180 
168,
178 
D5S630 
19.6
7 
231,
248 
254,
258 
248,
254 
248,
254 
231,
258 
248,
254 
231,
258 
248,
254 
248,
258 
248,
254 
248,
254 
248,
248 
231,
248 
231,
248 
248,
262 
248,
248 
231,
248 
248,
248 
D5S817 
22.8
8 
264,
268 
264,
268 
268,
268 
268,
268 
264,
264 
268,
268 
  
268,
272 
260,
268 
260,
268 
268,
268 
264,
268 
264,
268 
260,
272 
268,
272 
  
382 
 
D5S416 
28.7
6 
284,
286 
292,
292 
 
284,
292 
286,
292 
284,
292 
286,
292 
284,
292 
282,
284 
284,
288 
284,
284 
284,
286 
284,
286 
284,
286 
284,
290 
284,
284 
 
284,
284 
D5S419 
39.9
9 
212,
222 
218,
222 
212,
218 
212,
218 
 
222,
222 
218,
222 
212,
222 
206,
212 
222,
224 
212,
222 
212,
224 
 
206,
216 
  
216,
216 
206,
216 
D5S1470 
45.3
4 
173,
197 
177,
197 
197,
197 
197,
197 
173,
197 
197,
177 
  
177,
197 
181,
197 
197,
197 
181,
197 
173,
181 
177,
181 
189,
193 
181,
189 
  
D5S426 
51.9
9 
183,
193 
183,
199 
193,
199 
193,
199 
183,
199 
183,
193 
183,
199 
183,
199 
193,
203 
201,
201 
193,
201 
193,
201 
183,
201 
201,
203 
183,
199 
199,
201 
183,
203 
199,
201 
D5S418 
58.5
5 
215,
217 
213,
215 
213,
215 
213,
215 
213,
217 
215,
215 
213,
217 
215,
215 
215,
221 
215,
219 
215,
215 
215,
219 
213,
217 
213,
221 
215,
219 
213,
215 
219,
221 
213,
219 
D5S2500 
69.2
3 
157,
161 
153,
153 
153,
161 
153,
161 
153,
157 
153,
161 
153,
161 
153,
157 
161.
173 
161,
161 
161,
161 
161,
161 
149,
173 
149,
173 
153,
153 
153,
149 
  
D5S2072 
73.3
5 
159,
163 
159,
163 
163,
163 
163,
163 
163,
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159,
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161,
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159,
167 
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D5S647 
74.0
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140,
158 
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142 
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158 
142,
158 
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134,
136 
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138,
142 
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74.6
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123 
121,
123 
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123 
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113,
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121 
113,
121 
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123 
113,
121 
  
D5S2003 
78.3
1 
185,
189 
187,
177 
            
175,
189 
   
D5S424 
81.9
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130,
130 
128,
130 
130,
130 
130,
130 
 
128,
130 
130,
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130,
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124,
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130 
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130,
130 
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269 
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269 
267,
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265,
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275 
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245,
247 
241,
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241,
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200 
188,
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196,
204 
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204 
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208 
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D5S644 
104.
76 
97,9
9 
97,1
07 
97,9
9 
97,1
07 
97,9
7 
99,1
07 
97,9
7 
99,1
07 
95,9
7 
101,
107 
97,1
01 
97,1
07 
97,9
9 
 
95,9
9 
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9 
95,9
9 
95,9
9 
383 
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129.
83 
255,
259 
267,
259 
255,
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255,
259 
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259,
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251,
259 
267,
271 
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259,
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259 
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83 
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248 
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246 
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259,
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271,
273 
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248 
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246 
246,
248 
236,
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236,
248 
248,
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246 
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240 
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240 
236,
240 
236,
240 
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147.
49 
218,
236 
239,
236 
236,
239 
236,
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218,
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218,
236 
218,
218 
218,
236 
218,
218 
218,
236 
218,
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239,
239 
218,
239 
  
D5S410 
156.
47 
161,
169 
 
161,
163 
161,
169 
161,
169 
161,
163 
163,
169 
161,
163 
163,
169 
159,
169 
159,
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169,
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163,
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159,
163 
159,
163 
163,
163 
159,
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D5S400 
174.
80 
228,
234 
228,
230 
228,
230 
228,
230 
228,
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228,
228 
228,
230 
228,
228 
224,
230 
224,
228 
 
228,
234 
228,
230 
224,
228 
228,
228 
228,
228 
228,
228 
D5S211 
182.
89 
192,
200 
192,
192 
192,
192 
192,
200 
192,
192 
192,
200 
  
192,
200 
200,
200 
200,
200 
200,
192 
192,
202 
192,
202 
200,
202 
202,
202 
  
D5S408 
195.
49 
257,
257 
257,
257 
 
257,
257 
257,
257 
257,
257 
  
257,
257 
255,
257 
255,
257 
255,
257 
255,
257 
255,
257 
257,
259 
255,
257 
255,
259 
257,
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166 
174,
178 
166,
174 
166,
178 
166,
174 
166,
174 
166,
178 
166,
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174,
176 
160,
172 
160,
174 
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176 
166,
166 
166,
174 
166,
172 
166,
166 
166,
172 
166,
166 
D6S470 
18.2
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126,
138 
128,
130 
126,
130 
128,
138 
126,
130 
 
128,
138 
126,
128 
128,
130 
126,
128 
126,
130 
128,
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126,
138 
130,
138 
128,
130 
130,
138 
128,
138 
130,
138 
D6S2434 
25.0
8 
230,
230 
233,
227 
230,
233 
227,
230 
230,
233 
230,
233 
  
227,
230 
224,
230 
230,
230 
224,
227 
230,
230 
230,
233 
227,
233 
233,
233 
  
D6S289 
29.9
3 
219,
221 
221,
223 
219,
221 
221,
223 
219,
221 
221,
221 
221,
223 
219,
223 
217,
229 
217,
223 
217,
229 
 
219,
221 
 
219,
219 
 
219,
221 
221,
219 
D6S422 
35.6
6 
191,
197 
191,
207 
191,
197 
197,
207 
191,
191 
191,
197 
197,
207 
191,
207 
191,
197 
197,
211 
191,
211 
197,
197 
191,
197 
191,
195 
191,
195 
191,
195 
195,
195 
195,
195 
384 
 
D6S2439 
42.2
7 
250,
250 
230,
242 
242,
250 
230,
250 
242,
240 
242,
240 
  
250,
250 
234,
242 
242,
250 
250,
234 
242,
242 
242,
250 
238,
242 
238,
242 
  
D6S1051 
50.7
5 
231,
231 
231,
235 
231,
231 
231,
235 
231,
231 
231,
231 
231,
235 
231,
235 
227,
231 
227,
235 
227,
227 
231,
235 
231,
231 
231,
231 
231,
235 
231,
235 
  
D6S1610 
53.8
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133,
139 
133,
139 
139,
139 
133,
139 
133,
139 
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133,
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133,
139 
135,
137 
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135 
137,
139 
133,
139 
133,
139 
133,
133 
133,
133 
133,
133 
133,
133 
D6S1607 
59.3
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285,
279 
277,
279 
279,
279 
279,
279 
279,
285 
279,
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277,
279 
283,
283 
277,
283 
279,
283 
279,
285 
281,
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275,
287 
281,
287 
  
D6S2410 
73.1
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244,
248 
240,
252 
244,
252 
240,
248 
248,
252 
244,
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244,
244 
240,
240 
240,
244 
240,
244 
244,
248 
244,
248 
236,
244 
240,
244 
  
D6S257 
79.9
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174,
178 
178,
182 
178,
182 
174,
178 
174,
182 
178,
182 
174,
178 
174,
178 
176,
176 
176,
178 
176,
178 
176,
178 
174,
176 
174,
176 
174,
180 
174,
176 
174,
174 
174,
180 
D6S460 
89.9
3 
  
150,
160 
144,
158 
150,
160 
150,
158 
144,
158 
144,
158 
144,
144 
144,
152 
144,
144 
144,
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144,
158 
144,
158 
154,
158 
144,
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154,
158 
158,
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D6S462 
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285,
287 
285,
285 
285,
287 
285,
285 
285,
287 
285,
285 
285,
285 
285,
285 
285,
287 
285,
287 
825,
287 
285,
287 
285,
285 
285,
285 
285,
287 
285,
285 
285,
285 
285,
287 
D6S287 
121.
97 
159,
167 
161,
167 
167,
167 
161,
167 
159,
167 
161,
167 
167,
167 
161,
167 
161,
167 
161,
163 
163,
167 
161,
161 
159,
167 
159,
167 
141,
161 
141,
167 
159,
161 
159,
161 
D6S1040 
128.
93 
273,
277 
269,
277 
269,
277 
273,
277 
269,
277 
273,
277 
  
269,
277 
269,
277 
277,
277 
269,
269 
277,
277 
277,
277 
277,
269 
269,
277 
  
D6S262 
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179 
171,
179 
171,
179 
171,
179 
171,
179 
177,
179 
171,
177 
177,
179 
177,
179 
 
177,
183 
 
169,
179 
169,
179 
   
169,
179 
D6S292 
136.
97 
  
149,
149 
151,
157 
 
151,
157 
149,
157 
151,
157 
157,
157 
153,
153 
153,
157 
153,
157 
149,
157 
149,
157 
 
153,
157 
149,
153 
149,
153 
D6S308 
144.
46 
199,
199 
199,
199 
199,
199 
199,
199 
199,
199 
199,
199 
199,
199 
199,
199 
199,
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193,
199 
193,
199 
199,
199 
199,
199 
197,
197 
197,
199 
197,
199 
197,
199 
D6S441 
154.
10 
172,
180 
166,
180 
166,
172 
172,
180 
166,
172 
 
166,
180 
172,
180 
168,
172 
172,
174 
172,
172 
168,
172 
172,
180 
 
168,
172 
172,
180 
168,
172 
172,
172 
D6S2436 
154.
64 
121,
141 
121,
145 
121,
141 
141,
145 
131,
141 
121,
145 
  
121,
139 
121,
149 
121,
133 
121,
121 
121,
141 
121,
141 
121,
149 
121,
149 
  
385 
 
D6S1581 
164.
78 
219,
219 
219,
221 
219,
219 
219,
221 
219,
219 
219,
221 
219,
219 
219,
221 
219,
227 
229,
229 
219,
229 
 
219,
219 
219,
219 
215,
219 
215,
219 
219,
219 
215,
219 
D6S264 
179.
07 
114,
122 
108,
108 
108,
114 
108,
114 
108,
114 
 
108,
114 
108,
114 
114,
114 
114,
114 
114,
114 
114,
114 
114,
122 
114,
122 
108,
114 
108,
122 
114,
122 
114,
122 
D6S446 
189.
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201,
201 
203,
209 
201,
209 
201,
203 
201,
209 
201,
203 
201,
203 
201,
203 
201,
201 
201,
207 
201,
207 
  
201,
201 
201,
205 
 
201,
201 
201,
201 
D6S281 
190.
14 
 
209,
209 
207,
209 
207,
209 
207,
209 
207,
209 
207,
209 
207,
209 
207,
207 
203,
207 
 
203,
207 
203,
207 
203,
207 
203,
221 
203,
207 
203,
203 
203,
203 
D7S517 7.44 
247,
255 
245,
245 
245,
247 
245,
255 
245,
247 
245,
255 
245,
255 
245,
255 
245,
249 
251,
255 
 
245,
255 
245,
247 
247,
255 
251,
257 
247,
257 
247,
257 
255,
257 
D7S513 
17.7
4 
183,
195 
181,
195 
181,
183 
195,
195 
195,
195 
181,
195 
  
195,
199 
195,
195 
195,
199 
195,
195 
183,
195 
183,
191 
181,
195 
183,
195 
  
D7S3051 
29.2
8 
144,
170 
166,
166 
144,
166 
166,
170 
170,
166 
166,
170 
  
170,
170 
144,
170 
170,
170 
170,
170 
170,
144 
144,
170 
170,
170 
170,
170 
  
D7S493 
34.6
9 
210,
214 
214,
220 
210,
214 
214,
214 
214,
214 
214,
220 
214,
220 
214,
214 
194,
214 
210,
214 
194,
210 
194,
214 
210,
212 
210,
214 
210,
216 
210,
214 
210,
210 
210,
214 
D7S516 
41.6
9 
266,
266 
256,
260 
260,
266 
256,
266 
256,
266 
260,
266 
260,
266 
256,
266 
254,
260 
254,
262 
254,
262 
254,
254 
260,
266 
266,
266 
260,
266 
260,
266 
260,
266 
260,
266 
D7S484 
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99,1
05 
105,
105 
 
99,1
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105,
105 
105,
105 
105,
105 
105,
105 
105,
105 
103,
105 
 
105,
105 
99,1
05 
99,1
05 
105,
111 
105,
105 
 
105,
111 
D7S2846 
57.7
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180,
184 
180,
184 
180,
184 
180,
180 180 
180,
184 
  
180,
184 
188,
188 
180,
188 
180,
188 
180,
188 
180,
188 
180,
180 
180,
188 
  
D7S519 
69.0
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256,
272 
266,
272 
266,
272 
262,
272 
256,
262 
256,
266 
262,
272 
262,
266 
256,
262 
256,
266 
262,
266 
262,
266 
262,
266 
266,
272 
262,
266 
262,
266 
262,
272 
D7S3046 
78.6
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342 
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334 
334,
338 
334,
338 
334,
338 
339,
338 
  
332,
338 
334,
338 
334,
338 
334,
338 
322,
338 
322,
338 
322,
346 
322,
346 
  
D7S669 
90.4
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123,
137 
131,
139 
131,
137 
131,
137 
131,
137 
137,
139 
137,
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123,
131 
123,
137 
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137 
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131,
141 
123,
141 
123,
141 
123,
131 
D7S821 
109.
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258,
266 
254,
266 
258,
266 
266,
266 
266,
266 
254,
266 
  
262,
266 
258,
266 
262,
266 
258,
266 
250,
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250,
258 
258,
266 
258,
266 
  
386 
 
D7S530 
134.
55 
112,
114 
108,
114 
 
114,
144 
108,
112 
108,
114 
114,
114 
 
106,
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258,
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266 
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179 
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139 
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137,
139 
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160 
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148 
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D8S549 
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168,
170 
170,
170 
168,
170 
168,
170 
170,
170 
170,
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148,
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6 
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2 
  
74,7
4 
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224,
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226 
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D8S505 
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211 
203,
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203,
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207,
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203,
205 
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205,
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207,
207 
D8S532 
64.7
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239,
253 
251,
247 
247,
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251 
243,
251 
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251 
241,
251 
239,
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245,
251 
239,
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D8S285 
71.0
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120 
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122 
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122 
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108,
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118 
108,
120 
108,
118 
120,
120 
120,
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387 
 
D8S260 
79.3
6 
209,
205 
203,
207 
205,
203 
205,
207 
203,
205 
203,
205 
  
199,
203 
187,
205 
199,
205 
187,
199 
199,
205 
209,
203 
199,
205 
205,
209 
  
D8S2324 
94.0
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200,
216 
204,
204 
204,
216 
204,
216 
204,
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200,
204 
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216 
196,
212 
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208,
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204,
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204 
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204 
200,
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110.
20 
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140,
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152,
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148 
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D8S1784 
118.
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163,
167 
163,
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163,
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157,
165 
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165 
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217 
213,
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215 
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213,
217 
213,
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213,
215 
213,
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D8S1179 
135.
08 
182,
190 
182,
182 
182,
182 
182,
190 
182,
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183 
175,
183 
181,
183 
 
181,
183 
183,
183 
183,
183 
 
183,
183 
183,
183 
183,
183 
D17S1857 
43.0
1 
181,
181 
177,
181 
181,
181 
181,
181 
177,
181 
181,
181 
181,
181 
177,
181 
181,
181 
177,
181 
 
181,
181 
181,
185 
181,
185 
179,
181 
179,
185 
181,
185 
181,
181 
D17S2196 
44.6
2 
139,
151 
155,
147 
139,
155 
139,
155 
139,
155 
139,
155 
  
139,
155 
151,
155 
159,
159 
159,
159 
147,
151 
147,
151 
147,
151 
147,
147 
  
D17S1294 
50.7
4 
252,
256 
 
252,
252 
252,
252 
256,
256 
252,
252 
 
252,
256 
252,
252 
260,
264 
252,
260 
252,
260 
252,
256 
252,
260 
 
252,
256 
252,
256 
256,
260 
D17S798 
53.4
1 
223,
229 
223,
223 
223,
229 
223,
229 
223,
223 
223,
229 
223,
223 
223,
229 
209,
229 
209,
225 
209,
209 
209,
209 
223,
223 
223,
223 
209,
217 
209,
223 
209,
223 
217,
223 
D17S1868 
64.1
6 
190,
196 
188,
198 
188,
196 
188,
190 
190,
198 
188,
196 
188,
190 
196,
198 
190,
196 
196,
202 
190,
196 
190,
196 
192,
196 
190,
196 
192,
192 
190,
192 
192,
196 
190,
192 
D17S2180 
66.8
5 
122,
122 
119,
119 
119,
122 
119,
122 
119,
122 
119,
122 
  
122,
122 
119,
119 
119,
122 
119,
122 
122,
122 
119,
122 
116,
122 
116,
122 
  
D17S787 
74.9
9 
142,
152 
138,
138 
138,
152 
138,
142 
138,
142 
138,
152 
138,
142 
138,
142 
138,
152 
140,
142 
 
138,
142 
142,
152 
138,
144 
142,
152 
138,
142 
144,
152 
138,
152 
D17S944 
82.5
6 
212,
216 
212,
216 
212,
216 
216,
216 
212,
216 
212,
212 
216,
216 
216,
216 
212,
212 
216,
218 
 
212,
216 
212,
216 
212,
212 
216,
222 
212,
216 
212,
222 
212,
222 
D17S2193 
89.3
2 
141,
153 
141,
147 
141,
141 
141,
153 
141,
153 
141,
147 
  
141,
141 
141,
147 
141,
141 
141,
147 
141,
153 
141,
141 
147,
156 
141,
147 
  
D17S949 
93.2
7 
207,
221 
215,
223 
215,
221 
207,
215 
207,
223 
221,
223 
207,
215 
207,
215 
211,
221 
217,
221 
 
217,
221 
207,
221 
211,
221 
219,
221 
211,
221 
219.
221 
 
D17S785 
103.
53 
185,
189 
189,
189 
189,
189 
189,
189 
185,
189 
185,
189 
185,
189 
185,
189 
185,
195 
189,
197 
 
189,
195 
189,
195 
189,
195 
 
189,
197 
195,
197 
189,
197 
D17S784 
116.
86 
230,
234 
228,
232 
232,
234 
228,
234 
232,
234 
230,
232 
  
230,
234 
234,
236 
230,
236 
234,
234 
232,
234 
232,
234 
232,
234 
232,
234 
  
398 
 
D17S928 
126.
46 
149,
149 
149,
153 
149,
149 
149,
153 
149,
149 
149,
149 
149,
153 
149,
153 
145,
149 
151,
155 
 
145,
151 
145,
149 
145,
149 
 
145,
153 
145,
153 
149,
153 
D18S63 8.30 
255,
273 
277,
277 
273,
277 
255,
277 
 
255,
273 
255,
255 
255,
273 
255,
273 
255,
273 
255,
277 
255,
273 
269,
271 
255,
271 
255,
277 
273,
277 
  
D18S53 
41.2
4 
171,
171 
171,
173 
171,
173 
171,
173 
171,
171 
171,
171 
171,
171 
171,
171 
171,
175 
167,
175 
175,
175 
167,
175 
167,
171 
171,
171 
171,
173 
171,
171 
171,
171 
171,
171 
D18S452 
18.7
0 
135,
135 
133,
139 
135,
139 
135,
139 
135,
139 
133,
135 
131,
133 
 
131,
135 
133,
135 
133,
135 
133,
135 
131,
133 
131,
133 
133,
135 
133,
135 
131,
133 
133,
135 
D18S464 
31.1
7 
289,
291 
287,
289 
287,
291 
287,
289 
289,
291 
289,
291 
289,
291 
289,
289 
289,
291 
289,
289 
289,
291 
289,
291 
289,
291 
289,
289 
289,
291 
289,
291 
289,
291 
289,
289 
D18S53 
41.2
4 
171,
171 
171,
173 
171,
173 
171,
173 
171,
171 
171,
171 
171,
171 
171,
171 
171,
175 
167,
175 
175,
175 
167,
175 
167,
171 
171,
171 
171,
173 
171,
171 
171,
171 
171,
171 
D181102 
62.8
4 
214,
218 
210,
210 
210,
218 
210,
214 
210,
218 
216,
216 
 
210,
216 
216,
218 
214,
218 
210,
218 
214,
216 
210,
214 
214,
214 
 
210,
218 
214,
216 
214,
214 
D18S1134 
88.6
2 
215,
215 
211,
213 
211,
215 
211,
215 
213,
215 
213,
215 
213,
215 
213,
215 
211,
215 
211,
213 
213,
215 
213,
215 
211,
215 
211,
215 
209,
211 
209,
211 
  
D18S1148 
90.6
0 
144,
150 
148,
150 
148,
150 
148,
150 
144,
150 
150,
150 
144,
150 
144,
150 
148,
150 
142,
150 
150,
152 
150,
152 
148,
150 
144,
150 
148,
150 
148,
150 
  
D18S1147 
90.6
0 
226,
226 
210,
226 
226,
226 
226,
226 
210,
226 
210,
226 
210,
226 
210,
226 
216,
226 
212,
226 
212,
226 
212,
226 
216,
226 
212,
226 
210,
220 
212,
220 
  
D18S1148 
90.6
0 
144,
150 
148,
150 
148,
150 
148,
150 
144,
150 
150,
150 
144,
150 
144,
150 
148,
150 
142,
152 
150,
152 
150,
152 
148,
150 
144,
150 
148,
150 
148,
150 
  
D18S1147 
90.6
0 
226,
226 
210,
226 
226,
226 
226,
226 
210,
226 
210,
226 
210,
226 
210,
226 
216,
226 
212,
226 
212,
226 
212,
226 
216,
226 
212,
226 
210,
220 
212,
220 
  
D18S68 
96.4
8 
284,
288 
272,
288 
272,
284 
272,
284 
 
284,
284 
272,
280 
280,
284 
280,
284 
284,
284 
284,
288 
284,
288 
272,
284 
272,
284 
288,
288 
288,
288 
284,
288 
284,
284 
D18S465 
100.
11 
239,
239 
239,
241 
239,
241 
239,
241 
239,
239 
239,
239 
239,
239 
239,
239 
239,
237 
243,
245 
237,
245 
237,
245 
237,
245 
239,
239 
239,
239 
239,
239 
  
D18S61 
105.
03 
175,
179 
159,
175 
175,
175 
 
159,
179 
159,
179 
175,
175 
159,
175 
159,
175 
175,
175 
159,
175 
159,
175 
 
159,
175 
159,
179 
159,
179 
177,
179 
159,
177 
399 
 
D18S1161 
114.
26 
82,9
4 
94,9
4 
82,9
4 
94,9
4 
 
94,1
04 
94,9
4 
94,1
04 
94,1
04 
82,9
4 
94,9
4 
94,1
04 
82,9
0 
90,1
04 
94,9
4 
94,9
4 
82,9
4 
90,1
04 
D18S462 
120.
05 
187,
193 
185,
185 
185,
193 
185,
187 
185,
187 
185,
187 
181,
187 
181,
185 
185,
187 
187,
193 
185,
187 
185,
187 
183,
187 
187,
187 
185,
187 
185,
187 
185,
187 
183,
185 
D18S70 
126.
00 
112,
122 
106,
114 
106,
112 
106,
122 
114,
122 
112,
122 
114,
120 
114,
122 
120,
122 
112,
112 
114,
122 
112,
122 
 
112,
122 
114,
122 
106,
122 
112,
112 
120,
122 
CA19S322 0.00 
326,
326 
326,
326 
326,
326 
326,
326 
326,
326 
326,
326 
326,
326 
326,
326 
326,
326 
326,
326 
326,
326 
326,
326 
324,
326 
324,
326 
324,
326 
326,
326 
326,
326 
326,
326 
D19S886 0.00 
156,
158 
140,
160 
156,
160 
158,
160 
156,
160 
140,
156 
158,
160 
140,
158 
156,
158 
154,
156 
156,
156 
156,
156 
156,
158 
156,
158 
156,
156 
156,
156 
156,
156 
156,
156 
GT19S949 0.00 
272,
274 
256,
276 
272,
276 
274,
276 
272,
276 
256,
272 
274,
276 
256,
274 
272,
274 
270,
272 
272,
272 
272,
272 
272,
274 
272,
274 
272,
272 
272,
272 
272,
272 
272,
272 
ATA19S1
001 0.69 
408,
411 
402,
411 
408,
411 
411,
411 
408,
411 
402,
408 
411,
411 
402,
411 
408,
411 
393,
405 
393,
408 
393,
408 
402,
408 
402,
408 
389,
408 
408,
408 
408,
408 
389,
408 
GT19S949 5.54 
272,
274 
256,
276 
272,
276 
274,
276 
272,
276 
256,
272 
274,
276 
256,
274 
272,
274 
270,
272 
272,
272 
272,
272 
272,
274 
272,
274 
272,
272 
272,
272 
272,
272 
272,
272 
ATA19S1
001 5.54 
408,
411 
402,
411 
408,
411 
411,
411 
408,
411 
408,
411 
411,
411 
402,
411 
408,
411 
393,
405 
393,
408 
393,
408 
402,
408 
402,
408 
389,
408 
408,
408 
408,
408 
389,
408 
CA19S231
0 6.57 
270,
276 
272,
274 
274,
276 
270,
274 
274,
276 
272,
276 
270,
274 
270,
274 
270,
276 
266,
276 
276,
276 
276,
276 
266,
276 
266,
276 
268,
272 
268,
276 
268,
276 
266,
272 
D19S878 6.57 
212,
218 
214,
216 
216,
218 
212,
216 
216,
218 
214,
218 
212,
216 
212,
216 
212,
218 
208,
218 
218,
218 
218,
218 
208,
218 
208,
218 
210,
214 
210,
218 
210,
218 
208,
214 
D19S565 6.57 
166,
178 
186,
192 
178,
186 
166,
186 
178,
186 
178,
186 
166,
186 
166,
186 
166,
178 
178,
178 
166,
178 
178,
178 
176,
178 
176,
178 
176,
186 
176,
178 
176,
178 
176,
178 
GT192518 6.57 
293,
305 
315,
321 
305,
315 
293,
315 
305,
315 
305,
321 
293,
315 
293,
315 
293,
305 
305,
305 
293,
305 
305,
305 
303,
305 
303,
305 
303,
315 
303,
305 
303,
305 
303,
315 
D19S591 9.84 
104,
108 
104,
108 
104,
104 
108,
108 
104,
108 
104,
108 
104,
108 
104,
108 
104,
108 
104,
108 
104,
108 
104,
104 
100,
104 
100,
104 
100,
104 
104,
104 
104,
104 
100,
100 
D19S424 
10.9
7 
147,
155 
155,
155 
147,
155 
155,
155 
147,
155 
147,
155 
155,
155 
155,
155 
147,
155 
153,
155 
155,
155 
147,
155 
147,
147 
147,
147 
147,
157 
147,
147 
147,
147 
147,
157 
400 
 
D19S209 
10.9
7 
262,
268 
264,
266 
262,
266 
266,
268 
262,
266 
262,
264 
266,
268 
266,
268 
262,
268 
270,
270 
268,
270 
262,
270 
262,
272 
262,
272 
262,
264 
262,
262 
262,
262 
264,
272 
D19S894 
15.5
5 
144,
154 
158,
160 
144,
160 
154,
160 
144,
160 
154,
158 
154,
160 
154,
160 
144,
154 
160,
162 
154,
160 
144,
160 
144,
144 
144,
144 
144,
146 
144,
146 
144,
146 
144,
144 
D19S216 
20.0
1 
185,
187 
179,
187 
185,
187 
187,
187 
185,
187 
179,
187 
187,
187 
187,
187 
185,
187 
185,
191 
 
185,
191 
179,
185 
179,
185 
179,
185 
185,
185 
185,
185 
185,
185 
D19S1034 
20.7
5 
226,
234 
234,
234 
234,
234 
226,
234 
234,
234 
226,
234 
226,
234 
226,
234 
226,
234 
230,
234 
226,
234 
234,
234 
230,
234 
230,
234 
234,
238 
234,
238 
234,
238 
234,
234 
D19S884 
26.3
7 
218,
226 
224,
224 
224,
226 
218,
224 
224,
226 
218,
224 
218,
224 
218,
224 
226,
226 
226,
234 
226,
226 
226,
226 
218,
236 
218,
226 
 
226,
234 
222,
226 
218,
234 
D19S221 
36.2
2 
207,
207 
205,
207 
205,
207 
205,
207 
205,
207 
207,
207 
205,
207 
205,
207 
207,
207 
201,
203 
 
203,
207 
207,
207 
207,
207 
207,
207 
207,
207 
 
207,
207 
D19S226 
42.2
8 
253,
243 
241,
243 
235,
243 
243,
243 
243,
235 
241,
243 
243,
243 
243,
243 
253,
235 
233,
235 
235,
253 
233,
235 
243,
245 
235,
243 
243,
245 
235,
243 
  
D19S410 
45.4
8 
156,
170 
170,
170 
170,
170 
156,
170 
170,
170 
156,
170 
156,
170 
156,
170 
156,
170 
156,
156 
156,
156 
156,
170 
156,
156 
156,
170 
156,
170 
156,
170 
  
D19S414 
54.0
1 
163,
177 
179,
181 
177,
181 
181,
163 
181,
163 
163,
179 
163,
181 
163,
179 
177,
163 
181,
181 
181,
163 
177,
181 
163,
163 
163,
163 
163,
185 
163,
163 
  
D19S220 
62.0
3 
273,
277 
275,
277 
273,
275 
 
275,
277 
277,
277 
275,
277 
277,
277 
273,
281 
275,
279 
273,
279 
273,
275 
267,
277 
267,
277 
 
277,
279 
 
277,
279 
D19S420 
66.3
0 
255,
265 
259,
265 
259,
265 
255,
259 
255,
259 
255,
265 
255,
259 
255,
265 
257,
265 
263,
263 
257,
263 
263,
265 
255,
263 
255,
263 
257,
263 
255,
257 
255,
263 
255,
257 
D19S902 
72.7
2 
209,
217 
203,
209 
203,
217 
203,
209 
203,
209 
203,
209 
203,
209 
209,
209 
213,
217 
209,
211 
209,
213 
211,
217 
209,
217 
209,
213 
 
209,
209 
209,
211 
209,
209 
D19S210 
100.
01 
169,
175 
175,
175 
169,
175 
169,
175 
175,
175 
175,
175 
175,
175 
175,
175 
169,
169 
165,
169 
 
165,
169 
169,
175 
169,
175 
165,
165 
165,
175 
165,
169 
165,
175 
D20S864 0.00 
224,
226 
224,
26 
224,
226 
224,
226 
224,
226 
224,
226 
  
224,
228 
226,
228 
226,
228 
226,
228 
224,
226 
226,
228 
226,
228 
226,
228 
  
D20S199 6.25 
108,
120 
108,
120 
108,
108 
108,
108 
108,
108 
108,
120 
  
112,
116 
108,
120 
108,
116 
108,
116 
108,
120 
112,
116 
112,
114 
112,
112 
  
401 
 
D20S113 8.97 
178,
178 
178,
178 
178,
178 
178,
178 
178,
178 
178,
178 
  
178,
178 
178,
186 
178,
186 
178,
178 
178,
178 
178,
178 
178,
178 
178,
178 
  
D20S842 8.97 
164,
168 
160,
164 
160,
168 
160,
168 
160,
164 
160,
168 
  
164,
172 
172,
174 
172,
174 
164,
172 
166,
172 
164,
168 
156,
176 
156,
168 
  
D20S181 9.53 
156,
156 
164,
164 
156,
164 
156,
164 
156,
164 
156,
164 
  
156,
160 
164,
164 
160,
164 
156,
164 
156,
160 
156,
156 
164,
164 
156,
164 
  
D20S193 9.53 
150,
154 
150,
158 
154,
158 
154,
158 
150,
158 
154,
158 
  
150,
150 
150,
150 
150,
150 
150,
150 
150,
150 
150,
154 
150,
154 
150,
154 
  
D20S116 
11.2
0 
109,
109 
115,
119 
109,
119 
109,
119 
109,
119 
109,
110 
  
109,
121 
109,
111 
109,
121 
109,
111 
113,
121 
109,
109 
109,
117 
109,
117 
  
D20S889 
11.2
0 
266,
280 
272,
278 
266,
278 
266,
278 
278,
280 
266,
278 
278,
280 
266,
272 
280,
292 
272,
282 
 
272,
280 
290,
292 
266,
280 
 
266,
272 
 
280,
284 
D20S849 
13.9
8 
214,
230 
214,
216 
214,
214 
214,
214 
214,
230 
214,
214 
  
214,
230 
214,
230 
214,
230 
214,
230 
214,
230 
214,
230 
214,
230 
214,
230 
  
D20S895 
13.9
8 
216,
224 
216,
224 
216,
216 
216,
216 
216,
216 
216,
216 
  
224,
224 
216,
218 
216,
224 
218,
224 
224,
224 
216,
216 
220,
226 
216,
220 
  
D20S882 
15.0
5 
120,
126 
120,
122 
120,
122 
120,
120 
120,
126 
120,
120 
  
120,
126 
120,
120 
120,
120 
120,
126 
120,
126 
120,
126 
120,
126 
120,
120 
  
D20S115 
21.1
5 
234,
236 
232,
236 
236,
236 
232,
236 
232,
234 
232,
236 
232,
234 
232,
236 
234,
236 
234,
234 
 
234,
236 
234,
236 
234,
236 
236,
236 
236,
236 
234,
236 
234,
236 
D20S851 
24.7
0 
132,
132 
128,
136 
138,
132 
132,
136 
132,
136 
132,
136 
  
128,
132 
132,
146 
132,
146 
128,
132 
128,
132 
132,
132 
132,
134 
132,
134 
  
D20S186 
32.3
0 
 
127,
131 
121,
131 
121,
127 
125,
127 
121,
127 
125,
127 
121,
127 
113,
131 
113,
119 
 
113,
131 
125,
131 
121,
125 
 
113,
121 
121,
125 
121,
125 
D20S112 
39.2
5 
199,
211 
199,
207 
207,
211 
199,
211 
199,
199 
199,
199 
199,
211 
199,
211 
207,
213 
209,
219 
 
209,
213 
207,
213 
199,
211 
 
209,
211 
199,
209 
199,
209 
D20S107 
55.7
4 
266,
274 
272,
274 
266,
274 
266,
274 
266,
272 
266,
272 
266,
272 
266,
272 
266,
270 
268,
270 
 
26,2
70 
266,
270 
266,
270 
 
266,
270 
 
266,
270 
D20S119 
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